[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"\"}":3,"_public_publisher_byId_13653e74-411b-456e-811a-faec20bddea2":656,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"totalCitation\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:13653e74-411b-456e-811a-faec20bddea2,\"}":727},{"meta":4,"data":6},{"total":5},"117",[7,60,176,207,299,413,445,480,543,572],{"id":8,"createTime":9,"updateTime":10,"relativeEntities":11,"slug":12,"properties":13,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":27,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":29,"subjectFields":30,"manageAffiliations":31,"indexDatabases":32,"url":33,"thumbnailPath":34,"statistic":35,"gsStatistic":26,"type":26,"analyzePriority":26},"5a09599f-54d1-44c3-8f16-3847ac552024","2023-08-17T04:28:50.832+00:00","2025-10-13T23:58:52.517+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Truy%E1%BB%81n-nhi%E1%BB%85m-Vi%E1%BB%87t-Nam",{"country":14,"issn":16,"introduce":18,"title":21},{"VOID":15},"VN",{"VOID":17},"08667829",{"EN":19,"VI":20},"{\"ops\":[{\"insert\":\"Vietnam Journal of Infectious Diseases is a social - professional forum of the Vietnam Society for Infectious Diseases, whose responsibility is to introduce the researches, the scientific advances in Vietnam and from the world; to contribute to the improvement of knowledges for health care staffs about clinic, treatment, guideline, prevention, epidemiology for infectious diseases, HIV\u002FAIDS and community health care; to provide, exchange and publish scientific information to the public accurately and promptly.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Vietnam Journal of Infectious Diseases publishes in the whole country; serves the professional work for researchers, clinical staffs, administrators, undergraduate and postgraduate students who are working and studying in the infections, tropical diseases and HIV\u002FAIDS from central to local levels, also organizations and individuals in the world who are interested in infectious and tropical diseases and prevention for HIV\u002FAIDS.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Editor in Chief:\"},{\"attributes\":{\"header\":4},\"insert\":\"\\n\"},{\"insert\":\"Prof. Dr. Nguyen Van Kinh. - Chairman of Editorial Board\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"insert\":\"Prof. Dr. Nguyen Van Mui.\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Headquarter:\"},{\"attributes\":{\"header\":4},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Address:\"},{\"insert\":\" Level 6, National Hospital for Tropical Diseases, No. 78 Giai Phong Street, Dong Da District, Hanoi city, Vietnam.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Tel:\"},{\"insert\":\" \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:02435765464\"},\"insert\":\"02435765464\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:0913552672\"},\"insert\":\"0913552672\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:0913228072\"},\"insert\":\"0913228072\"},{\"insert\":\".\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Email\"},{\"insert\":\": \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Findex\u002Fadmin\u002Fcontexts\u002Fmailto:tungphamvan52@gmail.com\"},\"insert\":\"tungphamvan52@gmail.com\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Fmailto:tapchitruyennhiem@gmail.com\"},\"insert\":\"tapchitruyennhiem@gmail.com\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Bank account:\"},{\"insert\":\" 0021000275119, Vietcombank Hanoi Branch. Transaction office No. 7, 402 Tran Khat Chan, Hai Ba Trung District, Hanoi city, Vietnam.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}","{\"ops\":[{\"insert\":\"Tạp chí Truyền nhiễm Việt Nam là cơ quan ngôn luận của Hội Truyền nhiễm Việt Nam, chịu sự lãnh đạo, chỉ đạo trực tiếp của Thường vụ Ban Chấp hành Hội Truyền nhiễm Việt Nam; sự kiểm tra, giám sát về nghiệp vụ báo chí của các cơ quan chức năng quản lý báo chí thuộc Bộ Thông tin và Truyền thông và Ban Tuyên giáo Trung ương Đảng.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Tạp chí có trách nhiệm giới thiệu các công trình nghiên cứu khoa học, những tiến bộ khoa học trên thế giới và trong nước, góp phần nâng cao kiến thức khoa học cho cán bộ y tế về lâm sàng, điều trị, hướng dẫn, dự phòng, dịch tễ học các bệnh truyền nhiễm, HIV\u002FAIDS và chăm sóc sức khỏe cộng đồng; cung cấp, trao đổi, phổ biến các thông tin khoa học tới công chúng chính xác và kịp thời.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Tạp chí xuất bản 03 tháng\u002F01 kỳ và được phát hành qua Bưu điện và tự phát hành trong phạm vi toàn quốc.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Lãnh đạo Tạp chí: \"},{\"attributes\":{\"header\":4},\"insert\":\"\\n\"},{\"insert\":\"Tổng Biên tập: ThS.BSCKII Nguyễn Trung Cấp\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"insert\":\"Phó Tổng Biên tập:\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"insert\":\"            TS.BSCKII Phạm Ngọc Thạch\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Trụ sở tòa soạn:\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Địa chỉ: Tầng 6, Bệnh viện Bệnh Nhiệt đới Trung ương, 78 đường Giải Phóng, phường Phương Mai, quận Đống Đa, thành phố Hà Nội.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Điện thoại:\"},{\"insert\":\" \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:02435765464\"},\"insert\":\"02435765464\"},{\"insert\":\" - \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:0913228072\"},\"insert\":\"0913228072\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Email\"},{\"insert\":\": \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Findex\u002Fadmin\u002Fcontexts\u002Fmailto:tungphamvan52@gmail.com\"},\"insert\":\"tungphamvan52@gmail.com\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Fmailto:tapchitruyennhiem@gmail.com\"},\"insert\":\"tapchitruyennhiem@gmail.com\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Tài khoản:\"},{\"insert\":\" Số 0021000275119 Ngân hàng Ngoại thương Việt Nam, chi nhánh Hà Nội (Vietcombank Hà Nội). Phòng giao dịch số 7, 402 Trần Khát Chân, quận Hai Bà Trưng, Thành phố Hà Nội.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}",{"EN":22,"VI":23},"Vietnam Journal of Infectious Diseases","Tạp chí Truyền nhiễm Việt Nam","PUBLISHER","VERIFIED",null,"Admin update database","PENDING",51,[],[],[],"https:\u002F\u002Ftruyennhiemvietnam.vn\u002Findex.php\u002Fvjid","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F5a09599f-54d1-44c3-8f16-3847ac552024\u002Fadb0e52bf25e0de580fd4289519cb8bf.jpg",{"impactFactor":36,"impactFactorByYear":37,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":41,"totalPublicationByYear":42,"totalCitation":48,"totalCitationByYear":49,"totalCitationPerPublication":54,"totalCitationPerPublicationByYear":55,"hindexLast5Year":59,"hindex":59},0,{"2022":38,"2023":39,"2024":40},0.01,0.03,0.13,315,{"2020":43,"2021":44,"2022":45,"2023":46,"2024":47},63,58,57,65,72,43,{"2020":50,"2021":51,"2022":52,"2023":53},8,15,9,11,0.14,{"2020":40,"2021":56,"2022":57,"2023":58},0.26,0.16,0.17,3,{"id":61,"createTime":62,"updateTime":63,"relativeEntities":64,"slug":65,"properties":66,"entityType":24,"verifyStatus":25,"verifyTime":78,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":79,"subjectFields":80,"manageAffiliations":81,"indexDatabases":136,"url":137,"thumbnailPath":26,"statistic":138,"gsStatistic":155,"type":175,"analyzePriority":26},"25b6bd10-676c-40c0-8dc3-356d1679a284","2023-05-19T02:22:33.430+00:00","2026-06-18T23:33:57.141+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Y-D%C6%B0%E1%BB%A3c-h%E1%BB%8Dc-C%E1%BA%A7n-Th%C6%A1",{"country":67,"issn":68,"introduce":70,"title":73,"gsId":76},{"VOID":15},{"VOID":69},"23541210",{"EN":71,"VI":72},"\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">04\u002F10\u002F2015 Ministry of Information and Communications allowed Can Tho journal of medicine and pharmacy to operate (102 \u002FGP-BTTTT)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">07\u002F16\u002F2015 Can Tho journal of medicine and pharmacy is internationally recognized: ISSN 2354-1210\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">In 2016, The journal has been included in the list of medical science journals by The State Council for professorship which is awarded a work score of 0-0.5 points for a published article.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Can Tho Journal of Medicine and Pharmacy welcome original works that haven’t been submitted or published in other medical journals. Posts must contain content related to one of the journal’s categories.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The content published\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The journal is divided into 3 categories:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Scientific research article: are valuable scientific works, which have been researched and accepted.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Overview of medicine, biology and pharmacy: serving the objective of continuing training in the fields of medicine, biology and pharmacy; to systematize classical and modern knowledge.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Update information on new knowledge about medicine, biology, pharmacy in the country and in the world.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Scope\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Publication and introduction of scientific research in the fields:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Medicine (internal medicine, surgery, pediatrics, obstetrics and gynecology, odonto-stomatology, laboratory, oncology, traditional medicine, nursing).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Biology (genetics, biotechnology).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Pharmacology (pharmaceutics, drug quality analysis-control, synthetic pharmaceutical chemistry, biochemistry, pharmacognosy, botany, clinical pharmacy).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- To enhance the quality of undergraduate, postgraduate education, scientifically researching and meet the necessary treatment in hospital.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Introducing the updated domestic and oversea information about science technology to promote scientific research and exchanging technology in local, other universities.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Exchanging pharmaceutical and medical information for social health developing in the Mekong Delta and Vietnam.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The object\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Postgraduate students, student of Can Tho University of Medicine and Pharmacy, scientists from schools, research institutes, hospitals, health centers, pharmaceutical companies of the Mekong Delta; other provinces and regions in Vietnam and other country.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Address\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Headquarters of Can Tho Journal of Medicine and Pharmacy, located Scientific Research and International Cooperation Office: 179 Nguyen Van Cu Street, An Khanh Ward, Ninh Kieu District, Can Tho City, Vietnam.\u003C\u002Fspan>\u003C\u002Fp>","\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Ngày 16\u002F7\u002F2015, Tạp chí Y Dược học Cần Thơ được cấp chỉ số quốc tế: ISSN 2354-1210.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Từ tháng 4\u002F2016, Tạp chí đã được Hội đồng Giáo sư ngành Y đưa vào danh sách các tạp chí khoa học Y học được tính điểm công trình 0-0,5 điểm cho một bài báo đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Năm 2020 Tạp chí Y Dược học Cần Thơ đã được phê duyệt vào danh mục của các Hội đồng Giáo sư ngành Dược học được tính điểm công trình 0-0,5 điểm cho một bài báo đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ ra 12 số\u002Fnăm, 180-200 trang\u002Fsố.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Từ tháng 12\u002F2022 Tạp chí Y Dược học Cần Thơ là thành viên của hệ thống Crossref và từ tháng 01\u002F2023 tạp chí thực hiện bình duyệt online kín 2 chiều nhằm tăng tính minh bạch, tin cậy của các công trình nghiên cứu khoa học và đảm bảo tốt nhất chất lượng khoa học của bài viết.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tôn chỉ, mục đích và phạm vi của tạp chí\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tôn chỉ và mục đích hoạt động của tạp chí: xuất bản nhằm mục đích phổ biến kết quả từ các đề tài nghiên cứu khoa học; giao lưu trao đổi khoa học, chia sẻ kinh nghiệm, học tập, đồng thời cập nhật thông tin khoa học mới trong các lĩnh vực y, sinh, dược học trong và ngoài nước.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Phạm vi của tạp chí: Tạp chí xuất bản được chia thành 3 chuyên mục: (i) Bài báo nghiên cứu khoa học là kết quả công trình nghiên cứu khoa học có giá trị đã được triển khai nghiên cứu, (ii) Bài tổng quan y, sinh, dược học: phục vụ mục tiêu đào tạo liên tục trong lĩnh vực y, sinh, dược học; nhằm hệ thống hóa những kiến thức kinh điển và hiện đại; (iii) Thông tin cập nhật kiến thức mới về y, sinh, dược học trong nước và trên thế giới.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Chính sách truy cập mở\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ áp dụng chính sách truy cập mở đối với các bài báo đã xuất bản đến với độc giả, nhằm mở rộng cơ hội tiếp cận các kết quả nghiên cứu chất lượng cao và tăng cường trao đổi kiến thức. Tạp chí đăng tải trực tuyến (miễn phí) toàn văn các bài báo được công bố trên website của Tạp chí (https:\u002F\u002Ftapchi.ctump.edu.vn).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đạo đức xuất bản\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ cam kết tuân thủ đạo đức xuất bản phù hợp với các hướng dẫn và tiêu chuẩn của the Committee on Publication Ethics (COPE), tuân thủ các nguyên tắc của COPE’s Core Practices, Best Practices Guidelines for Journal Editors và Guidelines on Good Publication Practices.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Bản thảo bài báo chỉ được chấp nhận khi được tác giả chịu trách nhiệm chính cam kết các nội dung sau: Các nội dung của bản thảo chưa được đăng tải toàn bộ hoặc một phần ở các tạp chí khác; Tất cả các tác giả đều có đóng góp một cách đáng kể vào quá trình nghiên cứu hoặc chuẩn bị bản thảo và cùng chịu trách nhiệm về các nội dung của bản thảo; Tuân thủ các biện pháp đảm bảo đạo đức nghiên cứu (ví dụ thỏa thuận đồng ý tham gia nghiên cứu).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Cam kết bảo mật\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí cam kết thực hiện và tuân thủ các quy định của luật và các văn bản hướng dẫn liên quan đến bảo mật thông tin cá nhân trên không gian mạng. Các thông tin mà người dùng (tác giả, độc giả, biên tập viên, người phản biện) nhập vào các biểu mẫu trên Hệ thống Quản lý xuất bản trực tuyến của tạp chí chỉ được sử dụng vào các mục đích đã được tuyên bố rõ ràng và sẽ không được cung cấp cho bất kỳ bên thứ ba nào khác, hay dùng vào bất kỳ mục đích nào khác.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Phí gửi bài\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Lệ phí gửi đăng bài: 1.000.000đ\u002Fbài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Lệ phí gửi đăng nhanh: 1.500.000đ\u002Fbài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đối với tác giả là cán bộ viên chức thuộc Trường Đại học Y Dược Cần Thơ thì được hỗ trợ 50% lệ phí gửi đăng bài.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đối với sinh viên thực hiện đề tài nghiên cứu khoa học cấp trường được hỗ trợ 100% lệ phí đăng bài ( Tác giả gửi đính kèm “ Quyết định về việc giao tổ chức thực hiện đề tài nghiên cứu khoa học cấp Trường của sinh viên”).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Hình thức nộp lệ phí:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Tiền mặt:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Nộp trực tiếp tại Phòng Tài chính - Kế toán, Trường Đại học Y Dược Cần Thơ, số 179 Nguyễn Văn Cừ, P. An Khánh, Q. Ninh Kiều, thành phố Cần Thơ.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Chuyển khoản:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tên Tài khoản: Trường ĐHYD Cần Thơ, Số TK: 0111000115668, tại ngân hàng Vietcombank chi nhánh Cần Thơ.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Thời gian: Áp dụng từ ngày 01\u002F02\u002F2023.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">* Phí gửi bài không được hoàn trả khi bài viết bị từ chối hoặc tác giả xin rút bài viết.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Quy trình phản biện bài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ thực hiện quy trình phản biện kín hai chiều nghiêm ngặt. Danh tính của những người phản biện không được tiết lộ cho các tác giả và ngược lại. Quy trình thẩm định bài báo đăng gồm các bước sau:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tiếp nhận bản thảo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tác giả liên hệ gửi bản thảo đến Tạp chí qua hệ thống trực tuyến tại website: https:\u002F\u002Ftapchi.ctump.edu.vn. Hướng dẫn về cách đăng ký, gửi bài và chuẩn bị bản thảo được cung cấp trên website của Tạp chí.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Sàng lọc sơ bộ\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Sau khi Tòa soạn nhận được bài báo của tác giả, Ban Thư ký sẽ tiến hành kiểm tra sơ bộ bài báo (các yêu cầu về nội dung và hình thức). Những bài báo không đúng quy cách hoặc có nội dung không phù hợp hoặc vi phạm bản quyền sẽ bị từ chối (Ban Thư ký thông báo phản hồi đến tác giả trong vòng 1 tuần). Những bài báo đủ điều kiện, được Ban Thư ký tòa soạn chuyển đến Ban Biên tập có cùng chuyên môn với nội dung bài báo để đề xuất người phản biện. Thời gian kể từ khi Ban Biên tập nhận bài báo đến khi đề xuất người phản biện bài báo chậm nhất là 5 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Vòng phản biện\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Ban Thư ký gửi bài và yêu cầu phản biện đến 02 phản biện độc lập.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Các phản biện gởi nhận xét cho Ban Thư ký. Thời gian từ khi gửi bài cho phản biện đến khi nhận ý kiến của phản biện tối đa là 20 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Xử ký kết quả phản biện\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Nếu ý kiến đồng ý cho đăng và không cần chỉnh sửa, Ban Thư ký tiếp tục đăng bài theo qui trình.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Nếu ý kiến đồng ý đăng và cần chỉnh sửa, Ban Thư ký sẽ thông tin đến tác giả chỉnh sửa theo yêu cầu của người phản biện. Thời gian chỉnh sửa và gửi lại kéo dài không quá 2 tuần, từ khi tác giả bài báo nhận được thông tin (Quá trình này có thể lặp lại tối đa 2 lần\u002F1 bài báo). Khi có sự thống nhất, đồng ý của người phản biện; bài báo được tiếp tục đăng theo qui trình.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">3. Những bài báo có chất lượng không đạt yêu cầu, cả 2 phản biện không đồng ý cho đăng sẽ bị Tòa soạn từ chối đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Xuất bản\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Ban Thư ký tổng hợp các bản thảo đã được tác giả hoàn thiện sau thẩm định trình Ban Biên tập xem xét, Tổng Biên tập phê duyệt, quyết định bài đăng theo các tiêu chí: sự phù hợp nội dung với tôn chỉ và mục đích, thể loại bài viết (ưu tiên các bài có bài có nghiên cứu chuyên sâu, hàm lượng khoa học cao), đóng góp mới bài báo, bài báo được ưu tiên đăng trong số gần nhất của Tạp chí theo thứ tự: tính thời sự, chất lượng bài báo và thời gian gửi bài.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Ban Biên tập và Ban Thư ký biên tập bản thảo, chế bản, đọc rà soát lỗi. Thời gian hoàn thành từ 10-15 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">3. Ban Thư ký có trách nhiệm thông báo cho tác giả bài báo (bằng e-mail) về tình hình phê duyệt bài báo, thời gian, số kỳ, tập xuất bản bài báo theo qui định.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">4. Danh sách bài báo theo số Tạp chí được in ấn và phát hành trong năm định kỳ được công bố chính thức trên website: https:\u002F\u002Ftapchi.ctump.edu.vn\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>",{"EN":74,"VI":75},"Cantho Journal of Medicine and Pharmacy","Tạp chí Y Dược học Cần Thơ",{"VOID":77},"wcQ1uqwAAAAJ","2023-05-30T08:17:21.868+00:00",32,[],[82],{"id":83,"createTime":84,"updateTime":85,"relativeEntities":86,"slug":87,"properties":88,"entityType":98,"verifyStatus":25,"verifyTime":99,"verifyNote":26,"syncStatus":28,"languages":100,"translateLanguages":26,"viewCount":103,"url":104,"parentIds":105,"statistic":106},"6413896b-eca9-442b-a73f-182a58a0ce40","2023-06-12T14:59:13.446+00:00","2026-06-19T02:29:32.871+00:00",[],"Tr%C6%B0%E1%BB%9Dng-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Y-D%C6%B0%E1%BB%A3c-C%E1%BA%A7n-Th%C6%A1",{"country":89,"title":90,"address":93,"abbreviation":96},{"VOID":15},{"EN":91,"VI":92},"Can Tho University of Medicine and Pharmacy","Trường Đại học Y Dược Cần Thơ",{"VI":94,"EN":95},"Số 179, đường Nguyễn Văn Cừ, phường An Khánh, quận Ninh Kiều, thành phố Cần Thơ, Việt Nam","No 179, Nguyen Van Cu street, An Khanh ward, Ninh Kieu district, Can Tho city, Vietnam",{"VOID":97},"ctump","AFFILIATION","2023-08-01T14:07:27.977+00:00",[101,102],"VI","EN",12,"http:\u002F\u002Fwww.ctump.edu.vn\u002F",[],{"impactFactor":36,"impactFactorByYear":107,"i10Index":111,"i10IndexLast5Year":59,"totalPublication":112,"totalPublicationByYear":113,"totalCitation":122,"totalCitationByYear":123,"totalCitationPerPublication":128,"totalCitationPerPublicationByYear":129,"hindexLast5Year":135,"hindex":135},{"2022":108,"2023":109,"2024":110,"2025":38},0.1,0.05,0.07,4,1489,{"2013":114,"2014":115,"2015":115,"2016":111,"2017":115,"2018":59,"2019":114,"2020":116,"2021":117,"2022":118,"2023":119,"2024":120,"2025":121,"2026":111},2,1,10,84,281,680,260,156,313,{"2013":59,"2014":114,"2018":124,"2021":125,"2022":126,"2023":127},17,36,123,132,0.21,{"2013":130,"2014":114,"2018":131,"2021":132,"2022":133,"2023":134},1.5,5.67,0.43,0.44,0.19,6,[],"https:\u002F\u002Ftapchi.ctump.edu.vn\u002Findex.php\u002Fctump",{"impactFactor":36,"impactFactorByYear":139,"i10Index":114,"i10IndexLast5Year":114,"totalPublication":140,"totalPublicationByYear":141,"totalCitation":147,"totalCitationByYear":148,"totalCitationPerPublication":151,"totalCitationPerPublicationByYear":152,"hindexLast5Year":135,"hindex":135},{"2022":38,"2023":36,"2024":39,"2025":38},1956,{"0":114,"2019":114,"2020":50,"2021":142,"2022":143,"2023":144,"2024":145,"2025":146},76,403,789,305,371,524,{"0":114,"2019":135,"2021":124,"2022":149,"2023":150,"2024":111,"2025":114},287,206,0.27,{"0":115,"2019":59,"2021":153,"2022":154,"2023":56,"2024":38,"2025":38},0.22,0.71,{"impactFactor":26,"impactFactorByYear":26,"i10Index":114,"i10IndexLast5Year":114,"totalPublication":156,"totalPublicationByYear":157,"totalCitation":163,"totalCitationByYear":164,"totalCitationPerPublication":169,"totalCitationPerPublicationByYear":170,"hindexLast5Year":135,"hindex":135},461,{"0":158,"2019":114,"2021":159,"2022":160,"2023":161,"2024":158,"2025":162},7,37,296,107,5,419,{"2021":59,"2022":59,"2023":165,"2024":166,"2025":167,"2026":168},71,126,171,41,0.91,{"2021":171,"2022":38,"2023":172,"2024":173,"2025":174},0.08,0.66,18,34.2,"JOURNAL",{"id":177,"createTime":178,"updateTime":179,"relativeEntities":180,"slug":181,"properties":182,"entityType":24,"verifyStatus":25,"verifyTime":193,"verifyNote":26,"syncStatus":28,"languages":194,"translateLanguages":26,"viewCount":36,"subjectFields":195,"manageAffiliations":196,"indexDatabases":197,"url":198,"thumbnailPath":26,"statistic":26,"gsStatistic":199,"type":175,"analyzePriority":26},"f8d0bf97-8d89-482e-b58c-2fc481a0b79b","2025-10-27T06:27:08.591+00:00","2026-06-18T23:33:41.667+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Khoa-h%E1%BB%8Dc-v%C3%A0-C%C3%B4ng-ngh%E1%BB%87-nhi%E1%BB%87t-%C4%91%E1%BB%9Bi",{"country":183,"introduce":184,"gsId":186,"title":188,"issn":191},{"VOID":15},{"EN":185},"\u003Cp style=\"text-align:justify;\">     Journal of Tropical Science and Engineering (JTSE) is a multidisciplinary scientific journal, licensed to operate as a print journal in 2012 and an electronic journal in 2024 (License No.1479\u002FGP-BTTTT dated August 20, 2012 and No.91\u002FGP-BTTTT dated April 9, 2024 issued by the Ministry of Information and Communications of Vietnam). The JTSE is headquartered in Hanoi.\u003C\u002Fp>\u003Cp style=\"text-align:justify;\">        The JTSE is published every 3 months (4 issues\u002Fyear), publishing research results and overview articles in 3 groups of fields: Tropical Ecology and Environment; Chemistry and Material Sciences; Biomedicine and Pharmacy. In 2022, the JTSE registered the international identifier Digital Object Identifier (DOI): 10.58334\u002Fvrtc.jtst and assigned DOI codes to all articles of the journal. The members of the Editorial Board of the JTSE are prestigious scientists and leading scientists from Vietnam and many countries in the world. The JTSE has been recognized by the Vietnam State Council for Professorship to score scientific articles in Chemistry, Medicine and Biology with scores ranging from 0-0.75 points.\u003C\u002Fp>\u003Cp style=\"text-align:justify;\">      Currently, the JTSE is building and perfecting a set of criteria and making efforts to join the List of prestigious  international journals with a roadmap to enter Scopus and SCIE in the coming time.\u003C\u002Fp>",{"VOID":187},"MS2_GJQAAAAJ",{"VI":189,"EN":190},"Tạp chí Khoa học và Công nghệ nhiệt đới","Journal of Tropical Science and Engineering",{"VOID":192},"08667535","2025-10-27T06:27:25.058+00:00",[101,102],[],[],[],"https:\u002F\u002Ftapchikhcnnd.com.vn",{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":200,"totalPublicationByYear":201,"totalCitation":161,"totalCitationByYear":203,"totalCitationPerPublication":153,"totalCitationPerPublicationByYear":205,"hindexLast5Year":114,"hindex":114},481,{"0":115,"2020":115,"2021":115,"2022":114,"2024":115,"2025":202,"2026":115},474,{"2017":114,"2018":115,"2019":111,"2020":162,"2021":162,"2022":116,"2023":50,"2024":162,"2025":204,"2026":52},52,{"2020":162,"2021":162,"2022":162,"2024":162,"2025":206,"2026":52},0.11,{"id":208,"createTime":209,"updateTime":210,"relativeEntities":211,"slug":212,"properties":213,"entityType":24,"verifyStatus":25,"verifyTime":221,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":222,"subjectFields":223,"manageAffiliations":224,"indexDatabases":225,"url":226,"thumbnailPath":26,"statistic":227,"gsStatistic":276,"type":175,"analyzePriority":26},"a3d1e82a-57e2-40f9-940e-f5fa8b9ef64a","2023-06-01T07:11:26.039+00:00","2026-06-18T23:33:28.573+00:00",[],"VNU-Journal-of-Science-Earth-and-Environmental-Sciences",{"issn":214,"title":216,"country":218,"gsId":219},{"VOID":215},"26159279",{"EN":217},"VNU Journal of Science: Earth and Environmental Sciences",{"VOID":15},{"VOID":220},"UmXD8vEAAAAJ","2023-06-01T07:17:59.210+00:00",27,[],[],[],"https:\u002F\u002Fjs.vnu.edu.vn\u002FEES",{"impactFactor":36,"impactFactorByYear":228,"i10Index":234,"i10IndexLast5Year":36,"totalPublication":235,"totalPublicationByYear":236,"totalCitation":246,"totalCitationByYear":247,"totalCitationPerPublication":261,"totalCitationPerPublicationByYear":262,"hindexLast5Year":103,"hindex":103},{"2010":229,"2012":40,"2013":230,"2014":230,"2015":231,"2016":54,"2017":171,"2018":109,"2019":110,"2020":57,"2021":232,"2022":233,"2023":151,"2024":58},0.02,0.04,0.09,0.31,0.4,19,656,{"2008":237,"2009":238,"2010":239,"2011":238,"2012":240,"2013":241,"2014":239,"2015":242,"2016":243,"2017":244,"2018":245,"2019":165,"2020":125,"2021":168,"2022":125,"2023":222,"2024":111},23,24,22,28,25,20,146,29,78,1038,{"2008":248,"2009":249,"2010":250,"2011":251,"2012":252,"2013":253,"2014":254,"2015":255,"2016":256,"2017":257,"2018":161,"2019":258,"2020":259,"2021":29,"2022":260},119,64,66,86,38,73,59,31,129,39,97,53,26,1.58,{"2008":263,"2009":264,"2010":59,"2011":265,"2012":266,"2013":267,"2014":268,"2015":269,"2016":270,"2017":271,"2018":272,"2019":272,"2020":273,"2021":274,"2022":275},5.17,2.67,3.58,1.36,2.92,2.68,1.55,0.88,1.34,1.37,1.47,1.24,0.72,{"impactFactor":26,"impactFactorByYear":26,"i10Index":173,"i10IndexLast5Year":135,"totalPublication":277,"totalPublicationByYear":278,"totalCitation":279,"totalCitationByYear":280,"totalCitationPerPublication":288,"totalCitationPerPublicationByYear":289,"hindexLast5Year":158,"hindex":298},113,{"2007":114,"2008":103,"2009":173,"2010":116,"2011":51,"2012":239,"2013":103,"2014":162,"2015":53,"2016":135},616,{"2009":162,"2010":114,"2011":52,"2012":124,"2013":222,"2014":255,"2015":48,"2016":44,"2017":281,"2018":282,"2019":259,"2020":283,"2021":284,"2022":285,"2023":286,"2024":257,"2025":287,"2026":59},54,60,49,47,34,44,33,5.45,{"2009":290,"2010":291,"2011":292,"2012":293,"2013":294,"2014":295,"2015":296,"2016":297},0.28,0.2,0.6,0.77,2.25,6.2,3.91,9.67,14,{"id":300,"createTime":301,"updateTime":302,"relativeEntities":303,"slug":304,"properties":305,"entityType":24,"verifyStatus":25,"verifyTime":316,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":234,"subjectFields":317,"manageAffiliations":318,"indexDatabases":388,"url":389,"thumbnailPath":390,"statistic":391,"gsStatistic":409,"type":175,"analyzePriority":26},"a7166325-6c9e-4db3-8a59-7c879701a372","2023-07-31T04:28:49.231+00:00","2026-06-18T23:33:22.428+00:00",[],"VNU-Journal-of-Science-Policy-and-Management-Studies",{"country":306,"issn":307,"eissn":309,"title":311,"gsId":314},{"VOID":15},{"VOID":308},"26159295",{"VOID":310},"25881116",{"EN":312,"VI":313},"VNU Journal of Science: Policy and Management Studies","Tạp chí Nghiên cứu Chính sách và Quản lý",{"VOID":315},"xKW2E_cAAAAJ","2023-08-01T03:23:46.688+00:00",[],[319],{"id":320,"createTime":321,"updateTime":322,"relativeEntities":323,"slug":324,"properties":325,"entityType":98,"verifyStatus":25,"verifyTime":335,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":336,"url":337,"parentIds":338,"statistic":339},"12466116-8f60-4b01-8faf-2411483a0977","2023-05-30T09:37:38.472+00:00","2026-06-19T02:14:28.352+00:00",[],"Vietnam-National-University",{"country":326,"title":327,"abbreviation":330,"address":332},{"VOID":15},{"EN":328,"VI":329},"Vietnam National University, Hanoi","Đại học Quốc gia Hà Nội",{"VOID":331},"VNU",{"VI":333,"EN":334},"Số 144 Xuân Thủy, Phường Dịch Vọng Hậu, Quận Cầu Giấy, Hà Nội, Việt Nam","No. 144 Xuan Thuy Street, Dich Vong Hau Ward, Cau Giay District, Hanoi, Vietnam","2023-08-02T13:58:17.029+00:00",16,"http:\u002F\u002Fwww.vnu.edu.vn\u002F",[],{"impactFactor":36,"impactFactorByYear":340,"i10Index":285,"i10IndexLast5Year":162,"totalPublication":344,"totalPublicationByYear":345,"totalCitation":354,"totalCitationByYear":355,"totalCitationPerPublication":368,"totalCitationPerPublicationByYear":369,"hindexLast5Year":336,"hindex":336},{"2014":109,"2015":231,"2016":231,"2017":206,"2018":341,"2019":110,"2020":342,"2021":343,"2022":171,"2023":231,"2024":110,"2025":39},0.06,0.18,0.35,1247,{"2003":115,"2004":115,"2005":114,"2006":59,"2007":111,"2008":162,"2009":59,"2010":50,"2011":124,"2012":336,"2013":260,"2014":244,"2015":250,"2016":281,"2017":346,"2018":347,"2019":348,"2020":349,"2021":350,"2022":351,"2023":352,"2024":353,"2025":255,"2026":50},94,88,83,67,176,185,187,93,1644,{"2004":111,"2005":115,"2006":52,"2007":298,"2008":356,"2009":298,"2010":286,"2011":357,"2012":244,"2013":358,"2014":359,"2015":360,"2016":361,"2017":362,"2018":363,"2019":364,"2020":365,"2021":366,"2022":367,"2023":367,"2024":162},13,81,48,70,151,115,109,259,174,181,121,101,1.32,{"2004":111,"2005":370,"2006":59,"2007":371,"2008":372,"2009":373,"2010":374,"2011":375,"2012":376,"2013":377,"2014":378,"2015":379,"2016":380,"2017":381,"2018":382,"2019":383,"2020":384,"2021":385,"2022":386,"2023":387,"2024":109},0.5,3.5,2.6,4.67,5.5,4.76,1.81,1.85,2.41,2.29,2.13,1.16,2.94,2.1,2.7,0.69,0.55,0.54,[],"https:\u002F\u002Fjs.vnu.edu.vn\u002FPaM","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002Fa7166325-6c9e-4db3-8a59-7c879701a372\u002Fecfe83f4bcc60c7023ae04d8900fe0ac.jpg",{"impactFactor":36,"impactFactorByYear":392,"i10Index":111,"i10IndexLast5Year":36,"totalPublication":394,"totalPublicationByYear":395,"totalCitation":399,"totalCitationByYear":400,"totalCitationPerPublication":293,"totalCitationPerPublicationByYear":403,"hindexLast5Year":158,"hindex":158},{"2018":109,"2019":171,"2020":393,"2021":108,"2022":54,"2023":206,"2024":54},0.23,320,{"2015":50,"2016":239,"2017":286,"2018":396,"2019":397,"2020":159,"2021":398,"2022":168,"2023":79,"2024":255},30,35,40,247,{"2015":115,"2016":242,"2017":401,"2018":222,"2019":402,"2020":79,"2021":239,"2022":50,"2023":116},77,50,{"2015":404,"2016":169,"2017":405,"2018":406,"2019":407,"2020":408,"2021":386,"2022":291,"2023":232},0.12,1.75,0.9,1.43,0.86,{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":103,"totalPublicationByYear":410,"totalCitation":234,"totalCitationByYear":411,"totalCitationPerPublication":261,"totalCitationPerPublicationByYear":412,"hindexLast5Year":114,"hindex":59},{"2015":114,"2016":116},{"2016":115,"2017":114,"2018":114,"2019":59,"2020":114,"2021":59,"2022":114,"2023":114,"2024":115,"2026":115},{"2016":108},{"id":414,"createTime":415,"updateTime":416,"relativeEntities":417,"slug":418,"properties":419,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":238,"subjectFields":428,"manageAffiliations":429,"indexDatabases":430,"url":431,"thumbnailPath":26,"statistic":432,"gsStatistic":438,"type":175,"analyzePriority":26},"16e65a3f-d274-47dd-8691-56d76eb58c3d","2023-05-30T09:10:06.062+00:00","2026-06-18T23:33:17.679+00:00",[],"Vietnam-Journal-of-Otorhinolaryngology-Head-and-Neck-Surgery",{"country":420,"issn":421,"title":423,"gsId":426},{"VOID":15},{"VOID":422},"18593704",{"EN":424,"VI":425},"Vietnam Journal of Otorhinolaryngology - Head and Neck Surgery","Tạp chí Tai Mũi Họng Việt Nam",{"VOID":427},"L78B_eIAAAAJ",[],[],[],"https:\u002F\u002Ftapchitaimuihong.vn\u002Findex.php\u002Ftmh",{"impactFactor":36,"impactFactorByYear":433,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":434,"totalPublicationByYear":435,"totalCitation":111,"totalCitationByYear":436,"totalCitationPerPublication":230,"totalCitationPerPublicationByYear":437,"hindexLast5Year":115,"hindex":115},{"2024":229},95,{"2022":52,"2023":286,"2024":255,"2025":53},{"2023":111},{"2023":231},{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":240,"totalPublicationByYear":439,"totalCitation":234,"totalCitationByYear":440,"totalCitationPerPublication":441,"totalCitationPerPublicationByYear":442,"hindexLast5Year":114,"hindex":114},{"2023":53,"2024":116,"2025":135,"2026":115},{"2024":59,"2025":298,"2026":114},0.68,{"2024":443,"2025":444,"2026":114},0.3,2.33,{"id":446,"createTime":447,"updateTime":448,"relativeEntities":449,"slug":450,"properties":451,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":396,"subjectFields":460,"manageAffiliations":461,"indexDatabases":462,"url":463,"thumbnailPath":464,"statistic":465,"gsStatistic":472,"type":175,"analyzePriority":26},"25988add-c322-4eda-afda-63b1559bb824","2023-04-07T03:49:55.817+00:00","2026-06-18T23:32:23.776+00:00",[],"T%E1%BA%A1p%20ch%C3%AD%20Y%20-%20D%C6%B0%E1%BB%A3c%20h%E1%BB%8Dc%20qu%C3%A2n%20s%E1%BB%B1",{"country":452,"issn":453,"title":455,"gsId":458},{"VOID":15},{"VOID":454},"18590748",{"EN":456,"VI":457},"Journal of Military Pharmaco-medicine","Tạp chí Y - Dược học quân sự",{"VOID":459},"_pmQ8IEAAAAJ",[],[],[],"https:\u002F\u002Fjmpm.vn\u002Findex.php\u002Fjmpm","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F25988add-c322-4eda-afda-63b1559bb824\u002F09c6bc42157cf5ece95edc971ccddb52.jpg",{"impactFactor":36,"impactFactorByYear":466,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":467,"totalPublicationByYear":468,"totalCitation":135,"totalCitationByYear":470,"totalCitationPerPublication":38,"totalCitationPerPublicationByYear":471,"hindexLast5Year":115,"hindex":115},{"2023":229,"2024":38},475,{"2022":168,"2023":365,"2024":469,"2025":124},236,{"2022":114,"2023":111},{"2022":109,"2023":229},{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":277,"totalPublicationByYear":473,"totalCitation":401,"totalCitationByYear":474,"totalCitationPerPublication":441,"totalCitationPerPublicationByYear":475,"hindexLast5Year":59,"hindex":59},{"2015":115,"2018":114,"2019":115,"2020":115,"2021":59,"2022":103,"2023":159,"2024":287,"2025":237},{"2020":115,"2021":115,"2022":115,"2023":52,"2024":237,"2025":79,"2026":116},{"2020":115,"2021":476,"2022":171,"2023":477,"2024":478,"2025":479},0.33,0.24,0.7,1.39,{"id":481,"createTime":482,"updateTime":483,"relativeEntities":484,"slug":485,"properties":486,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":27,"syncStatus":28,"languages":496,"translateLanguages":26,"viewCount":45,"subjectFields":497,"manageAffiliations":498,"indexDatabases":525,"url":526,"thumbnailPath":527,"statistic":528,"gsStatistic":26,"type":26,"analyzePriority":26},"2b8d7b12-2d20-4777-be98-077f44f03c69","2023-09-07T07:40:58.286+00:00","2025-07-13T21:21:00.542+00:00",[],"VNU-Journal-of-Social-Sciences-and-Humanities",{"country":487,"issn":488,"introduce":490,"title":493},{"VOID":15},{"VOID":489},"23541172",{"EN":491,"VI":492},"{\"ops\":[{\"insert\":\"VNU Journal of Social Sciences and Humanities (ISSN 2354-1172) is a double-blind peer-reviewed journal published by University of Social Sciences and Humanities, Vietnam National University, Hanoi, Vietnam, under the publication permit no. 155\u002FGP-BTTTT, issued on 11\"},{\"attributes\":{\"script\":\"super\"},\"insert\":\"th \"},{\"insert\":\"May, 2015 by Ministry of Information and Communications. The journal publishes four Vietnamese issues and two English issues per year.\\nCurrently, there are 35 reputable professors in the editorial board. The main objectives of the journal include: providing an intellectual platform for Vietnamese and international scholars; promoting interdisciplinary studies in social sciences and humanities; becoming the leading journal in social sciences and humanities in Vietnam; being indexed by worldwide databases and having academic recognition internationally in the near future.\\nThe journal is currently indexed by Google Scholar, WorldCat, Open Archives, Cosmos Impact Factor, Advanced Sciences Index, Scientific Indexing Services, CrossRef, EBSCO Information Services and Vietnam National University’s digital archive.\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Journal of Social Sciences and Humanities-Vietnam\"},{\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"ISSN 2354-1172, email: tapchikhxhnv@gmail.com, tckhxhnv@vnu.edu.vn\"},{\"insert\":\"\\n\"}]}","{\"ops\":[{\"insert\":\"Được thành lập ngày 31\u002F8\u002F2015 (giấy phép hoạt động số 155\u002FGP-BVHTT ngày 11 tháng 5 năm 2015 của Bộ Thông tin và Truyền thông, mã số tiêu chuẩn quốc tế ISSN 2354-1172), Tạp chí Khoa học Xã hội và Nhân văn (Journal of Social Sciences and Humanities) là ấn phẩm khoa học chính thức, duy nhất của Trường Đại học Khoa học Xã hội và Nhân văn, ĐHQG Hà Nội, phát triển và kế thừa Chuyên san Khoa học Xã hội và Nhân văn, Tạp chí Khoa học, ĐHQG Hà Nội.\\nTạp chí xuất bản định kỳ (04 số tiếng Việt\u002Fnăm và 02 số tiếng Anh\u002Fnăm), có nhiệm vụ \"},{\"attributes\":{\"italic\":true},\"insert\":\"công bố, giới thiệu các công trình nghiên cứu khoa học khoa học xã hội và nhân văn của các tác giả là các nhà khoa học trong và ngoài nước, phục vụ giảng dạy, học tập và nghiên cứu khoa học\"},{\"insert\":\". Hội đồng biên tập của Tạp chí hiện bao gồm 33 nhà khoa học có uy tín trong nước và quốc tế. Tạp chí tập trung và ưu tiên đăng tải những bài báo theo định hướng của tinh thần cởi mở, sáng tạo, nhanh chóng vươn lên để tiếp cận và sánh ngang với các tạp chí có uy tín hàng đầu của khu vực và trên thế giới. Nội dung chính của Tạp chí bao gồm các Bài nghiên cứu (khoảng 6000 đến 15000 từ), các bài điểm sách, thông tin khoa học (khoảng 300 đến 1500 từ) được trình bày theo đúng cấu trúc và chuẩn mực của một tạp chí khoa học.\\nCác bài viết của Tạp chí hiện đang được trích dẫn bởi Google Scholar, WorldCat, Open Archives, Cosmos Impact Factor, Advanced Sciences Index, Scientific Indexing Services, CrossRef, EBSCO Information Services.\\nMọi thông tin xin liên hệ: \"},{\"attributes\":{\"italic\":true},\"insert\":\"Phòng Tạp chí, 701 - E, Trường Đại học Khoa học Xã hội và Nhân văn, 336 Nguyễn Trãi, Thanh Xuân, Hà Nội. ĐT: 024.35581984; email: tckhxhnv@vnu.edu.vn \"},{\"insert\":\"hoặc \"},{\"attributes\":{\"italic\":true},\"insert\":\"tapchikhxhnv@gmail.com \"},{\"insert\":\"\\n\"}]}",{"EN":494,"VI":495},"VNU Journal of Social Sciences and Humanities","Tạp chí Khoa học Xã hội và Nhân văn",[101,102],[],[499],{"id":500,"createTime":501,"updateTime":502,"relativeEntities":503,"slug":504,"properties":505,"entityType":98,"verifyStatus":25,"verifyTime":509,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":222,"url":26,"parentIds":510,"statistic":511},"8b6e349b-0daf-4895-9c3f-85f30f1bfd42","2023-07-31T12:55:58.430+00:00","2026-06-19T02:30:07.899+00:00",[],"Tr%C6%B0%E1%BB%9Dng-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Khoa-h%E1%BB%8Dc-X%C3%A3-h%E1%BB%99i-v%C3%A0-Nh%C3%A2n-v%C4%83n-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Qu%E1%BB%91c-gia-H%C3%A0-N%E1%BB%99i",{"title":506},{"EN":507,"VI":508},"VNU University of Social Sciences and Humanities","Trường Đại học Khoa học Xã hội và Nhân văn, Đại học Quốc gia Hà Nội","2023-08-02T15:28:49.057+00:00",[],{"impactFactor":36,"impactFactorByYear":512,"i10Index":59,"i10IndexLast5Year":115,"totalPublication":514,"totalPublicationByYear":515,"totalCitation":518,"totalCitationByYear":519,"totalCitationPerPublication":520,"totalCitationPerPublicationByYear":521,"hindexLast5Year":162,"hindex":162},{"2016":229,"2017":230,"2018":229,"2021":230,"2022":58,"2023":513,"2024":38},0.15,365,{"2013":115,"2014":158,"2015":125,"2016":252,"2017":44,"2018":516,"2019":286,"2020":396,"2021":259,"2022":517,"2023":396,"2024":115,"2025":59,"2026":115},21,42,169,{"2015":283,"2016":135,"2017":52,"2018":50,"2019":298,"2020":53,"2021":359,"2022":115,"2023":115},0.46,{"2015":266,"2016":57,"2017":57,"2018":522,"2019":523,"2020":524,"2021":368,"2022":229,"2023":39},0.38,0.32,0.37,[],"http:\u002F\u002Fjournal.ussh.vnu.edu.vn\u002Findex.php\u002Fvjossh","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F2b8d7b12-2d20-4777-be98-077f44f03c69\u002F0bd0751202944a4b4165b482e6e623e4.png",{"impactFactor":36,"impactFactorByYear":529,"i10Index":162,"i10IndexLast5Year":115,"totalPublication":530,"totalPublicationByYear":531,"totalCitation":537,"totalCitationByYear":538,"totalCitationPerPublication":343,"totalCitationPerPublicationByYear":540,"hindexLast5Year":135,"hindex":135},{"2016":341,"2017":39,"2018":229,"2019":38,"2020":110,"2021":231,"2022":231,"2023":341,"2024":39},764,{"2015":255,"2016":245,"2017":532,"2018":259,"2019":533,"2020":534,"2021":535,"2022":536,"2023":534,"2024":254,"2025":50},111,106,68,92,89,265,{"2015":539,"2016":241,"2017":168,"2018":51,"2019":349,"2020":260,"2021":244,"2022":298,"2023":114},46,{"2015":541,"2016":523,"2017":524,"2018":290,"2019":542,"2020":522,"2021":523,"2022":57,"2023":39},1.48,0.63,{"id":544,"createTime":545,"updateTime":546,"relativeEntities":547,"slug":548,"properties":549,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":558,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":50,"subjectFields":559,"manageAffiliations":560,"indexDatabases":561,"url":562,"thumbnailPath":563,"statistic":564,"gsStatistic":26,"type":26,"analyzePriority":26},"6ec01bd0-15c0-469a-86ac-41339076ae0a","2023-08-10T07:08:33.153+00:00","2026-01-31T21:19:06.362+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Da-li%E1%BB%85u-h%E1%BB%8Dc-Vi%E1%BB%87t-Nam",{"country":550,"issn":551,"introduce":553,"title":555},{"VOID":15},{"VOID":552},"18594824",{"VI":554},"{\"ops\":[{\"insert\":\"Tạp chí “Da liễu học Việt Nam” (Tiếng Anh: Vietnamese Journal of Dermatology and Venereology) thuộc Hội Da liễu Việt Nam, xuất bản 4 số mỗi năm bằng tiếng Việt hoặc tiếng Anh.\\nTạp chí Da liễu học Việt Nam hoạt động với mục đích, tôn chỉ là phổ biến, trao đổi thông tin trong lĩnh vực chuyên ngành da liễu; đăng tải các công trình nghiên cứu khoa học; chuyển giao công nghệ - kinh tế và khoa học kỹ thuật liên quan đến lĩnh vực da liễu.\\nPhạm vi của tạp chí là tất cả các bài báo khoa học, bài tổng quan, giới thiệu ca lâm sàng, … có liên quan tới chuyên ngành da liễu trong và ngoài nước. Tạp chí công bố các công trình nghiên cứu liên quan đến mô hình bệnh tật, các phương pháp chẩn đoán, điều trị, dự phòng và phục hồi chức năng các bệnh thuộc chuyên ngành da liễu. Ngoài ra, tạp chí còn đăng tải các bài tổng quan, cập nhật thông tin, kiến thức, hướng dẫn chẩn đoán, điều trị trong chuyên ngành da liễu trong nước và quốc tế; đăng tải các bài ca lâm sàng đặc biệt trong chuyên ngành da liễu.\\nTạp chí Da liễu học Việt Nam được biết tới là một tạp chí chuyên ngành có uy tín trong lĩnh vực da liễu. Các bài báo về nghiên cứu khoa học đăng trong Tạp chí được bình duyệt một cách nghiêm ngặt bởi ít nhất 2 chuyên gia. Hội đồng biên tập tạp chí bao gồm các nhà khoa học có uy tín (Giáo sư, Phó Giáo sư, Tiến sĩ, Bác sĩ…) trong chuyên ngành da liễu nhằm đảm bảo chất lượng và tính khách quan, khoa học cho các bài viết đăng trên Tạp chí.\\n\"}]}",{"EN":556,"VI":557},"Vietnamese Journal of Dermatology and Venereology","Tạp chí Da liễu học Việt Nam","Admin Import",[],[],[],"https:\u002F\u002Fvjdv.vn\u002Findex.php\u002Fvjdv","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F6ec01bd0-15c0-469a-86ac-41339076ae0a\u002F3cbc81720e58429dc7b1c4d7ab1935ca.jpg",{"impactFactor":36,"impactFactorByYear":565,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":566,"totalPublicationByYear":567,"totalCitation":116,"totalCitationByYear":570,"totalCitationPerPublication":109,"totalCitationPerPublicationByYear":571,"hindexLast5Year":115,"hindex":115},{"2023":38,"2024":230},182,{"2022":568,"2023":45,"2024":569},69,56,{"2022":52,"2023":115},{"2022":40,"2023":229},{"id":573,"createTime":574,"updateTime":575,"relativeEntities":576,"slug":577,"properties":578,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":27,"syncStatus":28,"languages":587,"translateLanguages":26,"viewCount":283,"subjectFields":588,"manageAffiliations":589,"indexDatabases":647,"url":648,"thumbnailPath":649,"statistic":650,"gsStatistic":26,"type":26,"analyzePriority":26},"19221551-7519-47ff-a892-331d1139c64b","2023-09-12T07:03:05.744+00:00","2026-01-24T20:54:40.144+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Khoa-h%E1%BB%8Dc-S%E1%BB%A9c-kho%E1%BA%BB-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Qu%E1%BB%91c-gia-Th%C3%A0nh-ph%E1%BB%91-H%E1%BB%93-Ch%C3%AD-Minh",{"country":579,"issn":580,"introduce":582,"title":584},{"VOID":15},{"VOID":581},"27349446",{"EN":583},"{\"ops\":[{\"attributes\":{\"bold\":true},\"insert\":\"1. History\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Science and Technology Development Journal\"},{\"insert\":\" (STDJ) (ISSN 2734-9446), Vietnam National University - Ho Chi Minh City (VNU-HCM) was established in 1997. And the first issue was published in January 1998 with ISSN 1859-0128. Since then, STDJ has become the most important scientific forum of scientists from VNU-HCM as well as other universities. The magazine has undergone 20 years of development and has become a bridge for scientific exchanges, as well as enriching reference materials for the faculty, doctoral students, students of VNU-HCM in particular and other universities, institutes...\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Science and Technology Development Journal - Health Sciences (STDJ-HS) is a subjournal of Science and Technology Development Journal since 2020.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\" \"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"2. Focus and Scope\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Publishing articles with contents on healthcare, research projects in the field of health, advanced directions in health education and management. Therefore, STDJ-HS will accept articles from doctors, administrators, teachers, researchers, graduate students and fellows. The authors will be responsible for the accuracy of the data, opinions, opinions and material cited in the article.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Facilitating the exchange of scientific and technological information and act as a bridge between theory and practice in the community of educators, scientists, managers, policy makers and enterprises in and out of the country.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}",{"EN":585,"VI":586},"VNUHCM JOURNAL OF HEALTH SCIENCES","Tạp chí Khoa học Sức khoẻ Đại học Quốc gia Thành phố Hồ Chí Minh",[101,102],[],[590],{"id":591,"createTime":592,"updateTime":593,"relativeEntities":594,"slug":595,"properties":596,"entityType":98,"verifyStatus":25,"verifyTime":606,"verifyNote":26,"syncStatus":28,"languages":607,"translateLanguages":26,"viewCount":608,"url":609,"parentIds":610,"statistic":611},"fc4c2560-868c-4677-acb1-8686bef88727","2023-06-26T04:48:23.774+00:00","2026-06-19T01:46:17.248+00:00",[],"%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Qu%E1%BB%91c-gia-Th%C3%A0nh-ph%E1%BB%91-H%E1%BB%93-Ch%C3%AD-Minh",{"country":597,"title":598,"abbreviation":601,"address":603},{"VOID":15},{"EN":599,"VI":600},"Vietnam National University Ho Chi Minh City","Đại học Quốc gia Thành phố Hồ Chí Minh",{"VOID":602},"VNUHCM",{"VI":604,"EN":605},"khu phố 6, Phường Linh Trung, Thành phố Thủ Đức, Thành phố Hồ Chí Minh, Việt Nam","Quarter 6, Linh Trung Ward, Thu Duc City, Ho Chi Minh City, Vietnam","2023-08-16T14:13:07.134+00:00",[101,102],45,"https:\u002F\u002Fvnuhcm.edu.vn\u002F",[],{"impactFactor":36,"impactFactorByYear":612,"i10Index":285,"i10IndexLast5Year":51,"totalPublication":613,"totalPublicationByYear":614,"totalCitation":624,"totalCitationByYear":625,"totalCitationPerPublication":634,"totalCitationPerPublicationByYear":635,"hindexLast5Year":124,"hindex":124},{"2014":36,"2015":38,"2016":109,"2017":39,"2018":229,"2019":38,"2020":110,"2021":171,"2022":110,"2023":110,"2024":171,"2025":229},3708,{"2005":115,"2006":115,"2007":115,"2008":135,"2009":111,"2010":53,"2011":52,"2012":568,"2013":615,"2014":351,"2015":616,"2016":469,"2017":617,"2018":127,"2019":618,"2020":619,"2021":620,"2022":621,"2023":622,"2024":623,"2025":159,"2026":50},164,266,177,226,603,931,314,246,74,2399,{"2006":115,"2008":50,"2010":162,"2011":242,"2012":222,"2013":43,"2014":626,"2015":627,"2016":628,"2017":629,"2018":258,"2019":630,"2020":631,"2021":632,"2022":633,"2023":353,"2024":115},250,124,157,162,152,385,559,128,0.65,{"2006":115,"2008":636,"2010":637,"2011":638,"2012":639,"2013":522,"2014":640,"2015":641,"2016":642,"2017":643,"2018":644,"2019":642,"2020":645,"2021":292,"2022":646,"2023":522,"2024":38},1.33,0.45,2.22,0.39,1.35,0.47,0.67,0.92,0.73,0.64,0.41,[],"http:\u002F\u002Fstdjhs.scienceandtechnology.com.vn\u002Findex.php\u002Fstdjhs","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F19221551-7519-47ff-a892-331d1139c64b\u002F2e10768b7d1e380c36a25ed0c714dd7e.png",{"impactFactor":36,"impactFactorByYear":651,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":652,"totalPublicationByYear":653,"totalCitation":516,"totalCitationByYear":654,"totalCitationPerPublication":151,"totalCitationPerPublicationByYear":655,"hindexLast5Year":59,"hindex":59},{"2022":57,"2023":108,"2024":39},79,{"2020":116,"2021":240,"2022":239,"2023":52,"2024":162,"2025":162},{"2020":59,"2021":51,"2022":59},{"2020":443,"2021":387,"2022":54},{"code":657,"data":658,"meta":26},"SUCCESS",{"id":659,"createTime":660,"updateTime":661,"relativeEntities":662,"slug":663,"properties":664,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":669,"manageAffiliations":678,"indexDatabases":688,"url":26,"thumbnailPath":26,"statistic":26,"gsStatistic":26,"type":26,"analyzePriority":26},"13653e74-411b-456e-811a-faec20bddea2","2023-12-05T06:18:35.203+00:00","2025-11-21T09:55:00.778+00:00",[],"Journal-of-Hepatology",{"issn":665,"title":667},{"VOID":666},"01688278",{"EN":668},"Journal of Hepatology",[670],{"id":671,"createTime":672,"updateTime":673,"relativeEntities":674,"label":675,"description":677,"parentId":26,"standard":26,"scholarHubFieldId":26},"01203b2d-e9ba-432d-a4b0-d0f3ced5dfa6","2023-05-29T10:24:07.274+00:00","2023-11-21T07:04:43.214+00:00",[],{"EN":676},"Hepatology",{},[679],{"id":680,"createTime":681,"updateTime":682,"relativeEntities":683,"slug":684,"properties":685,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":53,"url":26,"parentIds":687,"statistic":26},"c749757b-dddf-4e6f-9697-b9c441adc06c","2023-05-29T10:24:07.401+00:00","2025-11-21T10:06:14.206+00:00",[],"Elsevier",{"title":686},{"EN":684},[],[689,708],{"id":690,"indexDatabase":691,"url":705,"indexYears":26,"academicFieldIds":706,"indexDatabaseRanking":26},"a88f2708-4311-4f37-b214-37e8f36e8387",{"id":692,"createTime":693,"updateTime":694,"relativeEntities":695,"label":696,"description":698,"key":701,"publicationTags":702,"standard":26},"a4921856-b128-4d9f-8f1f-e80813d3bbd4","2023-05-22T09:59:31.026+00:00","2025-11-21T10:07:52.153+00:00",[],{"EN":697,"VI":697},"ISI\u002FSCIE - Science Citation Index Expanded",{"VI":699,"EN":700},"Cơ sở dữ liệu SCIE","SCIE database","scie",[703,704],"SCIE","ISI","https:\u002F\u002Fmjl.clarivate.com\u002Fsearch-results?issn=0168-8278",[707],"4b2c1694-c69d-4b20-b2eb-9687848dfb30",{"id":709,"indexDatabase":710,"url":722,"indexYears":723,"academicFieldIds":724,"indexDatabaseRanking":726},"d3317b6a-9aa5-40ad-9c0e-4183a5c0625e",{"id":711,"createTime":712,"updateTime":713,"relativeEntities":714,"label":715,"description":717,"key":719,"publicationTags":720,"standard":26},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9","2023-05-22T09:57:18.509+00:00","2025-11-21T10:07:52.274+00:00",[],{"EN":716,"VI":716},"Scopus - Elsevier",{"EN":716,"VI":718},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[721],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F25297","1985-2025",[725],"34ca0c58-3b99-4064-9bf3-a754a6e2e9a7","SCOPUS__Q1",{"meta":728,"data":730},{"total":729},"4490",[731,3454,4719,5366,6424,6570,7530,7649,8481,8949],{"id":732,"createTime":733,"updateTime":733,"relativeEntities":734,"slug":735,"properties":736,"entityType":749,"verifyStatus":25,"verifyTime":733,"verifyNote":750,"syncStatus":28,"languages":751,"translateLanguages":26,"viewCount":36,"primaryUrl":752,"fullTextUrl":26,"authors":753,"publicationType":895,"publisherRelationship":896,"citationCount":926,"citationInfo":927,"publishDate":941,"publishYear":942,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":943,"isForceReanalyzing":3453},"79ab8769-4ab5-4638-8ebb-1916a6b96677","2024-10-14T07:36:36.423+00:00",[],"EASL-Clinical-Practice-Guidelines-Management-of-hepatocellular-carcinoma",{"mag":737,"keywords":739,"openalex":740,"abstract":742,"title":743,"pm":745,"doi":747},{"VOID":738},"2277004004",{},{"VOID":741},"W2277004004",{},{"EN":744},"EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma",{"VOID":746},"29628281",{"VOID":748},"10.1016\u002Fj.jhep.2018.03.019","PUBLICATION","Auto Verify",[102],"https:\u002F\u002Flinkinghub.elsevier.com\u002Fretrieve\u002Fpii\u002FS0168827818302150",[754,776,793,810,827,844,861,878],{"id":755,"sortIndex":158,"researcher":26,"roles":756,"affiliations":757,"properties":769},"c4b1f7d7-a707-4e95-9789-20a4efa174f1",[],[758],{"id":759,"sortIndex":36,"affiliation":760,"properties":26},"540dcdb3-0203-47cd-87c0-142c195e9623",{"id":761,"createTime":762,"updateTime":763,"relativeEntities":764,"slug":765,"properties":766,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"0b58ee48-f8e4-4041-a13f-b1cf40f9ad87","2024-10-14T07:36:36.447+00:00","2025-06-12T00:13:38.888+00:00",[],"European-Association-for-the-Study-of-the-Liver-EASL-The-EASL-Building-Home-of-Hepatology-7-rue-Daubin-CH-1203-Geneva-Switzerland-",{"title":767},{"EN":768},"European Association for the Study of the Liver (EASL), The EASL Building -Home of Hepatology, 7 rue Daubin, CH 1203 Geneva, Switzerland.",{"openalex":770,"orcid":772,"title":774},{"VOID":771},"A5003233395",{"VOID":773},"https:\u002F\u002Forcid.org\u002F0000-0002-3568-7725",{"EN":775},"Valérie Vilgrain",{"id":777,"sortIndex":135,"researcher":26,"roles":778,"affiliations":779,"properties":786},"a9a4a7e4-53c3-4968-b781-dccd57a9f5bd",[],[780],{"id":781,"sortIndex":36,"affiliation":782,"properties":26},"7fbfb16f-8484-4ee2-8a8f-d260e9dd1f26",{"id":761,"createTime":762,"updateTime":763,"relativeEntities":783,"slug":765,"properties":784,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":785},{"EN":768},{"openalex":787,"orcid":789,"title":791},{"VOID":788},"A5081978650",{"VOID":790},"https:\u002F\u002Forcid.org\u002F0000-0002-0950-3339",{"EN":792},"Peter Schirmacher",{"id":794,"sortIndex":59,"researcher":26,"roles":795,"affiliations":796,"properties":803},"8d270cfd-2ff0-4260-9b3c-705f6d34f777",[],[797],{"id":798,"sortIndex":36,"affiliation":799,"properties":26},"00ddaa29-0e97-42ae-9b02-c984c90a011f",{"id":761,"createTime":762,"updateTime":763,"relativeEntities":800,"slug":765,"properties":801,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":802},{"EN":768},{"openalex":804,"orcid":806,"title":808},{"VOID":805},"A5064470324",{"VOID":807},"https:\u002F\u002Forcid.org\u002F0000-0002-4013-8085",{"EN":809},"Vincenzo Mazzaferro",{"id":811,"sortIndex":111,"researcher":26,"roles":812,"affiliations":813,"properties":820},"8bb736fa-fb37-463b-81a9-b26a2b63bca3",[],[814],{"id":815,"sortIndex":36,"affiliation":816,"properties":26},"85948082-c300-40c6-97b6-37694422d383",{"id":761,"createTime":762,"updateTime":763,"relativeEntities":817,"slug":765,"properties":818,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":819},{"EN":768},{"openalex":821,"orcid":823,"title":825},{"VOID":822},"A5032593836",{"VOID":824},"https:\u002F\u002Forcid.org\u002F0000-0001-8264-1845",{"EN":826},"Fabio Piscaglia",{"id":828,"sortIndex":114,"researcher":26,"roles":829,"affiliations":830,"properties":837},"100416fd-989c-4099-bb91-bc39795ca3d6",[],[831],{"id":832,"sortIndex":36,"affiliation":833,"properties":26},"e8efd166-3aee-413c-8a0e-b3bb69d07088",{"id":761,"createTime":762,"updateTime":763,"relativeEntities":834,"slug":765,"properties":835,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":836},{"EN":768},{"openalex":838,"orcid":840,"title":842},{"VOID":839},"A5052975894",{"VOID":841},"https:\u002F\u002Forcid.org\u002F0000-0003-0547-2667",{"EN":843},"Josep M. Llovet",{"id":845,"sortIndex":162,"researcher":26,"roles":846,"affiliations":847,"properties":854},"fc63181b-898e-4b4d-9ecb-0c20bf160a79",[],[848],{"id":849,"sortIndex":36,"affiliation":850,"properties":26},"9a1fa35d-a107-4b6c-861f-31dcb6b597f2",{"id":761,"createTime":762,"updateTime":763,"relativeEntities":851,"slug":765,"properties":852,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":853},{"EN":768},{"openalex":855,"orcid":857,"title":859},{"VOID":856},"A5079660535",{"VOID":858},"https:\u002F\u002Forcid.org\u002F0000-0001-6305-8953",{"EN":860},"Jean‐Luc Raoul",{"id":862,"sortIndex":115,"researcher":26,"roles":863,"affiliations":864,"properties":871},"fbe70a41-5861-4ec0-bfc6-3438ef103164",[],[865],{"id":866,"sortIndex":36,"affiliation":867,"properties":26},"3719c75a-3727-4bf9-aedd-815a054efb13",{"id":761,"createTime":762,"updateTime":763,"relativeEntities":868,"slug":765,"properties":869,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":870},{"EN":768},{"openalex":872,"orcid":874,"title":876},{"VOID":873},"A5067464504",{"VOID":875},"https:\u002F\u002Forcid.org\u002F0000-0002-9014-4950",{"EN":877},"Alejandro Forner",{"id":879,"sortIndex":36,"researcher":26,"roles":880,"affiliations":881,"properties":888},"33ca0b7b-dedf-4eee-bab1-4b14a4ad7422",[],[882],{"id":883,"sortIndex":36,"affiliation":884,"properties":26},"300446d7-435a-4145-8252-8d3ecfaf0ac8",{"id":761,"createTime":762,"updateTime":763,"relativeEntities":885,"slug":765,"properties":886,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":887},{"EN":768},{"openalex":889,"orcid":891,"title":893},{"VOID":890},"A5069151214",{"VOID":892},"https:\u002F\u002Forcid.org\u002F0000-0001-8294-0992",{"EN":894},"Peter R. Galle","ARTICLE",{"url":26,"publisher":897,"properties":919},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":898,"slug":663,"properties":899,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":902,"manageAffiliations":903,"indexDatabases":904,"url":26,"thumbnailPath":26,"statistic":26,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"issn":900,"title":901},{"VOID":666},{"EN":668},[],[],[905,912],{"id":690,"indexDatabase":906,"url":705,"indexYears":26,"academicFieldIds":911,"indexDatabaseRanking":26},{"id":692,"createTime":693,"updateTime":694,"relativeEntities":907,"label":908,"description":909,"key":701,"publicationTags":910,"standard":26},[],{"EN":697,"VI":697},{"VI":699,"EN":700},[703,704],[707],{"id":709,"indexDatabase":913,"url":722,"indexYears":723,"academicFieldIds":918,"indexDatabaseRanking":726},{"id":711,"createTime":712,"updateTime":713,"relativeEntities":914,"label":915,"description":916,"key":719,"publicationTags":917,"standard":26},[],{"EN":716,"VI":716},{"EN":716,"VI":718},[721],[725],{"volume":920,"pages":922,"issue":924},{"VOID":921},"69",{"VOID":923},"182-236",{"VOID":925},"1",9503,{"total":926,"publishYear":26,"statisticByYear":928},{"2012":608,"2013":929,"2014":930,"2015":931,"2016":932,"2017":933,"2018":934,"2019":935,"2020":936,"2021":937,"2022":938,"2023":939,"2024":940},195,310,361,354,443,521,865,1305,1470,1396,1333,877,"2018-07-01",2018,[944,948,952,956,960,964,968,972,975,979,983,987,991,995,998,1002,1006,1010,1014,1018,1022,1026,1030,1034,1038,1042,1046,1050,1054,1058,1062,1066,1070,1074,1078,1082,1086,1090,1094,1098,1102,1106,1110,1114,1118,1122,1126,1130,1134,1138,1142,1146,1150,1154,1157,1160,1163,1167,1171,1175,1179,1183,1187,1191,1195,1199,1203,1207,1211,1214,1218,1222,1226,1230,1234,1238,1242,1246,1250,1254,1258,1262,1266,1269,1273,1277,1281,1285,1288,1292,1296,1300,1304,1308,1312,1316,1320,1324,1328,1332,1336,1340,1344,1348,1352,1356,1360,1364,1368,1372,1376,1380,1384,1388,1392,1396,1400,1404,1408,1412,1416,1420,1424,1428,1432,1436,1440,1444,1448,1452,1456,1460,1464,1468,1472,1476,1480,1484,1488,1492,1496,1500,1504,1508,1512,1516,1519,1523,1527,1531,1535,1539,1543,1547,1551,1555,1559,1563,1567,1571,1575,1579,1583,1587,1591,1595,1599,1603,1607,1611,1615,1619,1623,1627,1631,1635,1639,1643,1647,1651,1655,1659,1663,1667,1671,1675,1679,1683,1687,1691,1695,1699,1703,1707,1711,1715,1719,1723,1727,1731,1733,1737,1741,1745,1749,1753,1757,1761,1765,1769,1773,1777,1780,1784,1788,1792,1796,1800,1804,1808,1811,1815,1819,1823,1827,1831,1835,1839,1842,1846,1850,1853,1857,1861,1865,1868,1872,1876,1880,1884,1888,1892,1896,1900,1904,1908,1912,1916,1920,1924,1928,1932,1936,1940,1944,1948,1952,1956,1960,1964,1968,1972,1976,1980,1984,1988,1992,1996,2000,2004,2008,2012,2016,2020,2024,2028,2032,2036,2040,2044,2048,2052,2056,2060,2064,2068,2072,2076,2080,2084,2088,2092,2096,2100,2104,2108,2112,2116,2120,2124,2128,2132,2136,2140,2144,2148,2152,2156,2160,2164,2168,2172,2176,2180,2184,2188,2191,2195,2199,2203,2207,2211,2215,2219,2223,2227,2231,2235,2239,2243,2247,2251,2255,2258,2262,2266,2270,2274,2278,2282,2286,2290,2294,2298,2302,2306,2310,2314,2318,2321,2325,2329,2333,2337,2341,2345,2349,2353,2357,2361,2365,2369,2373,2377,2381,2385,2389,2393,2397,2400,2404,2407,2411,2415,2419,2423,2427,2431,2435,2439,2443,2447,2451,2455,2459,2463,2467,2471,2475,2479,2483,2487,2491,2495,2499,2503,2507,2511,2515,2519,2523,2527,2531,2535,2539,2543,2547,2551,2555,2559,2563,2567,2571,2575,2579,2583,2587,2591,2595,2599,2603,2607,2611,2615,2618,2622,2626,2630,2634,2638,2642,2646,2650,2654,2658,2662,2666,2670,2674,2678,2682,2686,2690,2694,2698,2701,2705,2709,2713,2717,2721,2725,2729,2733,2737,2741,2745,2749,2753,2757,2760,2764,2768,2772,2776,2780,2784,2788,2791,2795,2799,2803,2807,2811,2815,2819,2823,2827,2831,2835,2839,2843,2847,2851,2855,2859,2863,2867,2871,2875,2879,2883,2887,2891,2895,2899,2903,2907,2911,2915,2919,2923,2927,2931,2935,2939,2942,2946,2950,2954,2958,2962,2966,2970,2974,2978,2982,2986,2990,2993,2997,3001,3005,3008,3012,3016,3020,3024,3028,3032,3036,3040,3044,3048,3052,3056,3060,3064,3068,3072,3076,3080,3084,3088,3092,3096,3100,3104,3108,3112,3115,3119,3123,3127,3131,3135,3138,3141,3145,3149,3153,3157,3161,3165,3169,3172,3176,3180,3184,3188,3192,3196,3200,3204,3208,3212,3216,3220,3224,3228,3232,3236,3240,3244,3248,3252,3256,3260,3264,3268,3272,3276,3280,3284,3288,3292,3296,3300,3304,3308,3312,3316,3320,3324,3328,3331,3335,3339,3343,3347,3351,3355,3359,3363,3367,3371,3375,3379,3383,3386,3390,3394,3398,3402,3405,3409,3413,3417,3421,3425,3429,3433,3437,3441,3445,3449],{"id":26,"text":945,"url":26,"identifiers":946},"2012, EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma, J Hepatol, 56, 908, 10.1016\u002Fj.jhep.2011.12.001",{"doi":947},"10.1016\u002Fj.jhep.2011.12.001",{"id":26,"text":949,"url":26,"identifiers":950},"Guyatt, 2008, GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ, 336, 924, 10.1136\u002Fbmj.39489.470347.AD",{"doi":951},"10.1136\u002Fbmj.39489.470347.AD",{"id":26,"text":953,"url":26,"identifiers":954},"Akinyemiju, 2017, The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level, JAMA Oncol, 3, 1683, 10.1001\u002Fjamaoncol.2017.3055",{"doi":955},"10.1001\u002Fjamaoncol.2017.3055",{"id":26,"text":957,"url":26,"identifiers":958},"El-Serag, 2012, Epidemiology of viral hepatitis and hepatocellular carcinoma, Gastroenterology, 142, 1264, 10.1053\u002Fj.gastro.2011.12.061",{"doi":959},"10.1053\u002Fj.gastro.2011.12.061",{"id":26,"text":961,"url":26,"identifiers":962},"White, 2017, Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012, Gastroenterology, 152, 812, 10.1053\u002Fj.gastro.2016.11.020",{"doi":963},"10.1053\u002Fj.gastro.2016.11.020",{"id":26,"text":965,"url":26,"identifiers":966},"Tanaka, 2008, Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003, Ann Intern Med, 148, 820, 10.7326\u002F0003-4819-148-11-200806030-00004",{"doi":967},"10.7326\u002F0003-4819-148-11-200806030-00004",{"id":26,"text":969,"url":26,"identifiers":970},"Qiu, 2009, A Joinpoint regression analysis of long-term trends in cancer mortality in Japan (1958–2004), Int J Cancer, 124, 443, 10.1002\u002Fijc.23911",{"doi":971},"10.1002\u002Fijc.23911",{"id":26,"text":973,"url":26,"identifiers":974},"Fact Sheets by Population-Globocan-IARC n.d. http:\u002F\u002Fglobocan.iarc.fr\u002FPages\u002Ffact_sheets_population.aspx (accessed December 18, 2017)",{},{"id":26,"text":976,"url":26,"identifiers":977},"Bosetti, 2008, Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004, Hepatology, 48, 137, 10.1002\u002Fhep.22312",{"doi":978},"10.1002\u002Fhep.22312",{"id":26,"text":980,"url":26,"identifiers":981},"Jemal, 2010, Cancer statistics, 2010, CA Cancer J Clin, 60, 277, 10.3322\u002Fcaac.20073",{"doi":982},"10.3322\u002Fcaac.20073",{"id":26,"text":984,"url":26,"identifiers":985},"Welzel, 2013, Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States, Am J Gastroenterol, 108, 1314, 10.1038\u002Fajg.2013.160",{"doi":986},"10.1038\u002Fajg.2013.160",{"id":26,"text":988,"url":26,"identifiers":989},"El-Serag, 2014, Epidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go?, Hepatology, 60, 1767, 10.1002\u002Fhep.27222",{"doi":990},"10.1002\u002Fhep.27222",{"id":26,"text":992,"url":26,"identifiers":993},"Chang, 2009, Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study, J Natl Cancer Inst, 101, 1348, 10.1093\u002Fjnci\u002Fdjp288",{"doi":994},"10.1093\u002Fjnci\u002Fdjp288",{"id":26,"text":996,"url":26,"identifiers":997},"Chang, 2016, Long-term effects of hepatitis B immunization of infants in preventing liver cancer, Gastroenterology, 21",{},{"id":26,"text":999,"url":26,"identifiers":1000},"Sangiovanni, 2006, The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients, Hepatology, 43, 1303, 10.1002\u002Fhep.21176",{"doi":1001},"10.1002\u002Fhep.21176",{"id":26,"text":1003,"url":26,"identifiers":1004},"Ioannou, 2007, Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis, Clin Gastroenterol Hepatol, 5, 938, 10.1016\u002Fj.cgh.2007.02.039",{"doi":1005},"10.1016\u002Fj.cgh.2007.02.039",{"id":26,"text":1007,"url":26,"identifiers":1008},"Lok, 2009, Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease, Gastroenterology, 136, 138, 10.1053\u002Fj.gastro.2008.09.014",{"doi":1009},"10.1053\u002Fj.gastro.2008.09.014",{"id":26,"text":1011,"url":26,"identifiers":1012},"Ripoll, 2009, Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis, J Hepatol, 50, 923, 10.1016\u002Fj.jhep.2009.01.014",{"doi":1013},"10.1016\u002Fj.jhep.2009.01.014",{"id":26,"text":1015,"url":26,"identifiers":1016},"Masuzaki, 2008, Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography, J Clin Gastroenterol, 42, 839, 10.1097\u002FMCG.0b013e318050074f",{"doi":1017},"10.1097\u002FMCG.0b013e318050074f",{"id":26,"text":1019,"url":26,"identifiers":1020},"Masuzaki, 2009, Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography, Hepatology, 49, 1954, 10.1002\u002Fhep.22870",{"doi":1021},"10.1002\u002Fhep.22870",{"id":26,"text":1023,"url":26,"identifiers":1024},"Jung, 2011, Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan), Hepatology, 53, 885, 10.1002\u002Fhep.24121",{"doi":1025},"10.1002\u002Fhep.24121",{"id":26,"text":1027,"url":26,"identifiers":1028},"Singh S, Fujii LL, Murad MH, Wang Z, Asrani SK, Ehman RL, et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013;11:1573–84-2-9.",{"doi":1029},"10.1016\u002Fj.cgh.2013.07.034",{"id":26,"text":1031,"url":26,"identifiers":1032},"Wong GL-H, Chan HL-Y, Wong CK-Y, Leung C, Chan CY, Ho PP-L, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol 2014;60:339–45.",{"doi":1033},"10.1016\u002Fj.jhep.2013.09.029",{"id":26,"text":1035,"url":26,"identifiers":1036},"Kim, 2015, Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis, Hepatology, 61, 1851, 10.1002\u002Fhep.27735",{"doi":1037},"10.1002\u002Fhep.27735",{"id":26,"text":1039,"url":26,"identifiers":1040},"Yang, 2002, Hepatitis B e antigen and the risk of hepatocellular carcinoma, N Engl J Med, 347, 168, 10.1056\u002FNEJMoa013215",{"doi":1041},"10.1056\u002FNEJMoa013215",{"id":26,"text":1043,"url":26,"identifiers":1044},"Chen, 2006, Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level, JAMA, 295, 65, 10.1001\u002Fjama.295.1.65",{"doi":1045},"10.1001\u002Fjama.295.1.65",{"id":26,"text":1047,"url":26,"identifiers":1048},"Yu, 2005, Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men, J Natl Cancer Inst, 97, 265, 10.1093\u002Fjnci\u002Fdji043",{"doi":1049},"10.1093\u002Fjnci\u002Fdji043",{"id":26,"text":1051,"url":26,"identifiers":1052},"Iloeje, 2006, Predicting cirrhosis risk based on the level of circulating hepatitis B viral load, Gastroenterology, 130, 678, 10.1053\u002Fj.gastro.2005.11.016",{"doi":1053},"10.1053\u002Fj.gastro.2005.11.016",{"id":26,"text":1055,"url":26,"identifiers":1056},"Raimondi, 2009, Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: A meta-analysis, J Hepatol, 50, 1142, 10.1016\u002Fj.jhep.2009.01.019",{"doi":1057},"10.1016\u002Fj.jhep.2009.01.019",{"id":26,"text":1059,"url":26,"identifiers":1060},"Kanwal, 2014, HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV, Hepatology, 60, 98, 10.1002\u002Fhep.27095",{"doi":1061},"10.1002\u002Fhep.27095",{"id":26,"text":1063,"url":26,"identifiers":1064},"Hsu, 1991, Mutational hotspot in the p53 gene in human hepatocellular carcinomas, Nature, 350, 427, 10.1038\u002F350427a0",{"doi":1065},"10.1038\u002F350427a0",{"id":26,"text":1067,"url":26,"identifiers":1068},"Nahon, 2009, Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis, Hepatology, 50, 1484, 10.1002\u002Fhep.23187",{"doi":1069},"10.1002\u002Fhep.23187",{"id":26,"text":1071,"url":26,"identifiers":1072},"Mancebo, 2012, Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups, Clin Gastroenterol Hepatol, 11, 95, 10.1016\u002Fj.cgh.2012.09.007",{"doi":1073},"10.1016\u002Fj.cgh.2012.09.007",{"id":26,"text":1075,"url":26,"identifiers":1076},"Deugnier, 1993, Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases, Gastroenterology, 104, 228, 10.1016\u002F0016-5085(93)90856-8",{"doi":1077},"10.1016\u002F0016-5085(93)90856-8",{"id":26,"text":1079,"url":26,"identifiers":1080},"Fracanzani, 2001, Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease, Hepatology, 33, 647, 10.1053\u002Fjhep.2001.22506",{"doi":1081},"10.1053\u002Fjhep.2001.22506",{"id":26,"text":1083,"url":26,"identifiers":1084},"Andant, 2000, Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors, J Hepatol, 32, 933, 10.1016\u002FS0168-8278(00)80097-5",{"doi":1085},"10.1016\u002FS0168-8278(00)80097-5",{"id":26,"text":1087,"url":26,"identifiers":1088},"Fracanzani, 2001, Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease, J Hepatol, 498, 10.1016\u002FS0168-8278(01)00160-X",{"doi":1089},"10.1016\u002FS0168-8278(01)00160-X",{"id":26,"text":1091,"url":26,"identifiers":1092},"Perlmutter, 2006, Pathogenesis of chronic liver injury and hepatocellular carcinoma in alpha-1-antitrypsin deficiency, Pediatr Res, 60, 233, 10.1203\u002F01.pdr.0000228350.61496.90",{"doi":1093},"10.1203\u002F01.pdr.0000228350.61496.90",{"id":26,"text":1095,"url":26,"identifiers":1096},"Schlesinger, 2013, Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort, Ann Oncol, 24, 2449, 10.1093\u002Fannonc\u002Fmdt204",{"doi":1097},"10.1093\u002Fannonc\u002Fmdt204",{"id":26,"text":1099,"url":26,"identifiers":1100},"Tsilidis, 2015, Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies, BMJ, 350, g7607, 10.1136\u002Fbmj.g7607",{"doi":1101},"10.1136\u002Fbmj.g7607",{"id":26,"text":1103,"url":26,"identifiers":1104},"Calle, 2003, Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults, N Engl J Med, 348, 1625, 10.1056\u002FNEJMoa021423",{"doi":1105},"10.1056\u002FNEJMoa021423",{"id":26,"text":1107,"url":26,"identifiers":1108},"Chen, 2008, Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B\u002FC infection: a follow-up study in Taiwan, Gastroenterology, 135, 111, 10.1053\u002Fj.gastro.2008.03.073",{"doi":1109},"10.1053\u002Fj.gastro.2008.03.073",{"id":26,"text":1111,"url":26,"identifiers":1112},"Yu, 2017, Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B: a large cohort study, Gastroenterology, 153, 1006, 10.1053\u002Fj.gastro.2017.07.001",{"doi":1113},"10.1053\u002Fj.gastro.2017.07.001",{"id":26,"text":1115,"url":26,"identifiers":1116},"Dyson, 2014, Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team, J Hepatol, 60, 110, 10.1016\u002Fj.jhep.2013.08.011",{"doi":1117},"10.1016\u002Fj.jhep.2013.08.011",{"id":26,"text":1119,"url":26,"identifiers":1120},"Kanwal F, Kramer JR, Duan Z, Yu X, White D, El-Serag HB. Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans. Clin Gastroenterol Hepatol 2016;14:301-8-2.",{"doi":1121},"10.1016\u002Fj.cgh.2015.08.010",{"id":26,"text":1123,"url":26,"identifiers":1124},"Younossi, 2015, Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009, Hepatology, 62, 1723, 10.1002\u002Fhep.28123",{"doi":1125},"10.1002\u002Fhep.28123",{"id":26,"text":1127,"url":26,"identifiers":1128},"Younossi, 2016, The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe, Hepatology, 64, 1577, 10.1002\u002Fhep.28785",{"doi":1129},"10.1002\u002Fhep.28785",{"id":26,"text":1131,"url":26,"identifiers":1132},"EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388–402.",{"doi":1133},"10.1016\u002Fj.jhep.2015.11.004",{"id":26,"text":1135,"url":26,"identifiers":1136},"Degasperi, 2016, Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease, Lancet Gastroenterol Hepatol, 1, 156, 10.1016\u002FS2468-1253(16)30018-8",{"doi":1137},"10.1016\u002FS2468-1253(16)30018-8",{"id":26,"text":1139,"url":26,"identifiers":1140},"Piscaglia, 2016, Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study, Hepatology, 63, 827, 10.1002\u002Fhep.28368",{"doi":1141},"10.1002\u002Fhep.28368",{"id":26,"text":1143,"url":26,"identifiers":1144},"Marrero, 2005, Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma, J Hepatol, 42, 218, 10.1016\u002Fj.jhep.2004.10.005",{"doi":1145},"10.1016\u002Fj.jhep.2004.10.005",{"id":26,"text":1147,"url":26,"identifiers":1148},"Trichopoulos, 2011, Hepatocellular carcinoma risk factors and disease burden in a european cohort: a nested case-control study, JNCI J Natl Cancer Inst, 103, 1686, 10.1093\u002Fjnci\u002Fdjr395",{"doi":1149},"10.1093\u002Fjnci\u002Fdjr395",{"id":26,"text":1151,"url":26,"identifiers":1152},"Ioannou, 2013, The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection, Hepatology, 57, 249, 10.1002\u002Fhep.25800",{"doi":1153},"10.1002\u002Fhep.25800",{"id":26,"text":1155,"url":26,"identifiers":1156},"Weekly epidemiological record Relevé épidémiologique hebdomadaire 2017;92:369–92.",{},{"id":26,"text":1158,"url":26,"identifiers":1159},"2017, EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection, J Hepatol, 2017, 370",{},{"id":26,"text":1161,"url":26,"identifiers":1162},"2018, European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018, J Hepatol",{},{"id":26,"text":1164,"url":26,"identifiers":1165},"Niederau, 1996, Long-term follow-up of HBeAg-positive patients treated with interferon Alfa for chronic hepatitis B, N Engl J Med, 334, 1422, 10.1056\u002FNEJM199605303342202",{"doi":1166},"10.1056\u002FNEJM199605303342202",{"id":26,"text":1168,"url":26,"identifiers":1169},"Papatheodoridis, 2015, Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy, J Hepatol, 62, 956, 10.1016\u002Fj.jhep.2015.01.002",{"doi":1170},"10.1016\u002Fj.jhep.2015.01.002",{"id":26,"text":1172,"url":26,"identifiers":1173},"Varbobitis, 2016, The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy, Clin Mol Hepatol, 22, 319, 10.3350\u002Fcmh.2016.0045",{"doi":1174},"10.3350\u002Fcmh.2016.0045",{"id":26,"text":1176,"url":26,"identifiers":1177},"Papatheodoridis, 2017, The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B, Hepatology, 66, 1444, 10.1002\u002Fhep.29320",{"doi":1178},"10.1002\u002Fhep.29320",{"id":26,"text":1180,"url":26,"identifiers":1181},"Su, 2016, Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients, Liver Int, 36, 1755, 10.1111\u002Fliv.13253",{"doi":1182},"10.1111\u002Fliv.13253",{"id":26,"text":1184,"url":26,"identifiers":1185},"van der Meer, 2012, Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis, JAMA, 308, 2584, 10.1001\u002Fjama.2012.144878",{"doi":1186},"10.1001\u002Fjama.2012.144878",{"id":26,"text":1188,"url":26,"identifiers":1189},"Morgan, 2013, Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies, Ann Intern Med, 158, 329, 10.7326\u002F0003-4819-158-5-201303050-00005",{"doi":1190},"10.7326\u002F0003-4819-158-5-201303050-00005",{"id":26,"text":1192,"url":26,"identifiers":1193},"Colombo, 2014, Role of antiviral treatment for HCC prevention, Best Pract Res Clin Gastroenterol, 28, 771, 10.1016\u002Fj.bpg.2014.07.017",{"doi":1194},"10.1016\u002Fj.bpg.2014.07.017",{"id":26,"text":1196,"url":26,"identifiers":1197},"D’Ambrosio, 2015, Hepatocellular carcinoma in patients with a sustained response to anti-hepatitis C therapy, Int J Mol Sci, 16, 19698, 10.3390\u002Fijms160819698",{"doi":1198},"10.3390\u002Fijms160819698",{"id":26,"text":1200,"url":26,"identifiers":1201},"2015, Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus, Hepatology, 62, 932, 10.1002\u002Fhep.27950",{"doi":1202},"10.1002\u002Fhep.27950",{"id":26,"text":1204,"url":26,"identifiers":1205},"Reig, 2016, Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy, J Hepatol, 65, 719, 10.1016\u002Fj.jhep.2016.04.008",{"doi":1206},"10.1016\u002Fj.jhep.2016.04.008",{"id":26,"text":1208,"url":26,"identifiers":1209},"Conti, 2016, Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals, J Hepatol, 65, 727, 10.1016\u002Fj.jhep.2016.06.015",{"doi":1210},"10.1016\u002Fj.jhep.2016.06.015",{"id":26,"text":1212,"url":26,"identifiers":1213},"Romano A, Capra F, Piovesan S, Chemello L, Cavalletto L, Anastassopoulos G, et al. Incidence and pattern of “de novo” hepatocellular carcinoma in HCV patients treated with oral DAAs. Hepatology 2016;64: Abstract 19.",{},{"id":26,"text":1215,"url":26,"identifiers":1216},"Foster, 2016, Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis, J Hepatol, 64, 1224, 10.1016\u002Fj.jhep.2016.01.029",{"doi":1217},"10.1016\u002Fj.jhep.2016.01.029",{"id":26,"text":1219,"url":26,"identifiers":1220},"Cheung, 2016, Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis, J Hepatol, 65, 741, 10.1016\u002Fj.jhep.2016.06.019",{"doi":1221},"10.1016\u002Fj.jhep.2016.06.019",{"id":26,"text":1223,"url":26,"identifiers":1224},"2016, Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts, J Hepatol, 65, 734, 10.1016\u002Fj.jhep.2016.05.045",{"doi":1225},"10.1016\u002Fj.jhep.2016.05.045",{"id":26,"text":1227,"url":26,"identifiers":1228},"Sugimoto, 2015, Comparison of daclatasvir and asunaprevir for chronic HCV 1b infection with telaprevir and simeprevir plus peginterferon and ribavirin, with a focus on the prevention of occurrence and recurrence of hepatocellular carcinoma, Oncology, 89, 42, 10.1159\u002F000440630",{"doi":1229},"10.1159\u002F000440630",{"id":26,"text":1231,"url":26,"identifiers":1232},"Kobayashi, 2017, Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection, J Med Virol, 89, 476, 10.1002\u002Fjmv.24663",{"doi":1233},"10.1002\u002Fjmv.24663",{"id":26,"text":1235,"url":26,"identifiers":1236},"Petta, 2017, Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon, Aliment Pharmacol Ther, 45, 160, 10.1111\u002Fapt.13821",{"doi":1237},"10.1111\u002Fapt.13821",{"id":26,"text":1239,"url":26,"identifiers":1240},"Cabibbo, 2017, Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study, Aliment Pharmacol Ther, 46, 688, 10.1111\u002Fapt.14256",{"doi":1241},"10.1111\u002Fapt.14256",{"id":26,"text":1243,"url":26,"identifiers":1244},"Waziry, 2017, Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression, J Hepatol, 67, 1204, 10.1016\u002Fj.jhep.2017.07.025",{"doi":1245},"10.1016\u002Fj.jhep.2017.07.025",{"id":26,"text":1247,"url":26,"identifiers":1248},"Kanwal, 2017, Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents, Gastroenterology, 153, 996, 10.1053\u002Fj.gastro.2017.06.012",{"doi":1249},"10.1053\u002Fj.gastro.2017.06.012",{"id":26,"text":1251,"url":26,"identifiers":1252},"Reig, 2017, Liver cancer emergence associated with antiviral treatment: an immune surveillance failure?, Semin Liver Dis, 37, 109, 10.1055\u002Fs-0037-1601349",{"doi":1253},"10.1055\u002Fs-0037-1601349",{"id":26,"text":1255,"url":26,"identifiers":1256},"Inoue, 2005, Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan, J Natl Cancer Inst, 97, 293, 10.1093\u002Fjnci\u002Fdji040",{"doi":1257},"10.1093\u002Fjnci\u002Fdji040",{"id":26,"text":1259,"url":26,"identifiers":1260},"Gelatti, 2005, Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study, J Hepatol, 42, 528, 10.1016\u002Fj.jhep.2004.11.039",{"doi":1261},"10.1016\u002Fj.jhep.2004.11.039",{"id":26,"text":1263,"url":26,"identifiers":1264},"Bravi, 2007, Coffee drinking and hepatocellular carcinoma risk: A meta-analysis, Hepatology, 46, 430, 10.1002\u002Fhep.21708",{"doi":1265},"10.1002\u002Fhep.21708",{"id":26,"text":1267,"url":26,"identifiers":1268},"Bravi, 2016, Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies, Eur J Cancer Prev",{},{"id":26,"text":1270,"url":26,"identifiers":1271},"Aleksandrova, 2015, The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition, Am J Clin Nutr, 102, 1498, 10.3945\u002Fajcn.115.116095",{"doi":1272},"10.3945\u002Fajcn.115.116095",{"id":26,"text":1274,"url":26,"identifiers":1275},"Setiawan VW, Wilkens LR, Lu SC, Hernandez BY, Le Marchand L, Henderson BE. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology 2015;148:118–25; quiz e15.",{"doi":1276},"10.1053\u002Fj.gastro.2014.10.005",{"id":26,"text":1278,"url":26,"identifiers":1279},"Prorok, 1992, Epidemiologic approach for cancer screening. Problems in design and analysis of trials, Am J Pediatr Hematol Oncol, 14, 117, 10.1097\u002F00043426-199205000-00005",{"doi":1280},"10.1097\u002F00043426-199205000-00005",{"id":26,"text":1282,"url":26,"identifiers":1283},"Forner, 2018, Hepatocellular carcinoma, Lancet, 10.1016\u002FS0140-6736(18)30010-2",{"doi":1284},"10.1016\u002FS0140-6736(18)30010-2",{"id":26,"text":1286,"url":26,"identifiers":1287},"Laupacis, 1992, How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations, CMAJ, 146, 473",{},{"id":26,"text":1289,"url":26,"identifiers":1290},"McCabe, 2008, The NICE cost-effectiveness threshold: what it is and what that means, Pharmacoeconomics, 26, 733, 10.2165\u002F00019053-200826090-00004",{"doi":1291},"10.2165\u002F00019053-200826090-00004",{"id":26,"text":1293,"url":26,"identifiers":1294},"Neumann, 2014, Updating cost-effectiveness — the curious resilience of the $50,000-per-QALY threshold, N Engl J Med, 371, 796, 10.1056\u002FNEJMp1405158",{"doi":1295},"10.1056\u002FNEJMp1405158",{"id":26,"text":1297,"url":26,"identifiers":1298},"Sarasin, 1996, Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis, Am J Med, 101, 422, 10.1016\u002FS0002-9343(96)00197-0",{"doi":1299},"10.1016\u002FS0002-9343(96)00197-0",{"id":26,"text":1301,"url":26,"identifiers":1302},"Sherman, 2014, Surveillance for hepatocellular carcinoma, Best Pract Res Clin Gastroenterol, 28, 783, 10.1016\u002Fj.bpg.2014.08.008",{"doi":1303},"10.1016\u002Fj.bpg.2014.08.008",{"id":26,"text":1305,"url":26,"identifiers":1306},"Díaz-González, 2016, Surveillance for hepatocellular carcinoma, Best Pract Res Clin Gastroenterol, 30, 1001, 10.1016\u002Fj.bpg.2016.10.006",{"doi":1307},"10.1016\u002Fj.bpg.2016.10.006",{"id":26,"text":1309,"url":26,"identifiers":1310},"Trevisani, 2007, Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate\u002Fadvanced cirrhosis?, Am J Gastroenterol, 102, 2448, 10.1111\u002Fj.1572-0241.2007.01395.x",{"doi":1311},"10.1111\u002Fj.1572-0241.2007.01395.x",{"id":26,"text":1313,"url":26,"identifiers":1314},"Sanchez-Tapias, 2002, Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients, Gastroenterology, 123, 1848, 10.1053\u002Fgast.2002.37041",{"doi":1315},"10.1053\u002Fgast.2002.37041",{"id":26,"text":1317,"url":26,"identifiers":1318},"Fattovich, 2008, Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors, J Hepatol, 48, 335, 10.1016\u002Fj.jhep.2007.11.011",{"doi":1319},"10.1016\u002Fj.jhep.2007.11.011",{"id":26,"text":1321,"url":26,"identifiers":1322},"Chen, 2009, Hepatitis B virus DNA levels and outcomes in chronic hepatitis B, Hepatology, 49, S72, 10.1002\u002Fhep.22884",{"doi":1323},"10.1002\u002Fhep.22884",{"id":26,"text":1325,"url":26,"identifiers":1326},"Yang, 2011, Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score, Lancet Oncol, 12, 568, 10.1016\u002FS1470-2045(11)70077-8",{"doi":1327},"10.1016\u002FS1470-2045(11)70077-8",{"id":26,"text":1329,"url":26,"identifiers":1330},"Wong VW-S, Janssen HLA. Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection? J Hepatol 2015;63:722–32.",{"doi":1331},"10.1016\u002Fj.jhep.2015.05.019",{"id":26,"text":1333,"url":26,"identifiers":1334},"Paradis, 2009, Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis, Hepatology, 49, 851, 10.1002\u002Fhep.22734",{"doi":1335},"10.1002\u002Fhep.22734",{"id":26,"text":1337,"url":26,"identifiers":1338},"Kolly, 2016, Surveillance for hepatocellular carcinoma in patients with NASH, Diagnostics, 6, 22, 10.3390\u002Fdiagnostics6020022",{"doi":1339},"10.3390\u002Fdiagnostics6020022",{"id":26,"text":1341,"url":26,"identifiers":1342},"Dongiovanni, 2014, Hepatocellular carcinoma in nonalcoholic fatty liver: Role of environmental and genetic factors, World J Gastroenterol, 20, 12945, 10.3748\u002Fwjg.v20.i36.12945",{"doi":1343},"10.3748\u002Fwjg.v20.i36.12945",{"id":26,"text":1345,"url":26,"identifiers":1346},"Ajmera, 2017, Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review, Hepatology, 65, 2090, 10.1002\u002Fhep.29055",{"doi":1347},"10.1002\u002Fhep.29055",{"id":26,"text":1349,"url":26,"identifiers":1350},"Burza, 2012, PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals, Dig Liver Dis, 44, 1037, 10.1016\u002Fj.dld.2012.05.006",{"doi":1351},"10.1016\u002Fj.dld.2012.05.006",{"id":26,"text":1353,"url":26,"identifiers":1354},"Liu, 2014, Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma, J Hepatol, 61, 75, 10.1016\u002Fj.jhep.2014.02.030",{"doi":1355},"10.1016\u002Fj.jhep.2014.02.030",{"id":26,"text":1357,"url":26,"identifiers":1358},"Yasui, 2011, Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma, Clin Gastroenterol Hepatol, 9, 428, 10.1016\u002Fj.cgh.2011.01.023",{"doi":1359},"10.1016\u002Fj.cgh.2011.01.023",{"id":26,"text":1361,"url":26,"identifiers":1362},"Wong GL-H, Chan HL-Y, Chan H-Y, Tse PC-H, Tse Y-K, Mak CW-H, et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology 2013;144:933–44.",{"doi":1363},"10.1053\u002Fj.gastro.2013.02.002",{"id":26,"text":1365,"url":26,"identifiers":1366},"Sung, 2008, Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma, Aliment Pharmacol Ther, 28, 1067, 10.1111\u002Fj.1365-2036.2008.03816.x",{"doi":1367},"10.1111\u002Fj.1365-2036.2008.03816.x",{"id":26,"text":1369,"url":26,"identifiers":1370},"Wang, 2016, Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy, Liver Int, 36, 1793, 10.1111\u002Fliv.13179",{"doi":1371},"10.1111\u002Fliv.13179",{"id":26,"text":1373,"url":26,"identifiers":1374},"Wang, 2013, Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients, Liver Int, 33, 756, 10.1111\u002Fliv.12118",{"doi":1375},"10.1111\u002Fliv.12118",{"id":26,"text":1377,"url":26,"identifiers":1378},"Lee, 2016, Predicting liver-related events using transient elastography in chronic hepatitis c patients with sustained virological response, Gut Liver, 10, 429, 10.5009\u002Fgnl150211",{"doi":1379},"10.5009\u002Fgnl150211",{"id":26,"text":1381,"url":26,"identifiers":1382},"Zanetto, 2017, Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals, Liver Transplant, 23, 1103, 10.1002\u002Flt.24790",{"doi":1383},"10.1002\u002Flt.24790",{"id":26,"text":1385,"url":26,"identifiers":1386},"Ogata, 2017, Outcome of all-oral direct-acting antiviral regimens on the rate of development of hepatocellular carcinoma in patients with hepatitis C virus genotype 1-related chronic liver disease, Oncology, 93, 92, 10.1159\u002F000470910",{"doi":1387},"10.1159\u002F000470910",{"id":26,"text":1389,"url":26,"identifiers":1390},"Calleja, 2017, Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort, J Hepatol, 66, 1138, 10.1016\u002Fj.jhep.2017.01.028",{"doi":1391},"10.1016\u002Fj.jhep.2017.01.028",{"id":26,"text":1393,"url":26,"identifiers":1394},"Papatheodoridis, 2016, PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy, J Hepatol, 64, 800, 10.1016\u002Fj.jhep.2015.11.035",{"doi":1395},"10.1016\u002Fj.jhep.2015.11.035",{"id":26,"text":1397,"url":26,"identifiers":1398},"Yuen, 2009, Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B, J Hepatol, 50, 80, 10.1016\u002Fj.jhep.2008.07.023",{"doi":1399},"10.1016\u002Fj.jhep.2008.07.023",{"id":26,"text":1401,"url":26,"identifiers":1402},"Yang, 2010, Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection, J Clin Oncol, 28, 2437, 10.1200\u002FJCO.2009.27.4456",{"doi":1403},"10.1200\u002FJCO.2009.27.4456",{"id":26,"text":1405,"url":26,"identifiers":1406},"Bolondi, 2003, Screening for hepatocellular carcinoma in cirrhosis, J Hepatol, 39, 1076, 10.1016\u002FS0168-8278(03)00349-0",{"doi":1407},"10.1016\u002FS0168-8278(03)00349-0",{"id":26,"text":1409,"url":26,"identifiers":1410},"Singal, 2009, Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis, Aliment Pharmacol Ther, 30, 37, 10.1111\u002Fj.1365-2036.2009.04014.x",{"doi":1411},"10.1111\u002Fj.1365-2036.2009.04014.x",{"id":26,"text":1413,"url":26,"identifiers":1414},"Lencioni, 2008, Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma, J Hepatol, 48, 848, 10.1016\u002Fj.jhep.2008.02.005",{"doi":1415},"10.1016\u002Fj.jhep.2008.02.005",{"id":26,"text":1417,"url":26,"identifiers":1418},"Pocha, 2013, Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography – a randomised study, Aliment Pharmacol Ther, 38, 303, 10.1111\u002Fapt.12370",{"doi":1419},"10.1111\u002Fapt.12370",{"id":26,"text":1421,"url":26,"identifiers":1422},"Runge, 2016, Safety of the gadolinium-based contrast agents for magnetic resonance imaging, focusing in part on their accumulation in the brain and especially the dentate nucleus, Invest Radiol, 51, 273, 10.1097\u002FRLI.0000000000000273",{"doi":1423},"10.1097\u002FRLI.0000000000000273",{"id":26,"text":1425,"url":26,"identifiers":1426},"Marrero, 2009, Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma, Gastroenterology, 137, 110, 10.1053\u002Fj.gastro.2009.04.005",{"doi":1427},"10.1053\u002Fj.gastro.2009.04.005",{"id":26,"text":1429,"url":26,"identifiers":1430},"Lok, 2010, Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma, Gastroenterology, 138, 493, 10.1053\u002Fj.gastro.2009.10.031",{"doi":1431},"10.1053\u002Fj.gastro.2009.10.031",{"id":26,"text":1433,"url":26,"identifiers":1434},"Capurro, 2003, Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma, Gastroenterology, 125, 89, 10.1016\u002FS0016-5085(03)00689-9",{"doi":1435},"10.1016\u002FS0016-5085(03)00689-9",{"id":26,"text":1437,"url":26,"identifiers":1438},"Tsukuma, 1993, Risk factors for hepatocellular carcinoma among patients with chronic liver disease, N Engl J Med, 328, 1797, 10.1056\u002FNEJM199306243282501",{"doi":1439},"10.1056\u002FNEJM199306243282501",{"id":26,"text":1441,"url":26,"identifiers":1442},"Chen, 2003, Screening for liver cancer: results of a randomised controlled trial in Qidong, China, J Med Screen, 10, 204, 10.1258\u002F096914103771773320",{"doi":1443},"10.1258\u002F096914103771773320",{"id":26,"text":1445,"url":26,"identifiers":1446},"McMahon, 2001, Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus, Ann Intern Med, 135, 759, 10.7326\u002F0003-4819-135-9-200111060-00006",{"doi":1447},"10.7326\u002F0003-4819-135-9-200111060-00006",{"id":26,"text":1449,"url":26,"identifiers":1450},"Biselli, 2015, A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis, Br J Cancer, 112, 69, 10.1038\u002Fbjc.2014.536",{"doi":1451},"10.1038\u002Fbjc.2014.536",{"id":26,"text":1453,"url":26,"identifiers":1454},"Di Bisceglie, 2005, Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial, J Hepatol, 43, 434, 10.1016\u002Fj.jhep.2005.03.019",{"doi":1455},"10.1016\u002Fj.jhep.2005.03.019",{"id":26,"text":1457,"url":26,"identifiers":1458},"Yamashita, 2008, EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma, Cancer Res, 68, 1451, 10.1158\u002F0008-5472.CAN-07-6013",{"doi":1459},"10.1158\u002F0008-5472.CAN-07-6013",{"id":26,"text":1461,"url":26,"identifiers":1462},"Villanueva, 2010, Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy, Annu Rev Med, 61, 317, 10.1146\u002Fannurev.med.080608.100623",{"doi":1463},"10.1146\u002Fannurev.med.080608.100623",{"id":26,"text":1465,"url":26,"identifiers":1466},"Hoshida, 2009, Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma, Cancer Res, 69, 7385, 10.1158\u002F0008-5472.CAN-09-1089",{"doi":1467},"10.1158\u002F0008-5472.CAN-09-1089",{"id":26,"text":1469,"url":26,"identifiers":1470},"Trevisani, 2001, Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status, J Hepatol, 34, 570, 10.1016\u002FS0168-8278(00)00053-2",{"doi":1471},"10.1016\u002FS0168-8278(00)00053-2",{"id":26,"text":1473,"url":26,"identifiers":1474},"Nishikawa, 2016, A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation, Medicine, 95, e4832, 10.1097\u002FMD.0000000000004832",{"doi":1475},"10.1097\u002FMD.0000000000004832",{"id":26,"text":1477,"url":26,"identifiers":1478},"Kim, 2015, Reappraisal of serum alpha-foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment, Liver Int, 35, 232, 10.1111\u002Fliv.12516",{"doi":1479},"10.1111\u002Fliv.12516",{"id":26,"text":1481,"url":26,"identifiers":1482},"Shim, 2014, Oral antiviral therapy improves the diagnostic accuracy of alpha-fetoprotein levels in patients with chronic hepatitis B, J Gastroenterol Hepatol, 29, 1699, 10.1111\u002Fjgh.12612",{"doi":1483},"10.1111\u002Fjgh.12612",{"id":26,"text":1485,"url":26,"identifiers":1486},"Wong, 2014, On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir, Hepatology, 59, 986, 10.1002\u002Fhep.26739",{"doi":1487},"10.1002\u002Fhep.26739",{"id":26,"text":1489,"url":26,"identifiers":1490},"Yang, 2015, Prediction of risk for hepatocellular carcinoma by response of serum α-fetoprotein to entecavir therapy, J Gastroenterol Hepatol, 30, 1175, 10.1111\u002Fjgh.12921",{"doi":1491},"10.1111\u002Fjgh.12921",{"id":26,"text":1493,"url":26,"identifiers":1494},"Sherman, 2001, Alphafetoprotein: an obituary, J Hepatol, 34, 603, 10.1016\u002FS0168-8278(01)00025-3",{"doi":1495},"10.1016\u002FS0168-8278(01)00025-3",{"id":26,"text":1497,"url":26,"identifiers":1498},"Koike, 2001, Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients, Cancer, 91, 561, 10.1002\u002F1097-0142(20010201)91:3\u003C561::AID-CNCR1035>3.0.CO;2-N",{"doi":1499},"10.1002\u002F1097-0142(20010201)91:3\u003C561::AID-CNCR1035>3.0.CO;2-N",{"id":26,"text":1501,"url":26,"identifiers":1502},"Sterling, 2007, Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis, Am J Gastroenterol, 102, 2196, 10.1111\u002Fj.1572-0241.2007.01405.x",{"doi":1503},"10.1111\u002Fj.1572-0241.2007.01405.x",{"id":26,"text":1505,"url":26,"identifiers":1506},"Zhang, 1999, Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer, J Med Screen, 6, 108, 10.1136\u002Fjms.6.2.108",{"doi":1507},"10.1136\u002Fjms.6.2.108",{"id":26,"text":1509,"url":26,"identifiers":1510},"Zhang, 2004, Randomized controlled trial of screening for hepatocellular carcinoma, J Cancer Res Clin Oncol, 130, 417, 10.1007\u002Fs00432-004-0552-0",{"doi":1511},"10.1007\u002Fs00432-004-0552-0",{"id":26,"text":1513,"url":26,"identifiers":1514},"Barbara, 1992, Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival, Hepatology, 16, 132, 10.1002\u002Fhep.1840160122",{"doi":1515},"10.1002\u002Fhep.1840160122",{"id":26,"text":1517,"url":26,"identifiers":1518},"Ebara, 1998, Natural course of small hepatocellular carcinoma with underlying cirrhosis. A study of 30 patients, Hepatogastroenterology, 45, 1214",{},{"id":26,"text":1520,"url":26,"identifiers":1521},"Thompson Coon, 2008, Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis, Br J Cancer, 98, 1166, 10.1038\u002Fsj.bjc.6604301",{"doi":1522},"10.1038\u002Fsj.bjc.6604301",{"id":26,"text":1524,"url":26,"identifiers":1525},"Sheu, 1985, Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications, Gastroenterology, 89, 259, 10.1016\u002F0016-5085(85)90324-5",{"doi":1526},"10.1016\u002F0016-5085(85)90324-5",{"id":26,"text":1528,"url":26,"identifiers":1529},"Trinchet, 2011, Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities, Hepatology, 54, 1987, 10.1002\u002Fhep.24545",{"doi":1530},"10.1002\u002Fhep.24545",{"id":26,"text":1532,"url":26,"identifiers":1533},"Santi, 2010, Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival, J Hepatol, 53, 291, 10.1016\u002Fj.jhep.2010.03.010",{"doi":1534},"10.1016\u002Fj.jhep.2010.03.010",{"id":26,"text":1536,"url":26,"identifiers":1537},"Santagostino, 2003, A 6-month vs. a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus, Blood, 102, 78, 10.1182\u002Fblood-2002-10-3310",{"doi":1538},"10.1182\u002Fblood-2002-10-3310",{"id":26,"text":1540,"url":26,"identifiers":1541},"Cucchetti, 2014, Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma, J Hepatol, 61, 333, 10.1016\u002Fj.jhep.2014.03.037",{"doi":1542},"10.1016\u002Fj.jhep.2014.03.037",{"id":26,"text":1544,"url":26,"identifiers":1545},"Trevisani, 2002, Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience), Am J Gastroenterol, 97, 734, 10.1111\u002Fj.1572-0241.2002.05557.x",{"doi":1546},"10.1111\u002Fj.1572-0241.2002.05557.x",{"id":26,"text":1548,"url":26,"identifiers":1549},"Andersson, 2008, Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis, Clin Gastroenterol Hepatol, 6, 1418, 10.1016\u002Fj.cgh.2008.08.005",{"doi":1550},"10.1016\u002Fj.cgh.2008.08.005",{"id":26,"text":1552,"url":26,"identifiers":1553},"Bruix, 2001, Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver, J Hepatol, 35, 421, 10.1016\u002FS0168-8278(01)00130-1",{"doi":1554},"10.1016\u002FS0168-8278(01)00130-1",{"id":26,"text":1556,"url":26,"identifiers":1557},"Bruix, 2005, Management of hepatocellular carcinoma, Hepatology, 42, 1208, 10.1002\u002Fhep.20933",{"doi":1558},"10.1002\u002Fhep.20933",{"id":26,"text":1560,"url":26,"identifiers":1561},"Matsui, 2011, Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis, Abdom Imaging, 36, 264, 10.1007\u002Fs00261-011-9685-1",{"doi":1562},"10.1007\u002Fs00261-011-9685-1",{"id":26,"text":1564,"url":26,"identifiers":1565},"Burrel, 2003, MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation, Hepatology, 38, 1034, 10.1002\u002Fhep.1840380430",{"doi":1566},"10.1002\u002Fhep.1840380430",{"id":26,"text":1568,"url":26,"identifiers":1569},"Forner, 2008, Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma, Hepatology, 47, 97, 10.1002\u002Fhep.21966",{"doi":1570},"10.1002\u002Fhep.21966",{"id":26,"text":1572,"url":26,"identifiers":1573},"Bolondi, 2001, Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis, Gut, 48, 251, 10.1136\u002Fgut.48.2.251",{"doi":1574},"10.1136\u002Fgut.48.2.251",{"id":26,"text":1576,"url":26,"identifiers":1577},"Sangiovanni, 2010, The diagnostic and economic impact of contrast imaging technique in the diagnosis of small hepatocellular carcinoma in cirrhosis, Gut, 59, 638, 10.1136\u002Fgut.2009.187286",{"doi":1578},"10.1136\u002Fgut.2009.187286",{"id":26,"text":1580,"url":26,"identifiers":1581},"Mueller C, Waldburger N, Stampfl U, Kauczor H-U, Schirmacher P, Sommer CM, et al. Non-invasive diagnosis of hepatocellular carcinoma revisited. Gut 2017:gutjnl-2017-314981.",{"doi":1582},"10.1136\u002Fgutjnl-2017-314981",{"id":26,"text":1584,"url":26,"identifiers":1585},"Khalili, 2011, Optimization of imaging diagnosis of 1–2 cm hepatocellular carcinoma: An analysis of diagnostic performance and resource utilization, J Hepatol, 54, 723, 10.1016\u002Fj.jhep.2010.07.025",{"doi":1586},"10.1016\u002Fj.jhep.2010.07.025",{"id":26,"text":1588,"url":26,"identifiers":1589},"Vilana, 2010, Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound, Hepatology, 51, 2020, 10.1002\u002Fhep.23600",{"doi":1590},"10.1002\u002Fhep.23600",{"id":26,"text":1592,"url":26,"identifiers":1593},"Galassi, 2013, Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound, Liver Int, 33, 771, 10.1111\u002Fliv.12124",{"doi":1594},"10.1111\u002Fliv.12124",{"id":26,"text":1596,"url":26,"identifiers":1597},"Hanna, 2016, Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma, Abdom Radiol, 41, 71, 10.1007\u002Fs00261-015-0592-8",{"doi":1598},"10.1007\u002Fs00261-015-0592-8",{"id":26,"text":1600,"url":26,"identifiers":1601},"Chou, 2015, Imaging techniques for the diagnosis of hepatocellular carcinoma, Ann Intern Med, 162, 697, 10.7326\u002FM14-2509",{"doi":1602},"10.7326\u002FM14-2509",{"id":26,"text":1604,"url":26,"identifiers":1605},"Lee, 2015, Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis, Radiology, 275, 97, 10.1148\u002Fradiol.14140690",{"doi":1606},"10.1148\u002Fradiol.14140690",{"id":26,"text":1608,"url":26,"identifiers":1609},"Aubé, 2017, EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice, Liver Int, 37, 1515, 10.1111\u002Fliv.13429",{"doi":1610},"10.1111\u002Fliv.13429",{"id":26,"text":1612,"url":26,"identifiers":1613},"Rimola, 2012, Non-invasive diagnosis of hepatocellular carcinoma ≤ 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI, J Hepatol, 56, 1317, 10.1016\u002Fj.jhep.2012.01.004",{"doi":1614},"10.1016\u002Fj.jhep.2012.01.004",{"id":26,"text":1616,"url":26,"identifiers":1617},"Sun, 2010, Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (\u003C or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging, Invest Radiol, 45, 96, 10.1097\u002FRLI.0b013e3181c5faf7",{"doi":1618},"10.1097\u002FRLI.0b013e3181c5faf7",{"id":26,"text":1620,"url":26,"identifiers":1621},"Haradome, 2011, Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: Comparison with dynamic triple-phase multidetector CT imaging, J Magn Reson Imaging, 34, 69, 10.1002\u002Fjmri.22588",{"doi":1622},"10.1002\u002Fjmri.22588",{"id":26,"text":1624,"url":26,"identifiers":1625},"Inoue, 2012, Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity vs. MDCT, J Gastroenterol, 47, 1036, 10.1007\u002Fs00535-012-0571-6",{"doi":1626},"10.1007\u002Fs00535-012-0571-6",{"id":26,"text":1628,"url":26,"identifiers":1629},"Granito, 2013, Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study, Aliment Pharmacol Ther, 37, 355, 10.1111\u002Fapt.12166",{"doi":1630},"10.1111\u002Fapt.12166",{"id":26,"text":1632,"url":26,"identifiers":1633},"Tsurusaki, 2016, Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study, J Gastroenterol, 51, 71, 10.1007\u002Fs00535-015-1097-5",{"doi":1634},"10.1007\u002Fs00535-015-1097-5",{"id":26,"text":1636,"url":26,"identifiers":1637},"Hidaka, 2013, The expression of transporter OATP2\u002FOATP8 decreases in undetectable hepatocellular carcinoma by Gd-EOB-MRI in the explanted cirrhotic liver, Hepatol Int, 7, 655, 10.1007\u002Fs12072-012-9379-y",{"doi":1638},"10.1007\u002Fs12072-012-9379-y",{"id":26,"text":1640,"url":26,"identifiers":1641},"Maiwald, 2014, Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma?, PLoS One, 9, e111935, 10.1371\u002Fjournal.pone.0111935",{"doi":1642},"10.1371\u002Fjournal.pone.0111935",{"id":26,"text":1644,"url":26,"identifiers":1645},"Park, 2014, Dynamic enhancement pattern of HCC smaller than 3cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT, Liver Int, 34, 1593, 10.1111\u002Fliv.12550",{"doi":1646},"10.1111\u002Fliv.12550",{"id":26,"text":1648,"url":26,"identifiers":1649},"Chen, 2016, Added value of a gadoxetic acid-enhanced hepatocyte-phase image to the LI-RADS system for diagnosing hepatocellular carcinoma, Magn Reson Med Sci, 15, 49, 10.2463\u002Fmrms.2014-0149",{"doi":1650},"10.2463\u002Fmrms.2014-0149",{"id":26,"text":1652,"url":26,"identifiers":1653},"Guo, 2016, Diagnostic performance of contrast-enhanced multidetector computed tomography and gadoxetic acid disodium-enhanced magnetic resonance imaging in detecting hepatocellular carcinoma: direct comparison and a meta-analysis, Abdom Radiol, 41, 1960, 10.1007\u002Fs00261-016-0807-7",{"doi":1654},"10.1007\u002Fs00261-016-0807-7",{"id":26,"text":1656,"url":26,"identifiers":1657},"Duncan, 2017, Gadoxetic acid-enhanced MRI for the characterization of hepatocellular carcinoma: A systematic review and meta-analysis, J Magn Reson Imaging, 45, 281, 10.1002\u002Fjmri.25345",{"doi":1658},"10.1002\u002Fjmri.25345",{"id":26,"text":1660,"url":26,"identifiers":1661},"Ye, 2015, Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging and multidetector-row computed tomography for the diagnosis of hepatocellular carcinoma, Medicine, 94, e1157, 10.1097\u002FMD.0000000000001157",{"doi":1662},"10.1097\u002FMD.0000000000001157",{"id":26,"text":1664,"url":26,"identifiers":1665},"Di Martino, 2013, Hepatocellular carcinoma in cirrhotic patients: prospective comparison of US, CT and MR imaging, Eur Radiol, 23, 887, 10.1007\u002Fs00330-012-2691-z",{"doi":1666},"10.1007\u002Fs00330-012-2691-z",{"id":26,"text":1668,"url":26,"identifiers":1669},"Pahade, 2016, Is there an added value of a hepatobiliary phase with gadoxetate disodium following conventional MRI with an extracellular gadolinium agent in a single imaging session for detection of primary hepatic malignancies?, Abdom Radiol, 41, 1270, 10.1007\u002Fs00261-016-0635-9",{"doi":1670},"10.1007\u002Fs00261-016-0635-9",{"id":26,"text":1672,"url":26,"identifiers":1673},"Owens, 2011, Physicians for the CGC of the AC of. High-Value, Cost-Conscious Health Care: Concepts for Clinicians to Evaluate the Benefits, Harms, and Costs of Medical Interventions, Ann Intern Med, 154, 174, 10.7326\u002F0003-4819-154-3-201102010-00007",{"doi":1674},"10.7326\u002F0003-4819-154-3-201102010-00007",{"id":26,"text":1676,"url":26,"identifiers":1677},"Narita, 2009, Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma, J Gastroenterol, 44, 793, 10.1007\u002Fs00535-009-0056-4",{"doi":1678},"10.1007\u002Fs00535-009-0056-4",{"id":26,"text":1680,"url":26,"identifiers":1681},"Kitao, 2010, Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging–correlation with molecular transporters and histopathologic features, Radiology, 256, 817, 10.1148\u002Fradiol.10092214",{"doi":1682},"10.1148\u002Fradiol.10092214",{"id":26,"text":1684,"url":26,"identifiers":1685},"Joo, 2015, Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout?, Eur Radiol, 25, 2859, 10.1007\u002Fs00330-015-3686-3",{"doi":1686},"10.1007\u002Fs00330-015-3686-3",{"id":26,"text":1688,"url":26,"identifiers":1689},"Phongkitkarun, 2013, Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients, World J Gastroenterol, 19, 8357, 10.3748\u002Fwjg.v19.i45.8357",{"doi":1690},"10.3748\u002Fwjg.v19.i45.8357",{"id":26,"text":1692,"url":26,"identifiers":1693},"Yu, 2014, Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid–enhanced MR Imaging, Radiology, 271, 748, 10.1148\u002Fradiol.14131996",{"doi":1694},"10.1148\u002Fradiol.14131996",{"id":26,"text":1696,"url":26,"identifiers":1697},"Péporté, 2013, Imaging features of intrahepatic cholangiocarcinoma in Gd-EOB-DTPA-enhanced MRI, Eur J Radiol, 82, e101, 10.1016\u002Fj.ejrad.2012.10.010",{"doi":1698},"10.1016\u002Fj.ejrad.2012.10.010",{"id":26,"text":1700,"url":26,"identifiers":1701},"Kim, 2015, Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival, Gastroenterology, 148, 1371, 10.1053\u002Fj.gastro.2015.02.051",{"doi":1702},"10.1053\u002Fj.gastro.2015.02.051",{"id":26,"text":1704,"url":26,"identifiers":1705},"Joo, 2016, Recent advances in the imaging diagnosis of hepatocellular carcinoma: value of gadoxetic acid-enhanced MRI, Liver Cancer, 5, 67, 10.1159\u002F000367750",{"doi":1706},"10.1159\u002F000367750",{"id":26,"text":1708,"url":26,"identifiers":1709},"Song, 2015, Subcentimeter hypervascular nodule with typical imaging findings of hepatocellular carcinoma in patients with history of hepatocellular carcinoma: natural course on serial gadoxetic acid-enhanced MRI and diffusion-weighted imaging, Eur Radiol, 25, 2789, 10.1007\u002Fs00330-015-3680-9",{"doi":1710},"10.1007\u002Fs00330-015-3680-9",{"id":26,"text":1712,"url":26,"identifiers":1713},"Davenport, 2013, Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality, Radiology, 266, 452, 10.1148\u002Fradiol.12120826",{"doi":1714},"10.1148\u002Fradiol.12120826",{"id":26,"text":1716,"url":26,"identifiers":1717},"Luetkens, 2015, Respiratory motion artefacts in dynamic liver MRI: a comparison using gadoxetate disodium and gadobutrol, Eur Radiol, 25, 3207, 10.1007\u002Fs00330-015-3736-x",{"doi":1718},"10.1007\u002Fs00330-015-3736-x",{"id":26,"text":1720,"url":26,"identifiers":1721},"Park, 2016, Hepatic arterial phase in gadoxetic acid-enhanced liver magnetic resonance imaging, Invest Radiol, 51, 127, 10.1097\u002FRLI.0000000000000211",{"doi":1722},"10.1097\u002FRLI.0000000000000211",{"id":26,"text":1724,"url":26,"identifiers":1725},"Terzi, 2018, Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules, J Hepatol, 68, 485, 10.1016\u002Fj.jhep.2017.11.007",{"doi":1726},"10.1016\u002Fj.jhep.2017.11.007",{"id":26,"text":1728,"url":26,"identifiers":1729},"Li, 2013, Dynamic enhancing vascular pattern of intrahepatic peripheral cholangiocarcinoma on contrast-enhanced ultrasound: the influence of chronic hepatitis and cirrhosis, Abdom Imaging, 38, 112, 10.1007\u002Fs00261-012-9854-x",{"doi":1730},"10.1007\u002Fs00261-012-9854-x",{"id":26,"text":1728,"url":26,"identifiers":1732},{"doi":1730},{"id":26,"text":1734,"url":26,"identifiers":1735},"de Sio, 2014, Optimized contrast-enhanced ultrasonography for characterization of focal liver lesions in cirrhosis: A single-center retrospective study, United Eur Gastroenterol J, 2, 279, 10.1177\u002F2050640614538964",{"doi":1736},"10.1177\u002F2050640614538964",{"id":26,"text":1738,"url":26,"identifiers":1739},"Yuan, 2015, Factors affecting the enhancement patterns of intrahepatic cholangiocarcinoma (ICC) on contrast-enhanced ultrasound (CEUS) and their pathological correlations in patients with a single lesion, Ultraschall Med, 37, 609, 10.1055\u002Fs-0034-1399485",{"doi":1740},"10.1055\u002Fs-0034-1399485",{"id":26,"text":1742,"url":26,"identifiers":1743},"Wildner, 2015, CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients - early or late washout matters: a subanalysis of the DEGUM multicenter trial, Ultraschall Med, 36, 132, 10.1055\u002Fs-0034-1399147",{"doi":1744},"10.1055\u002Fs-0034-1399147",{"id":26,"text":1746,"url":26,"identifiers":1747},"Liu, 2015, Contrast-enhanced ultrasound for the characterization of hepatocellular carcinoma and intrahepatic cholangiocarcinoma, Liver Cancer, 4, 241, 10.1159\u002F000367738",{"doi":1748},"10.1159\u002F000367738",{"id":26,"text":1750,"url":26,"identifiers":1751},"Wildner, 2014, Dynamic contrast-enhanced ultrasound (DCE-US) for the characterization of hepatocellular carcinoma and cholangiocellular carcinoma, Ultraschall Med, 35, 522, 10.1055\u002Fs-0034-1385170",{"doi":1752},"10.1055\u002Fs-0034-1385170",{"id":26,"text":1754,"url":26,"identifiers":1755},"Piscaglia, 2017, American College of Radiology Contrast Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for the diagnosis of Hepatocellular Carcinoma: a pictorial essay, Ultraschall Med, 38, 320, 10.1055\u002Fs-0042-124661",{"doi":1756},"10.1055\u002Fs-0042-124661",{"id":26,"text":1758,"url":26,"identifiers":1759},"Piscaglia, 2017, Diagnosis of hepatocellular carcinoma with non-invasive imaging: a plea for worldwide adoption of standard and precise terminology for describing enhancement criteria, Ultraschall Med, 38, 9, 10.1055\u002Fs-0042-124204",{"doi":1760},"10.1055\u002Fs-0042-124204",{"id":26,"text":1762,"url":26,"identifiers":1763},"Iavarone, 2013, Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis, J Hepatol, 58, 1188, 10.1016\u002Fj.jhep.2013.02.013",{"doi":1764},"10.1016\u002Fj.jhep.2013.02.013",{"id":26,"text":1766,"url":26,"identifiers":1767},"Piscaglia, 2015, Cholangiocarcinoma in cirrhosis: value of hepatocyte specific magnetic resonance imaging, Dig Dis, 33, 735, 10.1159\u002F000439097",{"doi":1768},"10.1159\u002F000439097",{"id":26,"text":1770,"url":26,"identifiers":1771},"Choi, 2017, Intrahepatic cholangiocarcinoma in patients with cirrhosis: differentiation from hepatocellular carcinoma by using gadoxetic acid–enhanced mr imaging and dynamic CT, Radiology, 282, 771, 10.1148\u002Fradiol.2016160639",{"doi":1772},"10.1148\u002Fradiol.2016160639",{"id":26,"text":1774,"url":26,"identifiers":1775},"Bolondi, 2013, Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma, Dig Liver Dis, 45, 712, 10.1016\u002Fj.dld.2013.01.012",{"doi":1776},"10.1016\u002Fj.dld.2013.01.012",{"id":26,"text":1778,"url":26,"identifiers":1779},"American College of Radiology. CEUS-LI-RADS version 2017. Accessed Mar 15, 2018. https:\u002F\u002Fwww.acr.org\u002F-\u002Fmedia\u002FACR\u002FFiles\u002FRADS\u002FLI-RADS\u002FCEUS-LI-RADS-2017-Core.pdf?la=en n.d.",{},{"id":26,"text":1781,"url":26,"identifiers":1782},"Manini MA, Sangiovanni A, Fornari F, Piscaglia F, Biolato M, Fanigliulo L, et al. Clinical and Economical Impact of 2010 AASLD Guidelines for the Diagnosis of Hepatocellular Carcinoma. J Hepatol 2014;60:995–1001.",{"doi":1783},"10.1016\u002Fj.jhep.2014.01.006",{"id":26,"text":1785,"url":26,"identifiers":1786},"Furlan, 2012, Enhancement pattern of small hepatocellular carcinoma (HCC) at contrast-enhanced US (CEUS), MDCT, and MRI: Intermodality agreement and comparison of diagnostic sensitivity between 2005 and 2010 American Association for the Study of Liver Diseases (AASLD), Eur J Radiol, 81, 2099, 10.1016\u002Fj.ejrad.2011.07.010",{"doi":1787},"10.1016\u002Fj.ejrad.2011.07.010",{"id":26,"text":1789,"url":26,"identifiers":1790},"Leoni, 2013, Characterization of primary and recurrent nodules in liver cirrhosis using contrast-enhanced ultrasound: which vascular criteria should be adopted?, Ultraschall Med, 34, 280, 10.1055\u002Fs-0033-1335024",{"doi":1791},"10.1055\u002Fs-0033-1335024",{"id":26,"text":1793,"url":26,"identifiers":1794},"Bolondi, 2005, Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma, Hepatology, 42, 27, 10.1002\u002Fhep.20728",{"doi":1795},"10.1002\u002Fhep.20728",{"id":26,"text":1797,"url":26,"identifiers":1798},"Forner, 2015, Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules, J Hepatol, 62, 150, 10.1016\u002Fj.jhep.2014.08.028",{"doi":1799},"10.1016\u002Fj.jhep.2014.08.028",{"id":26,"text":1801,"url":26,"identifiers":1802},"Cucchetti, 2013, Cost-effectiveness of hepatic resection vs. percutaneous radiofrequency ablation for early hepatocellular carcinoma, J Hepatol, 59, 300, 10.1016\u002Fj.jhep.2013.04.009",{"doi":1803},"10.1016\u002Fj.jhep.2013.04.009",{"id":26,"text":1805,"url":26,"identifiers":1806},"Roskams T. Anatomic pathology of hepatocellular carcinoma: impact on prognosis and response to therapy. Clin Liver Dis 2011;15:245–59, vii–x.",{"doi":1807},"10.1016\u002Fj.cld.2011.03.004",{"id":26,"text":1809,"url":26,"identifiers":1810},"American College of Radiology. Liver Imaging Reporting and Data System version 2017. Accessed Nov 27 2017, from https:\u002F\u002Fwww.acr.org\u002F~\u002Fmedia\u002FACR\u002FDocuments\u002FPDF\u002FQualitySafety\u002FResources\u002FLIRADS\u002F2017\u002FLIRADS_2017_Core.pdf?la=en n.d.",{},{"id":26,"text":1812,"url":26,"identifiers":1813},"Darnell, 2015, Liver imaging reporting and data system with MR imaging: evaluation in nodules 20 mm or smaller detected in cirrhosis at screening US, Radiology, 275, 698, 10.1148\u002Fradiol.15141132",{"doi":1814},"10.1148\u002Fradiol.15141132",{"id":26,"text":1816,"url":26,"identifiers":1817},"Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012;143:1253–60-4.",{"doi":1818},"10.1053\u002Fj.gastro.2012.07.018",{"id":26,"text":1820,"url":26,"identifiers":1821},"Piscaglia, 2010, Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation, Liver Transpl, 16, 658, 10.1002\u002Flt.22044",{"doi":1822},"10.1002\u002Flt.22044",{"id":26,"text":1824,"url":26,"identifiers":1825},"Rossi, 2008, Contrast-enhanced ultrasonography and spiral computed tomography in the detection and characterization of portal vein thrombosis complicating hepatocellular carcinoma, Eur Radiol, 18, 1749, 10.1007\u002Fs00330-008-0931-z",{"doi":1826},"10.1007\u002Fs00330-008-0931-z",{"id":26,"text":1828,"url":26,"identifiers":1829},"Sorrentino, 2011, Validation of an extension of the international non-invasive criteria for the diagnosis of hepatocellular carcinoma to the characterization of macroscopic portal vein thrombosis, J Gastroenterol Hepatol, 26, 669, 10.1111\u002Fj.1440-1746.2010.06564.x",{"doi":1830},"10.1111\u002Fj.1440-1746.2010.06564.x",{"id":26,"text":1832,"url":26,"identifiers":1833},"Catalano, 2010, Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted mr imaging, Radiology, 254, 154, 10.1148\u002Fradiol.09090304",{"doi":1834},"10.1148\u002Fradiol.09090304",{"id":26,"text":1836,"url":26,"identifiers":1837},"Castilla-Lièvre, 2016, Diagnostic value of combining 11C-choline and 18F-FDG PET\u002FCT in hepatocellular carcinoma, Eur J Nucl Med Mol Imaging, 43, 852, 10.1007\u002Fs00259-015-3241-0",{"doi":1838},"10.1007\u002Fs00259-015-3241-0",{"id":26,"text":1840,"url":26,"identifiers":1841},"Chotipanich, 2016, Diagnosis of hepatocellular carcinoma using C11 CHOLINE PET\u002FCT: comparison with F18 FDG, contrast enhanced MRI and MDCT, Asian Pac J Cancer Prev, 17, 3569",{},{"id":26,"text":1843,"url":26,"identifiers":1844},"Lin, 2017, Predictive value of 18F-FDG PET\u002FCT for vascular invasion in patients with hepatocellular carcinoma before liver transplantation, Clin Nucl Med, 42, e183, 10.1097\u002FRLU.0000000000001545",{"doi":1845},"10.1097\u002FRLU.0000000000001545",{"id":26,"text":1847,"url":26,"identifiers":1848},"Hong, 2016, Alpha-fetoprotein and 18F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation, J Hepatol, 64, 852, 10.1016\u002Fj.jhep.2015.11.033",{"doi":1849},"10.1016\u002Fj.jhep.2015.11.033",{"id":26,"text":1851,"url":26,"identifiers":1852},"Bosman, F.T., Carneiro, F., Hruban, R.H., Theise ND. WHO Classification of Tumours of the Digestive System. Fourth Edition - WHO - OMS -. Fourth Edi. IARC press; 2010",{},{"id":26,"text":1854,"url":26,"identifiers":1855},"2009, International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia, Hepatology, 49, 658, 10.1002\u002Fhep.22709",{"doi":1856},"10.1002\u002Fhep.22709",{"id":26,"text":1858,"url":26,"identifiers":1859},"Amin MB, Edge SB, American Joint Committee on Cancer. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.",{"doi":1860},"10.1007\u002F978-3-319-40618-3",{"id":26,"text":1862,"url":26,"identifiers":1863},"Calderaro, 2017, Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification, J Hepatol, 67, 727, 10.1016\u002Fj.jhep.2017.05.014",{"doi":1864},"10.1016\u002Fj.jhep.2017.05.014",{"id":26,"text":1866,"url":26,"identifiers":1867},"Ziol, 2017, Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance, Hepatology",{},{"id":26,"text":1869,"url":26,"identifiers":1870},"Bioulac-Sage, 2017, Hepatocellular adenoma: Classification, variants and clinical relevance, Semin Diagn Pathol, 34, 112, 10.1053\u002Fj.semdp.2016.12.007",{"doi":1871},"10.1053\u002Fj.semdp.2016.12.007",{"id":26,"text":1873,"url":26,"identifiers":1874},"Clinical, 2016, Practice Guidelines on the management of benign liver tumours, J Hepatol, 65, 386, 10.1016\u002Fj.jhep.2016.04.001",{"doi":1875},"10.1016\u002Fj.jhep.2016.04.001",{"id":26,"text":1877,"url":26,"identifiers":1878},"Müllhaupt, 2011, Is tumor biopsy necessary?, Liver Transplant, 17, S14, 10.1002\u002Flt.22374",{"doi":1879},"10.1002\u002Flt.22374",{"id":26,"text":1881,"url":26,"identifiers":1882},"Roskams, 2010, Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis, Semin Liver Dis, 30, 17, 10.1055\u002Fs-0030-1247129",{"doi":1883},"10.1055\u002Fs-0030-1247129",{"id":26,"text":1885,"url":26,"identifiers":1886},"Di Tommaso, 2007, Diagnostic value of HSP70, Glypican 3, and Glutamine Synthetase in hepatocellular nodules in cirrhosis, Hepatology, 45, 725, 10.1002\u002Fhep.21531",{"doi":1887},"10.1002\u002Fhep.21531",{"id":26,"text":1889,"url":26,"identifiers":1890},"Di Tommaso, 2009, The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma, J Hepatol, 50, 746, 10.1016\u002Fj.jhep.2008.11.014",{"doi":1891},"10.1016\u002Fj.jhep.2008.11.014",{"id":26,"text":1893,"url":26,"identifiers":1894},"Di Tommaso, 2011, Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma, Hepatology, 53, 1549, 10.1002\u002Fhep.24218",{"doi":1895},"10.1002\u002Fhep.24218",{"id":26,"text":1897,"url":26,"identifiers":1898},"Tremosini, 2012, Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma, Gut, 61, 1481, 10.1136\u002Fgutjnl-2011-301862",{"doi":1899},"10.1136\u002Fgutjnl-2011-301862",{"id":26,"text":1901,"url":26,"identifiers":1902},"Durnez, 2006, The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin, Histopathology, 49, 138, 10.1111\u002Fj.1365-2559.2006.02468.x",{"doi":1903},"10.1111\u002Fj.1365-2559.2006.02468.x",{"id":26,"text":1905,"url":26,"identifiers":1906},"Villanueva, 2011, Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma, Gastroenterology, 140, 1501, 10.1053\u002Fj.gastro.2011.02.006",{"doi":1907},"10.1053\u002Fj.gastro.2011.02.006",{"id":26,"text":1909,"url":26,"identifiers":1910},"Nault, 2013, A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection, Gastroenterology, 145, 176, 10.1053\u002Fj.gastro.2013.03.051",{"doi":1911},"10.1053\u002Fj.gastro.2013.03.051",{"id":26,"text":1913,"url":26,"identifiers":1914},"Miltiadous, 2015, Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation, J Hepatol, 63, 1368, 10.1016\u002Fj.jhep.2015.07.025",{"doi":1915},"10.1016\u002Fj.jhep.2015.07.025",{"id":26,"text":1917,"url":26,"identifiers":1918},"Rebouissou, 2017, Proliferation markers are associated with MET expression in hepatocellular carcinoma and predict tivantinib sensitivity in vitro, Clin Cancer Res, 23, 4364, 10.1158\u002F1078-0432.CCR-16-3118",{"doi":1919},"10.1158\u002F1078-0432.CCR-16-3118",{"id":26,"text":1921,"url":26,"identifiers":1922},"Silva, 2008, Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis, Gut, 57, 1592, 10.1136\u002Fgut.2008.149062",{"doi":1923},"10.1136\u002Fgut.2008.149062",{"id":26,"text":1925,"url":26,"identifiers":1926},"Fuks, 2014, Preoperative tumour biopsy does not affect the oncologic course of patients with transplantable HCC, J Hepatol, 61, 589, 10.1016\u002Fj.jhep.2014.04.046",{"doi":1927},"10.1016\u002Fj.jhep.2014.04.046",{"id":26,"text":1929,"url":26,"identifiers":1930},"Rockey, 2009, Liver biopsy, Hepatology, 49, 1017, 10.1002\u002Fhep.22742",{"doi":1931},"10.1002\u002Fhep.22742",{"id":26,"text":1933,"url":26,"identifiers":1934},"Lencioni, 2010, Modified RECIST (mRECIST) assessment for hepatocellular carcinoma, Semin Liver Dis, 30, 52, 10.1055\u002Fs-0030-1247132",{"doi":1935},"10.1055\u002Fs-0030-1247132",{"id":26,"text":1937,"url":26,"identifiers":1938},"Livraghi, 2008, Sustained complete response and complications rate after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis. Is resection still the treatment of choice?, Hepatology, 47, 82, 10.1002\u002Fhep.21933",{"doi":1939},"10.1002\u002Fhep.21933",{"id":26,"text":1941,"url":26,"identifiers":1942},"Kuang, 2011, Long-term outcome of percutaneous ablation in very early-stage hepatocellular carcinoma, J Gastrointest Surg, 15, 2165, 10.1007\u002Fs11605-011-1716-2",{"doi":1943},"10.1007\u002Fs11605-011-1716-2",{"id":26,"text":1945,"url":26,"identifiers":1946},"D’Amico, 2006, Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies, J Hepatol, 44, 217, 10.1016\u002Fj.jhep.2005.10.013",{"doi":1947},"10.1016\u002Fj.jhep.2005.10.013",{"id":26,"text":1949,"url":26,"identifiers":1950},"Okuda, 1985, Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients, Cancer, 56, 918, 10.1002\u002F1097-0142(19850815)56:4\u003C918::AID-CNCR2820560437>3.0.CO;2-E",{"doi":1951},"10.1002\u002F1097-0142(19850815)56:4\u003C918::AID-CNCR2820560437>3.0.CO;2-E",{"id":26,"text":1953,"url":26,"identifiers":1954},"A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751–5.",{"doi":1955},"10.1002\u002Fhep.510280322",{"id":26,"text":1957,"url":26,"identifiers":1958},"Llovet, 1999, Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials, Hepatology, 29, 62, 10.1002\u002Fhep.510290145",{"doi":1959},"10.1002\u002Fhep.510290145",{"id":26,"text":1961,"url":26,"identifiers":1962},"Villa, 2000, Natural history of inoperable hepatocellular carcinoma: estrogen receptors’ status in the tumor is the strongest prognostic factor for survival, Hepatology, 32, 233, 10.1053\u002Fjhep.2000.9603",{"doi":1963},"10.1053\u002Fjhep.2000.9603",{"id":26,"text":1965,"url":26,"identifiers":1966},"Cabibbo, 2010, A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma, Hepatology, 51, 1274, 10.1002\u002Fhep.23485",{"doi":1967},"10.1002\u002Fhep.23485",{"id":26,"text":1969,"url":26,"identifiers":1970},"Llovet, 1998, Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power, Hepatology, 27, 1572, 10.1002\u002Fhep.510270616",{"doi":1971},"10.1002\u002Fhep.510270616",{"id":26,"text":1973,"url":26,"identifiers":1974},"Chan ACY, Fan ST, Poon RTP, Cheung TT, Chok KSH, Chan SC, et al. Evaluation of the seventh edition of the American Joint Committee on Cancer tumour?node?metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system. HPB 2013;15:439–48.",{"doi":1975},"10.1111\u002Fj.1477-2574.2012.00617.x",{"id":26,"text":1977,"url":26,"identifiers":1978},"Chevret, 1999, A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire, J Hepatol, 31, 133, 10.1016\u002FS0168-8278(99)80173-1",{"doi":1979},"10.1016\u002FS0168-8278(99)80173-1",{"id":26,"text":1981,"url":26,"identifiers":1982},"Llovet, 1999, Prognosis of hepatocellular carcinoma: the BCLC staging classification, Semin Liver Dis, 19, 329, 10.1055\u002Fs-2007-1007122",{"doi":1983},"10.1055\u002Fs-2007-1007122",{"id":26,"text":1985,"url":26,"identifiers":1986},"Leung, 2002, Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients, Cancer, 94, 1760, 10.1002\u002Fcncr.10384",{"doi":1987},"10.1002\u002Fcncr.10384",{"id":26,"text":1989,"url":26,"identifiers":1990},"Yau, 2014, Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma, Gastroenterology, 146, 1691, 10.1053\u002Fj.gastro.2014.02.032",{"doi":1991},"10.1053\u002Fj.gastro.2014.02.032",{"id":26,"text":1993,"url":26,"identifiers":1994},"Kitai, 2008, Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score, Oncology, 75, 83, 10.1159\u002F000173428",{"doi":1995},"10.1159\u002F000173428",{"id":26,"text":1997,"url":26,"identifiers":1998},"Sohn, 2017, Validation of the Hong Kong liver cancer staging system in determining prognosis of the north american patients following intra-arterial therapy, Clin Gastroenterol Hepatol, 15, 746, 10.1016\u002Fj.cgh.2016.10.036",{"doi":1999},"10.1016\u002Fj.cgh.2016.10.036",{"id":26,"text":2001,"url":26,"identifiers":2002},"Sherman, 2014, Staging for hepatocellular carcinoma: complex and confusing, Gastroenterology, 146, 1599, 10.1053\u002Fj.gastro.2014.04.026",{"doi":2003},"10.1053\u002Fj.gastro.2014.04.026",{"id":26,"text":2005,"url":26,"identifiers":2006},"Marrero, 2005, Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort, Hepatology, 41, 707, 10.1002\u002Fhep.20636",{"doi":2007},"10.1002\u002Fhep.20636",{"id":26,"text":2009,"url":26,"identifiers":2010},"Cillo, 2004, The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available?, J Hepatol, 40, 124, 10.1016\u002Fj.jhep.2003.09.027",{"doi":2011},"10.1016\u002Fj.jhep.2003.09.027",{"id":26,"text":2013,"url":26,"identifiers":2014},"Guglielmi, 2008, Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response, Am J Gastroenterol, 103, 597, 10.1111\u002Fj.1572-0241.2007.01604.x",{"doi":2015},"10.1111\u002Fj.1572-0241.2007.01604.x",{"id":26,"text":2017,"url":26,"identifiers":2018},"Vitale, 2009, Validation of the BCLC prognostic system in surgical hepatocellular cancer patients, Transplant Proc, 41, 1260, 10.1016\u002Fj.transproceed.2009.03.054",{"doi":2019},"10.1016\u002Fj.transproceed.2009.03.054",{"id":26,"text":2021,"url":26,"identifiers":2022},"Llovet, 2003, Hepatocellular carcinoma, Lancet, 362, 1907, 10.1016\u002FS0140-6736(03)14964-1",{"doi":2023},"10.1016\u002FS0140-6736(03)14964-1",{"id":26,"text":2025,"url":26,"identifiers":2026},"Llovet, 2008, Design and endpoints of clinical trials in hepatocellular carcinoma, J Natl Cancer Inst, 100, 698, 10.1093\u002Fjnci\u002Fdjn134",{"doi":2027},"10.1093\u002Fjnci\u002Fdjn134",{"id":26,"text":2029,"url":26,"identifiers":2030},"Forner, 2012, Hepatocellular carcinoma, Lancet, 379, 1245, 10.1016\u002FS0140-6736(11)61347-0",{"doi":2031},"10.1016\u002FS0140-6736(11)61347-0",{"id":26,"text":2033,"url":26,"identifiers":2034},"Simon, 2009, Use of archived specimens in evaluation of prognostic and predictive biomarkers, J Natl Cancer Inst, 101, 1446, 10.1093\u002Fjnci\u002Fdjp335",{"doi":2035},"10.1093\u002Fjnci\u002Fdjp335",{"id":26,"text":2037,"url":26,"identifiers":2038},"Pinyol, 2017, Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial, J Hepatol, 66, S12, 10.1016\u002FS0168-8278(17)30287-8",{"doi":2039},"10.1016\u002FS0168-8278(17)30287-8",{"id":26,"text":2041,"url":26,"identifiers":2042},"Johnson, 2015, Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade, J Clin Oncol, 33, 550, 10.1200\u002FJCO.2014.57.9151",{"doi":2043},"10.1200\u002FJCO.2014.57.9151",{"id":26,"text":2045,"url":26,"identifiers":2046},"Pinato, 2017, The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma, J Hepatol, 66, 338, 10.1016\u002Fj.jhep.2016.09.008",{"doi":2047},"10.1016\u002Fj.jhep.2016.09.008",{"id":26,"text":2049,"url":26,"identifiers":2050},"Imamura, 2003, Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy, J Hepatol, 38, 200, 10.1016\u002FS0168-8278(02)00360-4",{"doi":2051},"10.1016\u002FS0168-8278(02)00360-4",{"id":26,"text":2053,"url":26,"identifiers":2054},"Ikai, 2004, Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey, Cancer, 101, 796, 10.1002\u002Fcncr.20426",{"doi":2055},"10.1002\u002Fcncr.20426",{"id":26,"text":2057,"url":26,"identifiers":2058},"Vibert, 2010, Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor, Am J Transpl, 10, 129, 10.1111\u002Fj.1600-6143.2009.02750.x",{"doi":2059},"10.1111\u002Fj.1600-6143.2009.02750.x",{"id":26,"text":2061,"url":26,"identifiers":2062},"Merani, 2011, The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma, J Hepatol, 55, 814, 10.1016\u002Fj.jhep.2010.12.040",{"doi":2063},"10.1016\u002Fj.jhep.2010.12.040",{"id":26,"text":2065,"url":26,"identifiers":2066},"Toso, 2012, A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list, Hepatology, 56, 149, 10.1002\u002Fhep.25603",{"doi":2067},"10.1002\u002Fhep.25603",{"id":26,"text":2069,"url":26,"identifiers":2070},"Duvoux, 2012, Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria, Gastroenterology, 143, 985, 10.1053\u002Fj.gastro.2012.05.052",{"doi":2071},"10.1053\u002Fj.gastro.2012.05.052",{"id":26,"text":2073,"url":26,"identifiers":2074},"Piñero, 2016, Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America, Uruguay Liver Int, 36, 1657, 10.1111\u002Fliv.13159",{"doi":2075},"10.1111\u002Fliv.13159",{"id":26,"text":2077,"url":26,"identifiers":2078},"Toso, 2015, Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation, Hepatology, 62, 158, 10.1002\u002Fhep.27787",{"doi":2079},"10.1002\u002Fhep.27787",{"id":26,"text":2081,"url":26,"identifiers":2082},"Notarpaolo, 2017, Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC, J Hepatol, 66, 552, 10.1016\u002Fj.jhep.2016.10.038",{"doi":2083},"10.1016\u002Fj.jhep.2016.10.038",{"id":26,"text":2085,"url":26,"identifiers":2086},"Mazzaferro, 2018, Metroticket 2.0 model for analysis of competing risks of death following liver transplantation for hepatocellular carcinoma, Gastroenterology, 154, 128, 10.1053\u002Fj.gastro.2017.09.025",{"doi":2087},"10.1053\u002Fj.gastro.2017.09.025",{"id":26,"text":2089,"url":26,"identifiers":2090},"Livraghi, 1995, Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection, Radiology, 197, 101, 10.1148\u002Fradiology.197.1.7568806",{"doi":2091},"10.1148\u002Fradiology.197.1.7568806",{"id":26,"text":2093,"url":26,"identifiers":2094},"N’Kontchou, 2009, Radiofrequency ablation of hepatocellular carcinoma: Long-term results and prognostic factors in 235 Western patients with cirrhosis, Hepatology, 50, 1475, 10.1002\u002Fhep.23181",{"doi":2095},"10.1002\u002Fhep.23181",{"id":26,"text":2097,"url":26,"identifiers":2098},"Takayasu, 2012, Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines, J Hepatol, 56, 886, 10.1016\u002Fj.jhep.2011.10.021",{"doi":2099},"10.1016\u002Fj.jhep.2011.10.021",{"id":26,"text":2101,"url":26,"identifiers":2102},"Llovet, 2012, Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma, Clin Cancer Res, 18, 2290, 10.1158\u002F1078-0432.CCR-11-2175",{"doi":2103},"10.1158\u002F1078-0432.CCR-11-2175",{"id":26,"text":2105,"url":26,"identifiers":2106},"Zhu, 2015, Ramucirumab vs. placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial, Lancet Oncol, 16, 859, 10.1016\u002FS1470-2045(15)00050-9",{"doi":2107},"10.1016\u002FS1470-2045(15)00050-9",{"id":26,"text":2109,"url":26,"identifiers":2110},"Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, et al. Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res 2015;45:n\u002Fa-n\u002Fa.",{"doi":2111},"10.1111\u002Fhepr.12464",{"id":26,"text":2113,"url":26,"identifiers":2114},"Hasegawa, 2013, Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey, J Hepatol, 58, 724, 10.1016\u002Fj.jhep.2012.11.009",{"doi":2115},"10.1016\u002Fj.jhep.2012.11.009",{"id":26,"text":2117,"url":26,"identifiers":2118},"Roayaie, 2013, Resection of hepatocellular cancer ≤2 cm: Results from two Western centers, Hepatology, 57, 1426, 10.1002\u002Fhep.25832",{"doi":2119},"10.1002\u002Fhep.25832",{"id":26,"text":2121,"url":26,"identifiers":2122},"Cho, 2010, Hepatic resection vs. radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis, Hepatology, 51, 1284, 10.1002\u002Fhep.23466",{"doi":2123},"10.1002\u002Fhep.23466",{"id":26,"text":2125,"url":26,"identifiers":2126},"Sala, 2004, High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation, Liver Transpl, 10, 1294, 10.1002\u002Flt.20202",{"doi":2127},"10.1002\u002Flt.20202",{"id":26,"text":2129,"url":26,"identifiers":2130},"Fuks, 2012, Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis, Hepatology, 55, 132, 10.1002\u002Fhep.24680",{"doi":2131},"10.1002\u002Fhep.24680",{"id":26,"text":2133,"url":26,"identifiers":2134},"Rodríguez de Lope, 2012, Management of HCC, J Hepatol, 56, S75, 10.1016\u002FS0168-8278(12)60009-9",{"doi":2135},"10.1016\u002FS0168-8278(12)60009-9",{"id":26,"text":2137,"url":26,"identifiers":2138},"Forner, 2010, Current strategy for staging and treatment: the BCLC update and future prospects, Semin Liver Dis, 30, 61, 10.1055\u002Fs-0030-1247133",{"doi":2139},"10.1055\u002Fs-0030-1247133",{"id":26,"text":2141,"url":26,"identifiers":2142},"Llovet, 1999, Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection vs. transplantation, Hepatology, 30, 1434, 10.1002\u002Fhep.510300629",{"doi":2143},"10.1002\u002Fhep.510300629",{"id":26,"text":2145,"url":26,"identifiers":2146},"Ishizawa, 2008, Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma, Gastroenterology, 134, 1908, 10.1053\u002Fj.gastro.2008.02.091",{"doi":2147},"10.1053\u002Fj.gastro.2008.02.091",{"id":26,"text":2149,"url":26,"identifiers":2150},"Berzigotti, 2015, Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis, Hepatology, 61, 526, 10.1002\u002Fhep.27431",{"doi":2151},"10.1002\u002Fhep.27431",{"id":26,"text":2153,"url":26,"identifiers":2154},"Lencioni, 2005, Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation, Radiology, 234, 961, 10.1148\u002Fradiol.2343040350",{"doi":2155},"10.1148\u002Fradiol.2343040350",{"id":26,"text":2157,"url":26,"identifiers":2158},"Choi, 2007, Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series, Eur Radiol, 17, 684, 10.1007\u002Fs00330-006-0461-5",{"doi":2159},"10.1007\u002Fs00330-006-0461-5",{"id":26,"text":2161,"url":26,"identifiers":2162},"Sala, 2004, Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma, Hepatology, 40, 1352, 10.1002\u002Fhep.20465",{"doi":2163},"10.1002\u002Fhep.20465",{"id":26,"text":2165,"url":26,"identifiers":2166},"Llovet, 2003, Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival, Hepatology, 37, 429, 10.1053\u002Fjhep.2003.50047",{"doi":2167},"10.1053\u002Fjhep.2003.50047",{"id":26,"text":2169,"url":26,"identifiers":2170},"Beaugrand, 2005, Treatment of advanced hepatocellular carcinoma by seocalcitol (a vit D analogue): an International randomized double-blind placebo-controlled study in 747 patients, J Hepatol, 42, 17A, 10.1016\u002FS0168-8278(05)81449-7",{"doi":2171},"10.1016\u002FS0168-8278(05)81449-7",{"id":26,"text":2173,"url":26,"identifiers":2174},"Llovet, 2002, Arterial embolisation or chemoembolisation vs. symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial, Lancet, 359, 1734, 10.1016\u002FS0140-6736(02)08649-X",{"doi":2175},"10.1016\u002FS0140-6736(02)08649-X",{"id":26,"text":2177,"url":26,"identifiers":2178},"Lo, 2002, Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma, Hepatology, 35, 1164, 10.1053\u002Fjhep.2002.33156",{"doi":2179},"10.1053\u002Fjhep.2002.33156",{"id":26,"text":2181,"url":26,"identifiers":2182},"Burrel, 2012, Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design, J Hepatol, 56, 1330, 10.1016\u002Fj.jhep.2012.01.008",{"doi":2183},"10.1016\u002Fj.jhep.2012.01.008",{"id":26,"text":2185,"url":26,"identifiers":2186},"Malagari K, Pomoni M, Moschouris H, Bouma E, Koskinas J, Stefaniotou A, et al. Chemoembolization With Doxorubicin-Eluting Beads for Unresectable Hepatocellular Carcinoma: Five-Year Survival Analysis. Cardiovasc Interv Radiol 2012;Oct;35:1119–28.",{"doi":2187},"10.1007\u002Fs00270-012-0394-0",{"id":26,"text":2189,"url":26,"identifiers":2190},"Bolondi, 2012, Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions, Semin Liver Dis, 32, 348",{},{"id":26,"text":2192,"url":26,"identifiers":2193},"Hucke F, Pinter M, Graziadei I, Vogel W, Müller C, Heinzl H, et al. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. J Hepatol 2014;61:1287–1296.",{"doi":2194},"10.1016\u002Fj.jhep.2014.07.002",{"id":26,"text":2196,"url":26,"identifiers":2197},"Bruix, 2011, Management of hepatocellular carcinoma: An update, Hepatology, 53, 1020, 10.1002\u002Fhep.24199",{"doi":2198},"10.1002\u002Fhep.24199",{"id":26,"text":2200,"url":26,"identifiers":2201},"Tsochatzis, 2014, Liver cirrhosis, Lancet, 17, 1749, 10.1016\u002FS0140-6736(14)60121-5",{"doi":2202},"10.1016\u002FS0140-6736(14)60121-5",{"id":26,"text":2204,"url":26,"identifiers":2205},"Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056\u002FNEJMoa0708857",{"doi":2206},"10.1056\u002FNEJMoa0708857",{"id":26,"text":2208,"url":26,"identifiers":2209},"Cheng, 2009, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol, 10, 25, 10.1016\u002FS1470-2045(08)70285-7",{"doi":2210},"10.1016\u002FS1470-2045(08)70285-7",{"id":26,"text":2212,"url":26,"identifiers":2213},"Bruix J, Qin S, Merle P, Granito A, Huang Y-H, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;Jan 7;389:56–66.",{"doi":2214},"10.1016\u002FS0140-6736(16)32453-9",{"id":26,"text":2216,"url":26,"identifiers":2217},"Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib vs. sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet n.d.; 2018: In press.",{"doi":2218},"10.1016\u002FS0140-6736(18)30207-1",{"id":26,"text":2220,"url":26,"identifiers":2221},"Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry A, Rimassa L, Ryoo B-Y, et al. Cabozantinib (C) vs. placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial. J Clin Oncol 2018;36:abstr 2017.",{"doi":2222},"10.1200\u002FJCO.2018.36.4_suppl.207",{"id":26,"text":2224,"url":26,"identifiers":2225},"Raoul, 2011, Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization, Cancer Treat Rev, 37, 212, 10.1016\u002Fj.ctrv.2010.07.006",{"doi":2226},"10.1016\u002Fj.ctrv.2010.07.006",{"id":26,"text":2228,"url":26,"identifiers":2229},"Forner, 2014, Treatment of intermediate-stage hepatocellular carcinoma, Nat Rev Clin Oncol, 11, 525, 10.1038\u002Fnrclinonc.2014.122",{"doi":2230},"10.1038\u002Fnrclinonc.2014.122",{"id":26,"text":2232,"url":26,"identifiers":2233},"Huitzil-Melendez, 2010, Advanced hepatocellular carcinoma: which staging systems best predict prognosis?, J Clin Oncol, 28, 2889, 10.1200\u002FJCO.2009.25.9895",{"doi":2234},"10.1200\u002FJCO.2009.25.9895",{"id":26,"text":2236,"url":26,"identifiers":2237},"Lang, 2005, Liver resection for hepatocellular carcinoma in non-cirrhotic liver without underlying viral hepatitis, Br J Surg, 92, 198, 10.1002\u002Fbjs.4763",{"doi":2238},"10.1002\u002Fbjs.4763",{"id":26,"text":2240,"url":26,"identifiers":2241},"Ertle, 2011, Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis, Int J Cancer, 128, 2436, 10.1002\u002Fijc.25797",{"doi":2242},"10.1002\u002Fijc.25797",{"id":26,"text":2244,"url":26,"identifiers":2245},"Viganò, 2015, Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: A multicenter matched analysis with HCV-related HCC, J Hepatol, 63, 93, 10.1016\u002Fj.jhep.2015.01.024",{"doi":2246},"10.1016\u002Fj.jhep.2015.01.024",{"id":26,"text":2248,"url":26,"identifiers":2249},"Cauchy, 2013, Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome, Br J Surg, 100, 113, 10.1002\u002Fbjs.8963",{"doi":2250},"10.1002\u002Fbjs.8963",{"id":26,"text":2252,"url":26,"identifiers":2253},"Makuuchi, 2004, The surgical approach to HCC: our progress and results in Japan, Liver Transpl, 10, S46, 10.1002\u002Flt.20044",{"doi":2254},"10.1002\u002Flt.20044",{"id":26,"text":2256,"url":26,"identifiers":2257},"Child, 1964, Surgery and portal hypertension, Major Probl Clin Surg, 1, 1",{},{"id":26,"text":2259,"url":26,"identifiers":2260},"Pugh, 1973, Transection of the oesophagus for bleeding oesophageal varices, Br J Surg, 60, 646, 10.1002\u002Fbjs.1800600817",{"doi":2261},"10.1002\u002Fbjs.1800600817",{"id":26,"text":2263,"url":26,"identifiers":2264},"Imamura H, Seyama Y, Kokudo N, Maema A, Sugawara Y, Sano K, et al. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg 2003;138:1198–206; discussion 1206.",{"doi":2265},"10.1001\u002Farchsurg.138.11.1198",{"id":26,"text":2267,"url":26,"identifiers":2268},"Cescon M, Colecchia A, Cucchetti A, Peri E, Montrone L, Ercolani G, et al. Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma. Ann Surg 2012;256:706–12-3.",{"doi":2269},"10.1097\u002FSLA.0b013e3182724ce8",{"id":26,"text":2271,"url":26,"identifiers":2272},"Donadon, 2015, Safe hepatectomy selection criteria for hepatocellular carcinoma patients: a validation of 336 consecutive hepatectomies. The BILCHE score, World J Surg, 39, 237, 10.1007\u002Fs00268-014-2786-6",{"doi":2273},"10.1007\u002Fs00268-014-2786-6",{"id":26,"text":2275,"url":26,"identifiers":2276},"De, 2016, Indocyanine green kinetics to assess liver function: Ready for a clinical dynamic assessment in major liver surgery?, World J Hepatol, 8, 355, 10.4254\u002Fwjh.v8.i7.355",{"doi":2277},"10.4254\u002Fwjh.v8.i7.355",{"id":26,"text":2279,"url":26,"identifiers":2280},"Lisotti, 2014, Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis, Hepatology, 59, 643, 10.1002\u002Fhep.26700",{"doi":2281},"10.1002\u002Fhep.26700",{"id":26,"text":2283,"url":26,"identifiers":2284},"Rahbari, 2011, Post-hepatectomy haemorrhage: a definition and grading by the International Study Group of Liver Surgery (ISGLS), HPB, 13, 528, 10.1111\u002Fj.1477-2574.2011.00319.x",{"doi":2285},"10.1111\u002Fj.1477-2574.2011.00319.x",{"id":26,"text":2287,"url":26,"identifiers":2288},"Llop, 2012, Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors, J Hepatol, 56, 103, 10.1016\u002Fj.jhep.2011.06.027",{"doi":2289},"10.1016\u002Fj.jhep.2011.06.027",{"id":26,"text":2291,"url":26,"identifiers":2292},"Wong JS-W, Wong GL-H, Chan AW-H, Wong VW-S, Cheung Y-S, Chong C-N, et al. Liver Stiffness Measurement by Transient Elastography as a Predictor on Posthepatectomy Outcomes. Ann Surg 2013;257:922–8.",{"doi":2293},"10.1097\u002FSLA.0b013e318269d2ec",{"id":26,"text":2295,"url":26,"identifiers":2296},"Nishio, 2016, Prediction of posthepatectomy liver failure based on liver stiffness measurement in patients with hepatocellular carcinoma, Surgery, 159, 399, 10.1016\u002Fj.surg.2015.06.024",{"doi":2297},"10.1016\u002Fj.surg.2015.06.024",{"id":26,"text":2299,"url":26,"identifiers":2300},"Zipprich, 2010, Incorporating indocyanin green clearance into the Model for End Stage Liver Disease (MELD-ICG) improves prognostic accuracy in intermediate to advanced cirrhosis, Gut, 59, 963, 10.1136\u002Fgut.2010.208595",{"doi":2301},"10.1136\u002Fgut.2010.208595",{"id":26,"text":2303,"url":26,"identifiers":2304},"Wagener, 2013, Assessment of hepatic function, operative candidacy, and medical management after liver resection in the patient with underlying liver disease, Semin Liver Dis, 33, 204, 10.1055\u002Fs-0033-1351777",{"doi":2305},"10.1055\u002Fs-0033-1351777",{"id":26,"text":2307,"url":26,"identifiers":2308},"Cucchetti, 2009, Is portal hypertension a contraindication to hepatic resection?, Ann Surg, 250, 922, 10.1097\u002FSLA.0b013e3181b977a5",{"doi":2309},"10.1097\u002FSLA.0b013e3181b977a5",{"id":26,"text":2311,"url":26,"identifiers":2312},"Roayaie, 2015, The role of hepatic resection in the treatment of hepatocellular cancer, Hepatology, 62, 440, 10.1002\u002Fhep.27745",{"doi":2313},"10.1002\u002Fhep.27745",{"id":26,"text":2315,"url":26,"identifiers":2316},"Citterio, 2016, Hierarchic interaction of factors associated with liver decompensation after resection for hepatocellular carcinoma, JAMA Surg, 151, 846, 10.1001\u002Fjamasurg.2016.1121",{"doi":2317},"10.1001\u002Fjamasurg.2016.1121",{"id":26,"text":2319,"url":26,"identifiers":2320},"Strasberg, 2000, Hpb EG-, 2000 U. The Brisbane 2000 terminology of liver anatomy and resections, HBP, 2000, 333",{},{"id":26,"text":2322,"url":26,"identifiers":2323},"Shindoh, 2015, Surgical approach for hepatitis C virus-related hepatocellular carcinoma, World J Hepatol, 7, 70, 10.4254\u002Fwjh.v7.i1.70",{"doi":2324},"10.4254\u002Fwjh.v7.i1.70",{"id":26,"text":2326,"url":26,"identifiers":2327},"Eguchi, 2008, Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey, Surgery, 143, 469, 10.1016\u002Fj.surg.2007.12.003",{"doi":2328},"10.1016\u002Fj.surg.2007.12.003",{"id":26,"text":2330,"url":26,"identifiers":2331},"Twaij, 2014, Laparoscopic vs open approach to resection of hepatocellular carcinoma in patients with known cirrhosis: Systematic review and meta-analysis, World J Gastroenterol, 20, 8274, 10.3748\u002Fwjg.v20.i25.8274",{"doi":2332},"10.3748\u002Fwjg.v20.i25.8274",{"id":26,"text":2334,"url":26,"identifiers":2335},"Franken, 2014, Comparison of short-term outcomes in laparoscopic vs. open hepatectomy, JAMA Surg, 149, 941, 10.1001\u002Fjamasurg.2014.1023",{"doi":2336},"10.1001\u002Fjamasurg.2014.1023",{"id":26,"text":2338,"url":26,"identifiers":2339},"Ciria, 2016, Comparative Short-term Benefits of Laparoscopic Liver Resection: 9000 Cases and Climbing, Ann Surg, 263, 761, 10.1097\u002FSLA.0000000000001413",{"doi":2340},"10.1097\u002FSLA.0000000000001413",{"id":26,"text":2342,"url":26,"identifiers":2343},"Han, 2015, Laparoscopic vs. open liver resection for hepatocellular carcinoma: Case - matched study with propensity score matching, J Hepatol, 63, 643, 10.1016\u002Fj.jhep.2015.04.005",{"doi":2344},"10.1016\u002Fj.jhep.2015.04.005",{"id":26,"text":2346,"url":26,"identifiers":2347},"Sposito, 2016, Propensity score analysis of outcomes following laparoscopic or open liver resection for hepatocellular carcinoma, Br J Surg, 103, 871, 10.1002\u002Fbjs.10137",{"doi":2348},"10.1002\u002Fbjs.10137",{"id":26,"text":2350,"url":26,"identifiers":2351},"Cucchetti, 2016, Effect of age on survival in patients undergoing resection of hepatocellular carcinoma, Br J Surg, 103, e93, 10.1002\u002Fbjs.10056",{"doi":2352},"10.1002\u002Fbjs.10056",{"id":26,"text":2354,"url":26,"identifiers":2355},"Vitale, 2015, Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study, J Hepatol, 62, 617, 10.1016\u002Fj.jhep.2014.10.037",{"doi":2356},"10.1016\u002Fj.jhep.2014.10.037",{"id":26,"text":2358,"url":26,"identifiers":2359},"Soubrane, 2014, Laparoscopic resection of hepatocellular carcinoma: a French survey in 351 patients, HPB, 16, 357, 10.1111\u002Fhpb.12142",{"doi":2360},"10.1111\u002Fhpb.12142",{"id":26,"text":2362,"url":26,"identifiers":2363},"Parks KR, Kuo Y-H, Davis JM, O’ Brien B, Hagopian EJ. Laparoscopic vs. open liver resection: a meta-analysis of long-term outcome. HPB (Oxford) 2014;16:109–18.",{"doi":2364},"10.1111\u002Fhpb.12117",{"id":26,"text":2366,"url":26,"identifiers":2367},"Morise, 2015, Can we expand the indications for laparoscopic liver resection? A systematic review and meta-analysis of laparoscopic liver resection for patients with hepatocellular carcinoma and chronic liver disease, J Hepatobiliary Pancreat Sci, 22, 342, 10.1002\u002Fjhbp.215",{"doi":2368},"10.1002\u002Fjhbp.215",{"id":26,"text":2370,"url":26,"identifiers":2371},"Takahara, 2015, Long-term and perioperative outcomes of laparoscopic vs. open liver resection for hepatocellular carcinoma with propensity score matching: a multi-institutional Japanese study, J Hepatobiliary Pancreat Sci, 22, 721, 10.1002\u002Fjhbp.276",{"doi":2372},"10.1002\u002Fjhbp.276",{"id":26,"text":2374,"url":26,"identifiers":2375},"Abu Hilal, 2017, The southampton consensus guidelines for laparoscopic liver surgery, Ann Surg, 10.1097\u002FSLA.0000000000002524",{"doi":2376},"10.1097\u002FSLA.0000000000002524",{"id":26,"text":2378,"url":26,"identifiers":2379},"Chen, 2006, A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma, Ann Surg, 243, 321, 10.1097\u002F01.sla.0000201480.65519.b8",{"doi":2380},"10.1097\u002F01.sla.0000201480.65519.b8",{"id":26,"text":2382,"url":26,"identifiers":2383},"Feng, 2012, A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma, J Hepatol, 57, 794, 10.1016\u002Fj.jhep.2012.05.007",{"doi":2384},"10.1016\u002Fj.jhep.2012.05.007",{"id":26,"text":2386,"url":26,"identifiers":2387},"Ng KKC, Chok KSH, Chan ACY, Cheung TT, Wong TCL, Fung JYY, et al. Randomized clinical trial of hepatic resection vs. radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg 2017;Dec;104:1775–84.",{"doi":2388},"10.1002\u002Fbjs.10677",{"id":26,"text":2390,"url":26,"identifiers":2391},"Huang, 2010, A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria, Ann Surg, 252, 903, 10.1097\u002FSLA.0b013e3181efc656",{"doi":2392},"10.1097\u002FSLA.0b013e3181efc656",{"id":26,"text":2394,"url":26,"identifiers":2395},"Wang, 2014, Radiofrequency ablation vs. hepatic resection for small hepatocellular carcinomas: a meta-analysis of randomized and nonrandomized controlled trials, PLoS One, 9, e84484, 10.1371\u002Fjournal.pone.0084484",{"doi":2396},"10.1371\u002Fjournal.pone.0084484",{"id":26,"text":2398,"url":26,"identifiers":2399},"Xin, 2016, Percutaneous radiofrequency ablation vs. surgical resection for the treatment of small hepatic carcinoma: a meta-analysis, Am J Cancer Prev, 4, 13",{},{"id":26,"text":2401,"url":26,"identifiers":2402},"Cucchetti, 2014, An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma, Dig Liver Dis, 46, 257, 10.1016\u002Fj.dld.2013.10.015",{"doi":2403},"10.1016\u002Fj.dld.2013.10.015",{"id":26,"text":2405,"url":26,"identifiers":2406},"Wakabayashi, 2015, Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka, Ann Surg, 261, 619",{},{"id":26,"text":2408,"url":26,"identifiers":2409},"Cheek, 2016, Evidence supporting laparoscopic major hepatectomy, J Hepatobiliary Pancreat Sci, 23, 257, 10.1002\u002Fjhbp.338",{"doi":2410},"10.1002\u002Fjhbp.338",{"id":26,"text":2412,"url":26,"identifiers":2413},"Lencioni, 2012, Local-regional treatment of hepatocellular carcinoma, Radiology, 262, 43, 10.1148\u002Fradiol.11110144",{"doi":2414},"10.1148\u002Fradiol.11110144",{"id":26,"text":2416,"url":26,"identifiers":2417},"Qi, 2013, Radiofrequency ablation vs. hepatic resection for small hepatocellular carcinoma: a meta-analysis of randomized controlled trials, J Clin Gastroenterol, 48, 450, 10.1097\u002FMCG.0000000000000008",{"doi":2418},"10.1097\u002FMCG.0000000000000008",{"id":26,"text":2420,"url":26,"identifiers":2421},"Nathan, 2013, Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-medicare analysis, Ann Surg, 258, 1022, 10.1097\u002FSLA.0b013e31827da749",{"doi":2422},"10.1097\u002FSLA.0b013e31827da749",{"id":26,"text":2424,"url":26,"identifiers":2425},"Torzilli, 2013, A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers, Ann Surg, 257, 929, 10.1097\u002FSLA.0b013e31828329b8",{"doi":2426},"10.1097\u002FSLA.0b013e31828329b8",{"id":26,"text":2428,"url":26,"identifiers":2429},"Yin, 2014, Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT, J Hepatol, 61, 82, 10.1016\u002Fj.jhep.2014.03.012",{"doi":2430},"10.1016\u002Fj.jhep.2014.03.012",{"id":26,"text":2432,"url":26,"identifiers":2433},"Zhong, 2013, Comparison of long-term survival of patients with bclc stage b hepatocellular carcinoma after liver resection or transarterial chemoembolization, PLoS One, 8, e68193, 10.1371\u002Fjournal.pone.0068193",{"doi":2434},"10.1371\u002Fjournal.pone.0068193",{"id":26,"text":2436,"url":26,"identifiers":2437},"Díaz-González, 2016, Treatment of hepatocellular carcinoma, Dig Dis, 34, 597, 10.1159\u002F000445275",{"doi":2438},"10.1159\u002F000445275",{"id":26,"text":2440,"url":26,"identifiers":2441},"Shi, 2010, Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus, Ann Surg Oncol, 17, 2073, 10.1245\u002Fs10434-010-0940-4",{"doi":2442},"10.1245\u002Fs10434-010-0940-4",{"id":26,"text":2444,"url":26,"identifiers":2445},"Lau, 2013, Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90, Oncology, 84, 311, 10.1159\u002F000348325",{"doi":2446},"10.1159\u002F000348325",{"id":26,"text":2448,"url":26,"identifiers":2449},"Mazzaferro, 2013, Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study, Hepatology, 57, 1826, 10.1002\u002Fhep.26014",{"doi":2450},"10.1002\u002Fhep.26014",{"id":26,"text":2452,"url":26,"identifiers":2453},"Kokudo, 2016, Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion, J Hepatol, 65, 938, 10.1016\u002Fj.jhep.2016.05.044",{"doi":2454},"10.1016\u002Fj.jhep.2016.05.044",{"id":26,"text":2456,"url":26,"identifiers":2457},"Kokudo, 2017, Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey, Hepatology, 66, 510, 10.1002\u002Fhep.29225",{"doi":2458},"10.1002\u002Fhep.29225",{"id":26,"text":2460,"url":26,"identifiers":2461},"Pawlik, 2005, Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: Results of a multicenter study, Surgery, 137, 403, 10.1016\u002Fj.surg.2004.12.012",{"doi":2462},"10.1016\u002Fj.surg.2004.12.012",{"id":26,"text":2464,"url":26,"identifiers":2465},"Chirica M, Scatton O, Massault P-P, Aloia T, Randone B, Dousset B, et al. Treatment of stage IVA hepatocellular carcinoma: should we reappraise the role of surgery? Arch Surg 2008;143:538–43; discussion 543.",{"doi":2466},"10.1001\u002Farchsurg.143.6.538",{"id":26,"text":2468,"url":26,"identifiers":2469},"Roayaie, 2013, Resection of hepatocellular carcinoma with macroscopic vascular invasion, Ann Surg Oncol, 20, 3754, 10.1245\u002Fs10434-013-3074-7",{"doi":2470},"10.1245\u002Fs10434-013-3074-7",{"id":26,"text":2472,"url":26,"identifiers":2473},"Pesi, 2015, Liver resection with thrombectomy as a treatment of hepatocellular carcinoma with major vascular invasion: results from a retrospective multicentric study, Am J Surg, 210, 35, 10.1016\u002Fj.amjsurg.2014.09.041",{"doi":2474},"10.1016\u002Fj.amjsurg.2014.09.041",{"id":26,"text":2476,"url":26,"identifiers":2477},"Mazzaferro, 2006, Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis, Hepatology, 44, 1543, 10.1002\u002Fhep.21415",{"doi":2478},"10.1002\u002Fhep.21415",{"id":26,"text":2480,"url":26,"identifiers":2481},"Shen, 2010, Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach, J Hepatol, 52, 889, 10.1016\u002Fj.jhep.2009.12.041",{"doi":2482},"10.1016\u002Fj.jhep.2009.12.041",{"id":26,"text":2484,"url":26,"identifiers":2485},"Samuel M, Chow PK-H, Chan Shih-Yen E, Machin D, Soo K-C. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 2009:CD001199.",{"doi":2486},"10.1002\u002F14651858.CD001199.pub2",{"id":26,"text":2488,"url":26,"identifiers":2489},"Takayama, 2000, Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial, Lancet, 356, 802, 10.1016\u002FS0140-6736(00)02654-4",{"doi":2490},"10.1016\u002FS0140-6736(00)02654-4",{"id":26,"text":2492,"url":26,"identifiers":2493},"Lee, 2015, Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma, Gastroenterology, 148, 1383, 10.1053\u002Fj.gastro.2015.02.055",{"doi":2494},"10.1053\u002Fj.gastro.2015.02.055",{"id":26,"text":2496,"url":26,"identifiers":2497},"Bruix, 2015, Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial, Lancet Oncol, 16, 1344, 10.1016\u002FS1470-2045(15)00198-9",{"doi":2498},"10.1016\u002FS1470-2045(15)00198-9",{"id":26,"text":2500,"url":26,"identifiers":2501},"Mazzaferro, 2016, The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors, Am J Transplant, 16, 2892, 10.1111\u002Fajt.13831",{"doi":2502},"10.1111\u002Fajt.13831",{"id":26,"text":2504,"url":26,"identifiers":2505},"Mazzaferro, 2018, Pro (With Caution): Extended oncologic indications in liver transplantation, Liver Transplant, 24, 98, 10.1002\u002Flt.24963",{"doi":2506},"10.1002\u002Flt.24963",{"id":26,"text":2508,"url":26,"identifiers":2509},"Kim, 2017, OPTN\u002FSRTR 2015 annual data report: liver, Am J Transplant, 17, 174, 10.1111\u002Fajt.14126",{"doi":2510},"10.1111\u002Fajt.14126",{"id":26,"text":2512,"url":26,"identifiers":2513},"Mazzaferro, 1996, Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis, N Engl J Med, 334, 693, 10.1056\u002FNEJM199603143341104",{"doi":2514},"10.1056\u002FNEJM199603143341104",{"id":26,"text":2516,"url":26,"identifiers":2517},"Clavien P-AP-A, Lesurtel M, Bossuyt PMM, Gores GJ, Langer B, Perrier A, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012;13:e11–22.",{"doi":2518},"10.1016\u002FS1470-2045(11)70175-9",{"id":26,"text":2520,"url":26,"identifiers":2521},"Mazzaferro, 2011, Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis of 15 years of experience, Liver Transplant, 17, S44, 10.1002\u002Flt.22365",{"doi":2522},"10.1002\u002Flt.22365",{"id":26,"text":2524,"url":26,"identifiers":2525},"Heimbach, 2018, AASLD guidelines for the treatment of hepatocellular carcinoma, Hepatology, 67, 358, 10.1002\u002Fhep.29086",{"doi":2526},"10.1002\u002Fhep.29086",{"id":26,"text":2528,"url":26,"identifiers":2529},"Yao, 2001, Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival, Hepatology, 33, 1394, 10.1053\u002Fjhep.2001.24563",{"doi":2530},"10.1053\u002Fjhep.2001.24563",{"id":26,"text":2532,"url":26,"identifiers":2533},"Yao, 2007, Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging, Am J Transpl, 7, 2587, 10.1111\u002Fj.1600-6143.2007.01965.x",{"doi":2534},"10.1111\u002Fj.1600-6143.2007.01965.x",{"id":26,"text":2536,"url":26,"identifiers":2537},"Mazzaferro, 2009, Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis, Lancet Oncol, 10, 35, 10.1016\u002FS1470-2045(08)70284-5",{"doi":2538},"10.1016\u002FS1470-2045(08)70284-5",{"id":26,"text":2540,"url":26,"identifiers":2541},"Toso, 2009, Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database, Hepatology, 49, 832, 10.1002\u002Fhep.22693",{"doi":2542},"10.1002\u002Fhep.22693",{"id":26,"text":2544,"url":26,"identifiers":2545},"Zheng, 2008, Liver transplantation for hepatocellular carcinoma: hangzhou experiences, Transplantation, 85, 1726, 10.1097\u002FTP.0b013e31816b67e4",{"doi":2546},"10.1097\u002FTP.0b013e31816b67e4",{"id":26,"text":2548,"url":26,"identifiers":2549},"Yang, 2007, A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma, Surgery, 141, 598, 10.1016\u002Fj.surg.2006.11.006",{"doi":2550},"10.1016\u002Fj.surg.2006.11.006",{"id":26,"text":2552,"url":26,"identifiers":2553},"Ravaioli, 2008, Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria, Am J Transpl, 8, 2547, 10.1111\u002Fj.1600-6143.2008.02409.x",{"doi":2554},"10.1111\u002Fj.1600-6143.2008.02409.x",{"id":26,"text":2556,"url":26,"identifiers":2557},"Levi, 2010, Liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease era, J Am Coll Surg, 210, 727, 10.1016\u002Fj.jamcollsurg.2010.01.007",{"doi":2558},"10.1016\u002Fj.jamcollsurg.2010.01.007",{"id":26,"text":2560,"url":26,"identifiers":2561},"Grąt, 2016, Relevance of pre-transplant α-fetoprotein dynamics in liver transplantation for hepatocellular cancer, Ann Transplant, 21, 115, 10.12659\u002FAOT.894644",{"doi":2562},"10.12659\u002FAOT.894644",{"id":26,"text":2564,"url":26,"identifiers":2565},"Lai, 2012, Combination of biological and morphological parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation, Clin Transplant, 26, E125, 10.1111\u002Fj.1399-0012.2011.01572.x",{"doi":2566},"10.1111\u002Fj.1399-0012.2011.01572.x",{"id":26,"text":2568,"url":26,"identifiers":2569},"Yao, 2015, Downstaging of hepatocellular cancer before liver transplant: Long-term outcome compared to tumors within Milan criteria, Hepatology, 61, 1968, 10.1002\u002Fhep.27752",{"doi":2570},"10.1002\u002Fhep.27752",{"id":26,"text":2572,"url":26,"identifiers":2573},"Berry, 2013, Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma, Liver Transplant, 19, 634, 10.1002\u002Flt.23652",{"doi":2574},"10.1002\u002Flt.23652",{"id":26,"text":2576,"url":26,"identifiers":2577},"Andreou, 2016, Predictive factors for extrahepatic recurrence of hepatocellular carcinoma following liver transplantation, Clin Transplant, 30, 819, 10.1111\u002Fctr.12755",{"doi":2578},"10.1111\u002Fctr.12755",{"id":26,"text":2580,"url":26,"identifiers":2581},"Murali, 2017, Locoregional therapy with curative intent vs. primary liver transplant for hepatocellular carcinoma: systematic review and meta-analysis, Transplantation, 101, e249, 10.1097\u002FTP.0000000000001730",{"doi":2582},"10.1097\u002FTP.0000000000001730",{"id":26,"text":2584,"url":26,"identifiers":2585},"Fondevila, 2014, A bridge too far: We have not overstepped the line for extended deceased donors, Liver Transpl, 20, S9, 10.1002\u002Flt.24000",{"doi":2586},"10.1002\u002Flt.24000",{"id":26,"text":2588,"url":26,"identifiers":2589},"Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol 2017;Apr;14:203–17.",{"doi":2590},"10.1038\u002Fnrgastro.2016.193",{"id":26,"text":2592,"url":26,"identifiers":2593},"Gruttadauria, 2008, Critical use of extended criteria donor liver grafts in adult-to-adult whole liver transplantation: A single-center experience, Liver Transplant, 14, 220, 10.1002\u002Flt.21359",{"doi":2594},"10.1002\u002Flt.21359",{"id":26,"text":2596,"url":26,"identifiers":2597},"Barbier, 2016, Liver transplantation with older donors: a comparison with younger donors in a context of organ shortage, Transplantation, 100, 2410, 10.1097\u002FTP.0000000000001401",{"doi":2598},"10.1097\u002FTP.0000000000001401",{"id":26,"text":2600,"url":26,"identifiers":2601},"Khorsandi, 2016, Does donation after cardiac death utilization adversely affect hepatocellular cancer survival?, Transplantation, 100, 1916, 10.1097\u002FTP.0000000000001150",{"doi":2602},"10.1097\u002FTP.0000000000001150",{"id":26,"text":2604,"url":26,"identifiers":2605},"Orci, 2015, Donor characteristics and risk of hepatocellular carcinoma recurrence after liver transplantation, Br J Surg, 102, 1250, 10.1002\u002Fbjs.9868",{"doi":2606},"10.1002\u002Fbjs.9868",{"id":26,"text":2608,"url":26,"identifiers":2609},"Mehta, 2013, Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy, Liver Transpl, 19, 1343, 10.1002\u002Flt.23753",{"doi":2610},"10.1002\u002Flt.23753",{"id":26,"text":2612,"url":26,"identifiers":2613},"Heimbach, 2015, Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States, Hepatology, 61, 1643, 10.1002\u002Fhep.27704",{"doi":2614},"10.1002\u002Fhep.27704",{"id":26,"text":2616,"url":26,"identifiers":2617},"UNOS-OPTN. OPTN Policies Policy 9: Allocation of Livers and Liver-Intestines. https:\u002F\u002Foptn.transplant.hrsa.gov\u002Fmedia\u002F1200\u002Foptn_policies.pdf#nameddest=Policy_09 (accessed December 30, 2017) n.d.",{},{"id":26,"text":2619,"url":26,"identifiers":2620},"Vitale, 2014, A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list, J Hepatol, 60, 290, 10.1016\u002Fj.jhep.2013.10.010",{"doi":2621},"10.1016\u002Fj.jhep.2013.10.010",{"id":26,"text":2623,"url":26,"identifiers":2624},"Marvin, 2015, MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma, Liver Transpl, 21, 612, 10.1002\u002Flt.24098",{"doi":2625},"10.1002\u002Flt.24098",{"id":26,"text":2627,"url":26,"identifiers":2628},"Halazun, 2014, Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment, Hepatology, 60, 1957, 10.1002\u002Fhep.27272",{"doi":2629},"10.1002\u002Fhep.27272",{"id":26,"text":2631,"url":26,"identifiers":2632},"Bittermann, 2014, Waitlist priority for hepatocellular carcinoma beyond milan criteria: a potentially appropriate decision without a structured approach, Am J Transplant, 14, 79, 10.1111\u002Fajt.12530",{"doi":2633},"10.1111\u002Fajt.12530",{"id":26,"text":2635,"url":26,"identifiers":2636},"Samoylova, 2014, Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation, Liver Transplant, 20, 937, 10.1002\u002Flt.23902",{"doi":2637},"10.1002\u002Flt.23902",{"id":26,"text":2639,"url":26,"identifiers":2640},"Mazzaferro, 2016, Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach, Hepatology, 63, 1707, 10.1002\u002Fhep.28420",{"doi":2641},"10.1002\u002Fhep.28420",{"id":26,"text":2643,"url":26,"identifiers":2644},"Montalti, 2014, Absence of viable HCC in the native liver is an independent protective factor of tumor recurrence after liver transplantation, Transplantation, 97, 220, 10.1097\u002FTP.0b013e3182a8607e",{"doi":2645},"10.1097\u002FTP.0b013e3182a8607e",{"id":26,"text":2647,"url":26,"identifiers":2648},"Cillo, 2015, A multistep, consensus-based approach to organ allocation in liver transplantation: toward a “Blended Principle Model”, Am J Transplant, 15, 2552, 10.1111\u002Fajt.13408",{"doi":2649},"10.1111\u002Fajt.13408",{"id":26,"text":2651,"url":26,"identifiers":2652},"Bhat, 2017, Proposal of a novel MELD exception point system for hepatocellular carcinoma based on tumor characteristics and dynamics, J Hepatol, 66, 374, 10.1016\u002Fj.jhep.2016.10.008",{"doi":2653},"10.1016\u002Fj.jhep.2016.10.008",{"id":26,"text":2655,"url":26,"identifiers":2656},"Flemming, 2017, Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy, Hepatology, 65, 804, 10.1002\u002Fhep.28923",{"doi":2657},"10.1002\u002Fhep.28923",{"id":26,"text":2659,"url":26,"identifiers":2660},"Roccaro, 2017, Early detection of hepatocellular carcinoma after treatment with direct-acting antivirals: selection bias or biologically plausible?, Gastroenterology, 152, 2072, 10.1053\u002Fj.gastro.2017.04.041",{"doi":2661},"10.1053\u002Fj.gastro.2017.04.041",{"id":26,"text":2663,"url":26,"identifiers":2664},"Viganò, 2017, Treatment of hepatitis C virus infection in Italy: A consensus report from an expert panel, Dig Liver Dis, 49, 731, 10.1016\u002Fj.dld.2017.03.027",{"doi":2665},"10.1016\u002Fj.dld.2017.03.027",{"id":26,"text":2667,"url":26,"identifiers":2668},"Bruix, 2014, Hepatocellular carcinoma: clinical frontiers and perspectives, Gut, 63, 844, 10.1136\u002Fgutjnl-2013-306627",{"doi":2669},"10.1136\u002Fgutjnl-2013-306627",{"id":26,"text":2671,"url":26,"identifiers":2672},"Berry, 2015, Comparison of liver transplant-related survival benefit in patients with vs. without hepatocellular carcinoma in the United States, Gastroenterology, 149, 669, 10.1053\u002Fj.gastro.2015.05.025",{"doi":2673},"10.1053\u002Fj.gastro.2015.05.025",{"id":26,"text":2675,"url":26,"identifiers":2676},"Schaubel, 2009, Survival benefit-based deceased-donor liver allocation, Am J Transplant, 9, 970, 10.1111\u002Fj.1600-6143.2009.02571.x",{"doi":2677},"10.1111\u002Fj.1600-6143.2009.02571.x",{"id":26,"text":2679,"url":26,"identifiers":2680},"Vitale, 2011, Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study, Lancet Oncol, 12, 654, 10.1016\u002FS1470-2045(11)70144-9",{"doi":2681},"10.1016\u002FS1470-2045(11)70144-9",{"id":26,"text":2683,"url":26,"identifiers":2684},"Berry, 2012, Are patients with Child’s a cirrhosis and hepatocellular carcinoma appropriate candidates for liver transplantation?, Am J Transplant, 12, 706, 10.1111\u002Fj.1600-6143.2011.03853.x",{"doi":2685},"10.1111\u002Fj.1600-6143.2011.03853.x",{"id":26,"text":2687,"url":26,"identifiers":2688},"Hsu, 2009, Predicting morbidity and mortality after hepatic resection in patients with hepatocellular carcinoma: the role of Model for End-Stage Liver Disease score, World J Surg, 33, 2412, 10.1007\u002Fs00268-009-0202-4",{"doi":2689},"10.1007\u002Fs00268-009-0202-4",{"id":26,"text":2691,"url":26,"identifiers":2692},"Roberts, 2010, Hepatocellular carcinoma: Ablate and wait vs. rapid transplantation, Liver Transpl, 16, 925, 10.1002\u002Flt.22103",{"doi":2693},"10.1002\u002Flt.22103",{"id":26,"text":2695,"url":26,"identifiers":2696},"Cucchetti, 2011, Improved diagnostic imaging and interventional therapies prolong survival after resection for hepatocellular carcinoma in cirrhosis: the university of bologna experience over 10 years, Ann Surg Oncol, 18, 1630, 10.1245\u002Fs10434-010-1463-8",{"doi":2697},"10.1245\u002Fs10434-010-1463-8",{"id":26,"text":2699,"url":26,"identifiers":2700},"Vibert, 2010, Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor, Am J Transplant, 10, 129, 10.1111\u002Fj.1600-6143.2009.02750.x",{"doi":2059},{"id":26,"text":2702,"url":26,"identifiers":2703},"Agopian VG, Harlander-Locke MP, Markovic D, Dumronggittigule W, Xia V, Kaldas FM, et al. Evaluation of Early Allograft Function Using the Liver Graft Assessment Following Transplantation Risk Score Model. JAMA Surg 2017.",{"doi":2704},"10.1001\u002Fjamasurg.2017.5040",{"id":26,"text":2706,"url":26,"identifiers":2707},"Ibrahim SM, Kulik L, Baker T, Ryu RK, Mulcahy MF, Abecassis M, et al. Treating and downstaging hepatocellular carcinoma in the caudate lobe with yttrium-90 radioembolization. Cardiovasc Interv Radiol n.d.; 35:1094–101.",{"doi":2708},"10.1007\u002Fs00270-011-0292-x",{"id":26,"text":2710,"url":26,"identifiers":2711},"Tsochatzis, 2013, Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma, Liver Int, 33, 944, 10.1111\u002Fliv.12144",{"doi":2712},"10.1111\u002Fliv.12144",{"id":26,"text":2714,"url":26,"identifiers":2715},"Parikh, 2015, Downstaging hepatocellular carcinoma: A systematic review and pooled analysis, Liver Transplant, 21, 1142, 10.1002\u002Flt.24169",{"doi":2716},"10.1002\u002Flt.24169",{"id":26,"text":2718,"url":26,"identifiers":2719},"Decaens, 2006, Impact of UCSF criteria according to pre- and post-OLT tumor features: Analysis of 479 patients listed for HCC with a short waiting time, Liver Transpl, 12, 1761, 10.1002\u002Flt.20884",{"doi":2720},"10.1002\u002Flt.20884",{"id":26,"text":2722,"url":26,"identifiers":2723},"Llovet, 2002, Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation, Gut, 50, 123, 10.1136\u002Fgut.50.1.123",{"doi":2724},"10.1136\u002Fgut.50.1.123",{"id":26,"text":2726,"url":26,"identifiers":2727},"Lei, 2013, Downstaging advanced hepatocellular carcinoma to the Milan criteria may provide a comparable outcome to conventional Milan criteria, J Gastrointest Surg, 17, 1440, 10.1007\u002Fs11605-013-2229-y",{"doi":2728},"10.1007\u002Fs11605-013-2229-y",{"id":26,"text":2730,"url":26,"identifiers":2731},"Bova, 2013, Predictive factors of downstaging of hepatocellular carcinoma beyond the Milan criteria treated with intra-arterial therapies, Cardiovasc Intervent Radiol, 36, 433, 10.1007\u002Fs00270-012-0458-1",{"doi":2732},"10.1007\u002Fs00270-012-0458-1",{"id":26,"text":2734,"url":26,"identifiers":2735},"Tsuchiya, 2014, Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma, Liver Transpl, 20, 291, 10.1002\u002Flt.23798",{"doi":2736},"10.1002\u002Flt.23798",{"id":26,"text":2738,"url":26,"identifiers":2739},"Finkenstedt, 2016, Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy, Liver Int, 36, 688, 10.1111\u002Fliv.12966",{"doi":2740},"10.1111\u002Fliv.12966",{"id":26,"text":2742,"url":26,"identifiers":2743},"Terzi, 2015, Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation, Liver Transpl, 21, 248, 10.1002\u002Flt.24041",{"doi":2744},"10.1002\u002Flt.24041",{"id":26,"text":2746,"url":26,"identifiers":2747},"Kim, 2015, Optimal methods for measuring eligibility for liver transplant in hepatocellular carcinoma patients undergoing transarterial chemoembolization, J Hepatol, 62, 1076, 10.1016\u002Fj.jhep.2014.12.013",{"doi":2748},"10.1016\u002Fj.jhep.2014.12.013",{"id":26,"text":2750,"url":26,"identifiers":2751},"Barakat, 2010, Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis, Liver Transpl, 16, 289, 10.1002\u002Flt.21994",{"doi":2752},"10.1002\u002Flt.21994",{"id":26,"text":2754,"url":26,"identifiers":2755},"Chapman, 2008, Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation, Ann Surg, 248, 617, 10.1097\u002FSLA.0b013e31818a07d4",{"doi":2756},"10.1097\u002FSLA.0b013e31818a07d4",{"id":26,"text":2758,"url":26,"identifiers":2759},"Nadalin, 2016, Living donor liver transplantation in Europe, Hepatobiliary Surg Nutr, 5, 159",{},{"id":26,"text":2761,"url":26,"identifiers":2762},"Fisher, 2007, Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation, Am J Transpl, 7, 1601, 10.1111\u002Fj.1600-6143.2007.01802.x",{"doi":2763},"10.1111\u002Fj.1600-6143.2007.01802.x",{"id":26,"text":2765,"url":26,"identifiers":2766},"Hong, 2016, Living donor liver transplantation for hepatocellular carcinoma in Seoul National University, HepatoBiliary Surg Nutr, 5, 453, 10.21037\u002Fhbsn.2016.08.07",{"doi":2767},"10.21037\u002Fhbsn.2016.08.07",{"id":26,"text":2769,"url":26,"identifiers":2770},"Lee, 2017, Macrovascular invasion is not an absolute contraindication for living donor liver transplantation, Liver Transplant, 23, 19, 10.1002\u002Flt.24610",{"doi":2771},"10.1002\u002Flt.24610",{"id":26,"text":2773,"url":26,"identifiers":2774},"Lim, 2014, Mistargeting after fusion imaging-guided percutaneous radiofrequency ablation of hepatocellular carcinomas, J Vasc Interv Radiol, 25, 307, 10.1016\u002Fj.jvir.2013.10.025",{"doi":2775},"10.1016\u002Fj.jvir.2013.10.025",{"id":26,"text":2777,"url":26,"identifiers":2778},"Hakime, 2012, Electromagnetic-tracked biopsy under ultrasound guidance: preliminary results, Cardiovasc Intervent Radiol, 35, 898, 10.1007\u002Fs00270-011-0278-8",{"doi":2779},"10.1007\u002Fs00270-011-0278-8",{"id":26,"text":2781,"url":26,"identifiers":2782},"Abdel-Rehim, 2015, Assessment of liver ablation using cone beam computed tomography, World J Gastroenterol, 21, 517, 10.3748\u002Fwjg.v21.i2.517",{"doi":2783},"10.3748\u002Fwjg.v21.i2.517",{"id":26,"text":2785,"url":26,"identifiers":2786},"Dietrich, 2016, EFSUMB guidelines on interventional ultrasound (INVUS), part III – abdominal treatment procedures (Short Version), Ultraschall Med, 37, 27, 10.1055\u002Fs-0035-1553965",{"doi":2787},"10.1055\u002Fs-0035-1553965",{"id":26,"text":2789,"url":26,"identifiers":2790},"Pompili, 2015, Single hepatocellular carcinoma smaller than 2 cm: are ethanol injection and radiofrequency ablation equally effective?, Anticancer Res, 35, 325",{},{"id":26,"text":2792,"url":26,"identifiers":2793},"Germani, 2010, Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis, J Hepatol, 52, 380, 10.1016\u002Fj.jhep.2009.12.004",{"doi":2794},"10.1016\u002Fj.jhep.2009.12.004",{"id":26,"text":2796,"url":26,"identifiers":2797},"Cho, 2009, Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies, Hepatology, 49, 453, 10.1002\u002Fhep.22648",{"doi":2798},"10.1002\u002Fhep.22648",{"id":26,"text":2800,"url":26,"identifiers":2801},"Orlando, 2009, Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials, Am J Gastroenterol, 104, 514, 10.1038\u002Fajg.2008.80",{"doi":2802},"10.1038\u002Fajg.2008.80",{"id":26,"text":2804,"url":26,"identifiers":2805},"Huo, 2003, Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study, Scand J Gastroenterol, 38, 770, 10.1080\u002F00365520310003048",{"doi":2806},"10.1080\u002F00365520310003048",{"id":26,"text":2808,"url":26,"identifiers":2809},"Schoppmeyer K, Weis S, Mössner J, Fleig WE. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database Syst Rev 2009:CD006745.",{"doi":2810},"10.1002\u002F14651858.CD006745.pub2",{"id":26,"text":2812,"url":26,"identifiers":2813},"Lee, 2014, Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis, Radiology, 270, 900, 10.1148\u002Fradiol.13130940",{"doi":2814},"10.1148\u002Fradiol.13130940",{"id":26,"text":2816,"url":26,"identifiers":2817},"Kang, 2016, Long-term therapeutic outcomes of radiofrequency ablation for subcapsular vs. nonsubcapsular hepatocellular carcinoma: a propensity score matched study, Radiology, 280, 300, 10.1148\u002Fradiol.2016151243",{"doi":2818},"10.1148\u002Fradiol.2016151243",{"id":26,"text":2820,"url":26,"identifiers":2821},"Francica, 2016, Radiofrequency and microwave ablation of subcapsular hepatocellular carcinoma accessed by direct puncture: Safety and efficacy, Eur J Radiol, 85, 739, 10.1016\u002Fj.ejrad.2016.01.020",{"doi":2822},"10.1016\u002Fj.ejrad.2016.01.020",{"id":26,"text":2824,"url":26,"identifiers":2825},"Seror, 2008, Large (>or=5.0-cm) HCCs: multipolar RF ablation with three internally cooled bipolar electrodes–initial experience in 26 patients, Radiology, 248, 288, 10.1148\u002Fradiol.2481071101",{"doi":2826},"10.1148\u002Fradiol.2481071101",{"id":26,"text":2828,"url":26,"identifiers":2829},"Seror, 2016, Hepatocellular carcinoma within Milan criteria: no-touch multibipolar radiofrequency ablation for treatment-long-term results, Radiology, 280, 981, 10.1148\u002Fradiol.2016164017",{"doi":2830},"10.1148\u002Fradiol.2016164017",{"id":26,"text":2832,"url":26,"identifiers":2833},"Cartier, 2016, Radiofrequency ablation of hepatocellular carcinoma: Mono or multipolar?, J Gastroenterol Hepatol, 31, 654, 10.1111\u002Fjgh.13179",{"doi":2834},"10.1111\u002Fjgh.13179",{"id":26,"text":2836,"url":26,"identifiers":2837},"Wang, 2016, Efficacy and safety of radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinomas compared with radiofrequency ablation alone: a time-to-event meta-analysis, Korean J Radiol, 17, 93, 10.3348\u002Fkjr.2016.17.1.93",{"doi":2838},"10.3348\u002Fkjr.2016.17.1.93",{"id":26,"text":2840,"url":26,"identifiers":2841},"Lan, 2016, Comparative efficacy of interventional therapies for early-stage hepatocellular carcinoma, Medicine, 95, e3185, 10.1097\u002FMD.0000000000003185",{"doi":2842},"10.1097\u002FMD.0000000000003185",{"id":26,"text":2844,"url":26,"identifiers":2845},"Qi, 2016, Management of hepatocellular carcinoma: anoverview of major findings from meta-analyses, Oncotarget, 7, 34703, 10.18632\u002Foncotarget.9157",{"doi":2846},"10.18632\u002Foncotarget.9157",{"id":26,"text":2848,"url":26,"identifiers":2849},"Majumdar A, Roccarina D, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with early- or very early-stage hepatocellular carcinoma. Cochrane Database Syst Rev 2017;3:CD011650.",{"doi":2850},"10.1002\u002F14651858.CD011650.pub2",{"id":26,"text":2852,"url":26,"identifiers":2853},"Leoni, 2014, Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: Experience of the Bologna Liver Oncology Group, Dig Liver Dis, 46, 549, 10.1016\u002Fj.dld.2014.02.012",{"doi":2854},"10.1016\u002Fj.dld.2014.02.012",{"id":26,"text":2856,"url":26,"identifiers":2857},"Poulou, 2015, Percutaneous microwave ablation vs. radiofrequency ablation in the treatment of hepatocellular carcinoma, World J Hepatol, 7, 1054, 10.4254\u002Fwjh.v7.i8.1054",{"doi":2858},"10.4254\u002Fwjh.v7.i8.1054",{"id":26,"text":2860,"url":26,"identifiers":2861},"Facciorusso, 2016, Microwave ablation vs. radiofrequency ablation for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis, Int J Hyperthermia, 32, 339, 10.3109\u002F02656736.2015.1127434",{"doi":2862},"10.3109\u002F02656736.2015.1127434",{"id":26,"text":2864,"url":26,"identifiers":2865},"Brunello, 2013, Radiofrequency ablation: technical and clinical long-term outcomes for single hepatocellular carcinoma up to 30 mm, Eur J Gastroenterol Hepatol, 25, 842, 10.1097\u002FMEG.0b013e32835ee5f1",{"doi":2866},"10.1097\u002FMEG.0b013e32835ee5f1",{"id":26,"text":2868,"url":26,"identifiers":2869},"Hoffmann, 2013, Comparison of four microwave ablation devices: an experimental study in ex vivo bovine liver, Radiology, 268, 89, 10.1148\u002Fradiol.13121127",{"doi":2870},"10.1148\u002Fradiol.13121127",{"id":26,"text":2872,"url":26,"identifiers":2873},"Di Costanzo, 2015, Radiofrequency ablation vs. laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial, J Gastroenterol Hepatol, 30, 559, 10.1111\u002Fjgh.12791",{"doi":2874},"10.1111\u002Fjgh.12791",{"id":26,"text":2876,"url":26,"identifiers":2877},"Francica, 2012, Effectiveness, safety, and local progression after percutaneous laser ablation for hepatocellular carcinoma nodules up to 4 cm are not affected by tumor location, AJR Am J Roentgenol, 199, 1393, 10.2214\u002FAJR.11.7850",{"doi":2878},"10.2214\u002FAJR.11.7850",{"id":26,"text":2880,"url":26,"identifiers":2881},"Wang, 2015, Multicenter randomized controlled trial of percutaneous cryoablation vs. radiofrequency ablation in hepatocellular carcinoma, Hepatology, 61, 1579, 10.1002\u002Fhep.27548",{"doi":2882},"10.1002\u002Fhep.27548",{"id":26,"text":2884,"url":26,"identifiers":2885},"Cheng, 2015, Irreversible electroporation can effectively ablate hepatocellular carcinoma to complete pathologic necrosis, J Vasc Interv Radiol, 26, 1184, 10.1016\u002Fj.jvir.2015.05.014",{"doi":2886},"10.1016\u002Fj.jvir.2015.05.014",{"id":26,"text":2888,"url":26,"identifiers":2889},"Sutter, 2017, Safety and efficacy of irreversible electroporation for the treatment of hepatocellular carcinoma not amenable to thermal ablation techniques: a retrospective single-center case series, Radiology, 284, 877, 10.1148\u002Fradiol.2017161413",{"doi":2890},"10.1148\u002Fradiol.2017161413",{"id":26,"text":2892,"url":26,"identifiers":2893},"Zhang, 2009, High-intensity focused ultrasound (HIFU): effective and safe therapy for hepatocellular carcinoma adjacent to major hepatic veins, Eur Radiol, 19, 437, 10.1007\u002Fs00330-008-1137-0",{"doi":2894},"10.1007\u002Fs00330-008-1137-0",{"id":26,"text":2896,"url":26,"identifiers":2897},"Ng, 2011, High-intensity focused ultrasound for hepatocellular carcinoma: a single-center experience, Ann Surg, 253, 981, 10.1097\u002FSLA.0b013e3182128a8b",{"doi":2898},"10.1097\u002FSLA.0b013e3182128a8b",{"id":26,"text":2900,"url":26,"identifiers":2901},"Nabavizadeh, 2017, Stereotactic body radiotherapy for patients with hepatocellular carcinoma and intermediate grade cirrhosis, Lancet Oncol, 18, e192, 10.1016\u002FS1470-2045(17)30162-6",{"doi":2902},"10.1016\u002FS1470-2045(17)30162-6",{"id":26,"text":2904,"url":26,"identifiers":2905},"Huo, 2015, Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis, JAMA Oncol, 1, 756, 10.1001\u002Fjamaoncol.2015.2189",{"doi":2906},"10.1001\u002Fjamaoncol.2015.2189",{"id":26,"text":2908,"url":26,"identifiers":2909},"Abdel-Rahman O, Elsayed Z. External beam radiotherapy for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2017;3:CD011314.",{"doi":2910},"10.1002\u002F14651858.CD011314.pub2",{"id":26,"text":2912,"url":26,"identifiers":2913},"Bush, 2016, Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis, Int J Radiat Oncol, 95, 477, 10.1016\u002Fj.ijrobp.2016.02.027",{"doi":2914},"10.1016\u002Fj.ijrobp.2016.02.027",{"id":26,"text":2916,"url":26,"identifiers":2917},"Cha, 2017, Clinical practice patterns of radiotherapy in patients with hepatocellular carcinoma: a Korean radiation oncology group study (KROG 14–07), Cancer Res Treat, 49, 61, 10.4143\u002Fcrt.2016.097",{"doi":2918},"10.4143\u002Fcrt.2016.097",{"id":26,"text":2920,"url":26,"identifiers":2921},"Im, 2017, Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area, Liver Int, 37, 90, 10.1111\u002Fliv.13191",{"doi":2922},"10.1111\u002Fliv.13191",{"id":26,"text":2924,"url":26,"identifiers":2925},"Choi, 2017, The possibility of radiotherapy as downstaging to living donor liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus, Liver Transpl, 23, 545, 10.1002\u002Flt.24729",{"doi":2926},"10.1002\u002Flt.24729",{"id":26,"text":2928,"url":26,"identifiers":2929},"Jeong, 2017, Liver transplantation after transarterial chemoembolization and radiotherapy for hepatocellular carcinoma with vascular invasion, J Gastrointest Surg, 21, 275, 10.1007\u002Fs11605-016-3302-0",{"doi":2930},"10.1007\u002Fs11605-016-3302-0",{"id":26,"text":2932,"url":26,"identifiers":2933},"Berger, 2017, External radiation or ablation for solitary hepatocellular carcinoma: A survival analysis of the SEER database, J Surg Oncol, 116, 307, 10.1002\u002Fjso.24661",{"doi":2934},"10.1002\u002Fjso.24661",{"id":26,"text":2936,"url":26,"identifiers":2937},"Sapisochin, 2017, Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis, J Hepatol, 67, 92, 10.1016\u002Fj.jhep.2017.02.022",{"doi":2938},"10.1016\u002Fj.jhep.2017.02.022",{"id":26,"text":2940,"url":26,"identifiers":2941},"Park, 2014, Current practice and future clinical trials, Liver Cancer, 2016, 162",{},{"id":26,"text":2943,"url":26,"identifiers":2944},"Keane, 2016, Liver-directed radiotherapy for hepatocellular carcinoma, Liver Cancer, 5, 198, 10.1159\u002F000367764",{"doi":2945},"10.1159\u002F000367764",{"id":26,"text":2947,"url":26,"identifiers":2948},"Feng M, Suresh K, Schipper MJ, Bazzi L, Ben-Josef E, Matuszak MM, et al. Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial. JAMA Oncol 2017.",{"doi":2949},"10.1001\u002Fjamaoncol.2017.2303",{"id":26,"text":2951,"url":26,"identifiers":2952},"Park, 2015, Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study, Liver Int, 35, 2155, 10.1111\u002Fliv.12818",{"doi":2953},"10.1111\u002Fliv.12818",{"id":26,"text":2955,"url":26,"identifiers":2956},"Sangro, 2011, Transarterial therapies for hepatocellular carcinoma, Expert Opin Pharmacother, 12, 1057, 10.1517\u002F14656566.2011.545346",{"doi":2957},"10.1517\u002F14656566.2011.545346",{"id":26,"text":2959,"url":26,"identifiers":2960},"Sangro, 2014, Transarterial chemoembolization and radioembolization, Semin Liver Dis, 34, 435, 10.1055\u002Fs-0034-1394142",{"doi":2961},"10.1055\u002Fs-0034-1394142",{"id":26,"text":2963,"url":26,"identifiers":2964},"de Baere, 2016, Treatment of liver tumors with lipiodol TACE: technical recommendations from experts opinion, Cardiovasc Intervent Radiol, 39, 334, 10.1007\u002Fs00270-015-1208-y",{"doi":2965},"10.1007\u002Fs00270-015-1208-y",{"id":26,"text":2967,"url":26,"identifiers":2968},"Takayasu, 2010, Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis, AJR Am J Roentgenol, 194, 830, 10.2214\u002FAJR.09.3308",{"doi":2969},"10.2214\u002FAJR.09.3308",{"id":26,"text":2971,"url":26,"identifiers":2972},"Lencioni, 2016, Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data, Hepatology, 64, 106, 10.1002\u002Fhep.28453",{"doi":2973},"10.1002\u002Fhep.28453",{"id":26,"text":2975,"url":26,"identifiers":2976},"Boulin, 2011, Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma, Anticancer Drugs, 22, 741, 10.1097\u002FCAD.0b013e328346a0c5",{"doi":2977},"10.1097\u002FCAD.0b013e328346a0c5",{"id":26,"text":2979,"url":26,"identifiers":2980},"Boulin, 2016, Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin, Eur Radiol, 26, 601, 10.1007\u002Fs00330-015-3855-4",{"doi":2981},"10.1007\u002Fs00330-015-3855-4",{"id":26,"text":2983,"url":26,"identifiers":2984},"Cammà, 2002, Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials, Radiology, 224, 47, 10.1148\u002Fradiol.2241011262",{"doi":2985},"10.1148\u002Fradiol.2241011262",{"id":26,"text":2987,"url":26,"identifiers":2988},"Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011;3:CD004787.",{"doi":2989},"10.1002\u002F14651858.CD004787.pub2",{"id":26,"text":2991,"url":26,"identifiers":2992},"Ogasawara, 2017, A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization, Hepatology",{},{"id":26,"text":2994,"url":26,"identifiers":2995},"Varela, 2007, Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics, J Hepatol, 46, 474, 10.1016\u002Fj.jhep.2006.10.020",{"doi":2996},"10.1016\u002Fj.jhep.2006.10.020",{"id":26,"text":2998,"url":26,"identifiers":2999},"Lammer, 2010, Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study, Cardiovasc Interv Radiol, 33, 41, 10.1007\u002Fs00270-009-9711-7",{"doi":3000},"10.1007\u002Fs00270-009-9711-7",{"id":26,"text":3002,"url":26,"identifiers":3003},"Golfieri, 2014, Randomised controlled trial of doxorubicin-eluting beads vs. conventional chemoembolisation for hepatocellular carcinoma, Br J Cancer, 111, 255, 10.1038\u002Fbjc.2014.199",{"doi":3004},"10.1038\u002Fbjc.2014.199",{"id":26,"text":3006,"url":26,"identifiers":3007},"Gao, 2013, Doxorubicin-eluting bead vs. conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis, Hepatogastroenterology, 60, 813",{},{"id":26,"text":3009,"url":26,"identifiers":3010},"Monier, 2017, Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion, Eur Radiol, 27, 1431, 10.1007\u002Fs00330-016-4488-y",{"doi":3011},"10.1007\u002Fs00330-016-4488-y",{"id":26,"text":3013,"url":26,"identifiers":3014},"Silva, 2017, Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis, HPB, 19, 659, 10.1016\u002Fj.hpb.2017.04.016",{"doi":3015},"10.1016\u002Fj.hpb.2017.04.016",{"id":26,"text":3017,"url":26,"identifiers":3018},"Ronot, 2016, Cone-beam CT angiography for determination of tumor-feeding vessels during chemoembolization of liver tumors: comparison of conventional and dedicated-software analysis, J Vasc Interv Radiol, 27, 32, 10.1016\u002Fj.jvir.2015.09.010",{"doi":3019},"10.1016\u002Fj.jvir.2015.09.010",{"id":26,"text":3021,"url":26,"identifiers":3022},"A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 1995;332:1256–61.",{"doi":3023},"10.1056\u002FNEJM199505113321903",{"id":26,"text":3025,"url":26,"identifiers":3026},"Sieghart, 2013, The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma, Hepatology, 57, 2261, 10.1002\u002Fhep.26256",{"doi":3027},"10.1002\u002Fhep.26256",{"id":26,"text":3029,"url":26,"identifiers":3030},"Hucke, 2014, The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE, J Hepatol, 60, 118, 10.1016\u002Fj.jhep.2013.08.022",{"doi":3031},"10.1016\u002Fj.jhep.2013.08.022",{"id":26,"text":3033,"url":26,"identifiers":3034},"Adhoute, 2015, Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process, J Hepatol, 62, 855, 10.1016\u002Fj.jhep.2014.11.014",{"doi":3035},"10.1016\u002Fj.jhep.2014.11.014",{"id":26,"text":3037,"url":26,"identifiers":3038},"Kadalayil, 2013, A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer, Ann Oncol, 24, 2565, 10.1093\u002Fannonc\u002Fmdt247",{"doi":3039},"10.1093\u002Fannonc\u002Fmdt247",{"id":26,"text":3041,"url":26,"identifiers":3042},"Arizumi, 2015, Evaluation of ART scores for repeated transarterial chemoembolization in Japanese patients with hepatocellular carcinoma, Oncology, 89, 4, 10.1159\u002F000440625",{"doi":3043},"10.1159\u002F000440625",{"id":26,"text":3045,"url":26,"identifiers":3046},"Kudo, 2014, Assessment for retreatment (ART) score for repeated transarterial chemoembolization in patients with hepatocellular carcinoma, Hepatology, 59, 2424, 10.1002\u002Fhep.26760",{"doi":3047},"10.1002\u002Fhep.26760",{"id":26,"text":3049,"url":26,"identifiers":3050},"Terzi, 2014, The ART score is not effective to select patients for transarterial chemoembolization retreatment in an Italian series, Dig Dis, 32, 711, 10.1159\u002F000368007",{"doi":3051},"10.1159\u002F000368007",{"id":26,"text":3053,"url":26,"identifiers":3054},"Pipa-Muñiz, 2017, The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study, Gastroenterol Hepatol, 40, 515, 10.1016\u002Fj.gastrohep.2017.05.009",{"doi":3055},"10.1016\u002Fj.gastrohep.2017.05.009",{"id":26,"text":3057,"url":26,"identifiers":3058},"Peng, 2013, Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial, J Clin Oncol, 31, 426, 10.1200\u002FJCO.2012.42.9936",{"doi":3059},"10.1200\u002FJCO.2012.42.9936",{"id":26,"text":3061,"url":26,"identifiers":3062},"Iezzi, 2015, Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma, Dig Liver Dis, 47, 242, 10.1016\u002Fj.dld.2014.12.007",{"doi":3063},"10.1016\u002Fj.dld.2014.12.007",{"id":26,"text":3065,"url":26,"identifiers":3066},"Lencioni, 2016, Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial, J Hepatol, 64, 1090, 10.1016\u002Fj.jhep.2016.01.012",{"doi":3067},"10.1016\u002Fj.jhep.2016.01.012",{"id":26,"text":3069,"url":26,"identifiers":3070},"Chao, 2015, The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: Final results of the START trial, Int J Cancer, 136, 1458, 10.1002\u002Fijc.29126",{"doi":3071},"10.1002\u002Fijc.29126",{"id":26,"text":3073,"url":26,"identifiers":3074},"Meyer, 2017, Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial, Lancet Gastroenterol Hepatol, 2, 565, 10.1016\u002FS2468-1253(17)30156-5",{"doi":3075},"10.1016\u002FS2468-1253(17)30156-5",{"id":26,"text":3077,"url":26,"identifiers":3078},"Kudo, 2014, Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial, Hepatology, 60, 1697, 10.1002\u002Fhep.27290",{"doi":3079},"10.1002\u002Fhep.27290",{"id":26,"text":3081,"url":26,"identifiers":3082},"Kudo, 2018, Orantinib vs. placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study, Lancet Gastroenterol Hepatol, 3, 37, 10.1016\u002FS2468-1253(17)30290-X",{"doi":3083},"10.1016\u002FS2468-1253(17)30290-X",{"id":26,"text":3085,"url":26,"identifiers":3086},"Marelli, 2007, Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies, Cardiovasc Intervent Radiol, 30, 6, 10.1007\u002Fs00270-006-0062-3",{"doi":3087},"10.1007\u002Fs00270-006-0062-3",{"id":26,"text":3089,"url":26,"identifiers":3090},"Xie, 2014, Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review, Tumour Biol, 35, 8451, 10.1007\u002Fs13277-014-2340-z",{"doi":3091},"10.1007\u002Fs13277-014-2340-z",{"id":26,"text":3093,"url":26,"identifiers":3094},"Meyer, 2013, A randomised phase II\u002FIII trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs. embolisation alone for hepatocellular carcinoma, Br J Cancer, 108, 1252, 10.1038\u002Fbjc.2013.85",{"doi":3095},"10.1038\u002Fbjc.2013.85",{"id":26,"text":3097,"url":26,"identifiers":3098},"Brown, 2016, Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone, J Clin Oncol, 34, 2046, 10.1200\u002FJCO.2015.64.0821",{"doi":3099},"10.1200\u002FJCO.2015.64.0821",{"id":26,"text":3101,"url":26,"identifiers":3102},"Pomfret, 2010, Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States, Liver Transpl, 16, 262, 10.1002\u002Flt.21999",{"doi":3103},"10.1002\u002Flt.21999",{"id":26,"text":3105,"url":26,"identifiers":3106},"Bargellini, 2014, Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the Italian Society of Interventional Radiology, Cardiovasc Intervent Radiol, 37, 438, 10.1007\u002Fs00270-013-0656-5",{"doi":3107},"10.1007\u002Fs00270-013-0656-5",{"id":26,"text":3109,"url":26,"identifiers":3110},"Terzi, 2012, Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”, J Hepatol, 57, 1258, 10.1016\u002Fj.jhep.2012.07.025",{"doi":3111},"10.1016\u002Fj.jhep.2012.07.025",{"id":26,"text":3113,"url":26,"identifiers":3114},"Raoul, 1997, Prospective randomized trial of chemoembolization vs. intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma, Hepatology, 26, 1156",{},{"id":26,"text":3116,"url":26,"identifiers":3117},"Kulik, 2008, Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis, Hepatology, 47, 71, 10.1002\u002Fhep.21980",{"doi":3118},"10.1002\u002Fhep.21980",{"id":26,"text":3120,"url":26,"identifiers":3121},"Salem, 2010, Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes, Gastroenterology, 138, 52, 10.1053\u002Fj.gastro.2009.09.006",{"doi":3122},"10.1053\u002Fj.gastro.2009.09.006",{"id":26,"text":3124,"url":26,"identifiers":3125},"Sangro, 2011, Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation, Hepatology, 54, 868, 10.1002\u002Fhep.24451",{"doi":3126},"10.1002\u002Fhep.24451",{"id":26,"text":3128,"url":26,"identifiers":3129},"Hilgard, 2010, Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival, Hepatology, 52, 1741, 10.1002\u002Fhep.23944",{"doi":3130},"10.1002\u002Fhep.23944",{"id":26,"text":3132,"url":26,"identifiers":3133},"Golfieri, 2013, Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma, J Hepatol, 59, 753, 10.1016\u002Fj.jhep.2013.05.025",{"doi":3134},"10.1016\u002Fj.jhep.2013.05.025",{"id":26,"text":3136,"url":26,"identifiers":3137},"Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux G-P, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 2017;Dec;18:1624–36.",{},{"id":26,"text":3139,"url":26,"identifiers":3140},"Chow PKH, Gandhi M, Tan S-B, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: Selective Internal Radiation Therapy vs. Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol 2018:JCO.2017.76.089.",{},{"id":26,"text":3142,"url":26,"identifiers":3143},"Salem, 2011, Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma, Gastroenterology, 140, 497, 10.1053\u002Fj.gastro.2010.10.049",{"doi":3144},"10.1053\u002Fj.gastro.2010.10.049",{"id":26,"text":3146,"url":26,"identifiers":3147},"Salem, 2013, Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization, Clin Gastroenterol Hepatol, 11, 1358, 10.1016\u002Fj.cgh.2013.04.028",{"doi":3148},"10.1016\u002Fj.cgh.2013.04.028",{"id":26,"text":3150,"url":26,"identifiers":3151},"Salem, 2016, Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma, Gastroenterology, 151, 1155, 10.1053\u002Fj.gastro.2016.08.029",{"doi":3152},"10.1053\u002Fj.gastro.2016.08.029",{"id":26,"text":3154,"url":26,"identifiers":3155},"Garlipp, 2014, Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization, Hepatology, 59, 1864, 10.1002\u002Fhep.26947",{"doi":3156},"10.1002\u002Fhep.26947",{"id":26,"text":3158,"url":26,"identifiers":3159},"Zucman-Rossi, 2015, Genetic landscape and biomarkers of hepatocellular carcinoma, Gastroenterology, 149, 1226, 10.1053\u002Fj.gastro.2015.05.061",{"doi":3160},"10.1053\u002Fj.gastro.2015.05.061",{"id":26,"text":3162,"url":26,"identifiers":3163},"Llovet, 2015, Advances in targeted therapies for hepatocellular carcinoma in the genomic era, Nat Rev Clin Oncol, 12, 408, 10.1038\u002Fnrclinonc.2015.103",{"doi":3164},"10.1038\u002Fnrclinonc.2015.103",{"id":26,"text":3166,"url":26,"identifiers":3167},"Schulze, 2015, Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets, Nat Genet, 47, 505, 10.1038\u002Fng.3252",{"doi":3168},"10.1038\u002Fng.3252",{"id":26,"text":3170,"url":26,"identifiers":3171},"El-Khoueiry, 2017, Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\u002F2 dose escalation and expansion trial, Lancet, 6736, 1",{},{"id":26,"text":3173,"url":26,"identifiers":3174},"Johnson, 2013, Brivanib vs. sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study, J Clin Oncol, 31, 3517, 10.1200\u002FJCO.2012.48.4410",{"doi":3175},"10.1200\u002FJCO.2012.48.4410",{"id":26,"text":3177,"url":26,"identifiers":3178},"Cainap C, Qin S, Huang W-T, Chung IJ, Pan H, Cheng Y, et al. Linifanib vs. Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial. J Clin Oncol 2015;Jan10, 33:172–9.",{"doi":3179},"10.1200\u002FJCO.2013.54.3298",{"id":26,"text":3181,"url":26,"identifiers":3182},"Cheng, 2013, Sunitinib vs. sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial, J Clin Oncol, 31, 4067, 10.1200\u002FJCO.2012.45.8372",{"doi":3183},"10.1200\u002FJCO.2012.45.8372",{"id":26,"text":3185,"url":26,"identifiers":3186},"Zhu, 2015, SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma, J Clin Oncol, 33, 559, 10.1200\u002FJCO.2013.53.7746",{"doi":3187},"10.1200\u002FJCO.2013.53.7746",{"id":26,"text":3189,"url":26,"identifiers":3190},"Abou-Alfa, 2010, Doxorubicin plus sorafenib vs. doxorubicin alone in patients with advanced hepatocellular carcinoma, JAMA, 304, 2154, 10.1001\u002Fjama.2010.1672",{"doi":3191},"10.1001\u002Fjama.2010.1672",{"id":26,"text":3193,"url":26,"identifiers":3194},"Qin, 2013, Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil\u002Fleucovorin vs. doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia, J Clin Oncol, 31, 3501, 10.1200\u002FJCO.2012.44.5643",{"doi":3195},"10.1200\u002FJCO.2012.44.5643",{"id":26,"text":3197,"url":26,"identifiers":3198},"Llovet, 2013, Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study, J Clin Oncol, 31, 3509, 10.1200\u002FJCO.2012.47.3009",{"doi":3199},"10.1200\u002FJCO.2012.47.3009",{"id":26,"text":3201,"url":26,"identifiers":3202},"Zhu, 2014, Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial, JAMA, 312, 57, 10.1001\u002Fjama.2014.7189",{"doi":3203},"10.1001\u002Fjama.2014.7189",{"id":26,"text":3205,"url":26,"identifiers":3206},"Rimassa L, Assenat E, Peck-Radosavljevic M, Zagonel V, Pracht M, Caremoli ER, et al. Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC). Lancet Oncol. 2018 Apr 3. pii: S1470-2045(18)30146-3. doi: 10.1016\u002FS1470-2045(18)30146-3. [Epub ahead of print].",{"doi":3207},"10.1016\u002FS1470-2045(18)30146-3",{"id":26,"text":3209,"url":26,"identifiers":3210},"Llovet, 2014, Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design, Clin Cancer Res, 20, 2072, 10.1158\u002F1078-0432.CCR-13-0547",{"doi":3211},"10.1158\u002F1078-0432.CCR-13-0547",{"id":26,"text":3213,"url":26,"identifiers":3214},"Abou-Alfa, 2006, Phase II study of sorafenib in patients with advanced hepatocellular carcinoma, J Clin Oncol, 24, 4293, 10.1200\u002FJCO.2005.01.3441",{"doi":3215},"10.1200\u002FJCO.2005.01.3441",{"id":26,"text":3217,"url":26,"identifiers":3218},"Iavarone, 2011, Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy, Hepatology, 54, 2055, 10.1002\u002Fhep.24644",{"doi":3219},"10.1002\u002Fhep.24644",{"id":26,"text":3221,"url":26,"identifiers":3222},"Ganten, 2017, Sorafenib in patients with hepatocellular carcinoma—results of the observational INSIGHT study, Clin Cancer Res, 23, 5720, 10.1158\u002F1078-0432.CCR-16-0919",{"doi":3223},"10.1158\u002F1078-0432.CCR-16-0919",{"id":26,"text":3225,"url":26,"identifiers":3226},"Lencioni, 2014, GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafeNib): second interim analysis, Int J Clin Pract, 68, 609, 10.1111\u002Fijcp.12352",{"doi":3227},"10.1111\u002Fijcp.12352",{"id":26,"text":3229,"url":26,"identifiers":3230},"Reig, 2013, Post-progression survival of patients with advanced hepatocellular carcinoma. Rationale for second line trial design, Hepatology, 58, 2023, 10.1002\u002Fhep.26586",{"doi":3231},"10.1002\u002Fhep.26586",{"id":26,"text":3233,"url":26,"identifiers":3234},"Hollebecque, 2011, Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score, Aliment Pharmacol Ther, 34, 1193, 10.1111\u002Fj.1365-2036.2011.04860.x",{"doi":3235},"10.1111\u002Fj.1365-2036.2011.04860.x",{"id":26,"text":3237,"url":26,"identifiers":3238},"Kim, 2011, Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function, Cancer Chemother Pharmacol, 68, 1285, 10.1007\u002Fs00280-011-1616-x",{"doi":3239},"10.1007\u002Fs00280-011-1616-x",{"id":26,"text":3241,"url":26,"identifiers":3242},"Marrero, 2016, Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study, J Hepatol, 65, 1140, 10.1016\u002Fj.jhep.2016.07.020",{"doi":3243},"10.1016\u002Fj.jhep.2016.07.020",{"id":26,"text":3245,"url":26,"identifiers":3246},"Matsui, 2008, Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase, Clin Cancer Res, 14, 5459, 10.1158\u002F1078-0432.CCR-07-5270",{"doi":3247},"10.1158\u002F1078-0432.CCR-07-5270",{"id":26,"text":3249,"url":26,"identifiers":3250},"Park, 2011, Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma, Clin Cancer Res, 17, 1973, 10.1158\u002F1078-0432.CCR-10-2011",{"doi":3251},"10.1158\u002F1078-0432.CCR-10-2011",{"id":26,"text":3253,"url":26,"identifiers":3254},"Spratlin, 2010, Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2, J Clin Oncol, 28, 780, 10.1200\u002FJCO.2009.23.7537",{"doi":3255},"10.1200\u002FJCO.2009.23.7537",{"id":26,"text":3257,"url":26,"identifiers":3258},"Villanueva, 2011, Targeted therapies for hepatocellular carcinoma, Gastroenterology, 140, 1410, 10.1053\u002Fj.gastro.2011.03.006",{"doi":3259},"10.1053\u002Fj.gastro.2011.03.006",{"id":26,"text":3261,"url":26,"identifiers":3262},"Taieb, 2006, Medical treatments for hepatocellular carcinoma (HCC): what’s next?, Ann Oncol, 17, x308, 10.1093\u002Fannonc\u002Fmdl279",{"doi":3263},"10.1093\u002Fannonc\u002Fmdl279",{"id":26,"text":3265,"url":26,"identifiers":3266},"Gish, 2007, Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin, J Clin Oncol, 25, 3069, 10.1200\u002FJCO.2006.08.4046",{"doi":3267},"10.1200\u002FJCO.2006.08.4046",{"id":26,"text":3269,"url":26,"identifiers":3270},"Yeo, 2005, A randomized phase III study of doxorubicin vs. cisplatin\u002Finterferon alpha-2b\u002Fdoxorubicin\u002Ffluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma, J Natl Cancer Inst, 97, 1532, 10.1093\u002Fjnci\u002Fdji315",{"doi":3271},"10.1093\u002Fjnci\u002Fdji315",{"id":26,"text":3273,"url":26,"identifiers":3274},"Edeline, 2009, Guillygomac’h A, Boudjema K, Boucher E. Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study, World J Gastroenterol, 15, 713, 10.3748\u002Fwjg.15.713",{"doi":3275},"10.3748\u002Fwjg.15.713",{"id":26,"text":3277,"url":26,"identifiers":3278},"Chow, 2002, High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial, Hepatology, 36, 1221, 10.1053\u002Fjhep.2002.36824",{"doi":3279},"10.1053\u002Fjhep.2002.36824",{"id":26,"text":3281,"url":26,"identifiers":3282},"Barbare, 2005, Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma, J Clin Oncol, 23, 4338, 10.1200\u002FJCO.2005.05.470",{"doi":3283},"10.1200\u002FJCO.2005.05.470",{"id":26,"text":3285,"url":26,"identifiers":3286},"Grimaldi, 1998, Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial, J Clin Oncol, 16, 411, 10.1200\u002FJCO.1998.16.2.411",{"doi":3287},"10.1200\u002FJCO.1998.16.2.411",{"id":26,"text":3289,"url":26,"identifiers":3290},"Posey, 2005, Results of a phase 2\u002F3 open-label, randomized trial of T138067 vs. doxorubicin in chemotherapy-naive, unresectable hepatocellular carcinoma, J Clin Oncol, 23, 10.1200\u002Fjco.2005.23.16_suppl.4035",{"doi":3291},"10.1200\u002Fjco.2005.23.16_suppl.4035",{"id":26,"text":3293,"url":26,"identifiers":3294},"Wilhelm, 2011, Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity, Int J Cancer, 129, 245, 10.1002\u002Fijc.25864",{"doi":3295},"10.1002\u002Fijc.25864",{"id":26,"text":3297,"url":26,"identifiers":3298},"Kelley, 2017, Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study, Ann Oncol, 28, 528, 10.1093\u002Fannonc\u002Fmdw651",{"doi":3299},"10.1093\u002Fannonc\u002Fmdw651",{"id":26,"text":3301,"url":26,"identifiers":3302},"Santoro, 2013, Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study, Lancet Oncol, 14, 55, 10.1016\u002FS1470-2045(12)70490-4",{"doi":3303},"10.1016\u002FS1470-2045(12)70490-4",{"id":26,"text":3305,"url":26,"identifiers":3306},"Zhu AX, Finn RS, Cattan S, Edeline J, Ogasawara S, Palmer DH, et al. KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. J Clin Oncol 2018;36:abstr 2019.",{"doi":3307},"10.1200\u002FJCO.2018.36.4_suppl.209",{"id":26,"text":3309,"url":26,"identifiers":3310},"Kumar, 2014, Role of supportive care for terminal stage hepatocellular carcinoma, J Clin Exp Hepatol, 4, S130, 10.1016\u002Fj.jceh.2014.03.049",{"doi":3311},"10.1016\u002Fj.jceh.2014.03.049",{"id":26,"text":3313,"url":26,"identifiers":3314},"Miaskowski, 2004, Symptom clusters: the new frontier in symptom management research, J Natl Cancer Inst Monogr, 2004, 17, 10.1093\u002Fjncimonographs\u002Flgh023",{"doi":3315},"10.1093\u002Fjncimonographs\u002Flgh023",{"id":26,"text":3317,"url":26,"identifiers":3318},"Lin, 2004, Hospice palliative care for patients with hepatocellular carcinoma in Taiwan, Palliat Med, 18, 93, 10.1191\u002F0269216304pm851oa",{"doi":3319},"10.1191\u002F0269216304pm851oa",{"id":26,"text":3321,"url":26,"identifiers":3322},"Rakoski, 2015, Palliative care for patients with end-stage liver disease: An overview, Clin Liver Dis, 6, 19, 10.1002\u002Fcld.478",{"doi":3323},"10.1002\u002Fcld.478",{"id":26,"text":3325,"url":26,"identifiers":3326},"Imani, 2014, The therapeutic use of analgesics in patients with liver cirrhosis: a literature review and evidence-based recommendations, Hepat Mon, 14, e23539, 10.5812\u002Fhepatmon.23539",{"doi":3327},"10.5812\u002Fhepatmon.23539",{"id":26,"text":3329,"url":26,"identifiers":3330},"Hamilton J, Runyon B, Bonis P, et al. Management of pain in patients with cirrhosis.uptodateonline.com. http:\u002F\u002Fwww.uptodate.com\u002Fcontents\u002Fmanagement-of-pain-in-patients-with-advanced-chronic-liver-disease-or-cirrhosis n.d.",{},{"id":26,"text":3332,"url":26,"identifiers":3333},"Bosilkovska, 2012, Analgesics in patients with hepatic impairment: pharmacology and clinical implications, Drugs, 72, 1645, 10.2165\u002F11635500-000000000-00000",{"doi":3334},"10.2165\u002F11635500-000000000-00000",{"id":26,"text":3336,"url":26,"identifiers":3337},"Smith, 2012, Low absolute bioavailability of oral naloxone in healthy subjects, Int J Clin Pharmacol Ther, 50, 360, 10.5414\u002FCP201646",{"doi":3338},"10.5414\u002FCP201646",{"id":26,"text":3340,"url":26,"identifiers":3341},"Guerriero, 2016, Long-term efficacy and safety of oxycodone-naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study, Drug Des Devel Ther, 10, 1515, 10.2147\u002FDDDT.S106025",{"doi":3342},"10.2147\u002FDDDT.S106025",{"id":26,"text":3344,"url":26,"identifiers":3345},"Madeo, 2015, Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson’s disease patients with chronic pain, J Neurol, 262, 2164, 10.1007\u002Fs00415-015-7823-3",{"doi":3346},"10.1007\u002Fs00415-015-7823-3",{"id":26,"text":3348,"url":26,"identifiers":3349},"Hayashi, 2014, Palliative external-beam radiotherapy for bone metastases from hepatocellular carcinoma, World J Hepatol, 6, 923, 10.4254\u002Fwjh.v6.i12.923",{"doi":3350},"10.4254\u002Fwjh.v6.i12.923",{"id":26,"text":3352,"url":26,"identifiers":3353},"Jung, 2017, High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinoma, Oncotarget, 8, 15182, 10.18632\u002Foncotarget.14858",{"doi":3354},"10.18632\u002Foncotarget.14858",{"id":26,"text":3356,"url":26,"identifiers":3357},"Hiraoka, 2017, Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib, Hepatol Res, 47, 558, 10.1111\u002Fhepr.12780",{"doi":3358},"10.1111\u002Fhepr.12780",{"id":26,"text":3360,"url":26,"identifiers":3361},"Pinato, 2012, A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI), Br J Cancer, 106, 1439, 10.1038\u002Fbjc.2012.92",{"doi":3362},"10.1038\u002Fbjc.2012.92",{"id":26,"text":3364,"url":26,"identifiers":3365},"Hsu, 2012, Mini-nutritional assessment predicts functional status and quality of life of patients with hepatocellular carcinoma in Taiwan, Nutr Cancer, 64, 543, 10.1080\u002F01635581.2012.675620",{"doi":3366},"10.1080\u002F01635581.2012.675620",{"id":26,"text":3368,"url":26,"identifiers":3369},"Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of psychological distress by cancer site. Psychooncology n.d.; 10:19–28.",{"doi":3370},"10.1002\u002F1099-1611(200101\u002F02)10:1\u003C19::AID-PON501>3.0.CO;2-6",{"id":26,"text":3372,"url":26,"identifiers":3373},"Maguire, 1999, Improving communication with cancer patients, Eur J Cancer, 35, 2058, 10.1016\u002FS0959-8049(99)00301-9",{"doi":3374},"10.1016\u002FS0959-8049(99)00301-9",{"id":26,"text":3376,"url":26,"identifiers":3377},"Fallowfield, 1998, Teaching senior oncologists communication skills: results from phase I of a comprehensive longitudinal program in the United Kingdom, J Clin Oncol, 16, 1961, 10.1200\u002FJCO.1998.16.5.1961",{"doi":3378},"10.1200\u002FJCO.1998.16.5.1961",{"id":26,"text":3380,"url":26,"identifiers":3381},"Tapper, 2015, Psychoactive medications increase the risk of falls and fall-related injuries in hospitalized patients with cirrhosis, Clin Gastroenterol Hepatol, 13, 1670, 10.1016\u002Fj.cgh.2015.03.019",{"doi":3382},"10.1016\u002Fj.cgh.2015.03.019",{"id":26,"text":3384,"url":26,"identifiers":3385},"WHO definition of palliative care. Geneva, World Health Organization, 2010 (http:\u002F\u002Fwww.who.int\u002Fcancer\u002Fpalliative\u002F definition\u002Fen, accessed 18 June 2017) n.d.",{},{"id":26,"text":3387,"url":26,"identifiers":3388},"Levy, 2009, NCCN clinical practice guidelines in oncology: palliative care, J Natl Compr Canc Netw, 7, 436, 10.6004\u002Fjnccn.2009.0031",{"doi":3389},"10.6004\u002Fjnccn.2009.0031",{"id":26,"text":3391,"url":26,"identifiers":3392},"Hamano, 2015, Surprise questions for survival prediction in patients with advanced cancer: a multicenter prospective cohort study, Oncologist, 20, 839, 10.1634\u002Ftheoncologist.2015-0015",{"doi":3393},"10.1634\u002Ftheoncologist.2015-0015",{"id":26,"text":3395,"url":26,"identifiers":3396},"Hwang, 2013, Hospice offers more palliative care but costs less than usual care for terminal geriatric hepatocellular carcinoma patients: a nationwide study, J Palliat Med, 16, 780, 10.1089\u002Fjpm.2012.0482",{"doi":3397},"10.1089\u002Fjpm.2012.0482",{"id":26,"text":3399,"url":26,"identifiers":3400},"Oppong Y, Navarro VJ, Reville B, Sohal PKB, Parks S. Palliative Care for Hepatocellular Carcinoma Patients. Gastroenterology 2011;140:S-925.",{"doi":3401},"10.1016\u002FS0016-5085(11)63839-0",{"id":26,"text":3403,"url":26,"identifiers":3404},"Clements A, Greenslade L. Nursing care for end-stage liver disease. Nurs Times n.d.; 110:16–9.",{},{"id":26,"text":3406,"url":26,"identifiers":3407},"Fleming, 2005, Surrogate endpoints and FDA’s accelerated approval process, Health Aff, 24, 67, 10.1377\u002Fhlthaff.24.1.67",{"doi":3408},"10.1377\u002Fhlthaff.24.1.67",{"id":26,"text":3410,"url":26,"identifiers":3411},"Lee, 2016, TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials, Br J Cancer, 115, 1201, 10.1038\u002Fbjc.2016.322",{"doi":3412},"10.1038\u002Fbjc.2016.322",{"id":26,"text":3414,"url":26,"identifiers":3415},"Iavarone M, Cabibbo G, Biolato M, Della Corte C, Maida M, Barbara M, et al. Predictors of survival of patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. Hepatology 2015;Sep;62:784–91.",{"doi":3416},"10.1002\u002Fhep.27729",{"id":26,"text":3418,"url":26,"identifiers":3419},"Okita, 2015, Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study, J Gastroenterol, 50, 191, 10.1007\u002Fs00535-014-0956-9",{"doi":3420},"10.1007\u002Fs00535-014-0956-9",{"id":26,"text":3422,"url":26,"identifiers":3423},"Lencioni, 2013, New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma, Clin Cancer Res, 19, 1312, 10.1158\u002F1078-0432.CCR-12-3796",{"doi":3424},"10.1158\u002F1078-0432.CCR-12-3796",{"id":26,"text":3426,"url":26,"identifiers":3427},"Fiteni, 2014, Endpoints in cancer clinical trials, J Visc Surg, 151, 17, 10.1016\u002Fj.jviscsurg.2013.10.001",{"doi":3428},"10.1016\u002Fj.jviscsurg.2013.10.001",{"id":26,"text":3430,"url":26,"identifiers":3431},"Vouche, 2014, Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy, Hepatology, 60, 192, 10.1002\u002Fhep.27057",{"doi":3432},"10.1002\u002Fhep.27057",{"id":26,"text":3434,"url":26,"identifiers":3435},"Seyal, 2015, Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma, Hepatology, 62, 1111, 10.1002\u002Fhep.27915",{"doi":3436},"10.1002\u002Fhep.27915",{"id":26,"text":3438,"url":26,"identifiers":3439},"Bargellini, 2013, Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants, Eur J Radiol, 82, e212, 10.1016\u002Fj.ejrad.2012.12.009",{"doi":3440},"10.1016\u002Fj.ejrad.2012.12.009",{"id":26,"text":3442,"url":26,"identifiers":3443},"Vincenzi, 2015, Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based meta-analysis, PLoS One, 10, e0133488, 10.1371\u002Fjournal.pone.0133488",{"doi":3444},"10.1371\u002Fjournal.pone.0133488",{"id":26,"text":3446,"url":26,"identifiers":3447},"Lencioni, 2017, Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC, J Hepatol, 66, 1166, 10.1016\u002Fj.jhep.2017.01.012",{"doi":3448},"10.1016\u002Fj.jhep.2017.01.012",{"id":26,"text":3450,"url":26,"identifiers":3451},"Meyer, 2017, MRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs. sorafenib, Liver Int, 37, 1047, 10.1111\u002Fliv.13359",{"doi":3452},"10.1111\u002Fliv.13359",false,{"id":3455,"createTime":3456,"updateTime":3456,"relativeEntities":3457,"slug":3458,"properties":3459,"entityType":749,"verifyStatus":28,"verifyTime":3456,"verifyNote":3469,"syncStatus":28,"languages":3470,"translateLanguages":26,"viewCount":36,"primaryUrl":3471,"fullTextUrl":26,"authors":3472,"publicationType":895,"publisherRelationship":3480,"citationCount":3510,"citationInfo":3511,"publishDate":3524,"publishYear":3525,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":3526,"isForceReanalyzing":3453},"088ee56e-3ffc-4dc7-973e-e11cb21ddcf5","2024-12-18T12:18:37.667+00:00",[],"EASL-EORTC-Clinical-Practice-Guidelines-Management-of-hepatocellular-carcinoma",{"keywords":3460,"openalex":3461,"abstract":3463,"title":3464,"pm":3466,"doi":3468},{},{"VOID":3462},"W4245784696",{},{"EN":3465},"EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma",{"VOID":3467},"22424438",{"VOID":947},"Author title is blank",[102],"https:\u002F\u002Flinkinghub.elsevier.com\u002Fretrieve\u002Fpii\u002FS0168827811008737",[3473],{"id":3474,"sortIndex":36,"researcher":26,"roles":3475,"affiliations":3476,"properties":3477},"7b3ab5c1-f38f-4aac-b65b-3cb6db484305",[],[],{"title":3478},{"EN":3479},"",{"url":26,"publisher":3481,"properties":3503},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":3482,"slug":663,"properties":3483,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":3486,"manageAffiliations":3487,"indexDatabases":3488,"url":26,"thumbnailPath":26,"statistic":26,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"issn":3484,"title":3485},{"VOID":666},{"EN":668},[],[],[3489,3496],{"id":690,"indexDatabase":3490,"url":705,"indexYears":26,"academicFieldIds":3495,"indexDatabaseRanking":26},{"id":692,"createTime":693,"updateTime":694,"relativeEntities":3491,"label":3492,"description":3493,"key":701,"publicationTags":3494,"standard":26},[],{"EN":697,"VI":697},{"VI":699,"EN":700},[703,704],[707],{"id":709,"indexDatabase":3497,"url":722,"indexYears":723,"academicFieldIds":3502,"indexDatabaseRanking":726},{"id":711,"createTime":712,"updateTime":713,"relativeEntities":3498,"label":3499,"description":3500,"key":719,"publicationTags":3501,"standard":26},[],{"EN":716,"VI":716},{"EN":716,"VI":718},[721],[725],{"volume":3504,"pages":3506,"issue":3508},{"VOID":3505},"56",{"VOID":3507},"908-943",{"VOID":3509},"4",4985,{"total":3510,"publishYear":26,"statisticByYear":3512},{"2012":402,"2013":3513,"2014":3514,"2015":3515,"2016":3516,"2017":3517,"2018":3518,"2019":3519,"2020":3520,"2021":3521,"2022":3522,"2023":363,"2024":3523},238,407,556,551,675,632,441,383,349,272,167,"2012-04-01",2012,[3527,3530,3533,3537,3540,3544,3547,3549,3553,3556,3559,3561,3563,3565,3567,3569,3573,3576,3579,3581,3584,3587,3589,3591,3593,3597,3601,3603,3606,3610,3614,3618,3622,3626,3629,3633,3637,3640,3644,3648,3652,3656,3660,3664,3668,3672,3674,3678,3680,3683,3687,3691,3695,3699,3703,3706,3709,3713,3715,3718,3722,3726,3728,3732,3736,3738,3742,3744,3748,3750,3754,3756,3760,3762,3764,3768,3771,3773,3775,3777,3780,3784,3786,3788,3792,3794,3796,3798,3802,3804,3808,3810,3813,3817,3821,3825,3828,3831,3833,3835,3837,3840,3844,3846,3849,3851,3855,3859,3863,3865,3868,3872,3875,3879,3883,3886,3888,3892,3896,3900,3903,3905,3907,3911,3913,3917,3921,3923,3925,3927,3930,3932,3934,3936,3938,3942,3944,3948,3951,3954,3957,3961,3964,3968,3972,3975,3978,3981,3983,3985,3987,3990,3992,3996,3998,4002,4006,4010,4013,4016,4020,4023,4026,4030,4034,4038,4040,4043,4046,4049,4051,4055,4059,4063,4067,4071,4075,4078,4082,4084,4088,4090,4092,4094,4098,4102,4106,4110,4113,4117,4121,4125,4129,4133,4135,4139,4143,4147,4149,4153,4156,4160,4164,4168,4172,4174,4178,4182,4186,4189,4193,4197,4199,4203,4207,4211,4214,4217,4221,4224,4226,4230,4232,4234,4238,4242,4246,4250,4254,4256,4260,4264,4267,4270,4274,4278,4282,4286,4289,4292,4296,4300,4304,4308,4312,4316,4320,4324,4328,4332,4335,4339,4343,4347,4351,4355,4359,4361,4365,4367,4371,4375,4379,4383,4387,4389,4392,4396,4400,4403,4407,4411,4413,4415,4419,4423,4427,4431,4435,4439,4443,4447,4451,4453,4456,4460,4464,4468,4472,4475,4479,4483,4485,4488,4491,4494,4497,4499,4501,4503,4507,4511,4515,4519,4523,4527,4531,4535,4539,4543,4547,4551,4555,4559,4563,4567,4571,4575,4579,4583,4587,4589,4591,4593,4596,4599,4603,4606,4610,4614,4618,4622,4626,4630,4634,4636,4640,4644,4648,4650,4653,4655,4658,4662,4665,4667,4670,4672,4676,4680,4683,4686,4690,4694,4698,4702,4706,4710,4714,4716],{"id":26,"text":3528,"url":26,"identifiers":3529},"Bruix, 2001, EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver, J Hepatol, 35, 421, 10.1016\u002FS0168-8278(01)00130-1",{"doi":1554},{"id":26,"text":3531,"url":26,"identifiers":3532},"National Cancer Institute. PDQ® levels of evidence for adult and pediatric cancer treatment studies. Bethesda, MD: National Cancer Institute. Date last modified 26\u002FAugust\u002F2010. \u003Chttp:\u002F\u002Fcancer.gov\u002Fcancertopics\u002Fpdq\u002Flevels-evidence-adult-treatment\u002Fhealthprofessional\u002F>; 2011 [accessed 01.03.11].",{},{"id":26,"text":3534,"url":26,"identifiers":3535},"Parkin, 2005, Global cancer statistics, 2002, CA Cancer J Clin, 55, 74, 10.3322\u002Fcanjclin.55.2.74",{"doi":3536},"10.3322\u002Fcanjclin.55.2.74",{"id":26,"text":3538,"url":26,"identifiers":3539},"IARC. \u003Chttp:\u002F\u002Fwww-dep.iarc.fr\u002F>; 2011 [accessed 01.11.11].",{},{"id":26,"text":3541,"url":26,"identifiers":3542},"El-Serag, 1999, Rising incidence of hepatocellular carcinoma in the United States, N Engl J Med, 340, 745, 10.1056\u002FNEJM199903113401001",{"doi":3543},"10.1056\u002FNEJM199903113401001",{"id":26,"text":3545,"url":26,"identifiers":3546},"Tanaka, 2008, Declining incidence of hepatocellular carcinoma in Osaka, Japan from 1990 to 2003, Ann Intern Med, 148, 820, 10.7326\u002F0003-4819-148-11-200806030-00004",{"doi":967},{"id":26,"text":976,"url":26,"identifiers":3548},{"doi":978},{"id":26,"text":3550,"url":26,"identifiers":3551},"Jemal, 2008, Cancer statistics, 2008, CA Cancer J Clin, 58, 71, 10.3322\u002FCA.2007.0010",{"doi":3552},"10.3322\u002FCA.2007.0010",{"id":26,"text":3554,"url":26,"identifiers":3555},"Chang, 2009, Taiwan Hepatoma Study Group. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study, J Natl Cancer Inst, 101, 1348, 10.1093\u002Fjnci\u002Fdjp288",{"doi":994},{"id":26,"text":3557,"url":26,"identifiers":3558},"Sangiovanni, 2006, The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients, Hepatology, 43, 1303, 10.1002\u002Fhep.21176",{"doi":1001},{"id":26,"text":1003,"url":26,"identifiers":3560},{"doi":1005},{"id":26,"text":1007,"url":26,"identifiers":3562},{"doi":1009},{"id":26,"text":1011,"url":26,"identifiers":3564},{"doi":1013},{"id":26,"text":1019,"url":26,"identifiers":3566},{"doi":1021},{"id":26,"text":1023,"url":26,"identifiers":3568},{"doi":1025},{"id":26,"text":3570,"url":26,"identifiers":3571},"Lok, 2004, Prevention of hepatitis B virus-related hepatocellular carcinoma, Gastroenterology, 127, S303, 10.1053\u002Fj.gastro.2004.09.045",{"doi":3572},"10.1053\u002Fj.gastro.2004.09.045",{"id":26,"text":3574,"url":26,"identifiers":3575},"Yang, 2002, Taiwan Community–Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma, N Engl J Med, 347, 168, 10.1056\u002FNEJMoa013215",{"doi":1041},{"id":26,"text":3577,"url":26,"identifiers":3578},"Chen, 2006, REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level, JAMA, 295, 65, 10.1001\u002Fjama.295.1.65",{"doi":1045},{"id":26,"text":1047,"url":26,"identifiers":3580},{"doi":1049},{"id":26,"text":3582,"url":26,"identifiers":3583},"Iloeje, 2006, Risk Evaluation of Viral Load Elevation and Associated Liver Disease\u002FCancer–In HBV (the REVEAL–HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load, Gastroenterology, 130, 678, 10.1053\u002Fj.gastro.2005.11.016",{"doi":1053},{"id":26,"text":3585,"url":26,"identifiers":3586},"Raimondi, 2009, Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis, J Hepatol, 50, 1142, 10.1016\u002Fj.jhep.2009.01.019",{"doi":1057},{"id":26,"text":1063,"url":26,"identifiers":3588},{"doi":1065},{"id":26,"text":1075,"url":26,"identifiers":3590},{"doi":1077},{"id":26,"text":1091,"url":26,"identifiers":3592},{"doi":1093},{"id":26,"text":3594,"url":26,"identifiers":3595},"Polio, 1989, Hepatocellular carcinoma in Wilson’s disease. Case report and review of the literature, J Clin Gastroenterol, 11, 220, 10.1097\u002F00004836-198904000-00022",{"doi":3596},"10.1097\u002F00004836-198904000-00022",{"id":26,"text":3598,"url":26,"identifiers":3599},"El-Serag, 2001, The role of diabetes in hepatocellular carcinoma: a case–control study among United States Veterans, Am J Gastroenterol, 96, 2462, 10.1111\u002Fj.1572-0241.2001.04054.x",{"doi":3600},"10.1111\u002Fj.1572-0241.2001.04054.x",{"id":26,"text":1143,"url":26,"identifiers":3602},{"doi":1145},{"id":26,"text":3604,"url":26,"identifiers":3605},"Trichopoulos, 2011, Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case–control study, J Natl Cancer Inst, 103, 1686, 10.1093\u002Fjnci\u002Fdjr395",{"doi":1149},{"id":26,"text":3607,"url":26,"identifiers":3608},"Marcellin, 2008, Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption, J Hepatol, 48, 200, 10.1016\u002Fj.jhep.2007.09.010",{"doi":3609},"10.1016\u002Fj.jhep.2007.09.010",{"id":26,"text":3611,"url":26,"identifiers":3612},"Miki, 1994, A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1, Science, 266, 66, 10.1126\u002Fscience.7545954",{"doi":3613},"10.1126\u002Fscience.7545954",{"id":26,"text":3615,"url":26,"identifiers":3616},"Marra, 1995, Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives, J Natl Cancer Inst, 87, 1114, 10.1093\u002Fjnci\u002F87.15.1114",{"doi":3617},"10.1093\u002Fjnci\u002F87.15.1114",{"id":26,"text":3619,"url":26,"identifiers":3620},"Tanabe, 2008, Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis, JAMA, 299, 53, 10.1001\u002Fjama.2007.65",{"doi":3621},"10.1001\u002Fjama.2007.65",{"id":26,"text":3623,"url":26,"identifiers":3624},"Clifford, 2010, Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma, Hepatology, 52, 2034, 10.1002\u002Fhep.23943",{"doi":3625},"10.1002\u002Fhep.23943",{"id":26,"text":3627,"url":26,"identifiers":3628},"World Health Organization. Hepatitis B vaccines. Weekly epidemiological record of the World Health Organization 2009;84;405–420.",{},{"id":26,"text":3630,"url":26,"identifiers":3631},"European Association for the Study of the Liver, 2009, EASL Clinical Practice Guidelines: management of chronic hepatitis B, J Hepatol, 50, 227, 10.1016\u002Fj.jhep.2008.10.001",{"doi":3632},"10.1016\u002Fj.jhep.2008.10.001",{"id":26,"text":3634,"url":26,"identifiers":3635},"European Association for the Study of the Liver, 2011, EASL Clinical Practice Guidelines: management of hepatitis C virus infection, J Hepatol, 55, 245, 10.1016\u002Fj.jhep.2011.02.023",{"doi":3636},"10.1016\u002Fj.jhep.2011.02.023",{"id":26,"text":3638,"url":26,"identifiers":3639},"Niederau, 1996, Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B, N Engl J Med, 334, 1422, 10.1056\u002FNEJM199605303342202",{"doi":1166},{"id":26,"text":3641,"url":26,"identifiers":3642},"Yuen, 2001, Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy, Hepatology, 34, 785, 10.1053\u002Fjhep.2001.27563",{"doi":3643},"10.1053\u002Fjhep.2001.27563",{"id":26,"text":3645,"url":26,"identifiers":3646},"Liaw, 2004, Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease, N Engl J Med, 351, 1521, 10.1056\u002FNEJMoa033364",{"doi":3647},"10.1056\u002FNEJMoa033364",{"id":26,"text":3649,"url":26,"identifiers":3650},"Singal, 2010, A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus, Clin Gastroenterol Hepatol, 8, 280, 10.1016\u002Fj.cgh.2009.11.018",{"doi":3651},"10.1016\u002Fj.cgh.2009.11.018",{"id":26,"text":3653,"url":26,"identifiers":3654},"Nishiguchi, 1995, Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis, Lancet, 346, 1051, 10.1016\u002FS0140-6736(95)91739-X",{"doi":3655},"10.1016\u002FS0140-6736(95)91739-X",{"id":26,"text":3657,"url":26,"identifiers":3658},"Valla, 1999, Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment, Hepatology, 29, 1870, 10.1002\u002Fhep.510290616",{"doi":3659},"10.1002\u002Fhep.510290616",{"id":26,"text":3661,"url":26,"identifiers":3662},"Lok, 2011, HALT-C Trial Group. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C, Gastroenterology, 140, 840, 10.1053\u002Fj.gastro.2010.11.050",{"doi":3663},"10.1053\u002Fj.gastro.2010.11.050",{"id":26,"text":3665,"url":26,"identifiers":3666},"Di Bisceglie, 2011, HALT-C Trial Group. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon, Hepatology, 53, 1100, 10.1002\u002Fhep.24169",{"doi":3667},"10.1002\u002Fhep.24169",{"id":26,"text":3669,"url":26,"identifiers":3670},"Bruix, 2011, EPIC3 Study Group. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C, Gastroenterology, 140, 1990, 10.1053\u002Fj.gastro.2011.03.010",{"doi":3671},"10.1053\u002Fj.gastro.2011.03.010",{"id":26,"text":1278,"url":26,"identifiers":3673},{"doi":1280},{"id":26,"text":3675,"url":26,"identifiers":3676},"El-Serag, 2011, Hepatocellular carcinoma, N Engl J Med, 365, 1118, 10.1056\u002FNEJMra1001683",{"doi":3677},"10.1056\u002FNEJMra1001683",{"id":26,"text":1286,"url":26,"identifiers":3679},{},{"id":26,"text":3681,"url":26,"identifiers":3682},"Sarasin, 1996, Cost–effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child–Pugh class A cirrhosis, Am J Med, 101, 422, 10.1016\u002FS0002-9343(96)00197-0",{"doi":1299},{"id":26,"text":3684,"url":26,"identifiers":3685},"Fattovich, 2004, Hepatocellular carcinoma in cirrhosis: incidence and risk factors, Gastroenterology, 127, S35, 10.1053\u002Fj.gastro.2004.09.014",{"doi":3686},"10.1053\u002Fj.gastro.2004.09.014",{"id":26,"text":3688,"url":26,"identifiers":3689},"Yoshida, 1999, Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy, Ann Intern Med, 131, 174, 10.7326\u002F0003-4819-131-3-199908030-00003",{"doi":3690},"10.7326\u002F0003-4819-131-3-199908030-00003",{"id":26,"text":3692,"url":26,"identifiers":3693},"Sangiovanni, 2004, Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance, Gastroenterology, 126, 1005, 10.1053\u002Fj.gastro.2003.12.049",{"doi":3694},"10.1053\u002Fj.gastro.2003.12.049",{"id":26,"text":3696,"url":26,"identifiers":3697},"Ganne-Carrié, 1996, Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis, Hepatology, 23, 1112, 10.1002\u002Fhep.510230527",{"doi":3698},"10.1002\u002Fhep.510230527",{"id":26,"text":3700,"url":26,"identifiers":3701},"Velázquez, 2003, Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis, Hepatology, 37, 520, 10.1053\u002Fjhep.2003.50093",{"doi":3702},"10.1053\u002Fjhep.2003.50093",{"id":26,"text":3704,"url":26,"identifiers":3705},"Trevisani, 2007, For the Italian Liver Cancer (ITA.LI.CA.) group. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate\u002Fadvanced cirrhosis?, Am J Gastroenterol, 102, 2448, 10.1111\u002Fj.1572-0241.2007.01395.x",{"doi":1311},{"id":26,"text":3707,"url":26,"identifiers":3708},"Bruix, 2011, Management of hepatocellular carcinoma: an update, Hepatology, 53, 1020, 10.1002\u002Fhep.24199",{"doi":2198},{"id":26,"text":3710,"url":26,"identifiers":3711},"Di Bisceglie, 2004, Issues in screening and surveillance for hepatocellular carcinoma, Gastroenterology, 127, S104, 10.1053\u002Fj.gastro.2004.09.022",{"doi":3712},"10.1053\u002Fj.gastro.2004.09.022",{"id":26,"text":1317,"url":26,"identifiers":3714},{"doi":1319},{"id":26,"text":3716,"url":26,"identifiers":3717},"Sánchez-Tapias, 2002, Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients, Gastroenterology, 123, 1848, 10.1053\u002Fgast.2002.37041",{"doi":1315},{"id":26,"text":3719,"url":26,"identifiers":3720},"Martínez, 2011, Noninvasive assessment of liver fibrosis, Hepatology, 53, 325, 10.1002\u002Fhep.24013",{"doi":3721},"10.1002\u002Fhep.24013",{"id":26,"text":3723,"url":26,"identifiers":3724},"Bosch, 2004, Primary liver cancer: worldwide incidence and trends, Gastroenterology, 127, S5, 10.1053\u002Fj.gastro.2004.09.011",{"doi":3725},"10.1053\u002Fj.gastro.2004.09.011",{"id":26,"text":1357,"url":26,"identifiers":3727},{"doi":1359},{"id":26,"text":3729,"url":26,"identifiers":3730},"Craxì, 2005, Prevention of hepatocellular carcinoma, Clin Liver Dis, 9, 329, 10.1016\u002Fj.cld.2004.12.008",{"doi":3731},"10.1016\u002Fj.cld.2004.12.008",{"id":26,"text":3733,"url":26,"identifiers":3734},"Bruno, 2007, Italian Association of the Study of the Liver Disease (AISF). Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study, Hepatology, 45, 579, 10.1002\u002Fhep.21492",{"doi":3735},"10.1002\u002Fhep.21492",{"id":26,"text":1365,"url":26,"identifiers":3737},{"doi":1367},{"id":26,"text":3739,"url":26,"identifiers":3740},"Lampertico, 2007, Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients, Gastroenterology, 133, 1445, 10.1053\u002Fj.gastro.2007.08.079",{"doi":3741},"10.1053\u002Fj.gastro.2007.08.079",{"id":26,"text":1405,"url":26,"identifiers":3743},{"doi":1407},{"id":26,"text":3745,"url":26,"identifiers":3746},"Kim, 2001, Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients, J Ultrasound Med, 20, 99, 10.7863\u002Fjum.2001.20.2.99",{"doi":3747},"10.7863\u002Fjum.2001.20.2.99",{"id":26,"text":1409,"url":26,"identifiers":3749},{"doi":1411},{"id":26,"text":3751,"url":26,"identifiers":3752},"Sato, 2009, Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C, Hepatol Int, 3, 544, 10.1007\u002Fs12072-009-9145-y",{"doi":3753},"10.1007\u002Fs12072-009-9145-y",{"id":26,"text":1413,"url":26,"identifiers":3755},{"doi":1415},{"id":26,"text":3757,"url":26,"identifiers":3758},"Marrero, 2003, Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients, Hepatology, 37, 1114, 10.1053\u002Fjhep.2003.50195",{"doi":3759},"10.1053\u002Fjhep.2003.50195",{"id":26,"text":1437,"url":26,"identifiers":3761},{"doi":1439},{"id":26,"text":1441,"url":26,"identifiers":3763},{"doi":1443},{"id":26,"text":3765,"url":26,"identifiers":3766},"McMahon, 2000, Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study, Hepatology, 32, 842, 10.1053\u002Fjhep.2000.17914",{"doi":3767},"10.1053\u002Fjhep.2000.17914",{"id":26,"text":3769,"url":26,"identifiers":3770},"Di Bisceglie, 2005, HALT-C Trial Group. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial, J Hepatol, 43, 434, 10.1016\u002Fj.jhep.2005.03.019",{"doi":1455},{"id":26,"text":1457,"url":26,"identifiers":3772},{"doi":1459},{"id":26,"text":1461,"url":26,"identifiers":3774},{"doi":1463},{"id":26,"text":1465,"url":26,"identifiers":3776},{"doi":1467},{"id":26,"text":3778,"url":26,"identifiers":3779},"Trevisani, 2001, Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HbsAg and anti-HCV status, J Hepatol, 34, 570, 10.1016\u002FS0168-8278(00)00053-2",{"doi":1471},{"id":26,"text":3781,"url":26,"identifiers":3782},"Pateron, 1994, Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis, J Hepatol, 20, 65, 10.1016\u002FS0168-8278(05)80468-4",{"doi":3783},"10.1016\u002FS0168-8278(05)80468-4",{"id":26,"text":1497,"url":26,"identifiers":3785},{"doi":1499},{"id":26,"text":1501,"url":26,"identifiers":3787},{"doi":1503},{"id":26,"text":3789,"url":26,"identifiers":3790},"Wang, 2009, Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma, Cancer Epidemiol Biomarkers Prev, 18, 1914, 10.1158\u002F1055-9965.EPI-08-0980",{"doi":3791},"10.1158\u002F1055-9965.EPI-08-0980",{"id":26,"text":1505,"url":26,"identifiers":3793},{"doi":1507},{"id":26,"text":1509,"url":26,"identifiers":3795},{"doi":1511},{"id":26,"text":1513,"url":26,"identifiers":3797},{"doi":1515},{"id":26,"text":3799,"url":26,"identifiers":3800},"Ebara, 1986, Natural history of minute hepatocellular carcinoma smaller than three centimetres complicating cirrhosis. A study in 22 patients, Gastroenterology, 90, 289, 10.1016\u002F0016-5085(86)90923-6",{"doi":3801},"10.1016\u002F0016-5085(86)90923-6",{"id":26,"text":1524,"url":26,"identifiers":3803},{"doi":1526},{"id":26,"text":3805,"url":26,"identifiers":3806},"Makuuchi, 2008, Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan, Hepatol Res, 38, 37, 10.1111\u002Fj.1872-034X.2007.00216.x",{"doi":3807},"10.1111\u002Fj.1872-034X.2007.00216.x",{"id":26,"text":1528,"url":26,"identifiers":3809},{"doi":1530},{"id":26,"text":3811,"url":26,"identifiers":3812},"Santagostino, 2003, A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus, Blood, 102, 78, 10.1182\u002Fblood-2002-10-3310",{"doi":1538},{"id":26,"text":3814,"url":26,"identifiers":3815},"Thompson Coon, 2007, Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis, Health Technol Assess, 11, 1, 10.3310\u002Fhta11340",{"doi":3816},"10.3310\u002Fhta11340",{"id":26,"text":3818,"url":26,"identifiers":3819},"Trevisani, 2004, Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis. Effects on cancer staging and patients survival, Am J Gastroenterol, 99, 1470, 10.1111\u002Fj.1572-0241.2004.30137.x",{"doi":3820},"10.1111\u002Fj.1572-0241.2004.30137.x",{"id":26,"text":3822,"url":26,"identifiers":3823},"Nouso, 2008, Cost–effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances, J Gastroenterol Hepatol, 23, 437, 10.1111\u002Fj.1440-1746.2007.05054.x",{"doi":3824},"10.1111\u002Fj.1440-1746.2007.05054.x",{"id":26,"text":3826,"url":26,"identifiers":3827},"Trevisani, 2002, Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patients survival (Italian experience), Am J Gastroenterol, 97, 734, 10.1111\u002Fj.1572-0241.2002.05557.x",{"doi":1546},{"id":26,"text":3829,"url":26,"identifiers":3830},"Santi, 2010, Italian Liver Cancer (ITA.LI.CA) Group. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival, J Hepatol, 53, 291, 10.1016\u002Fj.jhep.2010.03.010",{"doi":1534},{"id":26,"text":1548,"url":26,"identifiers":3832},{"doi":1550},{"id":26,"text":2021,"url":26,"identifiers":3834},{"doi":2023},{"id":26,"text":1933,"url":26,"identifiers":3836},{"doi":1935},{"id":26,"text":3838,"url":26,"identifiers":3839},"Roskams, 2011, Anatomic pathology impact on prognosis and response to therapy, Clin Liver Dis, 15, 245, 10.1016\u002Fj.cld.2011.03.004",{"doi":1807},{"id":26,"text":3841,"url":26,"identifiers":3842},"Llovet, 2008, Novel advancements in the management of hepatocellular carcinoma in 2008, J Hepatol, 48, S20, 10.1016\u002Fj.jhep.2008.01.022",{"doi":3843},"10.1016\u002Fj.jhep.2008.01.022",{"id":26,"text":1793,"url":26,"identifiers":3845},{"doi":1795},{"id":26,"text":3847,"url":26,"identifiers":3848},"Forner, 2008, Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma, Hepatology, 47, 97, 10.1002\u002Fhep.21966",{"doi":1570},{"id":26,"text":1881,"url":26,"identifiers":3850},{"doi":1883},{"id":26,"text":3852,"url":26,"identifiers":3853},"Terasaki, 1998, Histological features predicting malignant transformation of nonmalignant hepatocellular nodules: a prospective study, Gastroenterology, 115, 1216, 10.1016\u002FS0016-5085(98)70093-9",{"doi":3854},"10.1016\u002FS0016-5085(98)70093-9",{"id":26,"text":3856,"url":26,"identifiers":3857},"Borzio, 2003, Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development, J Hepatol, 39, 208, 10.1016\u002FS0168-8278(03)00190-9",{"doi":3858},"10.1016\u002FS0168-8278(03)00190-9",{"id":26,"text":3860,"url":26,"identifiers":3861},"Stigliano, 2007, Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC, Cancer Treat Rev, 33, 437, 10.1016\u002Fj.ctrv.2007.04.001",{"doi":3862},"10.1016\u002Fj.ctrv.2007.04.001",{"id":26,"text":1556,"url":26,"identifiers":3864},{"doi":1558},{"id":26,"text":3866,"url":26,"identifiers":3867},"Sangiovanni, 2010, The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis, Gut, 59, 638, 10.1136\u002Fgut.2009.187286",{"doi":1578},{"id":26,"text":3869,"url":26,"identifiers":3870},"Yu, 2011, CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis, Clin Gastroenterol Hepatol, 9, 161, 10.1016\u002Fj.cgh.2010.09.017",{"doi":3871},"10.1016\u002Fj.cgh.2010.09.017",{"id":26,"text":3873,"url":26,"identifiers":3874},"Sersté, 2011, Accuracy and disagreement of CT and MRI for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy, Hepatology",{},{"id":26,"text":3876,"url":26,"identifiers":3877},"Rimola, 2009, Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma, Hepatology, 50, 791, 10.1002\u002Fhep.23071",{"doi":3878},"10.1002\u002Fhep.23071",{"id":26,"text":3880,"url":26,"identifiers":3881},"Lencioni, 2005, Imaging diagnosis, Semin Liver Dis, 25, 162, 10.1055\u002Fs-2005-871196",{"doi":3882},"10.1055\u002Fs-2005-871196",{"id":26,"text":3884,"url":26,"identifiers":3885},"International Consensus Group for Hepatocellular Neoplasia, 2009, Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia, Hepatology, 49, 658, 10.1002\u002Fhep.22709",{"doi":1856},{"id":26,"text":1921,"url":26,"identifiers":3887},{"doi":1923},{"id":26,"text":3889,"url":26,"identifiers":3890},"Colombat, 2003, Quantitative RT-PCR in cirrhotic nodules reveals gene expression changes associated with liver carcinogenesis, J Pathol, 201, 260, 10.1002\u002Fpath.1451",{"doi":3891},"10.1002\u002Fpath.1451",{"id":26,"text":3893,"url":26,"identifiers":3894},"Llovet, 2006, A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis, Gastroenterology, 131, 1758, 10.1053\u002Fj.gastro.2006.09.014",{"doi":3895},"10.1053\u002Fj.gastro.2006.09.014",{"id":26,"text":3897,"url":26,"identifiers":3898},"Wurmbach, 2007, Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma, Hepatology, 45, 938, 10.1002\u002Fhep.21622",{"doi":3899},"10.1002\u002Fhep.21622",{"id":26,"text":3901,"url":26,"identifiers":3902},"Di Tommaso, 2007, Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis, Hepatology, 45, 725, 10.1002\u002Fhep.21531",{"doi":1887},{"id":26,"text":1433,"url":26,"identifiers":3904},{"doi":1435},{"id":26,"text":1889,"url":26,"identifiers":3906},{"doi":1891},{"id":26,"text":3908,"url":26,"identifiers":3909},"Tremosini S, Forner A, Boix L, Rimola J, Rodríguez de Lope C, Reig M, et al. Biopsy diagnosis of hepatocellular carcinoma \u003C2cm: prospective validation of glypican 3, heat-shock protein 70 and glutamine synthetase staining in fine needle biopsy samples. ILCA book of abstracts; 2011.",{"doi":3910},"10.1016\u002FS0168-8278(11)61018-0",{"id":26,"text":1901,"url":26,"identifiers":3912},{"doi":1903},{"id":26,"text":3914,"url":26,"identifiers":3915},"Kim, 2011, Human hepatocellular carcinomas with “Stemness”-related marker expression: keratin 19 expression and a poor prognosis, Hepatology, 54, 1707, 10.1002\u002Fhep.24559",{"doi":3916},"10.1002\u002Fhep.24559",{"id":26,"text":3918,"url":26,"identifiers":3919},"Colli, 2006, Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review, Am J Gastroenterol, 101, 513, 10.1111\u002Fj.1572-0241.2006.00467.x",{"doi":3920},"10.1111\u002Fj.1572-0241.2006.00467.x",{"id":26,"text":1564,"url":26,"identifiers":3922},{"doi":1566},{"id":26,"text":1945,"url":26,"identifiers":3924},{"doi":1947},{"id":26,"text":1949,"url":26,"identifiers":3926},{"doi":1951},{"id":26,"text":3928,"url":26,"identifiers":3929},"The Cancer of the Liver Italian Program (CLIP) Investigators, 1998, A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients, Hepatology, 28, 751, 10.1002\u002Fhep.510280322",{"doi":1955},{"id":26,"text":1957,"url":26,"identifiers":3931},{"doi":1959},{"id":26,"text":1961,"url":26,"identifiers":3933},{"doi":1963},{"id":26,"text":1965,"url":26,"identifiers":3935},{"doi":1967},{"id":26,"text":2033,"url":26,"identifiers":3937},{"doi":2035},{"id":26,"text":3939,"url":26,"identifiers":3940},"Ji, 2009, MicroRNA expression, survival, and response to interferon in liver cancer, N Engl J Med, 361, 1437, 10.1056\u002FNEJMoa0901282",{"doi":3941},"10.1056\u002FNEJMoa0901282",{"id":26,"text":1905,"url":26,"identifiers":3943},{"doi":1907},{"id":26,"text":3945,"url":26,"identifiers":3946},"Hoshida, 2008, Gene expression in fixed tissues and outcome in hepatocellular carcinoma, N Engl J Med, 359, 1995, 10.1056\u002FNEJMoa0804525",{"doi":3947},"10.1056\u002FNEJMoa0804525",{"id":26,"text":3949,"url":26,"identifiers":3950},"Llovet, 2008, Biomarkers predicting outcome of patients with advanced hepatocellular carcinoma (HCC) randomized in the phase III SHARP trial. Presidential plenary session, AASLD 59th annual meeting, San Francisco, Hepatology, 48, 372A",{},{"id":26,"text":3952,"url":26,"identifiers":3953},"Llovet, 2003, Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival, Hepatology, 37, 429, 10.1053\u002Fjhep.2003.50047",{"doi":2167},{"id":26,"text":3955,"url":26,"identifiers":3956},"Vibert, 2010, Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor, Am J Transplant, 10, 127, 10.1111\u002Fj.1600-6143.2009.02750.x",{"doi":2059},{"id":26,"text":3958,"url":26,"identifiers":3959},"Toso, 2008, Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma, Liver Transpl, 8, 1107, 10.1002\u002Flt.21484",{"doi":3960},"10.1002\u002Flt.21484",{"id":26,"text":3962,"url":26,"identifiers":3963},"N’Kontchou, 2009, Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis, Hepatology, 50, 1475, 10.1002\u002Fhep.23181",{"doi":2095},{"id":26,"text":3965,"url":26,"identifiers":3966},"Riaz, 2009, Radiologic–pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres, Hepatology, 49, 1185, 10.1002\u002Fhep.22747",{"doi":3967},"10.1002\u002Fhep.22747",{"id":26,"text":3969,"url":26,"identifiers":3970},"Vora, 2009, Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma, Oncologist, 14, 717, 10.1634\u002Ftheoncologist.2009-0038",{"doi":3971},"10.1634\u002Ftheoncologist.2009-0038",{"id":26,"text":3973,"url":26,"identifiers":3974},"2010",{},{"id":26,"text":3976,"url":26,"identifiers":3977},"Llovet, 1998, Liver transplantation for treatment of small hepatocellular carcinoma: the TNM classification does not have prognostic power, Hepatology, 27, 1572, 10.1002\u002Fhep.510270616",{"doi":1971},{"id":26,"text":3979,"url":26,"identifiers":3980},"Chevret, 1999, A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire, J Hepatol, 31, 133, 10.1016\u002FS0168-8278(99)80173-1",{"doi":1979},{"id":26,"text":1981,"url":26,"identifiers":3982},{"doi":1983},{"id":26,"text":2025,"url":26,"identifiers":3984},{"doi":2027},{"id":26,"text":1985,"url":26,"identifiers":3986},{"doi":1987},{"id":26,"text":3988,"url":26,"identifiers":3989},"Kitai, 2008, Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score, Oncology, 75, S83, 10.1159\u002F000173428",{"doi":1995},{"id":26,"text":2005,"url":26,"identifiers":3991},{"doi":2007},{"id":26,"text":3993,"url":26,"identifiers":3994},"Cillo, 2006, Prospective validation of the Barcelona Clinic Liver Cancer staging system, J Hepatol, 44, 723, 10.1016\u002Fj.jhep.2005.12.015",{"doi":3995},"10.1016\u002Fj.jhep.2005.12.015",{"id":26,"text":2013,"url":26,"identifiers":3997},{"doi":2015},{"id":26,"text":3999,"url":26,"identifiers":4000},"Kudo, 2007, Review of 4th Single Topic Conference on HCC. Hepatocellular carcinoma: international consensus and controversies, Hepatol Res, 37, S83, 10.1111\u002Fj.1872-034X.2007.00167.x",{"doi":4001},"10.1111\u002Fj.1872-034X.2007.00167.x",{"id":26,"text":4003,"url":26,"identifiers":4004},"Takayama, 1998, Early hepatocellular carcinoma as an entity with a high rate of surgical cure, Hepatology, 28, 1241, 10.1002\u002Fhep.510280511",{"doi":4005},"10.1002\u002Fhep.510280511",{"id":26,"text":4007,"url":26,"identifiers":4008},"Roayaie, 2009, A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma, Gastroenterology, 137, 850, 10.1053\u002Fj.gastro.2009.06.003",{"doi":4009},"10.1053\u002Fj.gastro.2009.06.003",{"id":26,"text":4011,"url":26,"identifiers":4012},"Roayaie S, Llovet JM, Obeidat K, Labow D, Sposito C, Pellegrinelli A, et al. Hepatic resection for hepatocellular carcinoma \u003C2cm in diameter. Hepatology, in press.",{},{"id":26,"text":4014,"url":26,"identifiers":4015},"Livraghi, 2008, Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?, Hepatology, 47, 82, 10.1002\u002Fhep.21933",{"doi":1939},{"id":26,"text":4017,"url":26,"identifiers":4018},"Arii, 2000, Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan, Hepatology, 32, 1224, 10.1053\u002Fjhep.2000.20456",{"doi":4019},"10.1053\u002Fjhep.2000.20456",{"id":26,"text":4021,"url":26,"identifiers":4022},"Llovet, 1999, Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation, Hepatology, 30, 1434, 10.1002\u002Fhep.510300629",{"doi":2143},{"id":26,"text":4024,"url":26,"identifiers":4025},"Sala, 2004, Barcelona Clínic Liver Cancer Group. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma, Hepatology, 40, 1352, 10.1002\u002Fhep.20465",{"doi":2163},{"id":26,"text":4027,"url":26,"identifiers":4028},"Lopez, 2006, Systematic review: evidence-based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials, Aliment Pharmacol Ther, 23, 1535, 10.1111\u002Fj.1365-2036.2006.02932.x",{"doi":4029},"10.1111\u002Fj.1365-2036.2006.02932.x",{"id":26,"text":4031,"url":26,"identifiers":4032},"Llovet, 2008, Molecular targeted therapies in hepatocellular carcinoma, Hepatology, 48, 1312, 10.1002\u002Fhep.22506",{"doi":4033},"10.1002\u002Fhep.22506",{"id":26,"text":4035,"url":26,"identifiers":4036},"Takayasu, 2006, Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients, Gastroenterology, 131, 461, 10.1053\u002Fj.gastro.2006.05.021",{"doi":4037},"10.1053\u002Fj.gastro.2006.05.021",{"id":26,"text":2994,"url":26,"identifiers":4039},{"doi":2996},{"id":26,"text":4041,"url":26,"identifiers":4042},"Burrel M, Reig M, Forner A, Barrufet M, Rodríguez de Lope C, Tremosini S, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolization (TACE) using DC beads. Implications for clinical practice and trial design. J Hepatol, in press.",{},{"id":26,"text":4044,"url":26,"identifiers":4045},"Llovet, 2008, SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056\u002FNEJMoa0708857",{"doi":2206},{"id":26,"text":4047,"url":26,"identifiers":4048},"Raoul, 2011, Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization, Cancer Treat Rev, 37, 212, 10.1016\u002Fj.ctrv.2010.07.006",{"doi":2226},{"id":26,"text":2232,"url":26,"identifiers":4050},{"doi":2234},{"id":26,"text":4052,"url":26,"identifiers":4053},"Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056\u002FNEJM200103153441101",{"doi":4054},"10.1056\u002FNEJM200103153441101",{"id":26,"text":4056,"url":26,"identifiers":4057},"Tsao, 2005, Erlotinib in lung cancer – molecular and clinical predictors of outcome, N Engl J Med, 353, 133, 10.1056\u002FNEJMoa050736",{"doi":4058},"10.1056\u002FNEJMoa050736",{"id":26,"text":4060,"url":26,"identifiers":4061},"Flaherty, 2010, Inhibition of mutated, activated BRAF in metastatic melanoma, N Engl J Med, 363, 809, 10.1056\u002FNEJMoa1002011",{"doi":4062},"10.1056\u002FNEJMoa1002011",{"id":26,"text":4064,"url":26,"identifiers":4065},"Boyault, 2007, Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets, Hepatology, 45, 42, 10.1002\u002Fhep.21467",{"doi":4066},"10.1002\u002Fhep.21467",{"id":26,"text":4068,"url":26,"identifiers":4069},"Chiang, 2008, Focal gains of VEGFA and molecular classification of hepatocellular carcinoma, Cancer Res, 68, 6779, 10.1158\u002F0008-5472.CAN-08-0742",{"doi":4070},"10.1158\u002F0008-5472.CAN-08-0742",{"id":26,"text":4072,"url":26,"identifiers":4073},"Llovet, 2005, Resection and liver transplantation for hepatocellular carcinoma, Semin Liver Dis, 25, 181, 10.1055\u002Fs-2005-871198",{"doi":4074},"10.1055\u002Fs-2005-871198",{"id":26,"text":4076,"url":26,"identifiers":4077},"Mazzaferro, 2011, Milan criteria in liver transplantation for HCC: an evidence-based analysis on 15 years of experience, Liver Transpl, 17, S44, 10.1002\u002Flt.22365",{"doi":2522},{"id":26,"text":4079,"url":26,"identifiers":4080},"Belghiti, 2000, Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection, J Am Coll Surg, 191, 38, 10.1016\u002FS1072-7515(00)00261-1",{"doi":4081},"10.1016\u002FS1072-7515(00)00261-1",{"id":26,"text":2236,"url":26,"identifiers":4083},{"doi":2238},{"id":26,"text":4085,"url":26,"identifiers":4086},"Poon, 2002, Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified?, Ann Surg, 236, 602, 10.1097\u002F00000658-200211000-00010",{"doi":4087},"10.1097\u002F00000658-200211000-00010",{"id":26,"text":2476,"url":26,"identifiers":4089},{"doi":2478},{"id":26,"text":2145,"url":26,"identifiers":4091},{"doi":2147},{"id":26,"text":2252,"url":26,"identifiers":4093},{"doi":2254},{"id":26,"text":4095,"url":26,"identifiers":4096},"Arii, 2010, Surgical strategies for hepatocellular carcinoma with special reference to anatomical hepatic resection and intraoperative contrast-enhanced ultrasonography, Oncology, 78, 125, 10.1159\u002F000315240",{"doi":4097},"10.1159\u002F000315240",{"id":26,"text":4099,"url":26,"identifiers":4100},"Shi, 2007, Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial, Ann Surg, 245, 36, 10.1097\u002F01.sla.0000231758.07868.71",{"doi":4101},"10.1097\u002F01.sla.0000231758.07868.71",{"id":26,"text":4103,"url":26,"identifiers":4104},"Makuuchi, 1993, Surgery for small liver cancers, Semin Surg Oncol, 9, 298, 10.1002\u002Fssu.2980090404",{"doi":4105},"10.1002\u002Fssu.2980090404",{"id":26,"text":4107,"url":26,"identifiers":4108},"Bruix, 1996, Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure, Gastroenterology, 111, 1018, 10.1016\u002FS0016-5085(96)70070-7",{"doi":4109},"10.1016\u002FS0016-5085(96)70070-7",{"id":26,"text":4111,"url":26,"identifiers":4112},"Simpson, 1995, Clinical evaluation of liver disease Baillieres, Clin Gastroenterol, 9, 639",{},{"id":26,"text":4114,"url":26,"identifiers":4115},"Cucchetti, 2009, Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population, Ann Surg Oncol, 16, 413, 10.1245\u002Fs10434-008-0232-4",{"doi":4116},"10.1245\u002Fs10434-008-0232-4",{"id":26,"text":4118,"url":26,"identifiers":4119},"Farges, 2003, Portal vein embolization before right hepatectomy: prospective clinical trial, Ann Surg, 237, 208, 10.1097\u002F01.SLA.0000048447.16651.7B",{"doi":4120},"10.1097\u002F01.SLA.0000048447.16651.7B",{"id":26,"text":4122,"url":26,"identifiers":4123},"Abulkhir, 2008, Preoperative portal vein embolization for major liver resection: a meta-analysis, Ann Surg, 247, 49, 10.1097\u002FSLA.0b013e31815f6e5b",{"doi":4124},"10.1097\u002FSLA.0b013e31815f6e5b",{"id":26,"text":4126,"url":26,"identifiers":4127},"Croome, 2010, Laparoscopic vs open hepatic resection for benign and malignant tumors: an updated meta-analysis, Arch Surg, 145, 1109, 10.1001\u002Farchsurg.2010.227",{"doi":4128},"10.1001\u002Farchsurg.2010.227",{"id":26,"text":4130,"url":26,"identifiers":4131},"Torzilli, 2004, Contrast-enhanced intraoperative ultrasonography in surgery for hepatocellular carcinoma in cirrhosis, Liver Transpl, 10, S34, 10.1002\u002Flt.20050",{"doi":4132},"10.1002\u002Flt.20050",{"id":26,"text":2053,"url":26,"identifiers":4134},{"doi":2055},{"id":26,"text":4136,"url":26,"identifiers":4137},"Vauthey, 2002, Simplified staging for hepatocellular carcinoma, J Clin Oncol, 20, 1527, 10.1200\u002FJCO.20.6.1527",{"doi":4138},"10.1200\u002FJCO.20.6.1527",{"id":26,"text":4140,"url":26,"identifiers":4141},"Belghiti, 1991, Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis, Ann Surg, 214, 114, 10.1097\u002F00000658-199108000-00004",{"doi":4142},"10.1097\u002F00000658-199108000-00004",{"id":26,"text":4144,"url":26,"identifiers":4145},"Finkelstein, 2003, Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma, Hepatology, 37, 871, 10.1053\u002Fjhep.2003.50134",{"doi":4146},"10.1053\u002Fjhep.2003.50134",{"id":26,"text":2049,"url":26,"identifiers":4148},{"doi":2051},{"id":26,"text":4150,"url":26,"identifiers":4151},"Miyake, 2010, Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma, J Viral Hepat, 17, 287, 10.1111\u002Fj.1365-2893.2009.01181.x",{"doi":4152},"10.1111\u002Fj.1365-2893.2009.01181.x",{"id":26,"text":4154,"url":26,"identifiers":4155},"Shen, 2010, Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach, J Hepatol, 52, 889, 10.1016\u002Fj.jhep.2009.12.041",{"doi":2482},{"id":26,"text":4157,"url":26,"identifiers":4158},"Singal, 2010, Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy, Aliment Pharmacol Ther, 32, 969, 10.1111\u002Fj.1365-2036.2010.04427.x",{"doi":4159},"10.1111\u002Fj.1365-2036.2010.04427.x",{"id":26,"text":4161,"url":26,"identifiers":4162},"Yamasaki, 1996, A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma, Jpn J Cancer Res, 87, 206, 10.1111\u002Fj.1349-7006.1996.tb03160.x",{"doi":4163},"10.1111\u002Fj.1349-7006.1996.tb03160.x",{"id":26,"text":4165,"url":26,"identifiers":4166},"Lau, 1999, Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial, Lancet, 353, 797, 10.1016\u002FS0140-6736(98)06475-7",{"doi":4167},"10.1016\u002FS0140-6736(98)06475-7",{"id":26,"text":4169,"url":26,"identifiers":4170},"Boucher, 2003, Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma, Hepatology, 38, 1237, 10.1053\u002Fjhep.2003.50473",{"doi":4171},"10.1053\u002Fjhep.2003.50473",{"id":26,"text":2488,"url":26,"identifiers":4173},{"doi":2490},{"id":26,"text":4175,"url":26,"identifiers":4176},"Muto, 1996, Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group, N Engl J Med, 334, 1561, 10.1056\u002FNEJM199606133342402",{"doi":4177},"10.1056\u002FNEJM199606133342402",{"id":26,"text":4179,"url":26,"identifiers":4180},"Okita K, Matsui O, Kumada H, Tanaka K, Kaneko S, Moriwaki H, et al. Peretinoin Study Group. Peretinoin reduces recurrence of hepatocellular carcinoma: results of a phase II\u002FIII randomized placebo-controlled trial. Book of Abstracts, ILCA 2010:11A.",{"doi":4181},"10.1200\u002Fjco.2010.28.15_suppl.4024",{"id":26,"text":4183,"url":26,"identifiers":4184},"Yoshida, 2011, Effect of vitamin K2 on the recurrence of hepatocellular carcinoma, Hepatology, 54, 532, 10.1002\u002Fhep.24430",{"doi":4185},"10.1002\u002Fhep.24430",{"id":26,"text":4187,"url":26,"identifiers":4188},"Samuel, 2009, Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma, Cochrane Database Syst Rev, 21, CD001199",{},{"id":26,"text":4190,"url":26,"identifiers":4191},"Iwatsuki, 1991, Hepatic resection versus transplantation for hepatocellular carcinoma, Ann Surg, 214, 221, 10.1097\u002F00000658-199109000-00005",{"doi":4192},"10.1097\u002F00000658-199109000-00005",{"id":26,"text":4194,"url":26,"identifiers":4195},"Iwatsuki, 1985, Liver transplantation for fulminant hepatic failure, Semin Liver Dis, 5, 325, 10.1055\u002Fs-2008-1040628",{"doi":4196},"10.1055\u002Fs-2008-1040628",{"id":26,"text":2512,"url":26,"identifiers":4198},{"doi":2514},{"id":26,"text":4200,"url":26,"identifiers":4201},"Bismuth, 1999, Liver transplantation for hepatocellular carcinoma, Semin Liver Dis, 19, 311, 10.1055\u002Fs-2007-1007120",{"doi":4202},"10.1055\u002Fs-2007-1007120",{"id":26,"text":4204,"url":26,"identifiers":4205},"Bismuth, 1993, Liver resection versus transplantation for hepatocellular carcinoma in cirrhosis, Ann Surg, 218, 145, 10.1097\u002F00000658-199308000-00005",{"doi":4206},"10.1097\u002F00000658-199308000-00005",{"id":26,"text":4208,"url":26,"identifiers":4209},"Jonas, 2001, Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis, Hepatology, 33, 1080, 10.1053\u002Fjhep.2001.23561",{"doi":4210},"10.1053\u002Fjhep.2001.23561",{"id":26,"text":4212,"url":26,"identifiers":4213},"ELTR – European Liver Transplant Registry. \u003Cwww.eltr.org\u002F>; 2011 [accessed 03.11].",{},{"id":26,"text":4215,"url":26,"identifiers":4216},"OPTN – Organ Procurement and Transplantation Network. \u003Chttp:\u002F\u002Fwww.ustransplant.org\u002Fannual_reports\u002Fcurrent\u002F>; 2011 [accessed 02.11].",{},{"id":26,"text":4218,"url":26,"identifiers":4219},"Freeman, 2002, UNOS\u002FOPTN Liver Disease Severity Score, UNOS\u002FOPTN Liver and Intestine, and UNOS\u002FOPTN Pediatric Transplantation Committees. The new liver allocation system: moving toward evidence-based transplantation policy, Liver Transpl, 8, 851, 10.1053\u002Fjlts.2002.35927",{"doi":4220},"10.1053\u002Fjlts.2002.35927",{"id":26,"text":4222,"url":26,"identifiers":4223},"Clavien, 2012, Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report, Lancet Oncol, 13, e11, 10.1016\u002FS1470-2045(11)70175-9",{"doi":2518},{"id":26,"text":2528,"url":26,"identifiers":4225},{"doi":2530},{"id":26,"text":4227,"url":26,"identifiers":4228},"Kamath, 2001, A model to predict survival in patients with end-stage liver disease, Hepatology, 33, 464, 10.1053\u002Fjhep.2001.22172",{"doi":4229},"10.1053\u002Fjhep.2001.22172",{"id":26,"text":3101,"url":26,"identifiers":4231},{"doi":3103},{"id":26,"text":2125,"url":26,"identifiers":4233},{"doi":2127},{"id":26,"text":4235,"url":26,"identifiers":4236},"Mazzaferro, 2004, Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study, Ann Surg, 240, 900, 10.1097\u002F01.sla.0000143301.56154.95",{"doi":4237},"10.1097\u002F01.sla.0000143301.56154.95",{"id":26,"text":4239,"url":26,"identifiers":4240},"Lu, 2005, Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation, Hepatology, 41, 1130, 10.1002\u002Fhep.20688",{"doi":4241},"10.1002\u002Fhep.20688",{"id":26,"text":4243,"url":26,"identifiers":4244},"Majno, 1997, Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis, Ann Surg, 226, 688, 10.1097\u002F00000658-199712000-00006",{"doi":4245},"10.1097\u002F00000658-199712000-00006",{"id":26,"text":4247,"url":26,"identifiers":4248},"Decaens, 2005, Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma, Liver Transpl, 11, 767, 10.1002\u002Flt.20418",{"doi":4249},"10.1002\u002Flt.20418",{"id":26,"text":4251,"url":26,"identifiers":4252},"Porrett, 2006, Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era, Liver Transpl, 12, 665, 10.1002\u002Flt.20636",{"doi":4253},"10.1002\u002Flt.20636",{"id":26,"text":2722,"url":26,"identifiers":4255},{"doi":2724},{"id":26,"text":4257,"url":26,"identifiers":4258},"Vitale, 2010, Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost–benefit analysis while awaiting data on sorafenib safety, Hepatology, 51, 165, 10.1002\u002Fhep.23260",{"doi":4259},"10.1002\u002Fhep.23260",{"id":26,"text":4261,"url":26,"identifiers":4262},"Truesdale, 2011, Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant, Transpl Int, 24, 991, 10.1111\u002Fj.1432-2277.2011.01299.x",{"doi":4263},"10.1111\u002Fj.1432-2277.2011.01299.x",{"id":26,"text":4265,"url":26,"identifiers":4266},"Yao, 2007, Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging, Am J Transplant, 7, 2587, 10.1111\u002Fj.1600-6143.2007.01965.x",{"doi":2534},{"id":26,"text":4268,"url":26,"identifiers":4269},"Mazzaferro, 2009, Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis, Lancet Oncol, 10, 35, 10.1016\u002FS1470-2045(08)70284-5",{"doi":2538},{"id":26,"text":4271,"url":26,"identifiers":4272},"Raj, 2011, Validation of the “Metroticket” predictor in a cohort of patients transplanted for predominantly HBV-related hepatocellular carcinoma, J Hepatol, 55, 1063, 10.1016\u002Fj.jhep.2011.01.052",{"doi":4273},"10.1016\u002Fj.jhep.2011.01.052",{"id":26,"text":4275,"url":26,"identifiers":4276},"Germani, 2011, Which matters most: number of tumors, size of the largest tumor, or total tumor volume?, Liver Transpl, 17, S58, 10.1002\u002Flt.22336",{"doi":4277},"10.1002\u002Flt.22336",{"id":26,"text":4279,"url":26,"identifiers":4280},"Schwartz, 2008, Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers, J Hepatol, 49, 581, 10.1016\u002Fj.jhep.2008.03.032",{"doi":4281},"10.1016\u002Fj.jhep.2008.03.032",{"id":26,"text":4283,"url":26,"identifiers":4284},"Yao, 2008, Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis, Hepatology, 48, 819, 10.1002\u002Fhep.22412",{"doi":4285},"10.1002\u002Fhep.22412",{"id":26,"text":4287,"url":26,"identifiers":4288},"Ravaioli, 2008, Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria, Am J Transplant, 8, 2547, 10.1111\u002Fj.1600-6143.2008.02409.x",{"doi":2554},{"id":26,"text":4290,"url":26,"identifiers":4291},"Neuberger, 2010, Liver allocation for patients with hepatocellular carcinoma, Liver Transpl, 16, 249",{},{"id":26,"text":4293,"url":26,"identifiers":4294},"Bhoori, 2010, The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis, Transpl Int, 23, 712, 10.1111\u002Fj.1432-2277.2010.01111.x",{"doi":4295},"10.1111\u002Fj.1432-2277.2010.01111.x",{"id":26,"text":4297,"url":26,"identifiers":4298},"Trotter, 2002, Adult-to-adult transplantation of the right hepatic lobe from a living donor, N Engl J Med, 346, 1074, 10.1056\u002FNEJMra011629",{"doi":4299},"10.1056\u002FNEJMra011629",{"id":26,"text":4301,"url":26,"identifiers":4302},"Clavien, 2007, Strategies for safer liver surgery and partial liver transplantation, N Engl J Med, 356, 1545, 10.1056\u002FNEJMra065156",{"doi":4303},"10.1056\u002FNEJMra065156",{"id":26,"text":4305,"url":26,"identifiers":4306},"Bruix, 2002, Prognostic prediction and treatment strategy in hepatocellular carcinoma, Hepatology, 35, 519, 10.1053\u002Fjhep.2002.32089",{"doi":4307},"10.1053\u002Fjhep.2002.32089",{"id":26,"text":4309,"url":26,"identifiers":4310},"Siegler, 2006, Recipient deaths during donor surgery: a new ethical problem in living donor liver transplantation (LDLT), Liver Transpl, 12, 358, 10.1002\u002Flt.20670",{"doi":4311},"10.1002\u002Flt.20670",{"id":26,"text":4313,"url":26,"identifiers":4314},"Ghobrial, 2008, A2ALL Study Group. Donor morbidity after living donation for liver transplantation, Gastroenterology, 135, 468, 10.1053\u002Fj.gastro.2008.04.018",{"doi":4315},"10.1053\u002Fj.gastro.2008.04.018",{"id":26,"text":4317,"url":26,"identifiers":4318},"Browns, 2008, Live donors in liver transplantation, Gastroenterology, 134, 1802, 10.1053\u002Fj.gastro.2008.02.092",{"doi":4319},"10.1053\u002Fj.gastro.2008.02.092",{"id":26,"text":4321,"url":26,"identifiers":4322},"Cronin, 2008, Living donor liver transplantation: the ethics and the practice, Hepatology, 47, 11, 10.1002\u002Fhep.22150",{"doi":4323},"10.1002\u002Fhep.22150",{"id":26,"text":4325,"url":26,"identifiers":4326},"Sarasin, 2001, Living donor liver transplantation for early hepatocellular carcinoma: a life-expectancy and cost–effectiveness perspective, Hepatology, 33, 1073, 10.1053\u002Fjhep.2001.23311",{"doi":4327},"10.1053\u002Fjhep.2001.23311",{"id":26,"text":4329,"url":26,"identifiers":4330},"Lo, 2007, Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma, Br J Surg, 94, 78, 10.1002\u002Fbjs.5528",{"doi":4331},"10.1002\u002Fbjs.5528",{"id":26,"text":4333,"url":26,"identifiers":4334},"Fisher, 2007, A2ALL Study Group. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation, Am J Transplant, 7, 1601, 10.1111\u002Fj.1600-6143.2007.01802.x",{"doi":2763},{"id":26,"text":4336,"url":26,"identifiers":4337},"Kulik, 2004, Living donor liver transplantation for hepatocellular carcinoma, Gastroenterology, 127, S277, 10.1053\u002Fj.gastro.2004.09.042",{"doi":4338},"10.1053\u002Fj.gastro.2004.09.042",{"id":26,"text":4340,"url":26,"identifiers":4341},"Majno, 2006, Living donor liver transplantation for hepatocellular carcinoma exceeding conventional criteria: questions, answers and demands for a common language, Liver Transpl, 12, 896, 10.1002\u002Flt.20808",{"doi":4342},"10.1002\u002Flt.20808",{"id":26,"text":4344,"url":26,"identifiers":4345},"Lencioni, 2010, Loco-regional treatment of hepatocellular carcinoma, Hepatology, 52, 762, 10.1002\u002Fhep.23725",{"doi":4346},"10.1002\u002Fhep.23725",{"id":26,"text":4348,"url":26,"identifiers":4349},"Livraghi, 1992, Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients, Cancer, 15, 925, 10.1002\u002F1097-0142(19920215)69:4\u003C925::AID-CNCR2820690415>3.0.CO;2-G",{"doi":4350},"10.1002\u002F1097-0142(19920215)69:4\u003C925::AID-CNCR2820690415>3.0.CO;2-G",{"id":26,"text":4352,"url":26,"identifiers":4353},"Kuang, 2009, Percutaneous ethanol ablation of early-stage hepatocellular carcinoma by using a multi-pronged needle with single treatment session and high-dose ethanol injection, Radiology, 253, 552, 10.1148\u002Fradiol.2532082021",{"doi":4354},"10.1148\u002Fradiol.2532082021",{"id":26,"text":4356,"url":26,"identifiers":4357},"Lencioni, 1995, Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Analysis of prognostic factors in 105 Western patients, Cancer, 76, 1737, 10.1002\u002F1097-0142(19951115)76:10\u003C1737::AID-CNCR2820761010>3.0.CO;2-P",{"doi":4358},"10.1002\u002F1097-0142(19951115)76:10\u003C1737::AID-CNCR2820761010>3.0.CO;2-P",{"id":26,"text":2089,"url":26,"identifiers":4360},{"doi":2091},{"id":26,"text":4362,"url":26,"identifiers":4363},"Khan, 2000, Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection, J Hepatol, 32, 269, 10.1016\u002FS0168-8278(00)80072-0",{"doi":4364},"10.1016\u002FS0168-8278(00)80072-0",{"id":26,"text":2804,"url":26,"identifiers":4366},{"doi":2806},{"id":26,"text":4368,"url":26,"identifiers":4369},"Lin, 2005, Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3cm or less, Gut, 54, 1151, 10.1136\u002Fgut.2004.045203",{"doi":4370},"10.1136\u002Fgut.2004.045203",{"id":26,"text":4372,"url":26,"identifiers":4373},"Shiina, 2005, A randomized controlled trial of radiofrequency ablation versus ethanol injection for small hepatocellular carcinoma, Gastroenterology, 129, 122, 10.1053\u002Fj.gastro.2005.04.009",{"doi":4374},"10.1053\u002Fj.gastro.2005.04.009",{"id":26,"text":4376,"url":26,"identifiers":4377},"Lin, 2004, Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma \u003C or =4cm, Gastroenterology, 127, 1714, 10.1053\u002Fj.gastro.2004.09.003",{"doi":4378},"10.1053\u002Fj.gastro.2004.09.003",{"id":26,"text":4380,"url":26,"identifiers":4381},"Lencioni, 2003, Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection, Radiology, 228, 235, 10.1148\u002Fradiol.2281020718",{"doi":4382},"10.1148\u002Fradiol.2281020718",{"id":26,"text":4384,"url":26,"identifiers":4385},"Brunello, 2008, Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial, Scand J Gastroenterol, 43, 727, 10.1080\u002F00365520701885481",{"doi":4386},"10.1080\u002F00365520701885481",{"id":26,"text":2796,"url":26,"identifiers":4388},{"doi":2798},{"id":26,"text":4390,"url":26,"identifiers":4391},"Germani, 2010, Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocellular carcinoma: a meta-analysis, J Hepatol, 52, 380, 10.1016\u002Fj.jhep.2009.12.004",{"doi":2794},{"id":26,"text":4393,"url":26,"identifiers":4394},"Bouza, 2009, Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma, BMC Gastroenterol, 9, 31, 10.1186\u002F1471-230X-9-31",{"doi":4395},"10.1186\u002F1471-230X-9-31",{"id":26,"text":4397,"url":26,"identifiers":4398},"Imamura, 2008, Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma, Am J Gastroenterol, 103, 3057, 10.1111\u002Fj.1572-0241.2008.02153.x",{"doi":4399},"10.1111\u002Fj.1572-0241.2008.02153.x",{"id":26,"text":4401,"url":26,"identifiers":4402},"Lencioni, 2005, Early-stage hepatocellular carcinoma in cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation, Radiology, 234, 961, 10.1148\u002Fradiol.2343040350",{"doi":2155},{"id":26,"text":4404,"url":26,"identifiers":4405},"Omata, 2004, Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation, Gastroenterology, 127, S159, 10.1053\u002Fj.gastro.2004.09.030",{"doi":4406},"10.1053\u002Fj.gastro.2004.09.030",{"id":26,"text":4408,"url":26,"identifiers":4409},"Lencioni, 2005, Percutaneous ethanol injection in hepatocellular carcinoma: alive or dead, J Hepatol, 43, 377, 10.1016\u002Fj.jhep.2005.06.001",{"doi":4410},"10.1016\u002Fj.jhep.2005.06.001",{"id":26,"text":2378,"url":26,"identifiers":4412},{"doi":2380},{"id":26,"text":2390,"url":26,"identifiers":4414},{"doi":2392},{"id":26,"text":4416,"url":26,"identifiers":4417},"Lu, 2005, Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver, Radiology, 234, 954, 10.1148\u002Fradiol.2343040153",{"doi":4418},"10.1148\u002Fradiol.2343040153",{"id":26,"text":4420,"url":26,"identifiers":4421},"Komorizono, 2003, Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation, Cancer, 97, 1253, 10.1002\u002Fcncr.11168",{"doi":4422},"10.1002\u002Fcncr.11168",{"id":26,"text":4424,"url":26,"identifiers":4425},"Llovet, 2001, Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma, Hepatology, 33, 1124, 10.1053\u002Fjhep.2001.24233",{"doi":4426},"10.1053\u002Fjhep.2001.24233",{"id":26,"text":4428,"url":26,"identifiers":4429},"Teratani, 2006, Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations, Hepatology, 43, 1101, 10.1002\u002Fhep.21164",{"doi":4430},"10.1002\u002Fhep.21164",{"id":26,"text":4432,"url":26,"identifiers":4433},"Yu, 2006, Hepatocellular carcinoma: microwave ablation with multiple straight and loop antenna clusters – pilot comparison with pathologic findings, Radiology, 239, 269, 10.1148\u002Fradiol.2383041592",{"doi":4434},"10.1148\u002Fradiol.2383041592",{"id":26,"text":4436,"url":26,"identifiers":4437},"Shibata, 2002, Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy, Radiology, 223, 331, 10.1148\u002Fradiol.2232010775",{"doi":4438},"10.1148\u002Fradiol.2232010775",{"id":26,"text":4440,"url":26,"identifiers":4441},"Pacella, 2009, Long-term outcome of cirrhotic patients with early hepatocellular carcinoma treated with ultrasound-guided percutaneous laser ablation: a retrospective analysis, J Clin Oncol, 27, 2615, 10.1200\u002FJCO.2008.19.0082",{"doi":4442},"10.1200\u002FJCO.2008.19.0082",{"id":26,"text":4444,"url":26,"identifiers":4445},"Orlacchio, 2008, Percutaneous cryoablation of small hepatocellular carcinoma with US guidance and CT monitoring: initial experience, Cardiovasc Intervent Radiol, 31, 587, 10.1007\u002Fs00270-008-9293-9",{"doi":4446},"10.1007\u002Fs00270-008-9293-9",{"id":26,"text":4448,"url":26,"identifiers":4449},"Guo, 2010, Irreversible electroporation therapy in the liver: longitudinal efficacy studies in a rat model of hepatocellular carcinoma, Cancer Res, 70, 1555, 10.1158\u002F0008-5472.CAN-09-3067",{"doi":4450},"10.1158\u002F0008-5472.CAN-09-3067",{"id":26,"text":2896,"url":26,"identifiers":4452},{"doi":2898},{"id":26,"text":4454,"url":26,"identifiers":4455},"Wang, 2009, A phase 1\u002F2 safety and efficacy study of intratumoral light-activated drug therapy using talaporfin sodium in patients with inoperable hepatocellular carcinoma, J Clin Oncol, 27A",{},{"id":26,"text":4457,"url":26,"identifiers":4458},"Bruix, 2004, Chemoembolization for hepatocellular carcinoma, Gastroenterology, 127, S179, 10.1053\u002Fj.gastro.2004.09.032",{"doi":4459},"10.1053\u002Fj.gastro.2004.09.032",{"id":26,"text":4461,"url":26,"identifiers":4462},"Brown, 2009, Society of Interventional Radiology Technology Assessment Committee and the International Working Group on Image-Guided Tumor Ablation. Image-guided tumor ablation: standardization of terminology and reporting criteria, J Vasc Interv Radiol, 20, S377, 10.1016\u002Fj.jvir.2009.04.011",{"doi":4463},"10.1016\u002Fj.jvir.2009.04.011",{"id":26,"text":4465,"url":26,"identifiers":4466},"Lin, 1988, Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma – a randomized controlled trial, Gastroenterology, 94, 453, 10.1016\u002F0016-5085(88)90436-2",{"doi":4467},"10.1016\u002F0016-5085(88)90436-2",{"id":26,"text":4469,"url":26,"identifiers":4470},"Pelletier, 1990, A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma, J Hepatol, 11, 181, 10.1016\u002F0168-8278(90)90110-D",{"doi":4471},"10.1016\u002F0168-8278(90)90110-D",{"id":26,"text":4473,"url":26,"identifiers":4474},"Group d’Etude et de Traitment du Carcinome Hépatocellulaire, 1995, A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma, N Engl J Med, 332, 1256, 10.1056\u002FNEJM199505113321903",{"doi":3023},{"id":26,"text":4476,"url":26,"identifiers":4477},"Bruix, 1998, Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution, Hepatology, 27, 1578, 10.1002\u002Fhep.510270617",{"doi":4478},"10.1002\u002Fhep.510270617",{"id":26,"text":4480,"url":26,"identifiers":4481},"Pelletier, 1998, Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial, J Hepatol, 29, 129, 10.1016\u002FS0168-8278(98)80187-6",{"doi":4482},"10.1016\u002FS0168-8278(98)80187-6",{"id":26,"text":2177,"url":26,"identifiers":4484},{"doi":2179},{"id":26,"text":4486,"url":26,"identifiers":4487},"Llovet, 2002, Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial, Lancet, 359, 1734, 10.1016\u002FS0140-6736(02)08649-X",{"doi":2175},{"id":26,"text":4489,"url":26,"identifiers":4490},"Oliveri, 2011, Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma, Cochrane Database Syst Rev, 3, CD004787",{},{"id":26,"text":4492,"url":26,"identifiers":4493},"Lammer, 2010, Prospective randomised study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study, Cardiovasc Intervent Radiol, 33, 41, 10.1007\u002Fs00270-009-9711-7",{"doi":3000},{"id":26,"text":4495,"url":26,"identifiers":4496},"Raoul, 1997, Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma, Hepatology, 26, 1156",{},{"id":26,"text":3120,"url":26,"identifiers":4498},{"doi":3122},{"id":26,"text":3116,"url":26,"identifiers":4500},{"doi":3118},{"id":26,"text":3128,"url":26,"identifiers":4502},{"doi":3130},{"id":26,"text":4504,"url":26,"identifiers":4505},"Sangro, 2009, Treatment of hepatocellular carcinoma by radioembolization using 90Y microspheres, Dig Dis, 27, 164, 10.1159\u002F000218349",{"doi":4506},"10.1159\u002F000218349",{"id":26,"text":4508,"url":26,"identifiers":4509},"Cheng, 2002, Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description, Radiother Oncol, 63, 41, 10.1016\u002FS0167-8140(02)00061-0",{"doi":4510},"10.1016\u002FS0167-8140(02)00061-0",{"id":26,"text":4512,"url":26,"identifiers":4513},"Ben-Josef, 2005, Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies, J Clin Oncol, 23, 8739, 10.1200\u002FJCO.2005.01.5354",{"doi":4514},"10.1200\u002FJCO.2005.01.5354",{"id":26,"text":4516,"url":26,"identifiers":4517},"Sridhara, 2010, Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007, J Natl Cancer Inst, 102, 230, 10.1093\u002Fjnci\u002Fdjp515",{"doi":4518},"10.1093\u002Fjnci\u002Fdjp515",{"id":26,"text":4520,"url":26,"identifiers":4521},"Farazi, 2006, Hepatocellular carcinoma pathogenesis: from genes to environment, Nat Rev Cancer, 6, 674, 10.1038\u002Fnrc1934",{"doi":4522},"10.1038\u002Fnrc1934",{"id":26,"text":4524,"url":26,"identifiers":4525},"Villanueva, 2007, Genomics and signaling pathways in hepatocellular carcinoma, Semin Liver Dis, 27, 55, 10.1055\u002Fs-2006-960171",{"doi":4526},"10.1055\u002Fs-2006-960171",{"id":26,"text":4528,"url":26,"identifiers":4529},"Roberts, 2005, Hepatocellular carcinoma: molecular pathways and new therapeutic targets, Semin Liver Dis, 25, 212, 10.1055\u002Fs-2005-871200",{"doi":4530},"10.1055\u002Fs-2005-871200",{"id":26,"text":4532,"url":26,"identifiers":4533},"Semela, 2004, Angiogenesis and hepatocellular carcinoma, J Hepatol, 41, 864, 10.1016\u002Fj.jhep.2004.09.006",{"doi":4534},"10.1016\u002Fj.jhep.2004.09.006",{"id":26,"text":4536,"url":26,"identifiers":4537},"Ito, 2001, Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma, Br J Cancer, 84, 1377, 10.1054\u002Fbjoc.2000.1580",{"doi":4538},"10.1054\u002Fbjoc.2000.1580",{"id":26,"text":4540,"url":26,"identifiers":4541},"Calvisi, 2006, Ubiquitous activation of Ras and Jak\u002FStat pathways in human HCC, Gastroenterology, 130, 1117, 10.1053\u002Fj.gastro.2006.01.006",{"doi":4542},"10.1053\u002Fj.gastro.2006.01.006",{"id":26,"text":4544,"url":26,"identifiers":4545},"Robinson, 2000, The protein tyrosine kinase family of the human genome, Oncogene, 19, 5548, 10.1038\u002Fsj.onc.1203957",{"doi":4546},"10.1038\u002Fsj.onc.1203957",{"id":26,"text":4548,"url":26,"identifiers":4549},"Wilhelm, 2008, Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling, Mol Cancer Ther, 7, 3129, 10.1158\u002F1535-7163.MCT-08-0013",{"doi":4550},"10.1158\u002F1535-7163.MCT-08-0013",{"id":26,"text":4552,"url":26,"identifiers":4553},"Villanueva, 2008, Pivotal role of mTOR signaling in hepatocellular carcinoma, Gastroenterology, 135, 1972, 10.1053\u002Fj.gastro.2008.08.008",{"doi":4554},"10.1053\u002Fj.gastro.2008.08.008",{"id":26,"text":4556,"url":26,"identifiers":4557},"Sahin, 2004, MTOR and P70 S6 kinase expression in primary liver neoplasms, Clin Cancer Res, 10, 8421, 10.1158\u002F1078-0432.CCR-04-0941",{"doi":4558},"10.1158\u002F1078-0432.CCR-04-0941",{"id":26,"text":4560,"url":26,"identifiers":4561},"Takami, 2007, Loss of hepatocyte growth factor\u002Fc-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis, Cancer Res, 67, 9844, 10.1158\u002F0008-5472.CAN-07-1905",{"doi":4562},"10.1158\u002F0008-5472.CAN-07-1905",{"id":26,"text":4564,"url":26,"identifiers":4565},"Breuhahn, 2006, Dysregulation of growth factor signaling in human hepatocellular carcinoma, Oncogene, 25, 3787, 10.1038\u002Fsj.onc.1209556",{"doi":4566},"10.1038\u002Fsj.onc.1209556",{"id":26,"text":4568,"url":26,"identifiers":4569},"Tovar, 2010, IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage, J Hepatol, 52, 550, 10.1016\u002Fj.jhep.2010.01.015",{"doi":4570},"10.1016\u002Fj.jhep.2010.01.015",{"id":26,"text":4572,"url":26,"identifiers":4573},"De La Coste, 1998, Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas, Proc Natl Acad Sci USA, 95, 8847, 10.1073\u002Fpnas.95.15.8847",{"doi":4574},"10.1073\u002Fpnas.95.15.8847",{"id":26,"text":4576,"url":26,"identifiers":4577},"Zucman-Rossi, 2007, Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas, Oncogene, 26, 774, 10.1038\u002Fsj.onc.1209824",{"doi":4578},"10.1038\u002Fsj.onc.1209824",{"id":26,"text":4580,"url":26,"identifiers":4581},"Colnot, 2004, Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas, Proc Natl Acad Sci USA, 101, 17216, 10.1073\u002Fpnas.0404761101",{"doi":4582},"10.1073\u002Fpnas.0404761101",{"id":26,"text":4584,"url":26,"identifiers":4585},"Toffanin, 2011, MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a, Gastroenterology, 140, 1618, 10.1053\u002Fj.gastro.2011.02.009",{"doi":4586},"10.1053\u002Fj.gastro.2011.02.009",{"id":26,"text":3257,"url":26,"identifiers":4588},{"doi":3259},{"id":26,"text":3213,"url":26,"identifiers":4590},{"doi":3215},{"id":26,"text":2208,"url":26,"identifiers":4592},{"doi":2210},{"id":26,"text":4594,"url":26,"identifiers":4595},"Kim, 2011, Sorafenib for hepatocellular carcinoma according to Child–Pugh class of liver function, Cancer Chemother Pharmacol, 68, 1285, 10.1007\u002Fs00280-011-1616-x",{"doi":3239},{"id":26,"text":4597,"url":26,"identifiers":4598},"Hollebecque, 2011, Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child–Pugh score, Aliment Pharmacol Ther, 34, 1193, 10.1111\u002Fj.1365-2036.2011.04860.x",{"doi":3235},{"id":26,"text":4600,"url":26,"identifiers":4601},"Dufour, 2010, Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study, Oncologist, 15, 1198, 10.1634\u002Ftheoncologist.2010-0180",{"doi":4602},"10.1634\u002Ftheoncologist.2010-0180",{"id":26,"text":4604,"url":26,"identifiers":4605},"Abou-Alfa, 2010, Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial, JAMA, 304, 2154, 10.1001\u002Fjama.2010.1672",{"doi":3191},{"id":26,"text":4607,"url":26,"identifiers":4608},"Decaens, 2008, Pilot study of sirolimus in cirrhotic patients with advanced hepatocellular carcinoma, J Hepatol, 48, S13, 10.1016\u002FS0168-8278(08)60030-6",{"doi":4609},"10.1016\u002FS0168-8278(08)60030-6",{"id":26,"text":4611,"url":26,"identifiers":4612},"Philip, 2005, Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer, J Clin Oncol, 23, 6657, 10.1200\u002FJCO.2005.14.696",{"doi":4613},"10.1200\u002FJCO.2005.14.696",{"id":26,"text":4615,"url":26,"identifiers":4616},"Bekaii-Saab, 2009, A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas, Clin Cancer Res, 15, 5895, 10.1158\u002F1078-0432.CCR-09-0465",{"doi":4617},"10.1158\u002F1078-0432.CCR-09-0465",{"id":26,"text":4619,"url":26,"identifiers":4620},"Faivre, 2009, Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study, Lancet Oncol, 10, 794, 10.1016\u002FS1470-2045(09)70171-8",{"doi":4621},"10.1016\u002FS1470-2045(09)70171-8",{"id":26,"text":4623,"url":26,"identifiers":4624},"Zhu, 2009, Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study, J Clin Oncol, 27, 3027, 10.1200\u002FJCO.2008.20.9908",{"doi":4625},"10.1200\u002FJCO.2008.20.9908",{"id":26,"text":4627,"url":26,"identifiers":4628},"Koeberle, 2010, Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77\u002F06), Oncologist, 15, 285, 10.1634\u002Ftheoncologist.2009-0316",{"doi":4629},"10.1634\u002Ftheoncologist.2009-0316",{"id":26,"text":4631,"url":26,"identifiers":4632},"Cheng, 2011, Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC), J Clin Oncol, 29, 10.1200\u002Fjco.2011.29.15_suppl.4000",{"doi":4633},"10.1200\u002Fjco.2011.29.15_suppl.4000",{"id":26,"text":3249,"url":26,"identifiers":4635},{"doi":3251},{"id":26,"text":4637,"url":26,"identifiers":4638},"Siegel, 2008, Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma, J Clin Oncol, 26, 2992, 10.1200\u002FJCO.2007.15.9947",{"doi":4639},"10.1200\u002FJCO.2007.15.9947",{"id":26,"text":4641,"url":26,"identifiers":4642},"Thomas, 2009, Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma, J Clin Oncol, 27, 843, 10.1200\u002FJCO.2008.18.3301",{"doi":4643},"10.1200\u002FJCO.2008.18.3301",{"id":26,"text":4645,"url":26,"identifiers":4646},"Zhu, 2006, Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma, J Clin Oncol, 24, 1898, 10.1200\u002FJCO.2005.04.9130",{"doi":4647},"10.1200\u002FJCO.2005.04.9130",{"id":26,"text":3253,"url":26,"identifiers":4649},{"doi":3255},{"id":26,"text":4651,"url":26,"identifiers":4652},"Taieb, 2006, Medical treatments for hepatocellular carcinoma (HCC): what’s next?, Ann Oncol, 10, 308, 10.1093\u002Fannonc\u002Fmdl279",{"doi":3263},{"id":26,"text":3265,"url":26,"identifiers":4654},{"doi":3267},{"id":26,"text":4656,"url":26,"identifiers":4657},"Yeo, 2005, A randomized phase III study of doxorubicin versus cisplatin\u002Finterferon alpha-2b\u002Fdoxorubicin\u002Ffluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma, J Natl Cancer Inst, 97, 1532, 10.1093\u002Fjnci\u002Fdji315",{"doi":3271},{"id":26,"text":4659,"url":26,"identifiers":4660},"Qin, 2010, Phase III study of oxaliplatin plus 5-fluorouracil\u002Fleucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients, J Clin Oncol, 28, 4008A, 10.1200\u002Fjco.2010.28.15_suppl.4008",{"doi":4661},"10.1200\u002Fjco.2010.28.15_suppl.4008",{"id":26,"text":4663,"url":26,"identifiers":4664},"Edeline, 2009, Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study, World J Gastroenterol, 15, 713, 10.3748\u002Fwjg.15.713",{"doi":3275},{"id":26,"text":3281,"url":26,"identifiers":4666},{"doi":3283},{"id":26,"text":4668,"url":26,"identifiers":4669},"Chow, 2002, Asian-Pacific Hepatocellular Carcinoma Trials Group. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial, Hepatology, 36, 1221, 10.1053\u002Fjhep.2002.36824",{"doi":3279},{"id":26,"text":3285,"url":26,"identifiers":4671},{"doi":3287},{"id":26,"text":4673,"url":26,"identifiers":4674},"Greten, 2006, Immunotherapy of hepatocellular carcinoma, J Hepatol, 45, 868, 10.1016\u002Fj.jhep.2006.09.004",{"doi":4675},"10.1016\u002Fj.jhep.2006.09.004",{"id":26,"text":4677,"url":26,"identifiers":4678},"Greten, 2008, Immunotherapy of HCC, Rev Recent Clin Trials, 3, 31, 10.2174\u002F157488708783330549",{"doi":4679},"10.2174\u002F157488708783330549",{"id":26,"text":4681,"url":26,"identifiers":4682},"Beaugrand, 2003, Treatment of advanced hepatocellular carcinoma by seocalcitol: an international randomized double-blind placebo-controlled study in 747 patients, J Hepatol, 42, 17A",{},{"id":26,"text":4684,"url":26,"identifiers":4685},"Posey, 2005, Results of a phase 2\u002F3 open-label, randomized trial of T138067 versus doxorubicin in chemotherapy-naive, unresectable hepatocellular carcinoma, J Clin Oncol, 23, 316, 10.1200\u002Fjco.2005.23.16_suppl.4035",{"doi":3291},{"id":26,"text":4687,"url":26,"identifiers":4688},"Cheng, 2008, Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3cm. A randomized controlled trial, JAMA, 299, 1669, 10.1001\u002Fjama.299.14.1669",{"doi":4689},"10.1001\u002Fjama.299.14.1669",{"id":26,"text":4691,"url":26,"identifiers":4692},"Miller, 1981, Reporting results of cancer treatment, Cancer, 47, 207, 10.1002\u002F1097-0142(19810101)47:1\u003C207::AID-CNCR2820470134>3.0.CO;2-6",{"doi":4693},"10.1002\u002F1097-0142(19810101)47:1\u003C207::AID-CNCR2820470134>3.0.CO;2-6",{"id":26,"text":4695,"url":26,"identifiers":4696},"Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, J Natl Cancer Inst, 92, 205, 10.1093\u002Fjnci\u002F92.3.205",{"doi":4697},"10.1093\u002Fjnci\u002F92.3.205",{"id":26,"text":4699,"url":26,"identifiers":4700},"Bogaerts, 2009, RECIST Working Party. Individual patient data analysis to assess modifications to the RECIST criteria, Eur J Cancer, 45, 248, 10.1016\u002Fj.ejca.2008.10.027",{"doi":4701},"10.1016\u002Fj.ejca.2008.10.027",{"id":26,"text":4703,"url":26,"identifiers":4704},"Forner, 2009, Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?, Cancer, 115, 616, 10.1002\u002Fcncr.24050",{"doi":4705},"10.1002\u002Fcncr.24050",{"id":26,"text":4707,"url":26,"identifiers":4708},"Gillmore, 2011, EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization, J Hepatol, 55, 1309, 10.1016\u002Fj.jhep.2011.03.007",{"doi":4709},"10.1016\u002Fj.jhep.2011.03.007",{"id":26,"text":4711,"url":26,"identifiers":4712},"Lambert, 2011, Intra-arterial treatment with (90)Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital, Eur J Nucl Med Mol Imaging, 38, 2117, 10.1007\u002Fs00259-011-1881-2",{"doi":4713},"10.1007\u002Fs00259-011-1881-2",{"id":26,"text":3217,"url":26,"identifiers":4715},{"doi":3219},{"id":26,"text":4717,"url":26,"identifiers":4718},"Edeline, 2011, Comparison of tumor response by response evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma, Cancer",{},{"id":4720,"createTime":4721,"updateTime":4721,"relativeEntities":4722,"slug":4723,"properties":4724,"entityType":749,"verifyStatus":28,"verifyTime":4721,"verifyNote":3469,"syncStatus":28,"languages":4736,"translateLanguages":26,"viewCount":36,"primaryUrl":4737,"fullTextUrl":26,"authors":4738,"publicationType":895,"publisherRelationship":4739,"citationCount":4769,"citationInfo":4770,"publishDate":4779,"publishYear":4780,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":4781,"isForceReanalyzing":3453},"998f32c6-554d-494e-9051-16e05e712f1a","2024-10-14T12:45:41.978+00:00",[],"EASL-EASD-EASO-Clinical-Practice-Guidelines-for-the-management-of-non-alcoholic-fatty-liver-disease",{"mag":4725,"keywords":4727,"openalex":4728,"abstract":4730,"title":4731,"pm":4733,"doi":4735},{"VOID":4726},"3143409077",{},{"VOID":4729},"W3143409077",{},{"EN":4732},"EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease",{"VOID":4734},"27062661",{"VOID":1133},[102],"https:\u002F\u002Flinkinghub.elsevier.com\u002Fretrieve\u002Fpii\u002FS0168827815007345",[],{"url":26,"publisher":4740,"properties":4762},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":4741,"slug":663,"properties":4742,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":4745,"manageAffiliations":4746,"indexDatabases":4747,"url":26,"thumbnailPath":26,"statistic":26,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"issn":4743,"title":4744},{"VOID":666},{"EN":668},[],[],[4748,4755],{"id":690,"indexDatabase":4749,"url":705,"indexYears":26,"academicFieldIds":4754,"indexDatabaseRanking":26},{"id":692,"createTime":693,"updateTime":694,"relativeEntities":4750,"label":4751,"description":4752,"key":701,"publicationTags":4753,"standard":26},[],{"EN":697,"VI":697},{"VI":699,"EN":700},[703,704],[707],{"id":709,"indexDatabase":4756,"url":722,"indexYears":723,"academicFieldIds":4761,"indexDatabaseRanking":726},{"id":711,"createTime":712,"updateTime":713,"relativeEntities":4757,"label":4758,"description":4759,"key":719,"publicationTags":4760,"standard":26},[],{"EN":716,"VI":716},{"EN":716,"VI":718},[721],[725],{"volume":4763,"pages":4765,"issue":4767},{"VOID":4764},"64",{"VOID":4766},"1388-1402",{"VOID":4768},"6",3964,{"total":4769,"publishYear":26,"statisticByYear":4771},{"2015":59,"2016":245,"2017":469,"2018":4772,"2019":4773,"2020":4774,"2021":4775,"2022":4776,"2023":4777,"2024":4778},318,428,618,697,607,610,360,"2016-06-01",2016,[4782,4786,4788,4792,4796,4800,4804,4808,4812,4816,4820,4824,4828,4832,4834,4838,4842,4846,4850,4854,4858,4862,4866,4870,4874,4878,4882,4886,4890,4894,4898,4902,4906,4910,4914,4918,4922,4926,4930,4933,4937,4941,4945,4949,4953,4957,4961,4965,4969,4973,4977,4981,4985,4989,4993,4997,5001,5005,5009,5013,5017,5021,5025,5029,5033,5037,5041,5045,5049,5053,5057,5061,5065,5069,5073,5077,5080,5083,5087,5091,5095,5099,5103,5107,5111,5115,5119,5123,5127,5131,5135,5139,5143,5147,5151,5155,5159,5163,5167,5171,5175,5179,5183,5187,5191,5194,5198,5202,5206,5210,5214,5218,5222,5226,5230,5234,5238,5242,5246,5250,5254,5258,5262,5266,5270,5274,5278,5282,5286,5290,5294,5298,5302,5306,5310,5314,5318,5322,5326,5330,5334,5338,5342,5346,5350,5354,5358,5362],{"id":26,"text":4783,"url":26,"identifiers":4784},"Ratziu, 2010, A position statement on NAFLD\u002FNASH based on the EASL 2009 special conference, J Hepatol, 53, 372, 10.1016\u002Fj.jhep.2010.04.008",{"doi":4785},"10.1016\u002Fj.jhep.2010.04.008",{"id":26,"text":949,"url":26,"identifiers":4787},{"doi":951},{"id":26,"text":4789,"url":26,"identifiers":4790},"Bellentani, 2000, Prevalence of and risk factors for hepatic steatosis in Northern Italy, Ann Intern Med, 132, 112, 10.7326\u002F0003-4819-132-2-200001180-00004",{"doi":4791},"10.7326\u002F0003-4819-132-2-200001180-00004",{"id":26,"text":4793,"url":26,"identifiers":4794},"Vernon, 2011, Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults, Aliment Pharmacol Ther, 34, 274, 10.1111\u002Fj.1365-2036.2011.04724.x",{"doi":4795},"10.1111\u002Fj.1365-2036.2011.04724.x",{"id":26,"text":4797,"url":26,"identifiers":4798},"Younossi, 2012, Nonalcoholic fatty liver disease in lean individuals in the United States, Medicine, 91, 319, 10.1097\u002FMD.0b013e3182779d49",{"doi":4799},"10.1097\u002FMD.0b013e3182779d49",{"id":26,"text":4801,"url":26,"identifiers":4802},"Fracanzani, 2008, Risk of severe liver disease in NAFLD with normal aminotransferase levels: a role for insulin resistance and diabetes, Hepatology, 48, 792, 10.1002\u002Fhep.22429",{"doi":4803},"10.1002\u002Fhep.22429",{"id":26,"text":4805,"url":26,"identifiers":4806},"Marchesini, 2015, NAFLD incidence and remission: only a matter of weight gain and weight loss?, J Hepatol, 62, 15, 10.1016\u002Fj.jhep.2014.10.023",{"doi":4807},"10.1016\u002Fj.jhep.2014.10.023",{"id":26,"text":4809,"url":26,"identifiers":4810},"Chalasani, 2012, The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association, Hepatology, 55, 2005, 10.1002\u002Fhep.25762",{"doi":4811},"10.1002\u002Fhep.25762",{"id":26,"text":4813,"url":26,"identifiers":4814},"Barrera, 2014, The role of diet and nutritional intervention for the management of patients with NAFLD, Clin Liver Dis, 18, 91, 10.1016\u002Fj.cld.2013.09.009",{"doi":4815},"10.1016\u002Fj.cld.2013.09.009",{"id":26,"text":4817,"url":26,"identifiers":4818},"Chiu, 2014, Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials, Eur J Clin Nutr, 68, 416, 10.1038\u002Fejcn.2014.8",{"doi":4819},"10.1038\u002Fejcn.2014.8",{"id":26,"text":4821,"url":26,"identifiers":4822},"Gerber, 2012, Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study, Aliment Pharmacol Ther, 36, 772, 10.1111\u002Fapt.12038",{"doi":4823},"10.1111\u002Fapt.12038",{"id":26,"text":4825,"url":26,"identifiers":4826},"Anstee, 2013, Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis, Nat Rev Gastroenterol Hepatol, 10, 330, 10.1038\u002Fnrgastro.2013.41",{"doi":4827},"10.1038\u002Fnrgastro.2013.41",{"id":26,"text":4829,"url":26,"identifiers":4830},"Valenti, 2010, Homozygosity for the patatin-like phospholipase-3\u002Fadiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease, Hepatology, 51, 1209, 10.1002\u002Fhep.23622",{"doi":4831},"10.1002\u002Fhep.23622",{"id":26,"text":1353,"url":26,"identifiers":4833},{"doi":1355},{"id":26,"text":4835,"url":26,"identifiers":4836},"Liu, 2014, TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease, Nat Commun, 5, 4309, 10.1038\u002Fncomms5309",{"doi":4837},"10.1038\u002Fncomms5309",{"id":26,"text":4839,"url":26,"identifiers":4840},"Dongiovanni, 2015, Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease, Hepatology, 61, 506, 10.1002\u002Fhep.27490",{"doi":4841},"10.1002\u002Fhep.27490",{"id":26,"text":4843,"url":26,"identifiers":4844},"Valenti, 2010, I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease, Hepatology, 52, 1274, 10.1002\u002Fhep.23823",{"doi":4845},"10.1002\u002Fhep.23823",{"id":26,"text":4847,"url":26,"identifiers":4848},"Nobili, 2014, A 4-polymorphism risk score predicts steatohepatitis in children with nonalcoholic fatty liver disease, J Pediatr Gastroenterol Nutr, 58, 632, 10.1097\u002FMPG.0000000000000279",{"doi":4849},"10.1097\u002FMPG.0000000000000279",{"id":26,"text":4851,"url":26,"identifiers":4852},"Ratziu, 2005, Sampling variability of liver biopsy in nonalcoholic fatty liver disease, Gastroenterology, 128, 1898, 10.1053\u002Fj.gastro.2005.03.084",{"doi":4853},"10.1053\u002Fj.gastro.2005.03.084",{"id":26,"text":4855,"url":26,"identifiers":4856},"Kleiner, 2012, Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research, Semin Liver Dis, 32, 3, 10.1055\u002Fs-0032-1306421",{"doi":4857},"10.1055\u002Fs-0032-1306421",{"id":26,"text":4859,"url":26,"identifiers":4860},"Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002\u002Fhep.20701",{"doi":4861},"10.1002\u002Fhep.20701",{"id":26,"text":4863,"url":26,"identifiers":4864},"Bedossa, 2014, Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease, Hepatology, 60, 565, 10.1002\u002Fhep.27173",{"doi":4865},"10.1002\u002Fhep.27173",{"id":26,"text":4867,"url":26,"identifiers":4868},"Brunt, 2011, Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings, Hepatology, 53, 810, 10.1002\u002Fhep.24127",{"doi":4869},"10.1002\u002Fhep.24127",{"id":26,"text":4871,"url":26,"identifiers":4872},"Ekstedt, 2015, Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up, Hepatology, 61, 1547, 10.1002\u002Fhep.27368",{"doi":4873},"10.1002\u002Fhep.27368",{"id":26,"text":4875,"url":26,"identifiers":4876},"Brunt, 2009, Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network, Hepatology, 49, 809, 10.1002\u002Fhep.22724",{"doi":4877},"10.1002\u002Fhep.22724",{"id":26,"text":4879,"url":26,"identifiers":4880},"Alkhouri, 2012, Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease, J Hepatol, 57, 1312, 10.1016\u002Fj.jhep.2012.07.027",{"doi":4881},"10.1016\u002Fj.jhep.2012.07.027",{"id":26,"text":4883,"url":26,"identifiers":4884},"Saadeh, 2002, The utility of radiological imaging in nonalcoholic fatty liver disease, Gastroenterology, 123, 745, 10.1053\u002Fgast.2002.35354",{"doi":4885},"10.1053\u002Fgast.2002.35354",{"id":26,"text":4887,"url":26,"identifiers":4888},"Fishbein, 2005, Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound, J Clin Gastroenterol, 39, 619, 10.1097\u002F00004836-200508000-00012",{"doi":4889},"10.1097\u002F00004836-200508000-00012",{"id":26,"text":4891,"url":26,"identifiers":4892},"Ryan, 2002, One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation, Liver Transpl, 8, 1114, 10.1053\u002Fjlts.2002.36740",{"doi":4893},"10.1053\u002Fjlts.2002.36740",{"id":26,"text":4895,"url":26,"identifiers":4896},"Fedchuk, 2014, Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease, Aliment Pharmacol Ther, 40, 1209, 10.1111\u002Fapt.12963",{"doi":4897},"10.1111\u002Fapt.12963",{"id":26,"text":4899,"url":26,"identifiers":4900},"Machado, 2013, Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal, J Hepatol, 58, 1007, 10.1016\u002Fj.jhep.2012.11.021",{"doi":4901},"10.1016\u002Fj.jhep.2012.11.021",{"id":26,"text":4903,"url":26,"identifiers":4904},"2015, EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis, J Hepatol, 63, 237, 10.1016\u002Fj.jhep.2015.04.006",{"doi":4905},"10.1016\u002Fj.jhep.2015.04.006",{"id":26,"text":4907,"url":26,"identifiers":4908},"Cusi, 2014, Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease, J Hepatol, 60, 167, 10.1016\u002Fj.jhep.2013.07.042",{"doi":4909},"10.1016\u002Fj.jhep.2013.07.042",{"id":26,"text":4911,"url":26,"identifiers":4912},"Kwok, 2014, Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease–the role of transient elastography and plasma cytokeratin-18 fragments, Aliment Pharmacol Ther, 39, 254, 10.1111\u002Fapt.12569",{"doi":4913},"10.1111\u002Fapt.12569",{"id":26,"text":4915,"url":26,"identifiers":4916},"Vuppalanchi, 2014, Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 12, e2121, 10.1016\u002Fj.cgh.2014.05.010",{"doi":4917},"10.1016\u002Fj.cgh.2014.05.010",{"id":26,"text":4919,"url":26,"identifiers":4920},"Guha, 2008, Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers, Hepatology, 47, 455, 10.1002\u002Fhep.21984",{"doi":4921},"10.1002\u002Fhep.21984",{"id":26,"text":4923,"url":26,"identifiers":4924},"McPherson, 2013, Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?, Eur J Gastroenterol Hepatol, 25, 652, 10.1097\u002FMEG.0b013e32835d72cf",{"doi":4925},"10.1097\u002FMEG.0b013e32835d72cf",{"id":26,"text":4927,"url":26,"identifiers":4928},"Wong, 2010, Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease, Hepatology, 51, 454, 10.1002\u002Fhep.23312",{"doi":4929},"10.1002\u002Fhep.23312",{"id":26,"text":4931,"url":26,"identifiers":4932},"Castera, 2010, Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations, Hepatology, 51, 828",{},{"id":26,"text":4934,"url":26,"identifiers":4935},"Wong, 2012, Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease, Am J Gastroenterol, 107, 1862, 10.1038\u002Fajg.2012.331",{"doi":4936},"10.1038\u002Fajg.2012.331",{"id":26,"text":4938,"url":26,"identifiers":4939},"Petta, 2015, The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease, Liver Int, 35, 1566, 10.1111\u002Fliv.12584",{"doi":4940},"10.1111\u002Fliv.12584",{"id":26,"text":4942,"url":26,"identifiers":4943},"Vajro, 2012, Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee, J Pediatr Gastroenterol Nutr, 54, 700, 10.1097\u002FMPG.0b013e318252a13f",{"doi":4944},"10.1097\u002FMPG.0b013e318252a13f",{"id":26,"text":4946,"url":26,"identifiers":4947},"Nobili, 2013, A 360-degree overview of paediatric NAFLD: recent insights, J Hepatol, 58, 1218, 10.1016\u002Fj.jhep.2012.12.003",{"doi":4948},"10.1016\u002Fj.jhep.2012.12.003",{"id":26,"text":4950,"url":26,"identifiers":4951},"Gaggini, 2013, Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease, Nutrients, 5, 1544, 10.3390\u002Fnu5051544",{"doi":4952},"10.3390\u002Fnu5051544",{"id":26,"text":4954,"url":26,"identifiers":4955},"Alberti, 2005, Review article: chronic hepatitis C–natural history and cofactors, Aliment Pharmacol Ther, 22, 74, 10.1111\u002Fj.1365-2036.2005.02602.x",{"doi":4956},"10.1111\u002Fj.1365-2036.2005.02602.x",{"id":26,"text":4958,"url":26,"identifiers":4959},"Koliaki, 2015, Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis, Cell Metab, 21, 739, 10.1016\u002Fj.cmet.2015.04.004",{"doi":4960},"10.1016\u002Fj.cmet.2015.04.004",{"id":26,"text":4962,"url":26,"identifiers":4963},"Yki-Jarvinen, 2014, Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome, Lancet Diabetes Endocrinol, 2, 901, 10.1016\u002FS2213-8587(14)70032-4",{"doi":4964},"10.1016\u002FS2213-8587(14)70032-4",{"id":26,"text":4966,"url":26,"identifiers":4967},"Matthews, 1985, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia, 28, 412, 10.1007\u002FBF00280883",{"doi":4968},"10.1007\u002FBF00280883",{"id":26,"text":4970,"url":26,"identifiers":4971},"McPherson, 2015, Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management, J Hepatol, 62, 1148, 10.1016\u002Fj.jhep.2014.11.034",{"doi":4972},"10.1016\u002Fj.jhep.2014.11.034",{"id":26,"text":4974,"url":26,"identifiers":4975},"Pais, 2013, A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver, J Hepatol, 59, 550, 10.1016\u002Fj.jhep.2013.04.027",{"doi":4976},"10.1016\u002Fj.jhep.2013.04.027",{"id":26,"text":4978,"url":26,"identifiers":4979},"Bedogni, 2005, Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study, Hepatology, 42, 44, 10.1002\u002Fhep.20734",{"doi":4980},"10.1002\u002Fhep.20734",{"id":26,"text":4982,"url":26,"identifiers":4983},"Frith, 2010, Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease, J Hepatol, 52, 112, 10.1016\u002Fj.jhep.2009.10.010",{"doi":4984},"10.1016\u002Fj.jhep.2009.10.010",{"id":26,"text":4986,"url":26,"identifiers":4987},"Caldwell, 2004, The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease, J Hepatol, 40, 578, 10.1016\u002Fj.jhep.2004.02.013",{"doi":4988},"10.1016\u002Fj.jhep.2004.02.013",{"id":26,"text":4990,"url":26,"identifiers":4991},"Aron-Wisnewsky, 2012, Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese, J Hepatol, 56, 225, 10.1016\u002Fj.jhep.2011.04.022",{"doi":4992},"10.1016\u002Fj.jhep.2011.04.022",{"id":26,"text":4994,"url":26,"identifiers":4995},"Gomez-Ambrosi, 2012, Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity, Int J Obes (Lond), 36, 286, 10.1038\u002Fijo.2011.100",{"doi":4996},"10.1038\u002Fijo.2011.100",{"id":26,"text":4998,"url":26,"identifiers":4999},"Chang, 2012, Impact of BMI on the incidence of metabolic abnormalities in metabolically healthy men, Int J Obes (Lond), 36, 1187, 10.1038\u002Fijo.2011.247",{"doi":5000},"10.1038\u002Fijo.2011.247",{"id":26,"text":5002,"url":26,"identifiers":5003},"Gomez-Ambrosi, 2014, Increased cardiometabolic risk factors and inflammation in adipose tissue in obese subjects classified as metabolically healthy, Diabetes Care, 37, 2813, 10.2337\u002Fdc14-0937",{"doi":5004},"10.2337\u002Fdc14-0937",{"id":26,"text":5006,"url":26,"identifiers":5007},"Ghouri, 2010, Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data, Hepatology, 52, 1156, 10.1002\u002Fhep.23789",{"doi":5008},"10.1002\u002Fhep.23789",{"id":26,"text":5010,"url":26,"identifiers":5011},"Gastaldelli, 2007, Relationship between hepatic\u002Fvisceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects, Gastroenterology, 133, 496, 10.1053\u002Fj.gastro.2007.04.068",{"doi":5012},"10.1053\u002Fj.gastro.2007.04.068",{"id":26,"text":5014,"url":26,"identifiers":5015},"Kotronen, 2008, Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects, Diabetes Care, 31, 165, 10.2337\u002Fdc07-1463",{"doi":5016},"10.2337\u002Fdc07-1463",{"id":26,"text":5018,"url":26,"identifiers":5019},"Loomba, 2012, Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis, Hepatology, 56, 943, 10.1002\u002Fhep.25772",{"doi":5020},"10.1002\u002Fhep.25772",{"id":26,"text":5022,"url":26,"identifiers":5023},"Armstrong, 2014, Extrahepatic complications of nonalcoholic fatty liver disease, Hepatology, 59, 1174, 10.1002\u002Fhep.26717",{"doi":5024},"10.1002\u002Fhep.26717",{"id":26,"text":5026,"url":26,"identifiers":5027},"American Diabetes Association, 2014, Standards of medical care in diabetes–2014, Diabetes Care, 37, S14, 10.2337\u002Fdc14-S014",{"doi":5028},"10.2337\u002Fdc14-S014",{"id":26,"text":5030,"url":26,"identifiers":5031},"Ortiz-Lopez, 2012, Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD), Diabetes Care, 35, 873, 10.2337\u002Fdc11-1849",{"doi":5032},"10.2337\u002Fdc11-1849",{"id":26,"text":5034,"url":26,"identifiers":5035},"Juurinen, 2007, Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes, Am J Physiol Endocrinol Metab, 292, E829, 10.1152\u002Fajpendo.00133.2006",{"doi":5036},"10.1152\u002Fajpendo.00133.2006",{"id":26,"text":5038,"url":26,"identifiers":5039},"Llaurado, 2015, Liver fat content and hepatic insulin sensitivity in overweight patients with type 1 diabetes, J Clin Endocrinol Metab, 100, 607, 10.1210\u002Fjc.2014-3050",{"doi":5040},"10.1210\u002Fjc.2014-3050",{"id":26,"text":5042,"url":26,"identifiers":5043},"Anderwald, 2002, Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle, Diabetes, 51, 3025, 10.2337\u002Fdiabetes.51.10.3025",{"doi":5044},"10.2337\u002Fdiabetes.51.10.3025",{"id":26,"text":5046,"url":26,"identifiers":5047},"Singh, 2015, Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies, Clin Gastroenterol Hepatol, 13, 643, 10.1016\u002Fj.cgh.2014.04.014",{"doi":5048},"10.1016\u002Fj.cgh.2014.04.014",{"id":26,"text":5050,"url":26,"identifiers":5051},"Haflidadottir, 2014, Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease, BMC Gastroenterol, 14, 166, 10.1186\u002F1471-230X-14-166",{"doi":5052},"10.1186\u002F1471-230X-14-166",{"id":26,"text":5054,"url":26,"identifiers":5055},"Kim, 2013, Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States, Hepatology, 57, 1357, 10.1002\u002Fhep.26156",{"doi":5056},"10.1002\u002Fhep.26156",{"id":26,"text":5058,"url":26,"identifiers":5059},"Schwimmer, 2005, Histopathology of pediatric nonalcoholic fatty liver disease, Hepatology, 42, 641, 10.1002\u002Fhep.20842",{"doi":5060},"10.1002\u002Fhep.20842",{"id":26,"text":5062,"url":26,"identifiers":5063},"Oni, 2013, A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?, Atherosclerosis, 230, 258, 10.1016\u002Fj.atherosclerosis.2013.07.052",{"doi":5064},"10.1016\u002Fj.atherosclerosis.2013.07.052",{"id":26,"text":5066,"url":26,"identifiers":5067},"Targher, 2010, Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease, N Engl J Med, 363, 1341, 10.1056\u002FNEJMra0912063",{"doi":5068},"10.1056\u002FNEJMra0912063",{"id":26,"text":5070,"url":26,"identifiers":5071},"Bhatia, 2012, Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?, Eur Heart J, 33, 1190, 10.1093\u002Feurheartj\u002Fehr453",{"doi":5072},"10.1093\u002Feurheartj\u002Fehr453",{"id":26,"text":5074,"url":26,"identifiers":5075},"Calori, 2011, Fatty liver index and mortality: the Cremona study in the 15th year of follow-up, Hepatology, 54, 145, 10.1002\u002Fhep.24356",{"doi":5076},"10.1002\u002Fhep.24356",{"id":26,"text":5078,"url":26,"identifiers":5079},"Pacifico, 2014, Nonalcoholic fatty liver disease and the heart in children and adolescents, World J Gastroenterol, 20, 9055",{},{"id":26,"text":5081,"url":26,"identifiers":5082},"Dyson, 2014, Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team, J Hepatol, 60, 110, 10.1016\u002Fj.jhep.2013.08.011",{"doi":1117},{"id":26,"text":5084,"url":26,"identifiers":5085},"Wong, 2014, Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S., Hepatology, 59, 2188, 10.1002\u002Fhep.26986",{"doi":5086},"10.1002\u002Fhep.26986",{"id":26,"text":5088,"url":26,"identifiers":5089},"Musso, 2014, Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis, PLoS Med, 11, e1001680, 10.1371\u002Fjournal.pmed.1001680",{"doi":5090},"10.1371\u002Fjournal.pmed.1001680",{"id":26,"text":5092,"url":26,"identifiers":5093},"Targher, 2010, Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients, Diabetologia, 53, 1341, 10.1007\u002Fs00125-010-1720-1",{"doi":5094},"10.1007\u002Fs00125-010-1720-1",{"id":26,"text":5096,"url":26,"identifiers":5097},"Kim, 2014, Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population, Heart, 100, 938, 10.1136\u002Fheartjnl-2013-305099",{"doi":5098},"10.1136\u002Fheartjnl-2013-305099",{"id":26,"text":5100,"url":26,"identifiers":5101},"Hazlehurst, 2013, Non-alcoholic fatty liver disease in common endocrine disorders, Eur J Endocrinol, 169, R27, 10.1530\u002FEJE-13-0296",{"doi":5102},"10.1530\u002FEJE-13-0296",{"id":26,"text":5104,"url":26,"identifiers":5105},"Lindor, 2004, Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial, Hepatology, 39, 770, 10.1002\u002Fhep.20092",{"doi":5106},"10.1002\u002Fhep.20092",{"id":26,"text":5108,"url":26,"identifiers":5109},"Bugianesi, 2005, A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease, Am J Gastroenterol, 100, 1082, 10.1111\u002Fj.1572-0241.2005.41583.x",{"doi":5110},"10.1111\u002Fj.1572-0241.2005.41583.x",{"id":26,"text":5112,"url":26,"identifiers":5113},"Belfort, 2006, A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis, N Engl J Med, 355, 2297, 10.1056\u002FNEJMoa060326",{"doi":5114},"10.1056\u002FNEJMoa060326",{"id":26,"text":5116,"url":26,"identifiers":5117},"Zelber-Sagi, 2006, A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 4, 639, 10.1016\u002Fj.cgh.2006.02.004",{"doi":5118},"10.1016\u002Fj.cgh.2006.02.004",{"id":26,"text":5120,"url":26,"identifiers":5121},"Dufour, 2006, Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis, Clin Gastroenterol Hepatol, 4, 1537, 10.1016\u002Fj.cgh.2006.09.025",{"doi":5122},"10.1016\u002Fj.cgh.2006.09.025",{"id":26,"text":5124,"url":26,"identifiers":5125},"Ratziu, 2008, Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial, Gastroenterology, 135, 100, 10.1053\u002Fj.gastro.2008.03.078",{"doi":5126},"10.1053\u002Fj.gastro.2008.03.078",{"id":26,"text":5128,"url":26,"identifiers":5129},"Aithal, 2008, Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis, Gastroenterology, 135, 1176, 10.1053\u002Fj.gastro.2008.06.047",{"doi":5130},"10.1053\u002Fj.gastro.2008.06.047",{"id":26,"text":5132,"url":26,"identifiers":5133},"Haukeland, 2009, Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial, Scand J Gastroenterol, 44, 853, 10.1080\u002F00365520902845268",{"doi":5134},"10.1080\u002F00365520902845268",{"id":26,"text":5136,"url":26,"identifiers":5137},"Harrison, 2009, Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial, Hepatology, 49, 80, 10.1002\u002Fhep.22575",{"doi":5138},"10.1002\u002Fhep.22575",{"id":26,"text":5140,"url":26,"identifiers":5141},"Shields, 2009, The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial, Therap Adv Gastroenterol, 2, 157, 10.1177\u002F1756283X09105462",{"doi":5142},"10.1177\u002F1756283X09105462",{"id":26,"text":5144,"url":26,"identifiers":5145},"Promrat, 2010, Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis, Hepatology, 51, 121, 10.1002\u002Fhep.23276",{"doi":5146},"10.1002\u002Fhep.23276",{"id":26,"text":5148,"url":26,"identifiers":5149},"Ratziu, 2010, Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial, Hepatology, 51, 445, 10.1002\u002Fhep.23270",{"doi":5150},"10.1002\u002Fhep.23270",{"id":26,"text":5152,"url":26,"identifiers":5153},"Sanyal, 2010, Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis, N Engl J Med, 362, 1675, 10.1056\u002FNEJMoa0907929",{"doi":5154},"10.1056\u002FNEJMoa0907929",{"id":26,"text":5156,"url":26,"identifiers":5157},"Leuschner, 2010, High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial, Hepatology, 52, 472, 10.1002\u002Fhep.23727",{"doi":5158},"10.1002\u002Fhep.23727",{"id":26,"text":5160,"url":26,"identifiers":5161},"Zein, 2011, Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial, Hepatology, 54, 1610, 10.1002\u002Fhep.24544",{"doi":5162},"10.1002\u002Fhep.24544",{"id":26,"text":5164,"url":26,"identifiers":5165},"Lavine, 2011, Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial, JAMA, 305, 1659, 10.1001\u002Fjama.2011.520",{"doi":5166},"10.1001\u002Fjama.2011.520",{"id":26,"text":5168,"url":26,"identifiers":5169},"Neuschwander-Tetri, 2015, Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial, Lancet, 385, 956, 10.1016\u002FS0140-6736(14)61933-4",{"doi":5170},"10.1016\u002FS0140-6736(14)61933-4",{"id":26,"text":5172,"url":26,"identifiers":5173},"Valenti, 2014, A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia, World J Gastroenterol, 20, 3002, 10.3748\u002Fwjg.v20.i11.3002",{"doi":5174},"10.3748\u002Fwjg.v20.i11.3002",{"id":26,"text":5176,"url":26,"identifiers":5177},"Takeshita, 2014, The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial, Diabetologia, 57, 878, 10.1007\u002Fs00125-013-3149-9",{"doi":5178},"10.1007\u002Fs00125-013-3149-9",{"id":26,"text":5180,"url":26,"identifiers":5181},"Sanyal, 2014, No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial, Gastroenterology, 147, e371, 10.1053\u002Fj.gastro.2014.04.046",{"doi":5182},"10.1053\u002Fj.gastro.2014.04.046",{"id":26,"text":5184,"url":26,"identifiers":5185},"Loomba, 2015, Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial), Hepatology, 61, 1239, 10.1002\u002Fhep.27647",{"doi":5186},"10.1002\u002Fhep.27647",{"id":26,"text":5188,"url":26,"identifiers":5189},"Argo, 2015, Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial, J Hepatol, 62, 190, 10.1016\u002Fj.jhep.2014.08.036",{"doi":5190},"10.1016\u002Fj.jhep.2014.08.036",{"id":26,"text":5192,"url":26,"identifiers":5193},"Armstrong, 2015, Liraglutide safety and effi cacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study, Lancet",{},{"id":26,"text":5195,"url":26,"identifiers":5196},"Zelber-Sagi, 2011, Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence, World J Gastroenterol, 17, 3377, 10.3748\u002Fwjg.v17.i29.3377",{"doi":5197},"10.3748\u002Fwjg.v17.i29.3377",{"id":26,"text":5199,"url":26,"identifiers":5200},"Boden, 2009, High- or low-carbohydrate diets: which is better for weight loss, insulin resistance, and fatty livers?, Gastroenterology, 136, 1490, 10.1053\u002Fj.gastro.2009.03.019",{"doi":5201},"10.1053\u002Fj.gastro.2009.03.019",{"id":26,"text":5203,"url":26,"identifiers":5204},"Lazo, 2010, Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes, Diabetes Care, 33, 2156, 10.2337\u002Fdc10-0856",{"doi":5205},"10.2337\u002Fdc10-0856",{"id":26,"text":5207,"url":26,"identifiers":5208},"Perreault, 2012, Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study, Lancet, 379, 2243, 10.1016\u002FS0140-6736(12)60525-X",{"doi":5209},"10.1016\u002FS0140-6736(12)60525-X",{"id":26,"text":5211,"url":26,"identifiers":5212},"Thoma, 2012, Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review, J Hepatol, 56, 255, 10.1016\u002Fj.jhep.2011.06.010",{"doi":5213},"10.1016\u002Fj.jhep.2011.06.010",{"id":26,"text":5215,"url":26,"identifiers":5216},"Ryan, 2013, The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease, J Hepatol, 59, 138, 10.1016\u002Fj.jhep.2013.02.012",{"doi":5217},"10.1016\u002Fj.jhep.2013.02.012",{"id":26,"text":5219,"url":26,"identifiers":5220},"Liangpunsakul, 2012, What should we recommend to our patients with NAFLD regarding alcohol use?, Am J Gastroenterol, 107, 976, 10.1038\u002Fajg.2012.20",{"doi":5221},"10.1038\u002Fajg.2012.20",{"id":26,"text":5223,"url":26,"identifiers":5224},"Kwon, 2014, Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease, Liver Int, 34, 129, 10.1111\u002Fliv.12230",{"doi":5225},"10.1111\u002Fliv.12230",{"id":26,"text":5227,"url":26,"identifiers":5228},"Dunn, 2012, Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD), J Hepatol, 57, 384, 10.1016\u002Fj.jhep.2012.03.024",{"doi":5229},"10.1016\u002Fj.jhep.2012.03.024",{"id":26,"text":5231,"url":26,"identifiers":5232},"Ascha, 2010, The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis, Hepatology, 51, 1972, 10.1002\u002Fhep.23527",{"doi":5233},"10.1002\u002Fhep.23527",{"id":26,"text":5235,"url":26,"identifiers":5236},"Saab, 2014, Impact of coffee on liver diseases: a systematic review, Liver Int, 34, 495, 10.1111\u002Fliv.12304",{"doi":5237},"10.1111\u002Fliv.12304",{"id":26,"text":5239,"url":26,"identifiers":5240},"Keating, 2012, Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis, J Hepatol, 57, 157, 10.1016\u002Fj.jhep.2012.02.023",{"doi":5241},"10.1016\u002Fj.jhep.2012.02.023",{"id":26,"text":5243,"url":26,"identifiers":5244},"Bacchi, 2013, Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial), Hepatology, 58, 1287, 10.1002\u002Fhep.26393",{"doi":5245},"10.1002\u002Fhep.26393",{"id":26,"text":5247,"url":26,"identifiers":5248},"Petersen, 2005, Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes, Diabetes, 54, 603, 10.2337\u002Fdiabetes.54.3.603",{"doi":5249},"10.2337\u002Fdiabetes.54.3.603",{"id":26,"text":5251,"url":26,"identifiers":5252},"Vilar-Gomez, 2015, Weight loss via lifestyle modification significantly reduces features of nonalcoholic steatohepatitis, Gastroenterology, 149, 367, 10.1053\u002Fj.gastro.2015.04.005",{"doi":5253},"10.1053\u002Fj.gastro.2015.04.005",{"id":26,"text":5255,"url":26,"identifiers":5256},"Rodriguez, 2012, Physical activity: an essential component of lifestyle modification in NAFLD, Nat Rev Gastroenterol Hepatol, 9, 726, 10.1038\u002Fnrgastro.2012.200",{"doi":5257},"10.1038\u002Fnrgastro.2012.200",{"id":26,"text":5259,"url":26,"identifiers":5260},"Adams, 2005, The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies, J Hepatol, 42, 132, 10.1016\u002Fj.jhep.2004.09.012",{"doi":5261},"10.1016\u002Fj.jhep.2004.09.012",{"id":26,"text":5263,"url":26,"identifiers":5264},"Sanyal, 2015, Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop, Hepatology, 61, 1392, 10.1002\u002Fhep.27678",{"doi":5265},"10.1002\u002Fhep.27678",{"id":26,"text":5267,"url":26,"identifiers":5268},"Younossi, 2014, Systematic review with meta-analysis: non-alcoholic steatohepatitis – A case for personalised treatment based on pathogenic targets, Aliment Pharmacol Ther, 39, 3, 10.1111\u002Fapt.12543",{"doi":5269},"10.1111\u002Fapt.12543",{"id":26,"text":5271,"url":26,"identifiers":5272},"Mazzella, 2014, The role of medications for the management of patients with NAFLD, Clin Liver Dis, 18, 73, 10.1016\u002Fj.cld.2013.09.005",{"doi":5273},"10.1016\u002Fj.cld.2013.09.005",{"id":26,"text":5275,"url":26,"identifiers":5276},"Ratziu, 2015, Current efforts and trends in the treatment of NASH, J Hepatol, 62, S65, 10.1016\u002Fj.jhep.2015.02.041",{"doi":5277},"10.1016\u002Fj.jhep.2015.02.041",{"id":26,"text":5279,"url":26,"identifiers":5280},"Tiikkainen, 2004, Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes, Diabetes, 53, 2169, 10.2337\u002Fdiabetes.53.8.2169",{"doi":5281},"10.2337\u002Fdiabetes.53.8.2169",{"id":26,"text":5283,"url":26,"identifiers":5284},"Bhalla, 2012, Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis, Cancer Prev Res (Phila), 5, 544, 10.1158\u002F1940-6207.CAPR-11-0228",{"doi":5285},"10.1158\u002F1940-6207.CAPR-11-0228",{"id":26,"text":5287,"url":26,"identifiers":5288},"Zhang, 2012, Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis, J Clin Endocrinol Metab, 97, 2347, 10.1210\u002Fjc.2012-1267",{"doi":5289},"10.1210\u002Fjc.2012-1267",{"id":26,"text":5291,"url":26,"identifiers":5292},"Vilsboll, 2012, Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials, BMJ, 344, d7771, 10.1136\u002Fbmj.d7771",{"doi":5293},"10.1136\u002Fbmj.d7771",{"id":26,"text":5295,"url":26,"identifiers":5296},"Hoofnagle, 2013, Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis, Aliment Pharmacol Ther, 38, 134, 10.1111\u002Fapt.12352",{"doi":5297},"10.1111\u002Fapt.12352",{"id":26,"text":5299,"url":26,"identifiers":5300},"Bjelakovic, 2007, Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis, JAMA, 297, 842, 10.1001\u002Fjama.297.8.842",{"doi":5301},"10.1001\u002Fjama.297.8.842",{"id":26,"text":5303,"url":26,"identifiers":5304},"Schurks, 2010, Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials, BMJ, 341, c5702, 10.1136\u002Fbmj.c5702",{"doi":5305},"10.1136\u002Fbmj.c5702",{"id":26,"text":5307,"url":26,"identifiers":5308},"Klein, 2011, Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT), JAMA, 306, 1549, 10.1001\u002Fjama.2011.1437",{"doi":5309},"10.1001\u002Fjama.2011.1437",{"id":26,"text":5311,"url":26,"identifiers":5312},"Mudaliar, 2013, Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease, Gastroenterology, 145, e571, 10.1053\u002Fj.gastro.2013.05.042",{"doi":5313},"10.1053\u002Fj.gastro.2013.05.042",{"id":26,"text":5315,"url":26,"identifiers":5316},"Parker, 2012, Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis, J Hepatol, 56, 944, 10.1016\u002Fj.jhep.2011.08.018",{"doi":5317},"10.1016\u002Fj.jhep.2011.08.018",{"id":26,"text":5319,"url":26,"identifiers":5320},"Dongiovanni, 2015, Statin use and nonalcoholic steatohepatitis in at risk individuals, J Hepatol, 63, 705, 10.1016\u002Fj.jhep.2015.05.006",{"doi":5321},"10.1016\u002Fj.jhep.2015.05.006",{"id":26,"text":5323,"url":26,"identifiers":5324},"Valenti, 2007, Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study, Am J Gastroenterol, 102, 1251, 10.1111\u002Fj.1572-0241.2007.01192.x",{"doi":5325},"10.1111\u002Fj.1572-0241.2007.01192.x",{"id":26,"text":5327,"url":26,"identifiers":5328},"Nobili, 2009, Pediatric non-alcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention, World J Gastroenterol, 15, 6017, 10.3748\u002Fwjg.15.6017",{"doi":5329},"10.3748\u002Fwjg.15.6017",{"id":26,"text":5331,"url":26,"identifiers":5332},"Mitchel, 2014, Review article: the management of paediatric nonalcoholic fatty liver disease, Aliment Pharmacol Ther, 40, 1155, 10.1111\u002Fapt.12972",{"doi":5333},"10.1111\u002Fapt.12972",{"id":26,"text":5335,"url":26,"identifiers":5336},"Feldstein, 2009, The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years, Gut, 58, 1538, 10.1136\u002Fgut.2008.171280",{"doi":5337},"10.1136\u002Fgut.2008.171280",{"id":26,"text":5339,"url":26,"identifiers":5340},"Schauer, 2014, Bariatric surgery versus intensive medical therapy for diabetes–3-year outcomes, N Engl J Med, 370, 2002, 10.1056\u002FNEJMoa1401329",{"doi":5341},"10.1056\u002FNEJMoa1401329",{"id":26,"text":5343,"url":26,"identifiers":5344},"Caiazzo, 2014, Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study, Ann Surg, 260, 893, 10.1097\u002FSLA.0000000000000945",{"doi":5345},"10.1097\u002FSLA.0000000000000945",{"id":26,"text":5347,"url":26,"identifiers":5348},"Lassailly, 2015, Bariatric surgery reduces features of non-alcoholic steatohepatitis in morbidly obese patients, Gastroenterology, 149, 377, 10.1053\u002Fj.gastro.2015.04.014",{"doi":5349},"10.1053\u002Fj.gastro.2015.04.014",{"id":26,"text":5351,"url":26,"identifiers":5352},"Charlton, 2011, Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States, Gastroenterology, 141, 1249, 10.1053\u002Fj.gastro.2011.06.061",{"doi":5353},"10.1053\u002Fj.gastro.2011.06.061",{"id":26,"text":5355,"url":26,"identifiers":5356},"Wang, 2014, Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis, Clin Gastroenterol Hepatol, 12, e391, 10.1016\u002Fj.cgh.2013.09.023",{"doi":5357},"10.1016\u002Fj.cgh.2013.09.023",{"id":26,"text":5359,"url":26,"identifiers":5360},"Heuer, 2012, Liver transplantation in nonalcoholic steatohepatitis is associated with high mortality and post-transplant complications: a single-center experience, Digestion, 86, 107, 10.1159\u002F000339344",{"doi":5361},"10.1159\u002F000339344",{"id":26,"text":5363,"url":26,"identifiers":5364},"Sebagh, 2012, Twenty-year protocol liver biopsies: invasive but useful for the management of liver recipients, J Hepatol, 56, 840, 10.1016\u002Fj.jhep.2011.11.016",{"doi":5365},"10.1016\u002Fj.jhep.2011.11.016",{"id":5367,"createTime":5368,"updateTime":5368,"relativeEntities":5369,"slug":5370,"properties":5371,"entityType":749,"verifyStatus":25,"verifyTime":5368,"verifyNote":750,"syncStatus":28,"languages":5384,"translateLanguages":26,"viewCount":36,"primaryUrl":5385,"fullTextUrl":26,"authors":5386,"publicationType":895,"publisherRelationship":6152,"citationCount":6181,"citationInfo":6182,"publishDate":6188,"publishYear":6189,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":6190,"isForceReanalyzing":3453},"a01cba70-80a3-4141-b604-5997c41effc1","2024-10-15T22:53:46.347+00:00",[],"A-new-definition-for-metabolic-dysfunction-associated-fatty-liver-disease-An-international-expert-consensus-statement",{"mag":5372,"keywords":5374,"openalex":5375,"abstract":5377,"title":5378,"pm":5380,"doi":5382},{"VOID":5373},"3015579983",{},{"VOID":5376},"W3015579983",{},{"EN":5379},"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement",{"VOID":5381},"32278004",{"VOID":5383},"10.1016\u002Fj.jhep.2020.03.039",[102],"https:\u002F\u002Flinkinghub.elsevier.com\u002Fretrieve\u002Fpii\u002FS0168827820302014",[5387,5408,5441,5463,5496,5518,5539,5561,5583,5605,5626,5648,5670,5692,5713,5730,5750,5771,5793,5814,5836,5857,5879,5901,5934,5967,6011,6033,6054,6087,6109,6130],{"id":5388,"sortIndex":356,"researcher":26,"roles":5389,"affiliations":5390,"properties":5401},"092af371-e2a0-4d0f-8bee-cb66c359af61",[],[5391],{"id":5392,"sortIndex":36,"affiliation":5393,"properties":26},"06755e5a-ece3-4fa7-9ec1-2afdbe5b931e",{"id":5394,"createTime":5395,"updateTime":5395,"relativeEntities":5396,"slug":5397,"properties":5398,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"6e84864a-c716-414e-810a-32601a069cb5","2024-10-15T22:53:46.399+00:00",[],"Hepatology-and-Gastroenterology-Unit-Internal-Medicine-Department-Faculty-of-Medicine-Mansoura-University-Egypt",{"title":5399},{"EN":5400},"Hepatology and Gastroenterology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Egypt",{"openalex":5402,"orcid":5404,"title":5406},{"VOID":5403},"A5062545400",{"VOID":5405},"https:\u002F\u002Forcid.org\u002F0000-0002-9338-8854",{"EN":5407},"Gamal Shiha",{"id":5409,"sortIndex":135,"researcher":26,"roles":5410,"affiliations":5411,"properties":5434},"c553aa2c-9c90-465d-9deb-148200e23d10",[],[5412,5423],{"id":5413,"sortIndex":115,"affiliation":5414,"properties":26},"31d57594-19a7-43d1-bcb9-5b4becca7fe4",{"id":5415,"createTime":5416,"updateTime":5417,"relativeEntities":5418,"slug":5419,"properties":5420,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"15048814-2cb2-4716-81f1-a229db72156a","2024-01-21T19:45:17.791+00:00","2025-01-30T16:42:21.396+00:00",[],"School-of-Public-Health-University-of-Haifa-Haifa-Israel",{"title":5421},{"VI":5422},"School of Public Health, University of Haifa, Haifa, Israel",{"id":5424,"sortIndex":36,"affiliation":5425,"properties":26},"d9f37a3a-66bc-4dac-90fd-8d43f3e365a1",{"id":5426,"createTime":5427,"updateTime":5428,"relativeEntities":5429,"slug":5430,"properties":5431,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"567488f3-3848-4e56-92fa-b3083a51f435","2023-12-02T16:18:11.839+00:00","2024-10-15T22:53:46.483+00:00",[],"Department-of-Gastroenterology-Tel-Aviv-Medical-Center-Tel-Aviv-Israel",{"title":5432},{"VI":5433},"Department of Gastroenterology, Tel Aviv Medical Center, Tel Aviv, Israel",{"openalex":5435,"orcid":5437,"title":5439},{"VOID":5436},"A5028555246",{"VOID":5438},"https:\u002F\u002Forcid.org\u002F0000-0002-1324-7497",{"EN":5440},"Shira Zelber‐Sagi",{"id":5442,"sortIndex":255,"researcher":26,"roles":5443,"affiliations":5444,"properties":5456},"346cd537-0580-4634-8b39-ac034a5072cb",[],[5445],{"id":5446,"sortIndex":36,"affiliation":5447,"properties":26},"92a9516a-f8eb-4fe4-94d5-653e8ad8be7a",{"id":5448,"createTime":5449,"updateTime":5450,"relativeEntities":5451,"slug":5452,"properties":5453,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"163e258c-6861-416d-8cbd-655e72abb80d","2024-02-08T19:36:17.860+00:00","2024-10-15T22:53:46.390+00:00",[],"Storr-Liver-Centre-Westmead-Institute-for-Medical-Research-Westmead-Hospital-and-University-of-Sydney-NSW-Australia",{"title":5454},{"VI":5455},"Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, NSW, Australia",{"openalex":5457,"orcid":5459,"title":5461},{"VOID":5458},"A5011865871",{"VOID":5460},"https:\u002F\u002Forcid.org\u002F0000-0002-8421-5476",{"EN":5462},"Jacob George",{"id":5464,"sortIndex":173,"researcher":26,"roles":5465,"affiliations":5466,"properties":5489},"d500ad2a-aa0e-4ee1-a4f1-aef022b8a75b",[],[5467,5478],{"id":5468,"sortIndex":36,"affiliation":5469,"properties":26},"712936a0-30d4-4b0d-bd4f-73f8381002f2",{"id":5470,"createTime":5471,"updateTime":5472,"relativeEntities":5473,"slug":5474,"properties":5475,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"af736bf9-a5ac-4489-9452-b76f4ea5b9ca","2023-12-21T08:53:38.397+00:00","2024-10-15T22:53:46.556+00:00",[],"Department-of-Gastroenterology-School-of-Medicine-Marmara-University-Istanbul-Turkey",{"title":5476},{"VI":5477},"Department of Gastroenterology, School of Medicine, Marmara University, Istanbul, Turkey",{"id":5479,"sortIndex":115,"affiliation":5480,"properties":26},"66d624fc-dace-4d48-987b-9f251f4b186d",{"id":5481,"createTime":5482,"updateTime":5483,"relativeEntities":5484,"slug":5485,"properties":5486,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"33251706-0107-4a65-867e-1c02feb1702d","2024-01-13T00:41:53.096+00:00","2024-10-15T22:53:46.559+00:00",[],"Institute-of-Gastroenterology-Marmara-University-Istanbul-Turkey",{"title":5487},{"VI":5488},"Institute of Gastroenterology, Marmara University, Istanbul, Turkey",{"openalex":5490,"orcid":5492,"title":5494},{"VOID":5491},"A5076455574",{"VOID":5493},"https:\u002F\u002Forcid.org\u002F0000-0003-4518-5283",{"EN":5495},"Yusuf Yılmaz",{"id":5497,"sortIndex":114,"researcher":26,"roles":5498,"affiliations":5499,"properties":5511},"5564bfad-15c8-4748-9ed4-b8ce4d191bff",[],[5500],{"id":5501,"sortIndex":36,"affiliation":5502,"properties":26},"175c1581-42ea-469d-8262-3d15443d9995",{"id":5503,"createTime":5504,"updateTime":5505,"relativeEntities":5506,"slug":5507,"properties":5508,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"00a479c2-8ebb-4cca-b725-68f5d99e6d02","2024-01-11T00:42:45.227+00:00","2025-06-11T14:08:16.355+00:00",[],"Department-of-Hepatology-Institute-of-Liver-and-Biliary-Sciences-New-Delhi-India",{"title":5509},{"VI":5510},"Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India",{"openalex":5512,"orcid":5514,"title":5516},{"VOID":5513},"A5026415059",{"VOID":5515},"https:\u002F\u002Forcid.org\u002F0000-0002-0544-5610",{"EN":5517},"Shiv Kumar Sarin",{"id":5519,"sortIndex":103,"researcher":26,"roles":5520,"affiliations":5521,"properties":5532},"d0a4b0e1-b779-44f8-b60c-cf04da9ffa60",[],[5522],{"id":5523,"sortIndex":36,"affiliation":5524,"properties":26},"5d8a5345-88b0-434e-9c42-d51530fbd39c",{"id":5525,"createTime":5526,"updateTime":5526,"relativeEntities":5527,"slug":5528,"properties":5529,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"59b51c27-5126-436b-b887-aef594fad150","2024-10-15T22:53:46.651+00:00",[],"Department-of-Pathophysiology-and-Transplantation-Universit%C3%A0-degli-Studi-di-Milano-and-Translational-Medicine-Department-of-Transfusion-Medicine-and-Hematology-Fondazione-IRCCS-Ca-Granda-Ospedale-Maggiore-Policlinico-Milano-Italy",{"title":5530},{"EN":5531},"Department of Pathophysiology and Transplantation, Università degli Studi di Milano, and Translational Medicine, Department of Transfusion Medicine and Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy",{"openalex":5533,"orcid":5535,"title":5537},{"VOID":5534},"A5050497878",{"VOID":5536},"https:\u002F\u002Forcid.org\u002F0000-0001-8909-0345",{"EN":5538},"Luca Valenti",{"id":5540,"sortIndex":116,"researcher":26,"roles":5541,"affiliations":5542,"properties":5554},"eee0f35e-db75-482f-aa6e-6dc5beb1c558",[],[5543],{"id":5544,"sortIndex":36,"affiliation":5545,"properties":26},"edeb71c2-7ba5-4e78-a1fc-d1c3b0c40482",{"id":5546,"createTime":5547,"updateTime":5548,"relativeEntities":5549,"slug":5550,"properties":5551,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"6a685f39-7dfe-40f7-8ef4-636af86c4c18","2023-12-29T18:54:24.222+00:00","2024-11-30T14:23:23.926+00:00",[],"Division-of-Gastroenterology-Department-of-Medicine-Kurume-University-School-of-Medicine-Kurume-Japan",{"title":5552},{"VI":5553},"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan",{"openalex":5555,"orcid":5557,"title":5559},{"VOID":5556},"A5101842545",{"VOID":5558},"https:\u002F\u002Forcid.org\u002F0000-0002-7064-4325",{"EN":5560},"Takumi Kawaguchi",{"id":5562,"sortIndex":124,"researcher":26,"roles":5563,"affiliations":5564,"properties":5576},"df8c23ee-4517-4052-97b1-4ea475491fc0",[],[5565],{"id":5566,"sortIndex":36,"affiliation":5567,"properties":26},"5d1db92f-a9b9-410b-a969-3bb2d44593dc",{"id":5568,"createTime":5569,"updateTime":5570,"relativeEntities":5571,"slug":5572,"properties":5573,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"3e054484-fb35-418f-b064-8d1ddcabc4cc","2023-12-25T22:32:17.074+00:00","2024-10-15T22:53:46.504+00:00",[],"Department-of-Hepatology-Gastroenterology-Aarhus-University-Hospital-Aarhus-Denmark",{"title":5574},{"VI":5575},"Department of Hepatology & Gastroenterology, Aarhus University Hospital, Aarhus, Denmark",{"openalex":5577,"orcid":5579,"title":5581},{"VOID":5578},"A5083375223",{"VOID":5580},"https:\u002F\u002Forcid.org\u002F0000-0001-8998-7910",{"EN":5582},"Henning Grønbæk",{"id":5584,"sortIndex":222,"researcher":26,"roles":5585,"affiliations":5586,"properties":5598},"4d5b46cc-6d29-4992-babe-8d8c16871cc8",[],[5587],{"id":5588,"sortIndex":36,"affiliation":5589,"properties":26},"5558d259-aa98-40af-a169-f6676951b92d",{"id":5590,"createTime":5591,"updateTime":5592,"relativeEntities":5593,"slug":5594,"properties":5595,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"5daa975b-be7c-4a02-a3a6-8172ec48d73b","2023-12-31T06:30:56.497+00:00","2024-12-27T17:13:54.501+00:00",[],"Department-of-Internal-Medicine-Yonsei-University-College-of-Medicine-Seoul-South-Korea",{"title":5596},{"VI":5597},"Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea",{"openalex":5599,"orcid":5601,"title":5603},{"VOID":5600},"A5006412769",{"VOID":5602},"https:\u002F\u002Forcid.org\u002F0000-0002-3629-4624",{"EN":5604},"Sang Hoon Ahn",{"id":5606,"sortIndex":240,"researcher":26,"roles":5607,"affiliations":5608,"properties":5619},"5303f021-819d-45a8-8062-4d62fa64d317",[],[5609],{"id":5610,"sortIndex":36,"affiliation":5611,"properties":26},"b662e4db-a3ec-4546-95ab-f9136e0800ee",{"id":5612,"createTime":5613,"updateTime":5613,"relativeEntities":5614,"slug":5615,"properties":5616,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"e224493f-f811-46a5-a612-b81a04b64f6b","2024-10-15T22:53:46.513+00:00",[],"Universit%C3%A9-Paris-VII-Inserm-Umr-1149-Centre-de-Recherche-Sur-L-inflammation-Paris-France",{"title":5617},{"EN":5618},"Université Paris VII, Inserm Umr 1149, Centre de Recherche Sur L'inflammation, Paris, France",{"openalex":5620,"orcid":5622,"title":5624},{"VOID":5621},"A5009242334",{"VOID":5623},"https:\u002F\u002Forcid.org\u002F0000-0002-6715-8588",{"EN":5625},"Laurent Castéra",{"id":5627,"sortIndex":244,"researcher":26,"roles":5628,"affiliations":5629,"properties":5641},"ea023014-74c9-41a7-bce3-ec76041983c9",[],[5630],{"id":5631,"sortIndex":36,"affiliation":5632,"properties":26},"bc6628e8-e4c8-4697-9af3-bbf1704f7112",{"id":5633,"createTime":5634,"updateTime":5635,"relativeEntities":5636,"slug":5637,"properties":5638,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"325f6a22-b985-44d5-8856-414a77fb4a81","2024-02-11T18:59:48.405+00:00","2024-10-15T22:53:46.675+00:00",[],"Division-of-Gastroenterology-and-Hepatology-Department-of-Medical-Sciences-University-of-Turin-Turin-Italy",{"title":5639},{"VI":5640},"Division of Gastroenterology and Hepatology, Department of Medical Sciences, University of Turin, Turin, Italy",{"openalex":5642,"orcid":5644,"title":5646},{"VOID":5643},"A5039389628",{"VOID":5645},"https:\u002F\u002Forcid.org\u002F0000-0002-0502-4381",{"EN":5647},"Elisabetta Bugianesi",{"id":5649,"sortIndex":242,"researcher":26,"roles":5650,"affiliations":5651,"properties":5663},"4cd7ce7a-dc08-49fa-9490-dc18dc9bdace",[],[5652],{"id":5653,"sortIndex":36,"affiliation":5654,"properties":26},"157a46dd-8193-4a10-8abf-e71457925285",{"id":5655,"createTime":5656,"updateTime":5657,"relativeEntities":5658,"slug":5659,"properties":5660,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"57394c2c-345f-44a4-87ac-0c309b69c372","2024-04-15T03:53:29.266+00:00","2024-10-15T22:53:46.452+00:00",[],"Department-of-Gastroenterology-University-of-Sao-Paulo-School-of-Medicine-Sao-Paulo-Brazil",{"title":5661},{"EN":5662},"Department of Gastroenterology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil",{"openalex":5664,"orcid":5666,"title":5668},{"VOID":5665},"A5072591143",{"VOID":5667},"https:\u002F\u002Forcid.org\u002F0000-0002-2848-417X",{"EN":5669},"Cláudia P. Oliveira",{"id":5671,"sortIndex":516,"researcher":26,"roles":5672,"affiliations":5673,"properties":5685},"0900b14d-918f-40c6-a84f-4170a592f57b",[],[5674],{"id":5675,"sortIndex":36,"affiliation":5676,"properties":26},"8f246a3b-87f1-459f-9233-dcd547f97c12",{"id":5677,"createTime":5678,"updateTime":5679,"relativeEntities":5680,"slug":5681,"properties":5682,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"dffc7b0e-957e-47eb-aedf-001891fa7a2a","2024-02-13T20:49:11.451+00:00","2024-10-15T22:53:46.623+00:00",[],"Department-of-Pathology-Physiology-and-Imaging-Beaujon-Hospital-Paris-Diderot-University-Paris-France",{"title":5683},{"VI":5684},"Department of Pathology, Physiology and Imaging, Beaujon Hospital Paris Diderot University, Paris, France",{"openalex":5686,"orcid":5688,"title":5690},{"VOID":5687},"A5038609111",{"VOID":5689},"https:\u002F\u002Forcid.org\u002F0000-0002-8487-7322",{"EN":5691},"Pierre Bédossa",{"id":5693,"sortIndex":51,"researcher":26,"roles":5694,"affiliations":5695,"properties":5706},"afcfc10f-cee5-4e4c-9ed6-86ad2549ee45",[],[5696],{"id":5697,"sortIndex":36,"affiliation":5698,"properties":26},"01784966-97b2-47e3-b03c-86e0a4fbbaa9",{"id":5699,"createTime":5700,"updateTime":5700,"relativeEntities":5701,"slug":5702,"properties":5703,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"6ca9ca99-5d71-44b6-ad0c-bd2065dfc0e2","2024-10-15T22:53:46.364+00:00",[],"Department-of-Medicine-University-of-Helsinki-and-Helsinki-University-Hospital-and-Minerva-Foundation-Institute-for-Medical-Research-Helsinki-Finland",{"title":5704},{"EN":5705},"Department of Medicine, University of Helsinki and Helsinki University Hospital, and Minerva Foundation Institute for Medical Research, Helsinki, Finland",{"openalex":5707,"orcid":5709,"title":5711},{"VOID":5708},"A5028953583",{"VOID":5710},"https:\u002F\u002Forcid.org\u002F0000-0001-6766-1549",{"EN":5712},"Hannele Yki‐Järvinen",{"id":5714,"sortIndex":36,"researcher":26,"roles":5715,"affiliations":5716,"properties":5723},"eb31b6b3-d3b2-4a7f-b1a8-2be4d0f3beb4",[],[5717],{"id":5718,"sortIndex":36,"affiliation":5719,"properties":26},"f89fb1b7-7639-42bd-81b0-676f0fa2bdfc",{"id":5448,"createTime":5449,"updateTime":5450,"relativeEntities":5720,"slug":5452,"properties":5721,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":5722},{"VI":5455},{"openalex":5724,"orcid":5726,"title":5728},{"VOID":5725},"A5071565406",{"VOID":5727},"https:\u002F\u002Forcid.org\u002F0000-0002-4315-4144",{"EN":5729},"Mohammed Eslam",{"id":5731,"sortIndex":336,"researcher":26,"roles":5732,"affiliations":5733,"properties":5745},"77b9e73d-3272-4d96-a215-b01df8f8a44e",[],[5734],{"id":5735,"sortIndex":36,"affiliation":5736,"properties":26},"1377774a-4c6e-419a-94aa-994a10d739a2",{"id":5737,"createTime":5738,"updateTime":5739,"relativeEntities":5740,"slug":5741,"properties":5742,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"a5294174-65b9-44f6-9fe4-e98c81c717d0","2024-01-04T13:31:03.153+00:00","2024-10-15T22:53:46.524+00:00",[],"Center-for-Fatty-Liver-Department-of-Gastroenterology-Xin-Hua-Hospital-Affiliated-To-Shanghai-Jiao-Tong-University-School-of-Medicine-Shanghai-Key-Lab-of-Pediatric-Gastroenterology-and-Nutrition-Shanghai-China",{"title":5743},{"VI":5744},"Center for Fatty Liver, Department of Gastroenterology, Xin Hua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai Key Lab of Pediatric Gastroenterology and Nutrition, Shanghai, China",{"openalex":5746,"title":5748},{"VOID":5747},"A5100825514",{"EN":5749},"Jian-Gao Fan",{"id":5751,"sortIndex":298,"researcher":26,"roles":5752,"affiliations":5753,"properties":5764},"ddfad766-d84f-4021-ba56-7c14e99b5f37",[],[5754],{"id":5755,"sortIndex":36,"affiliation":5756,"properties":26},"c10ab5bf-c18a-4a0d-8b78-ec2f6faadbab",{"id":5757,"createTime":5758,"updateTime":5758,"relativeEntities":5759,"slug":5760,"properties":5761,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"8d337fe4-8396-4049-a31a-ad8456b213e7","2024-10-15T22:53:46.585+00:00",[],"Liver-Center-Italian-Liver-Foundation-Trieste-Italy",{"title":5762},{"EN":5763},"Liver Center, Italian Liver Foundation, Trieste, Italy",{"openalex":5765,"orcid":5767,"title":5769},{"VOID":5766},"A5071646464",{"VOID":5768},"https:\u002F\u002Forcid.org\u002F0000-0001-6596-7595",{"EN":5770},"Claudio Tiribelli",{"id":5772,"sortIndex":239,"researcher":26,"roles":5773,"affiliations":5774,"properties":5786},"b0abdc2e-10db-454a-a2e2-12e816c2dce0",[],[5775],{"id":5776,"sortIndex":36,"affiliation":5777,"properties":26},"bbcd2781-c4c3-4dc5-b932-0ac9f15063d5",{"id":5778,"createTime":5779,"updateTime":5780,"relativeEntities":5781,"slug":5782,"properties":5783,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"9028f4ad-d79e-4c9e-9a84-1c8ff7560e24","2024-04-06T21:41:53.468+00:00","2024-10-15T22:53:46.596+00:00",[],"Medical-School-Sir-Charles-Gairdner-Hospital-Unit-University-of-Western-Australia-Nedlands-WA-Australia",{"title":5784},{"VI":5785},"Medical School, Sir Charles Gairdner Hospital Unit, University of Western Australia, Nedlands, WA, Australia",{"openalex":5787,"orcid":5789,"title":5791},{"VOID":5788},"A5090087138",{"VOID":5790},"https:\u002F\u002Forcid.org\u002F0000-0002-3968-7909",{"EN":5792},"Leon A. Adams",{"id":5794,"sortIndex":162,"researcher":26,"roles":5795,"affiliations":5796,"properties":5807},"ab4f56fe-2bee-435c-b251-faf5b9404f68",[],[5797],{"id":5798,"sortIndex":36,"affiliation":5799,"properties":26},"019d282a-df83-48f9-86ff-bb7a4711dac9",{"id":5800,"createTime":5801,"updateTime":5801,"relativeEntities":5802,"slug":5803,"properties":5804,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"9c8a5ae6-f63e-4933-820c-5c6f8fdf0bb4","2024-10-15T22:53:46.442+00:00",[],"UCM-Digestive-Diseases-Virgen-del-Rocio-University-Hospital-Instituto-de-Biomedicina-de-Sevilla-CIBEREHD-University-of-Seville-Sevilla-Spain",{"title":5805},{"EN":5806},"UCM Digestive Diseases, Virgen del Rocio University Hospital, Instituto de Biomedicina de Sevilla, CIBEREHD, University of Seville, Sevilla, Spain",{"openalex":5808,"orcid":5810,"title":5812},{"VOID":5809},"A5037480677",{"VOID":5811},"https:\u002F\u002Forcid.org\u002F0000-0001-8494-8947",{"EN":5813},"Manuel Romero‐Gómez",{"id":5815,"sortIndex":158,"researcher":26,"roles":5816,"affiliations":5817,"properties":5829},"1f5c4fbd-cbc9-4c62-bc64-814b8fc33ba8",[],[5818],{"id":5819,"sortIndex":36,"affiliation":5820,"properties":26},"a8685d66-831d-4df8-bad0-16ada8ea5e0f",{"id":5821,"createTime":5822,"updateTime":5823,"relativeEntities":5824,"slug":5825,"properties":5826,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"0c3a0bb5-546d-4c7e-9846-718a52b59d07","2024-02-07T15:25:45.246+00:00","2025-06-12T01:03:32.046+00:00",[],"Department-of-Medicine-and-Therapeutics-The-Chinese-University-of-Hong-Kong-Hong-Kong",{"title":5827},{"VI":5828},"Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong",{"openalex":5830,"orcid":5832,"title":5834},{"VOID":5831},"A5087968813",{"VOID":5833},"https:\u002F\u002Forcid.org\u002F0000-0002-2863-9389",{"EN":5835},"Grace Lai‐Hung Wong",{"id":5837,"sortIndex":238,"researcher":26,"roles":5838,"affiliations":5839,"properties":5850},"3c707d2f-616d-4b6d-878d-4ab85c99c0b1",[],[5840],{"id":5841,"sortIndex":36,"affiliation":5842,"properties":26},"d3441728-d9a4-4695-954b-a472c7c60339",{"id":5843,"createTime":5844,"updateTime":5844,"relativeEntities":5845,"slug":5846,"properties":5847,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"197dd34e-cd0b-4875-aebf-0feba525d5e8","2024-10-15T22:53:46.662+00:00",[],"Department-of-Gastroenterology-Hepatology-and-Endemic-Medicine-Faculty-of-Medicine-Minia-University-Hospitals-Minya-Egypt",{"title":5848},{"EN":5849},"Department of Gastroenterology, Hepatology and Endemic Medicine, Faculty of Medicine, Minia University Hospitals, Minya, Egypt",{"openalex":5851,"orcid":5853,"title":5855},{"VOID":5852},"A5023790424",{"VOID":5854},"https:\u002F\u002Forcid.org\u002F0000-0001-7989-5318",{"EN":5856},"Yasser Fouad",{"id":5858,"sortIndex":260,"researcher":26,"roles":5859,"affiliations":5860,"properties":5872},"839e967d-3249-4dca-b80f-0d93e5a891a2",[],[5861],{"id":5862,"sortIndex":36,"affiliation":5863,"properties":26},"6c622349-8e2f-419a-9277-ef63ab11ce63",{"id":5864,"createTime":5865,"updateTime":5866,"relativeEntities":5867,"slug":5868,"properties":5869,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"cda8daa4-68d3-40e1-8205-a450e3ccd172","2023-12-29T16:00:51.342+00:00","2024-10-15T22:53:46.567+00:00",[],"Liver-Research-Unit-Medica-Sur-Clinic-Foundation-and-Faculty-of-Medicine-National-Autonomous-University-of-Mexico-Mexico-City-Mexico",{"title":5870},{"VI":5871},"Liver Research Unit, Medica Sur Clinic & Foundation and Faculty of Medicine. National Autonomous University of Mexico, Mexico City, Mexico",{"openalex":5873,"orcid":5875,"title":5877},{"VOID":5874},"A5037581187",{"VOID":5876},"https:\u002F\u002Forcid.org\u002F0000-0001-5257-8048",{"EN":5878},"Nahúm Méndez‐Sánchez",{"id":5880,"sortIndex":52,"researcher":26,"roles":5881,"affiliations":5882,"properties":5894},"0f0b6480-3ed8-47a5-98d0-e36c89844058",[],[5883],{"id":5884,"sortIndex":36,"affiliation":5885,"properties":26},"b065f8e5-d56c-4c63-bf62-d0627aee3eb2",{"id":5886,"createTime":5887,"updateTime":5888,"relativeEntities":5889,"slug":5890,"properties":5891,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"0170102b-6b26-4b2e-a004-350853178418","2024-10-15T22:53:46.576+00:00","2025-06-11T14:53:43.735+00:00",[],"Department-of-Medicine-University-Medical-Centre-Johannes-Gutenberg-University-Mainz-Germany",{"title":5892},{"EN":5893},"Department of Medicine, University Medical Centre, Johannes Gutenberg University Mainz, Germany",{"openalex":5895,"orcid":5897,"title":5899},{"VOID":5896},"A5090959657",{"VOID":5898},"https:\u002F\u002Forcid.org\u002F0000-0002-4224-4703",{"EN":5900},"Jörn M. Schattenberg",{"id":5902,"sortIndex":237,"researcher":26,"roles":5903,"affiliations":5904,"properties":5927},"87587462-77c1-4d9a-ade0-f90fe1f0a8bf",[],[5905,5916],{"id":5906,"sortIndex":36,"affiliation":5907,"properties":26},"04c9accf-f73d-40d6-9c8f-cd931cac68d3",{"id":5908,"createTime":5909,"updateTime":5910,"relativeEntities":5911,"slug":5912,"properties":5913,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"3cf05f59-7b01-4dba-9e4d-7e759b1994fa","2024-01-20T18:41:47.450+00:00","2024-10-15T22:53:46.462+00:00",[],"Institute-of-Hepatology-Wenzhou-Medical-University-Wenzhou-China",{"title":5914},{"VI":5915},"Institute of Hepatology, Wenzhou Medical University, Wenzhou, China",{"id":5917,"sortIndex":115,"affiliation":5918,"properties":26},"9d81f5c4-45ff-4543-9891-f81cef3f9870",{"id":5919,"createTime":5920,"updateTime":5921,"relativeEntities":5922,"slug":5923,"properties":5924,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"4d922088-993b-4fac-80d9-831d2dc31fb3","2023-12-21T13:48:29.668+00:00","2024-10-15T22:53:46.464+00:00",[],"NAFLD-Research-Center-Department-of-Hepatology-The-First-Affiliated-Hospital-of-Wenzhou-Medical-University-Wenzhou-China",{"title":5925},{"VI":5926},"NAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China",{"openalex":5928,"orcid":5930,"title":5932},{"VOID":5929},"A5030038857",{"VOID":5931},"https:\u002F\u002Forcid.org\u002F0000-0003-4984-2631",{"EN":5933},"Ming‐Hua Zheng",{"id":5935,"sortIndex":59,"researcher":26,"roles":5936,"affiliations":5937,"properties":5960},"0f493b82-8381-4b7c-80a5-da640e31ea2b",[],[5938,5949],{"id":5939,"sortIndex":36,"affiliation":5940,"properties":26},"4293419c-116b-4c95-a7ad-915139b78c24",{"id":5941,"createTime":5942,"updateTime":5943,"relativeEntities":5944,"slug":5945,"properties":5946,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"f275e78e-ab91-4497-8c6b-5f3557d439c4","2024-01-25T15:25:56.373+00:00","2024-10-15T22:53:46.418+00:00",[],"Newcastle-NIHR-Biomedical-Research-Centre-Newcastle-upon-Tyne-Hospitals-NHS-Foundation-Trust-Newcastle-upon-Tyne-United-Kingdom",{"title":5947},{"VI":5948},"Newcastle NIHR Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom",{"id":5950,"sortIndex":115,"affiliation":5951,"properties":26},"666fc67b-a929-4ae4-9598-70960131c113",{"id":5952,"createTime":5953,"updateTime":5954,"relativeEntities":5955,"slug":5956,"properties":5957,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"9b1257f5-1338-43fc-81aa-e8d18988c614","2024-01-25T15:25:56.323+00:00","2024-10-15T22:53:46.420+00:00",[],"Translational-Clinical-Research-Institute-Faculty-of-Medical-Sciences-Newcastle-University-Newcastle-upon-Tyne-United-Kingdom",{"title":5958},{"VI":5959},"Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom",{"openalex":5961,"orcid":5963,"title":5965},{"VOID":5962},"A5059068278",{"VOID":5964},"https:\u002F\u002Forcid.org\u002F0000-0002-9518-0088",{"EN":5966},"Quentin M. Anstee",{"id":5968,"sortIndex":115,"researcher":26,"roles":5969,"affiliations":5970,"properties":6004},"57b0a568-8540-4ca5-8bcd-55045864bff7",[],[5971,5982,5993],{"id":5972,"sortIndex":36,"affiliation":5973,"properties":26},"b39f3cad-a641-47e6-b2c5-725c0d9ad1b1",{"id":5974,"createTime":5975,"updateTime":5976,"relativeEntities":5977,"slug":5978,"properties":5979,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"2027f0a0-b28f-4f8d-bc85-1575cfe0a204","2024-01-11T03:43:44.570+00:00","2024-10-15T22:53:46.374+00:00",[],"Centre-for-Liver-and-Gastrointestinal-Research-Institute-of-Immunology-and-Immunotherapy-University-of-Birmingham-UK",{"title":5980},{"VI":5981},"Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, UK",{"id":5983,"sortIndex":114,"affiliation":5984,"properties":26},"490a34ed-798b-4c52-84b3-c8c4967ad228",{"id":5985,"createTime":5986,"updateTime":5987,"relativeEntities":5988,"slug":5989,"properties":5990,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"b56aa466-aebe-415d-9178-d2acd76707b2","2024-01-11T03:43:44.565+00:00","2024-10-15T22:53:46.379+00:00",[],"National-Institute-for-Health-Research-Biomedical-Research-Centre-at-University-Hospitals-Birmingham-NHS-Foundation-Trust-and-the-University-of-Birmingham-UK",{"title":5991},{"VI":5992},"National Institute for Health Research Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, UK",{"id":5994,"sortIndex":115,"affiliation":5995,"properties":26},"d7aed3db-578b-4fc4-833d-3864dc23f76e",{"id":5996,"createTime":5997,"updateTime":5998,"relativeEntities":5999,"slug":6000,"properties":6001,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"e9bbf4c4-feb5-421e-9a0f-2e750beedfe0","2023-12-24T02:54:32.384+00:00","2024-10-15T22:53:46.377+00:00",[],"Liver-Unit-University-Hospitals-Birmingham-NHS-Foundation-Trust-Birmingham-UK",{"title":6002},{"VI":6003},"Liver Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK",{"openalex":6005,"orcid":6007,"title":6009},{"VOID":6006},"A5044832887",{"VOID":6008},"https:\u002F\u002Forcid.org\u002F0000-0001-6085-3652",{"EN":6010},"Philip N. Newsome",{"id":6012,"sortIndex":241,"researcher":26,"roles":6013,"affiliations":6014,"properties":6026},"61d998e2-ac68-4602-bd4f-567aee03aaec",[],[6015],{"id":6016,"sortIndex":36,"affiliation":6017,"properties":26},"dc509ce0-fd19-448e-9c16-6812cb6e5d04",{"id":6018,"createTime":6019,"updateTime":6020,"relativeEntities":6021,"slug":6022,"properties":6023,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"ef782cce-b239-4e19-8bfa-0baf57f0ea76","2023-11-25T10:26:25.598+00:00","2024-10-15T22:53:46.615+00:00",[],"Gastroenterology-and-Hepatology-Unit-Department-of-Medicine-Faculty-of-Medicine-University-of-Malaya-Kuala-Lumpur-Malaysia",{"title":6024},{"VI":6025},"Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia",{"openalex":6027,"orcid":6029,"title":6031},{"VOID":6028},"A5077981491",{"VOID":6030},"https:\u002F\u002Forcid.org\u002F0000-0002-9105-5837",{"EN":6032},"Wah‐Kheong Chan",{"id":6034,"sortIndex":234,"researcher":26,"roles":6035,"affiliations":6036,"properties":6047},"17074deb-07f0-4ff3-84bf-7141890a5416",[],[6037],{"id":6038,"sortIndex":36,"affiliation":6039,"properties":26},"ce2b82ec-e007-4964-b7ac-adde87772120",{"id":6040,"createTime":6041,"updateTime":6041,"relativeEntities":6042,"slug":6043,"properties":6044,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"a53c1715-858e-4657-8983-a8d6c1fbafef","2024-10-15T22:53:46.534+00:00",[],"Cl%C3%ADnica-Universit%C3%A1ria-de-Gastrenterologia-Laborat%C3%B3rio-de-Nutri%C3%A7%C3%A3o-Faculdade-de-Medicina-Universidade-de-Lisboa-Portugal",{"title":6045},{"EN":6046},"Clínica Universitária de Gastrenterologia, Laboratório de Nutrição, Faculdade de Medicina, Universidade de Lisboa, Portugal",{"openalex":6048,"orcid":6050,"title":6052},{"VOID":6049},"A5027348289",{"VOID":6051},"https:\u002F\u002Forcid.org\u002F0000-0002-8537-8744",{"EN":6053},"Helena Cortez‐Pinto",{"id":6055,"sortIndex":50,"researcher":26,"roles":6056,"affiliations":6057,"properties":6080},"6f15e363-472d-445b-8d0f-63f8696e9eaf",[],[6058,6069],{"id":6059,"sortIndex":36,"affiliation":6060,"properties":26},"70bbdb5a-2d5b-4df6-8d67-b28045da875f",{"id":6061,"createTime":6062,"updateTime":6063,"relativeEntities":6064,"slug":6065,"properties":6066,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"ca6b268b-c54a-43e2-a107-51a3d76df6be","2024-02-02T15:52:45.796+00:00","2024-10-15T22:53:46.544+00:00",[],"Department-of-Biomedical-Research-University-of-Bern-Switzerland",{"title":6067},{"VI":6068},"Department of Biomedical Research, University of Bern, Switzerland",{"id":6070,"sortIndex":115,"affiliation":6071,"properties":26},"f0124ee8-7987-4000-8967-1a11d73ab738",{"id":6072,"createTime":6073,"updateTime":6074,"relativeEntities":6075,"slug":6076,"properties":6077,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"dc5b3b16-eb4d-4971-8eaa-503c63b47ec9","2024-01-16T23:38:02.886+00:00","2024-10-15T22:53:46.547+00:00",[],"University-Clinic-for-Visceral-Surgery-and-Medicine-Inselspital-University-of-Bern-Switzerland",{"title":6078},{"VI":6079},"University Clinic for Visceral Surgery and Medicine, Inselspital, University of Bern. Switzerland",{"openalex":6081,"orcid":6083,"title":6085},{"VOID":6082},"A5107024891",{"VOID":6084},"https:\u002F\u002Forcid.org\u002F0000-0002-8062-1346",{"EN":6086},"Jean‐François Dufour",{"id":6088,"sortIndex":111,"researcher":26,"roles":6089,"affiliations":6090,"properties":6102},"543e184c-3942-496e-a77d-9f785560e9d2",[],[6091],{"id":6092,"sortIndex":36,"affiliation":6093,"properties":26},"ae779536-17a2-4bc4-8b86-04252bcc1a4b",{"id":6094,"createTime":6095,"updateTime":6096,"relativeEntities":6097,"slug":6098,"properties":6099,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"eb46bb02-e580-42ab-bb0c-baf6730f64b2","2023-12-13T05:06:57.052+00:00","2024-10-15T22:53:46.431+00:00",[],"Section-of-Endocrinology-Diabetes-and-Metabolism-Department-of-Medicine-University-and-Azienda-Ospedaliera-Universitaria-Integrata-of-Verona-Verona-Italy",{"title":6100},{"VI":6101},"Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy",{"openalex":6103,"orcid":6105,"title":6107},{"VOID":6104},"A5071075382",{"VOID":6106},"https:\u002F\u002Forcid.org\u002F0000-0002-4325-3900",{"EN":6108},"Giovanni Targher",{"id":6110,"sortIndex":396,"researcher":26,"roles":6111,"affiliations":6112,"properties":6123},"0bcdd5a4-cc3b-4621-aa01-a17cead12aa9",[],[6113],{"id":6114,"sortIndex":36,"affiliation":6115,"properties":26},"8309d363-08b6-4f65-97af-e5a1691ee349",{"id":6116,"createTime":6117,"updateTime":6117,"relativeEntities":6118,"slug":6119,"properties":6120,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"e8dc9235-d5ca-4475-8954-d9c3ee7e29be","2024-10-15T22:53:46.606+00:00",[],"Sorbonne-Universit%C3%A9-Assistance-Publique-H%C3%B4pitaux-de-Paris-H%C3%B4pital-Piti%C3%A9-Salp%C3%AAtri%C3%A8re-Institute-of-Cardiometabolism-and-Nutrition-ICAN-Paris-France",{"title":6121},{"EN":6122},"Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié Salpêtrière-, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France",{"openalex":6124,"orcid":6126,"title":6128},{"VOID":6125},"A5072395263",{"VOID":6127},"https:\u002F\u002Forcid.org\u002F0000-0002-6865-3791",{"EN":6129},"Vlad Ratziu",{"id":6131,"sortIndex":53,"researcher":26,"roles":6132,"affiliations":6133,"properties":6145},"2b1a8337-3590-4891-8d57-56c54c3b6dc1",[],[6134],{"id":6135,"sortIndex":36,"affiliation":6136,"properties":26},"0a975060-a516-45b7-aa9a-1f09b136633b",{"id":6137,"createTime":6138,"updateTime":6139,"relativeEntities":6140,"slug":6141,"properties":6142,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"97e53ef2-997b-4ecf-9b1d-9d321c376f7e","2024-01-03T16:08:25.943+00:00","2024-10-15T22:53:46.642+00:00",[],"Departamento-de-Gastroenterolog%C3%ADa-Escuela-de-Medicina-Pontificia-Universidad-Cat%C3%B3lica-de-Chile-Santiago-Chile-and-Centro-de-Envejecimiento-y-Regeneracion-CARE-Departamento-de-Biologia-Celular-y-Molecular-Facultad-de-Ciencias-Biologicas-Pontificia-Universidad-Catolica-de-Chile-Santiago-Chile",{"title":6143},{"VI":6144},"Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile and Centro de Envejecimiento y Regeneracion (CARE), Departamento de Biologia Celular y Molecular, Facultad de Ciencias Biologicas Pontificia Universidad Catolica de Chile, Santiago, Chile",{"openalex":6146,"orcid":6148,"title":6150},{"VOID":6147},"A5052604947",{"VOID":6149},"https:\u002F\u002Forcid.org\u002F0000-0002-0499-4191",{"EN":6151},"Marco Arrese",{"url":26,"publisher":6153,"properties":6175},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":6154,"slug":663,"properties":6155,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":6158,"manageAffiliations":6159,"indexDatabases":6160,"url":26,"thumbnailPath":26,"statistic":26,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"issn":6156,"title":6157},{"VOID":666},{"EN":668},[],[],[6161,6168],{"id":690,"indexDatabase":6162,"url":705,"indexYears":26,"academicFieldIds":6167,"indexDatabaseRanking":26},{"id":692,"createTime":693,"updateTime":694,"relativeEntities":6163,"label":6164,"description":6165,"key":701,"publicationTags":6166,"standard":26},[],{"EN":697,"VI":697},{"VI":699,"EN":700},[703,704],[707],{"id":709,"indexDatabase":6169,"url":722,"indexYears":723,"academicFieldIds":6174,"indexDatabaseRanking":726},{"id":711,"createTime":712,"updateTime":713,"relativeEntities":6170,"label":6171,"description":6172,"key":719,"publicationTags":6173,"standard":26},[],{"EN":716,"VI":716},{"EN":716,"VI":718},[721],[725],{"volume":6176,"pages":6178,"issue":6180},{"VOID":6177},"73",{"VOID":6179},"202-209",{"VOID":925},2801,{"total":6181,"publishYear":26,"statisticByYear":6183},{"2019":114,"2020":6184,"2021":3516,"2022":6185,"2023":6186,"2024":6187},178,658,796,601,"2020-07-01",2020,[6191,6195,6199,6203,6207,6211,6215,6219,6223,6227,6231,6235,6239,6243,6247,6251,6254,6258,6262,6266,6270,6274,6278,6282,6286,6290,6294,6298,6302,6306,6310,6314,6318,6322,6326,6329,6332,6336,6340,6344,6348,6351,6355,6359,6363,6367,6371,6375,6379,6383,6387,6391,6395,6399,6401,6405,6409,6413,6417,6421],{"id":26,"text":6192,"url":26,"identifiers":6193},"Eslam, 2020, MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease, Gastroenterology, 10.1053\u002Fj.gastro.2019.11.312",{"doi":6194},"10.1053\u002Fj.gastro.2019.11.312",{"id":26,"text":6196,"url":26,"identifiers":6197},"Younossi, 2018, Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention, Nat Rev Gastroenterol Hepatol, 15, 11, 10.1038\u002Fnrgastro.2017.109",{"doi":6198},"10.1038\u002Fnrgastro.2017.109",{"id":26,"text":6200,"url":26,"identifiers":6201},"Sarin, 2020, Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & hepatology Commission, Lancet Gastroenterol Hepatol, 5, 167, 10.1016\u002FS2468-1253(19)30342-5",{"doi":6202},"10.1016\u002FS2468-1253(19)30342-5",{"id":26,"text":6204,"url":26,"identifiers":6205},"Inoue, 2018, Epidemiology of obesity in adults: latest trends, Curr Obes Rep, 7, 276, 10.1007\u002Fs13679-018-0317-8",{"doi":6206},"10.1007\u002Fs13679-018-0317-8",{"id":26,"text":6208,"url":26,"identifiers":6209},"Stefan, 2017, Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans, Cell Metab, 26, 292, 10.1016\u002Fj.cmet.2017.07.008",{"doi":6210},"10.1016\u002Fj.cmet.2017.07.008",{"id":26,"text":6212,"url":26,"identifiers":6213},"Araujo, 2019, Prevalence of optimal metabolic health in American adults: national health and nutrition examination survey 2009-2016, Metab Syndr Relat Disord, 17, 46, 10.1089\u002Fmet.2018.0105",{"doi":6214},"10.1089\u002Fmet.2018.0105",{"id":26,"text":6216,"url":26,"identifiers":6217},"Eslam, 2019, Toward more accurate nomenclature for fatty liver diseases, Gastroenterology, 157, 590, 10.1053\u002Fj.gastro.2019.05.064",{"doi":6218},"10.1053\u002Fj.gastro.2019.05.064",{"id":26,"text":6220,"url":26,"identifiers":6221},"Byrne, 2015, NAFLD: a multisystem disease, J Hepatol, 62, S47, 10.1016\u002Fj.jhep.2014.12.012",{"doi":6222},"10.1016\u002Fj.jhep.2014.12.012",{"id":26,"text":6224,"url":26,"identifiers":6225},"Cleeman, 2001, Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III), JAMA, 285, 2486, 10.1001\u002Fjama.285.19.2486",{"doi":6226},"10.1001\u002Fjama.285.19.2486",{"id":26,"text":6228,"url":26,"identifiers":6229},"Black, 2003, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report, JAMA, 289, 2560, 10.1001\u002Fjama.289.19.2560",{"doi":6230},"10.1001\u002Fjama.289.19.2560",{"id":26,"text":6232,"url":26,"identifiers":6233},"Grundy, 2005, Diagnosis and management of the metabolic syndrome: an American Heart Association\u002FNational Heart, Lung, and Blood Institute scientific statement, Circulation, 112, 2735, 10.1161\u002FCIRCULATIONAHA.105.169404",{"doi":6234},"10.1161\u002FCIRCULATIONAHA.105.169404",{"id":26,"text":6236,"url":26,"identifiers":6237},"Alberti, 2009, Circulation, 120, 1640, 10.1161\u002FCIRCULATIONAHA.109.192644",{"doi":6238},"10.1161\u002FCIRCULATIONAHA.109.192644",{"id":26,"text":6240,"url":26,"identifiers":6241},"Whelton, 2018, J Am Coll Cardiol, 71, e127, 10.1016\u002Fj.jacc.2017.11.006",{"doi":6242},"10.1016\u002Fj.jacc.2017.11.006",{"id":26,"text":6244,"url":26,"identifiers":6245},"Association, 2018, 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2018, Diabetes Care, 41, S13, 10.2337\u002Fdc18-S002",{"doi":6246},"10.2337\u002Fdc18-S002",{"id":26,"text":6248,"url":26,"identifiers":6249},"Siddiqui, 2018, Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science, Hepatology, 67, 2001, 10.1002\u002Fhep.29607",{"doi":6250},"10.1002\u002Fhep.29607",{"id":26,"text":6252,"url":26,"identifiers":6253},"2016, EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease, J Hepatol, 64, 1388, 10.1016\u002Fj.jhep.2015.11.004",{"doi":1133},{"id":26,"text":6255,"url":26,"identifiers":6256},"Wong, 2018, Asia-pacific working party on non-alcoholic fatty liver disease guidelines 2017-Part 1: definition, risk factors and assessment, J Gastroenterol Hepatol, 33, 70, 10.1111\u002Fjgh.13857",{"doi":6257},"10.1111\u002Fjgh.13857",{"id":26,"text":6259,"url":26,"identifiers":6260},"Chalasani, 2018, The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases, Hepatology, 67, 328, 10.1002\u002Fhep.29367",{"doi":6261},"10.1002\u002Fhep.29367",{"id":26,"text":6263,"url":26,"identifiers":6264},"Eddowes, 2019, Accuracy of FibroScan controlled attenuation parameter and liver Stiffness Measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease, Gastroenterology, 156, 1717, 10.1053\u002Fj.gastro.2019.01.042",{"doi":6265},"10.1053\u002Fj.gastro.2019.01.042",{"id":26,"text":6267,"url":26,"identifiers":6268},"Caussy, 2018, Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials, Hepatology, 68, 763, 10.1002\u002Fhep.29797",{"doi":6269},"10.1002\u002Fhep.29797",{"id":26,"text":6271,"url":26,"identifiers":6272},"Di Angelantonio, 2016, Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents, Lancet, 388, 776, 10.1016\u002FS0140-6736(16)30175-1",{"doi":6273},"10.1016\u002FS0140-6736(16)30175-1",{"id":26,"text":6275,"url":26,"identifiers":6276},"Shea, 2011, The prevalence of metabolically healthy obese subjects defined by BMI and dual-energy X-Ray absorptiometry, Obesity, 19, 624, 10.1038\u002Foby.2010.174",{"doi":6277},"10.1038\u002Foby.2010.174",{"id":26,"text":6279,"url":26,"identifiers":6280},"Munoz-Garach, 2016, Does metabolically healthy obesity exist?, Nutrients, 8, 10.3390\u002Fnu8060320",{"doi":6281},"10.3390\u002Fnu8060320",{"id":26,"text":6283,"url":26,"identifiers":6284},"Eckel, 2018, Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses' Health Study): 30 year follow-up from a prospective cohort study, Lancet Diabetes Endocrinol, 6, 714, 10.1016\u002FS2213-8587(18)30137-2",{"doi":6285},"10.1016\u002FS2213-8587(18)30137-2",{"id":26,"text":6287,"url":26,"identifiers":6288},"Caleyachetty, 2017, Metabolically healthy obese and incident cardiovascular disease events among 3.5 Million men and women, J Am Coll Cardiol, 70, 1429, 10.1016\u002Fj.jacc.2017.07.763",{"doi":6289},"10.1016\u002Fj.jacc.2017.07.763",{"id":26,"text":6291,"url":26,"identifiers":6292},"Lassale, 2018, Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis, Eur Heart J, 39, 397, 10.1093\u002Feurheartj\u002Fehx448",{"doi":6293},"10.1093\u002Feurheartj\u002Fehx448",{"id":26,"text":6295,"url":26,"identifiers":6296},"Ampuero, 2018, The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity, Aliment Pharmacol Ther, 48, 1260, 10.1111\u002Fapt.15015",{"doi":6297},"10.1111\u002Fapt.15015",{"id":26,"text":6299,"url":26,"identifiers":6300},"Williams, 2011, Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study, Gastroenterology, 140, 124, 10.1053\u002Fj.gastro.2010.09.038",{"doi":6301},"10.1053\u002Fj.gastro.2010.09.038",{"id":26,"text":6303,"url":26,"identifiers":6304},"Arrese, 2019, Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations, Expert Rev Gastroenterol Hepatol, 13, 849, 10.1080\u002F17474124.2019.1649981",{"doi":6305},"10.1080\u002F17474124.2019.1649981",{"id":26,"text":6307,"url":26,"identifiers":6308},"Chen, 2020, Lean NAFLD: a distinct entity shaped by differential metabolic adaptation, Hepatology, 71, 1213, 10.1002\u002Fhep.30908",{"doi":6309},"10.1002\u002Fhep.30908",{"id":26,"text":6311,"url":26,"identifiers":6312},"Rastogi, 2017, Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study, APMIS, 125, 962, 10.1111\u002Fapm.12742",{"doi":6313},"10.1111\u002Fapm.12742",{"id":26,"text":6315,"url":26,"identifiers":6316},"Cho, 2019, Implications of the dynamic nature of metabolic health status and obesity on risk of incident cardiovascular events and mortality: a nationwide population-based cohort study, Metabolism, 97, 50, 10.1016\u002Fj.metabol.2019.05.002",{"doi":6317},"10.1016\u002Fj.metabol.2019.05.002",{"id":26,"text":6319,"url":26,"identifiers":6320},"Bril, 2017, Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease, Hepatology, 65, 1132, 10.1002\u002Fhep.28985",{"doi":6321},"10.1002\u002Fhep.28985",{"id":26,"text":6323,"url":26,"identifiers":6324},"Rotman, 2017, Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit, Hepatology, 65, 1088, 10.1002\u002Fhep.29094",{"doi":6325},"10.1002\u002Fhep.29094",{"id":26,"text":6327,"url":26,"identifiers":6328},"McPherson, 2015, Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management, J Hepatol, 62, 1148, 10.1016\u002Fj.jhep.2014.11.034",{"doi":4972},{"id":26,"text":6330,"url":26,"identifiers":6331},"Pais, 2013, A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver, J Hepatol, 59, 550, 10.1016\u002Fj.jhep.2013.04.027",{"doi":4976},{"id":26,"text":6333,"url":26,"identifiers":6334},"Vilar-Gomez, 2018, Fibrosis severity as a determinant of cause-specific mortality in patients with Advanced nonalcoholic fatty liver disease: a multi-national cohort study, Gastroenterology, 155, 443, 10.1053\u002Fj.gastro.2018.04.034",{"doi":6335},"10.1053\u002Fj.gastro.2018.04.034",{"id":26,"text":6337,"url":26,"identifiers":6338},"Adams, 2005, The natural history of nonalcoholic fatty liver disease: a population-based cohort study, Gastroenterology, 129, 113, 10.1053\u002Fj.gastro.2005.04.014",{"doi":6339},"10.1053\u002Fj.gastro.2005.04.014",{"id":26,"text":6341,"url":26,"identifiers":6342},"Kleiner, 2019, Association of histologic disease activity with progression of nonalcoholic fatty liver disease, JAMA Netw Open, 2, e1912565, 10.1001\u002Fjamanetworkopen.2019.12565",{"doi":6343},"10.1001\u002Fjamanetworkopen.2019.12565",{"id":26,"text":6345,"url":26,"identifiers":6346},"Brunt, 2019, Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the nonalcoholic steatohepatitis clinical research network treatment trials, Hepatology, 70, 522, 10.1002\u002Fhep.30418",{"doi":6347},"10.1002\u002Fhep.30418",{"id":26,"text":6349,"url":26,"identifiers":6350},"Ratziu V, Harrison SA, Francque S, Bedossa P, Anstee QM, Ben S, et al. ALT as a non-invasive biomarker of histological response to pharmacotherapy in NASH patients: insights from the elafibranor GOLDEN505 trial. 67th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2016; 2016: Newcastle University.",{},{"id":26,"text":6352,"url":26,"identifiers":6353},"Dufour, 2016, Time to abandon NASH?, Hepatology, 63, 9, 10.1002\u002Fhep.28276",{"doi":6354},"10.1002\u002Fhep.28276",{"id":26,"text":6356,"url":26,"identifiers":6357},"Thuluvath, 2018, Is cryptogenic cirrhosis different from NASH cirrhosis?, J Hepatol, 68, 519, 10.1016\u002Fj.jhep.2017.11.018",{"doi":6358},"10.1016\u002Fj.jhep.2017.11.018",{"id":26,"text":6360,"url":26,"identifiers":6361},"Caldwell, 2018, Cryptogenic vs. NASH-cirrhosis: the rose exists well before its name…, J Hepatol, 68, 391, 10.1016\u002Fj.jhep.2017.12.006",{"doi":6362},"10.1016\u002Fj.jhep.2017.12.006",{"id":26,"text":6364,"url":26,"identifiers":6365},"Younossi, 2018, The conundrum of cryptogenic cirrhosis: adverse outcomes without treatment options, J Hepatol, 69, 1365, 10.1016\u002Fj.jhep.2018.08.013",{"doi":6366},"10.1016\u002Fj.jhep.2018.08.013",{"id":26,"text":6368,"url":26,"identifiers":6369},"Singal, 2018, ACG clinical guideline: alcoholic liver disease, Am J Gastroenterol, 113, 175, 10.1038\u002Fajg.2017.469",{"doi":6370},"10.1038\u002Fajg.2017.469",{"id":26,"text":6372,"url":26,"identifiers":6373},"Boyle, 2018, The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease, J Hepatol, 68, 251, 10.1016\u002Fj.jhep.2017.11.006",{"doi":6374},"10.1016\u002Fj.jhep.2017.11.006",{"id":26,"text":6376,"url":26,"identifiers":6377},"Brunt, 2003, Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease, Mod Pathol, 16, 49, 10.1097\u002F01.MP.0000042420.21088.C7",{"doi":6378},"10.1097\u002F01.MP.0000042420.21088.C7",{"id":26,"text":6380,"url":26,"identifiers":6381},"Sanchez-Munoz, 2004, Histologic features of steatohepatitis in patients with a clinical diagnosis of autoimmune cholestasis, Dig Dis Sci, 49, 1957, 10.1007\u002Fs10620-004-9600-5",{"doi":6382},"10.1007\u002Fs10620-004-9600-5",{"id":26,"text":6384,"url":26,"identifiers":6385},"Cotrim, 1999, Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers, Liver, 19, 299, 10.1111\u002Fj.1478-3231.1999.tb00053.x",{"doi":6386},"10.1111\u002Fj.1478-3231.1999.tb00053.x",{"id":26,"text":6388,"url":26,"identifiers":6389},"De Luca-Johnson, 2016, Natural history of patients presenting with autoimmune hepatitis and coincident nonalcoholic fatty liver disease, Dig Dis Sci, 61, 2710, 10.1007\u002Fs10620-016-4213-3",{"doi":6390},"10.1007\u002Fs10620-016-4213-3",{"id":26,"text":6392,"url":26,"identifiers":6393},"Choi, 2020, Non-Alcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B, Hepatology, 71, 539, 10.1002\u002Fhep.30857",{"doi":6394},"10.1002\u002Fhep.30857",{"id":26,"text":6396,"url":26,"identifiers":6397},"Chiang, 2014, The impact of obesity and metabolic syndrome on alcoholic liver disease, Clin Liver Dis, 18, 157, 10.1016\u002Fj.cld.2013.09.006",{"doi":6398},"10.1016\u002Fj.cld.2013.09.006",{"id":26,"text":1345,"url":26,"identifiers":6400},{"doi":1347},{"id":26,"text":6402,"url":26,"identifiers":6403},"Ceballos, 2017, Editor's corner: binge drinking and the evolving language of alcohol research, J Stud Alcohol Drugs, 78, 488, 10.15288\u002Fjsad.2017.78.488",{"doi":6404},"10.15288\u002Fjsad.2017.78.488",{"id":26,"text":6406,"url":26,"identifiers":6407},"Cespiati, 2020, Genetics and epigenetics in the clinic: precision medicine in the management of fatty liver disease, Curr Pharm Des, 10.2174\u002F1381612826666200122151251",{"doi":6408},"10.2174\u002F1381612826666200122151251",{"id":26,"text":6410,"url":26,"identifiers":6411},"Eslam, 2020, Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology, Nat Rev Gastroenterol Hepatol, 17, 40, 10.1038\u002Fs41575-019-0212-0",{"doi":6412},"10.1038\u002Fs41575-019-0212-0",{"id":26,"text":6414,"url":26,"identifiers":6415},"Eslam, 2018, Genetics and epigenetics of NAFLD and NASH: clinical impact, J Hepatol, 68, 268, 10.1016\u002Fj.jhep.2017.09.003",{"doi":6416},"10.1016\u002Fj.jhep.2017.09.003",{"id":26,"text":6418,"url":26,"identifiers":6419},"Fracanzani, 2017, Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity, Clin Gastroenterol Hepatol, 15, 1604, 10.1016\u002Fj.cgh.2017.04.045",{"doi":6420},"10.1016\u002Fj.cgh.2017.04.045",{"id":26,"text":6422,"url":26,"identifiers":6423},"Hulley, 2007",{},{"id":6425,"createTime":6426,"updateTime":6426,"relativeEntities":6427,"slug":6428,"properties":6429,"entityType":749,"verifyStatus":25,"verifyTime":6426,"verifyNote":750,"syncStatus":28,"languages":6442,"translateLanguages":26,"viewCount":36,"primaryUrl":6443,"fullTextUrl":26,"authors":6444,"publicationType":895,"publisherRelationship":6466,"citationCount":6496,"citationInfo":6497,"publishDate":6505,"publishYear":6506,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":6507,"isForceReanalyzing":3453},"8c9725d9-6a06-4dc1-9f74-2b65b62a4eb6","2024-09-01T12:15:12.381+00:00",[],"Expanding-consensus-in-portal-hypertension",{"mag":6430,"keywords":6432,"openalex":6433,"abstract":6435,"title":6436,"pm":6438,"doi":6440},{"VOID":6431},"571628560",{},{"VOID":6434},"W571628560",{},{"EN":6437},"Expanding consensus in portal hypertension",{"VOID":6439},"26047908",{"VOID":6441},"10.1016\u002Fj.jhep.2015.05.022",[102],"https:\u002F\u002Flinkinghub.elsevier.com\u002Fretrieve\u002Fpii\u002FS0168827815003499",[6445],{"id":6446,"sortIndex":36,"researcher":26,"roles":6447,"affiliations":6448,"properties":6459},"f63a3108-c805-451a-be4c-14db5ba95a45",[],[6449],{"id":6450,"sortIndex":36,"affiliation":6451,"properties":26},"4d5c8658-af41-4e61-8245-56c40b8b7ba1",{"id":6452,"createTime":6453,"updateTime":6453,"relativeEntities":6454,"slug":6455,"properties":6456,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"d2a25d71-2d17-455e-b97b-9a2a77c60bbb","2024-09-01T12:15:12.400+00:00",[],"Department-of-Biomedical-and-Clinical-Sciences-University-of-Milan-Gastroenterology-Unit-Luigi-Sacco-University-Hospital-Milan-Italy-Electronic-address-Roberto-defranchis-unimi-it-",{"title":6457},{"EN":6458},"Department of Biomedical and Clinical Sciences, University of Milan, Gastroenterology Unit, Luigi Sacco University Hospital, Milan, Italy. Electronic address: Roberto.defranchis@unimi.it.",{"openalex":6460,"orcid":6462,"title":6464},{"VOID":6461},"A5064451267",{"VOID":6463},"https:\u002F\u002Forcid.org\u002F0000-0002-4401-2340",{"EN":6465},"Andrea De Gottardi",{"url":26,"publisher":6467,"properties":6489},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":6468,"slug":663,"properties":6469,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":6472,"manageAffiliations":6473,"indexDatabases":6474,"url":26,"thumbnailPath":26,"statistic":26,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"issn":6470,"title":6471},{"VOID":666},{"EN":668},[],[],[6475,6482],{"id":690,"indexDatabase":6476,"url":705,"indexYears":26,"academicFieldIds":6481,"indexDatabaseRanking":26},{"id":692,"createTime":693,"updateTime":694,"relativeEntities":6477,"label":6478,"description":6479,"key":701,"publicationTags":6480,"standard":26},[],{"EN":697,"VI":697},{"VI":699,"EN":700},[703,704],[707],{"id":709,"indexDatabase":6483,"url":722,"indexYears":723,"academicFieldIds":6488,"indexDatabaseRanking":726},{"id":711,"createTime":712,"updateTime":713,"relativeEntities":6484,"label":6485,"description":6486,"key":719,"publicationTags":6487,"standard":26},[],{"EN":716,"VI":716},{"EN":716,"VI":718},[721],[725],{"volume":6490,"pages":6492,"issue":6494},{"VOID":6491},"63",{"VOID":6493},"743-752",{"VOID":6495},"3",2698,{"total":6496,"publishYear":26,"statisticByYear":6498},{"2014":115,"2015":234,"2016":6499,"2017":6500,"2018":149,"2019":394,"2020":6501,"2021":6502,"2022":3514,"2023":6503,"2024":6504},143,207,413,416,257,145,"2015-09-01",2015,[6508,6511,6515,6519,6522,6526,6530,6534,6537,6541,6544,6548,6552,6555,6558,6562,6566],{"id":26,"text":6509,"url":26,"identifiers":6510},"1987",{},{"id":26,"text":6512,"url":26,"identifiers":6513},"de Franchis, 1992, Definitions, methodology and therapeutic strategies in portal hypertension. A consensus development workshop, J Hepatol, 15, 256, 10.1016\u002F0168-8278(92)90044-P",{"doi":6514},"10.1016\u002F0168-8278(92)90044-P",{"id":26,"text":6516,"url":26,"identifiers":6517},"de Franchis, 1996, Developing consensus in portal hypertension, J Hepatol, 25, 390, 10.1016\u002FS0168-8278(96)80127-9",{"doi":6518},"10.1016\u002FS0168-8278(96)80127-9",{"id":26,"text":6520,"url":26,"identifiers":6521},"1996",{},{"id":26,"text":6523,"url":26,"identifiers":6524},"Spina, 1994, Gastric endoscopic features in portal hypertension: final report of a consensus conference, J Hepatol, 21, 461, 10.1016\u002FS0168-8278(05)80329-0",{"doi":6525},"10.1016\u002FS0168-8278(05)80329-0",{"id":26,"text":6527,"url":26,"identifiers":6528},"Grace, 1998, Portal hypertension and variceal bleeding: an AASLD single topic symposium, Hepatology, 28, 868, 10.1002\u002Fhep.510280339",{"doi":6529},"10.1002\u002Fhep.510280339",{"id":26,"text":6531,"url":26,"identifiers":6532},"de Franchis, 2000, Updating consensus in portal hypertension: report of the Baveno III consensus workshop on definitions, methodology and therapeutic strategies in portal hypertension, J Hepatol, 33, 846, 10.1016\u002FS0168-8278(00)80320-7",{"doi":6533},"10.1016\u002FS0168-8278(00)80320-7",{"id":26,"text":6535,"url":26,"identifiers":6536},"2001",{},{"id":26,"text":6538,"url":26,"identifiers":6539},"de Franchis, 2005, Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension, J Hepatol, 43, 167, 10.1016\u002Fj.jhep.2005.05.009",{"doi":6540},"10.1016\u002Fj.jhep.2005.05.009",{"id":26,"text":6542,"url":26,"identifiers":6543},"2006",{},{"id":26,"text":6545,"url":26,"identifiers":6546},"Garcia-Tsao, 2008, Portal hypertension and variceal bleeding, unresolved issues. Summary of an American Association for the study of liver disease and of the European Association for the Study of the Liver single-topic conference, Hepatology, 47, 1764, 10.1002\u002Fhep.22273",{"doi":6547},"10.1002\u002Fhep.22273",{"id":26,"text":6549,"url":26,"identifiers":6550},"de Franchis, 2010, Report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension, J Hepatol, 53, 762, 10.1016\u002Fj.jhep.2010.06.004",{"doi":6551},"10.1016\u002Fj.jhep.2010.06.004",{"id":26,"text":6553,"url":26,"identifiers":6554},"2011",{},{"id":26,"text":6556,"url":26,"identifiers":6557},"Available from \u003Chttp:\u002F\u002Fwww.cebm.net\u002Fdownloads\u002FOxford_EBM_Levels_5.rtf>.",{},{"id":26,"text":6559,"url":26,"identifiers":6560},"de Franchis R, Editor. Portal Hypertension VI. Proceedings of the VIth Baveno international consensus workshop. New York, USA: Springer, in press.",{"doi":6561},"10.1007\u002F978-3-319-23018-4",{"id":26,"text":6563,"url":26,"identifiers":6564},"Moore, 2003, The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club, Hepatology, 38, 258, 10.1053\u002Fjhep.2003.50315",{"doi":6565},"10.1053\u002Fjhep.2003.50315",{"id":26,"text":6567,"url":26,"identifiers":6568},"Angeli, 2015, Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites, J Hepatol, 62, 968, 10.1016\u002Fj.jhep.2014.12.029",{"doi":6569},"10.1016\u002Fj.jhep.2014.12.029",{"id":6571,"createTime":6572,"updateTime":6572,"relativeEntities":6573,"slug":6574,"properties":6575,"entityType":749,"verifyStatus":28,"verifyTime":6572,"verifyNote":3469,"syncStatus":28,"languages":6586,"translateLanguages":26,"viewCount":36,"primaryUrl":6587,"fullTextUrl":26,"authors":6588,"publicationType":895,"publisherRelationship":6595,"citationCount":6624,"citationInfo":6625,"publishDate":6638,"publishYear":3525,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":6639,"isForceReanalyzing":3453},"bcf8009b-e655-4e9a-a149-81b14fdfdad8","2024-07-18T05:30:10.399+00:00",[],"EASL-Clinical-Practice-Guidelines-Management-of-chronic-hepatitis-B-virus-infection",{"keywords":6576,"openalex":6577,"abstract":6579,"title":6580,"pm":6582,"doi":6584},{},{"VOID":6578},"W4211026375",{},{"EN":6581},"EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection",{"VOID":6583},"22436845",{"VOID":6585},"10.1016\u002Fj.jhep.2012.02.010",[102],"https:\u002F\u002Flinkinghub.elsevier.com\u002Fretrieve\u002Fpii\u002FS0168827812001675",[6589],{"id":6590,"sortIndex":36,"researcher":26,"roles":6591,"affiliations":6592,"properties":6593},"5d010820-ef77-45fd-bbf0-0a7b2f60470b",[],[],{"title":6594},{"EN":3479},{"url":26,"publisher":6596,"properties":6618},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":6597,"slug":663,"properties":6598,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":6601,"manageAffiliations":6602,"indexDatabases":6603,"url":26,"thumbnailPath":26,"statistic":26,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"issn":6599,"title":6600},{"VOID":666},{"EN":668},[],[],[6604,6611],{"id":690,"indexDatabase":6605,"url":705,"indexYears":26,"academicFieldIds":6610,"indexDatabaseRanking":26},{"id":692,"createTime":693,"updateTime":694,"relativeEntities":6606,"label":6607,"description":6608,"key":701,"publicationTags":6609,"standard":26},[],{"EN":697,"VI":697},{"VI":699,"EN":700},[703,704],[707],{"id":709,"indexDatabase":6612,"url":722,"indexYears":723,"academicFieldIds":6617,"indexDatabaseRanking":726},{"id":711,"createTime":712,"updateTime":713,"relativeEntities":6613,"label":6614,"description":6615,"key":719,"publicationTags":6616,"standard":26},[],{"EN":716,"VI":716},{"EN":716,"VI":718},[721],[725],{"volume":6619,"pages":6621,"issue":6623},{"VOID":6620},"57",{"VOID":6622},"167-185",{"VOID":925},2689,{"total":6624,"publishYear":26,"statisticByYear":6626},{"2012":48,"2013":6627,"2014":6628,"2015":6629,"2016":6630,"2017":6631,"2018":6632,"2019":6633,"2020":6634,"2021":6635,"2022":6636,"2023":6637,"2024":241},269,342,444,431,381,223,130,118,99,75,62,"2012-07-01",[6640,6643,6647,6651,6655,6659,6663,6667,6671,6675,6679,6681,6685,6687,6691,6695,6699,6703,6707,6711,6715,6719,6723,6727,6731,6735,6739,6743,6747,6751,6755,6759,6763,6767,6769,6773,6777,6781,6785,6789,6793,6797,6801,6805,6809,6813,6817,6821,6825,6829,6833,6837,6841,6845,6848,6852,6856,6860,6864,6868,6872,6876,6880,6884,6888,6892,6896,6900,6904,6908,6912,6916,6920,6924,6928,6932,6936,6940,6944,6948,6952,6956,6960,6964,6967,6971,6975,6979,6983,6987,6991,6995,6999,7003,7007,7011,7014,7018,7021,7025,7029,7033,7037,7041,7045,7049,7053,7057,7061,7065,7069,7073,7077,7081,7085,7089,7093,7097,7099,7103,7107,7111,7115,7118,7122,7126,7130,7134,7138,7142,7146,7150,7154,7158,7162,7165,7169,7173,7177,7181,7185,7189,7193,7197,7200,7204,7208,7212,7216,7220,7224,7228,7232,7236,7240,7244,7248,7252,7256,7260,7264,7268,7272,7276,7280,7284,7288,7292,7296,7300,7304,7308,7312,7316,7320,7324,7328,7332,7336,7340,7344,7348,7352,7356,7360,7364,7368,7372,7376,7380,7384,7388,7392,7396,7400,7404,7408,7412,7416,7420,7424,7428,7432,7436,7439,7442,7446,7450,7454,7458,7462,7466,7470,7474,7478,7482,7486,7490,7494,7498,7502,7506,7510,7514,7518,7522,7526],{"id":26,"text":6641,"url":26,"identifiers":6642},"European Association for the Study of the Liver, 2009, EASL clinical practice guidelines: management of chronic hepatitis B, J Hepatol, 50, 227, 10.1016\u002Fj.jhep.2008.10.001",{"doi":3632},{"id":26,"text":6644,"url":26,"identifiers":6645},"Fattovich, 2003, Natural history and prognosis of hepatitis B, Semin Liver Dis, 23, 47, 10.1055\u002Fs-2003-37590",{"doi":6646},"10.1055\u002Fs-2003-37590",{"id":26,"text":6648,"url":26,"identifiers":6649},"McMahon, 2004, The natural history of chronic hepatitis B virus infection, Semin Liver Dis, 24, 17, 10.1055\u002Fs-2004-828674",{"doi":6650},"10.1055\u002Fs-2004-828674",{"id":26,"text":6652,"url":26,"identifiers":6653},"Hadziyannis, 2006, Hepatitis Be antigen negative chronic hepatitis B – natural history and treatment, Semin Liver Dis, 26, 130, 10.1055\u002Fs-2006-939751",{"doi":6654},"10.1055\u002Fs-2006-939751",{"id":26,"text":6656,"url":26,"identifiers":6657},"Ganem, 2004, Hepatitis B virus infection – natural history and clinical consequences, N Engl J Med, 350, 1118, 10.1056\u002FNEJMra031087",{"doi":6658},"10.1056\u002FNEJMra031087",{"id":26,"text":6660,"url":26,"identifiers":6661},"Hoofnagle, 2007, Management of hepatitis B: summary of a clinical research workshop, Hepatology, 45, 1056, 10.1002\u002Fhep.21627",{"doi":6662},"10.1002\u002Fhep.21627",{"id":26,"text":6664,"url":26,"identifiers":6665},"Liaw, 2005, Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma, Semin Liver Dis, 25, 40, 10.1055\u002Fs-2005-915649",{"doi":6666},"10.1055\u002Fs-2005-915649",{"id":26,"text":6668,"url":26,"identifiers":6669},"Lok, 2007, Chronic hepatitis B, Hepatology, 45, 507, 10.1002\u002Fhep.21513",{"doi":6670},"10.1002\u002Fhep.21513",{"id":26,"text":6672,"url":26,"identifiers":6673},"Zarski, 2006, Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases, J Hepatol, 45, 343, 10.1016\u002Fj.jhep.2006.03.007",{"doi":6674},"10.1016\u002Fj.jhep.2006.03.007",{"id":26,"text":6676,"url":26,"identifiers":6677},"Funk, 2002, World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants, J Viral Hepat, 9, 52, 10.1046\u002Fj.1365-2893.2002.00304.x",{"doi":6678},"10.1046\u002Fj.1365-2893.2002.00304.x",{"id":26,"text":1317,"url":26,"identifiers":6680},{"doi":1319},{"id":26,"text":6682,"url":26,"identifiers":6683},"Fattovich, 2008, Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years, Gut, 57, 84, 10.1136\u002Fgut.2007.128496",{"doi":6684},"10.1136\u002Fgut.2007.128496",{"id":26,"text":3684,"url":26,"identifiers":6686},{"doi":3686},{"id":26,"text":6688,"url":26,"identifiers":6689},"Papatheodoridis GV, Manolakopoulos S, Liaw Y-F, Lok A. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J Hepatol 2012, in press.",{"doi":6690},"10.1016\u002Fj.jhep.2011.11.030",{"id":26,"text":6692,"url":26,"identifiers":6693},"Martinot-Peignoux, 2002, Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers, J Hepatol, 36, 543, 10.1016\u002FS0168-8278(02)00004-1",{"doi":6694},"10.1016\u002FS0168-8278(02)00004-1",{"id":26,"text":6696,"url":26,"identifiers":6697},"Manesis, 2003, Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with HBeAg-negative chronic hepatitis B virus infection, Am J Gastroenterol, 98, 2261, 10.1111\u002Fj.1572-0241.2003.07715.x",{"doi":6698},"10.1111\u002Fj.1572-0241.2003.07715.x",{"id":26,"text":6700,"url":26,"identifiers":6701},"Papatheodoridis, 2008, Is there a meaningful serum HBV DNA cut-off level for therapeutic decisions in HBeAg-negative chronic hepatitis B virus infection?, Hepatology, 48, 1451, 10.1002\u002Fhep.22518",{"doi":6702},"10.1002\u002Fhep.22518",{"id":26,"text":6704,"url":26,"identifiers":6705},"de Franchis, 1993, The natural history of asymptomatic hepatitis B surface antigen carriers, Ann Intern Med, 118, 191, 10.7326\u002F0003-4819-118-3-199302010-00006",{"doi":6706},"10.7326\u002F0003-4819-118-3-199302010-00006",{"id":26,"text":6708,"url":26,"identifiers":6709},"Tai, 2009, Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time, Hepatology, 49, 1859, 10.1002\u002Fhep.22878",{"doi":6710},"10.1002\u002Fhep.22878",{"id":26,"text":6712,"url":26,"identifiers":6713},"Chen, 2012, Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion, J Viral Hepat, 19, 138, 10.1111\u002Fj.1365-2893.2011.01450.x",{"doi":6714},"10.1111\u002Fj.1365-2893.2011.01450.x",{"id":26,"text":6716,"url":26,"identifiers":6717},"Papatheodoridis, 2008, Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection, J Viral Hepat, 15, 434, 10.1111\u002Fj.1365-2893.2007.00957.x",{"doi":6718},"10.1111\u002Fj.1365-2893.2007.00957.x",{"id":26,"text":6720,"url":26,"identifiers":6721},"Brunetto, 2010, Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers, Gastroenterology, 139, 483, 10.1053\u002Fj.gastro.2010.04.052",{"doi":6722},"10.1053\u002Fj.gastro.2010.04.052",{"id":26,"text":6724,"url":26,"identifiers":6725},"Hadziyannis, 2001, Hepatitis B e antigen-negative chronic hepatitis B, Hepatology, 34, 617, 10.1053\u002Fjhep.2001.27834",{"doi":6726},"10.1053\u002Fjhep.2001.27834",{"id":26,"text":6728,"url":26,"identifiers":6729},"Brunetto, 1991, ‘e’ Antigen defective hepatitis B virus and course of chronic infection, J Hepatol, 13, S82, 10.1016\u002F0168-8278(91)90031-6",{"doi":6730},"10.1016\u002F0168-8278(91)90031-6",{"id":26,"text":6732,"url":26,"identifiers":6733},"Brunetto, 2002, Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long-term cohort study, J Hepatol, 36, 263, 10.1016\u002FS0168-8278(01)00266-5",{"doi":6734},"10.1016\u002FS0168-8278(01)00266-5",{"id":26,"text":6736,"url":26,"identifiers":6737},"Raimondo, 2008, Statements from the Taormina expert meeting on occult hepatitis B virus infection, J Hepatol, 49, 652, 10.1016\u002Fj.jhep.2008.07.014",{"doi":6738},"10.1016\u002Fj.jhep.2008.07.014",{"id":26,"text":6740,"url":26,"identifiers":6741},"Knoll, 2005, Solid-organ transplantation in HBsAg-negative patients with antibodies to HBV core antigen: low risk of HBV reactivation, Transplantation, 79, 1631, 10.1097\u002F01.TP.0000163468.80223.74",{"doi":6742},"10.1097\u002F01.TP.0000163468.80223.74",{"id":26,"text":6744,"url":26,"identifiers":6745},"Marcellin, 1991, Redevelopment of hepatitis-B surface-antigen after renal-transplantation, Gastroenterology, 100, 1432, 10.1016\u002F0016-5085(91)70034-U",{"doi":6746},"10.1016\u002F0016-5085(91)70034-U",{"id":26,"text":6748,"url":26,"identifiers":6749},"Huo, 1998, Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis, Hepatology, 28, 231, 10.1002\u002Fhep.510280130",{"doi":6750},"10.1002\u002Fhep.510280130",{"id":26,"text":6752,"url":26,"identifiers":6753},"Chen, 2002, Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection, Gastroenterology, 123, 1084, 10.1053\u002Fgast.2002.36026",{"doi":6754},"10.1053\u002Fgast.2002.36026",{"id":26,"text":6756,"url":26,"identifiers":6757},"Simonetti, 2010, Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus, Hepatology, 51, 1531, 10.1002\u002Fhep.23464",{"doi":6758},"10.1002\u002Fhep.23464",{"id":26,"text":6760,"url":26,"identifiers":6761},"Guyatt, 2008, Going from evidence to recommendations, BMJ, 336, 1049, 10.1136\u002Fbmj.39493.646875.AE",{"doi":6762},"10.1136\u002Fbmj.39493.646875.AE",{"id":26,"text":6764,"url":26,"identifiers":6765},"Guyatt, 2008, What is “quality of evidence” and why is it important to clinicians?, BMJ, 336, 995, 10.1136\u002Fbmj.39490.551019.BE",{"doi":6766},"10.1136\u002Fbmj.39490.551019.BE",{"id":26,"text":949,"url":26,"identifiers":6768},{"doi":951},{"id":26,"text":6770,"url":26,"identifiers":6771},"Guyatt, 2008, Incorporating considerations of resources use into grading recommendations, BMJ, 336, 1170, 10.1136\u002Fbmj.39504.506319.80",{"doi":6772},"10.1136\u002Fbmj.39504.506319.80",{"id":26,"text":6774,"url":26,"identifiers":6775},"Jaeschke, 2008, Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive, BMJ, 337, a744, 10.1136\u002Fbmj.a744",{"doi":6776},"10.1136\u002Fbmj.a744",{"id":26,"text":6778,"url":26,"identifiers":6779},"Schunemann, 2008, Grading quality of evidence and strength of recommendations for diagnostic tests and strategies, BMJ, 336, 1106, 10.1136\u002Fbmj.39500.677199.AE",{"doi":6780},"10.1136\u002Fbmj.39500.677199.AE",{"id":26,"text":6782,"url":26,"identifiers":6783},"Stelzl, 2004, Rapid quantification of hepatitis B virus DNA by automated sample preparation and real-time PCR, J Clin Microbiol, 42, 2445, 10.1128\u002FJCM.42.6.2445-2449.2004",{"doi":6784},"10.1128\u002FJCM.42.6.2445-2449.2004",{"id":26,"text":6786,"url":26,"identifiers":6787},"Thibault, 2007, Characterization of a new sensitive PCR assay for quantification of viral DNA isolated from patients with hepatitis B virus infections, J Clin Microbiol, 45, 3948, 10.1128\u002FJCM.01180-07",{"doi":6788},"10.1128\u002FJCM.01180-07",{"id":26,"text":6790,"url":26,"identifiers":6791},"Chevaliez, 2008, Performance of the Cobas AmpliPrep\u002FCobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification, J Clin Microbiol, 46, 1716, 10.1128\u002FJCM.01248-07",{"doi":6792},"10.1128\u002FJCM.01248-07",{"id":26,"text":6794,"url":26,"identifiers":6795},"Pawlotsky, 2008, Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach, Gastroenterology, 134, 405, 10.1053\u002Fj.gastro.2007.11.036",{"doi":6796},"10.1053\u002Fj.gastro.2007.11.036",{"id":26,"text":6798,"url":26,"identifiers":6799},"Saldanha, 2001, An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques, Vox Sanguinis, 80, 63, 10.1046\u002Fj.1423-0410.2001.00003.x",{"doi":6800},"10.1046\u002Fj.1423-0410.2001.00003.x",{"id":26,"text":6802,"url":26,"identifiers":6803},"Bedossa, 2003, Sampling variability of liver fibrosis in chronic hepatitis C, Hepatology, 38, 1449, 10.1016\u002Fj.hep.2003.09.022",{"doi":6804},"10.1016\u002Fj.hep.2003.09.022",{"id":26,"text":6806,"url":26,"identifiers":6807},"Myers, 2003, Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B, J Hepatol, 39, 222, 10.1016\u002FS0168-8278(03)00171-5",{"doi":6808},"10.1016\u002FS0168-8278(03)00171-5",{"id":26,"text":6810,"url":26,"identifiers":6811},"Poynard, 2007, Meta-analyses of FibroTest diagnostic value in chronic liver disease, BMC Gastroenterol, 7, 40, 10.1186\u002F1471-230X-7-40",{"doi":6812},"10.1186\u002F1471-230X-7-40",{"id":26,"text":6814,"url":26,"identifiers":6815},"Marcellin, 2009, Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B, Liver Int, 29, 242, 10.1111\u002Fj.1478-3231.2008.01802.x",{"doi":6816},"10.1111\u002Fj.1478-3231.2008.01802.x",{"id":26,"text":6818,"url":26,"identifiers":6819},"Castera, 2009, Transient elastography and other non-invasive tests to assess hepatic fibrosis in patients with viral hepatitis, J Viral Hepat, 16, 300, 10.1111\u002Fj.1365-2893.2009.01087.x",{"doi":6820},"10.1111\u002Fj.1365-2893.2009.01087.x",{"id":26,"text":6822,"url":26,"identifiers":6823},"Castera, 2011, Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers, Aliment Pharmacol Ther, 33, 455, 10.1111\u002Fj.1365-2036.2010.04547.x",{"doi":6824},"10.1111\u002Fj.1365-2036.2010.04547.x",{"id":26,"text":6826,"url":26,"identifiers":6827},"Fraquelli, 2011, The role of transient elastography in patients with hepatitis B viral disease, Dig Liver Dis, 43, S25, 10.1016\u002FS1590-8658(10)60689-5",{"doi":6828},"10.1016\u002FS1590-8658(10)60689-5",{"id":26,"text":6830,"url":26,"identifiers":6831},"Cardoso, 2011, Transient elastography in chronic viral hepatitis: a critical appraisal, Gut, 60, 759, 10.1136\u002Fgut.2010.220863",{"doi":6832},"10.1136\u002Fgut.2010.220863",{"id":26,"text":6834,"url":26,"identifiers":6835},"Cardoso, 2012, Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C, Liver Int, 32, 612, 10.1111\u002Fj.1478-3231.2011.02660.x",{"doi":6836},"10.1111\u002Fj.1478-3231.2011.02660.x",{"id":26,"text":6838,"url":26,"identifiers":6839},"Arena, 2008, Acute viral hepatitis increases liver stiffness values measured by transient elastography, Hepatology, 47, 380, 10.1002\u002Fhep.22007",{"doi":6840},"10.1002\u002Fhep.22007",{"id":26,"text":6842,"url":26,"identifiers":6843},"Tsochatzis, 2011, Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy, J Hepatol, 54, 650, 10.1016\u002Fj.jhep.2010.07.033",{"doi":6844},"10.1016\u002Fj.jhep.2010.07.033",{"id":26,"text":6846,"url":26,"identifiers":6847},"Liaw, 2004, Lamivudine for patients with chronic hepatitis B and advanced liver disease, N Engl J Med, 351, 1521, 10.1056\u002FNEJMoa033364",{"doi":3647},{"id":26,"text":6849,"url":26,"identifiers":6850},"Brechot, 1981, State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases, Proc Natl Acad Sci USA, 78, 3906, 10.1073\u002Fpnas.78.6.3906",{"doi":6851},"10.1073\u002Fpnas.78.6.3906",{"id":26,"text":6853,"url":26,"identifiers":6854},"Brechot, 2001, Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely “occult”?, Hepatology, 34, 194, 10.1053\u002Fjhep.2001.25172",{"doi":6855},"10.1053\u002Fjhep.2001.25172",{"id":26,"text":6857,"url":26,"identifiers":6858},"Brechot, 2004, Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms, Gastroenterology, 127, S56, 10.1053\u002Fj.gastro.2004.09.016",{"doi":6859},"10.1053\u002Fj.gastro.2004.09.016",{"id":26,"text":6861,"url":26,"identifiers":6862},"Bonilla, 2005, The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma, J Hepatol, 42, 760, 10.1016\u002Fj.jhep.2005.02.005",{"doi":6863},"10.1016\u002Fj.jhep.2005.02.005",{"id":26,"text":6865,"url":26,"identifiers":6866},"Pollicino, 2011, Hepatocellular carcinoma: the point of view of the hepatitis B virus, Carcinogenesis, 32, 1122, 10.1093\u002Fcarcin\u002Fbgr108",{"doi":6867},"10.1093\u002Fcarcin\u002Fbgr108",{"id":26,"text":6869,"url":26,"identifiers":6870},"Shim, 2010, Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis, J Hepatol, 52, 176, 10.1016\u002Fj.jhep.2009.11.007",{"doi":6871},"10.1016\u002Fj.jhep.2009.11.007",{"id":26,"text":6873,"url":26,"identifiers":6874},"Liaw, 2011, Tenofovir disoproxil fumarate (TDF), emtricitabine\u002FTDF, and entecavir in patients with decompensated chronic hepatitis B liver disease, Hepatology, 53, 62, 10.1002\u002Fhep.23952",{"doi":6875},"10.1002\u002Fhep.23952",{"id":26,"text":6877,"url":26,"identifiers":6878},"Liaw, 2011, Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study, Hepatology, 54, 91, 10.1002\u002Fhep.24361",{"doi":6879},"10.1002\u002Fhep.24361",{"id":26,"text":6881,"url":26,"identifiers":6882},"Lau, 2005, Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B, N Engl J Med, 352, 2682, 10.1056\u002FNEJMoa043470",{"doi":6883},"10.1056\u002FNEJMoa043470",{"id":26,"text":6885,"url":26,"identifiers":6886},"Janssen, 2005, Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial, Lancet, 365, 123, 10.1016\u002FS0140-6736(05)17701-0",{"doi":6887},"10.1016\u002FS0140-6736(05)17701-0",{"id":26,"text":6889,"url":26,"identifiers":6890},"Lai, 1998, A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group, N Engl J Med, 339, 61, 10.1056\u002FNEJM199807093390201",{"doi":6891},"10.1056\u002FNEJM199807093390201",{"id":26,"text":6893,"url":26,"identifiers":6894},"Dienstag, 1999, Lamivudine as initial treatment for chronic hepatitis B in the United States, N Engl J Med, 341, 1256, 10.1056\u002FNEJM199910213411702",{"doi":6895},"10.1056\u002FNEJM199910213411702",{"id":26,"text":6897,"url":26,"identifiers":6898},"Chang, 2006, A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B, N Engl J Med, 354, 1001, 10.1056\u002FNEJMoa051285",{"doi":6899},"10.1056\u002FNEJMoa051285",{"id":26,"text":6901,"url":26,"identifiers":6902},"Lai, 2007, Telbivudine versus lamivudine in patients with chronic hepatitis B, N Engl J Med, 357, 2576, 10.1056\u002FNEJMoa066422",{"doi":6903},"10.1056\u002FNEJMoa066422",{"id":26,"text":6905,"url":26,"identifiers":6906},"Marcellin, 2003, Adefovir dipivoxil for the treatment of hepatitis B antigen-positive chronic hepatitis B, N Engl J Med, 348, 808, 10.1056\u002FNEJMoa020681",{"doi":6907},"10.1056\u002FNEJMoa020681",{"id":26,"text":6909,"url":26,"identifiers":6910},"Marcellin, 2008, Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B, N Engl J Med, 359, 2442, 10.1056\u002FNEJMoa0802878",{"doi":6911},"10.1056\u002FNEJMoa0802878",{"id":26,"text":6913,"url":26,"identifiers":6914},"Liaw, 2011, Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C, Hepatology, 54, 1591, 10.1002\u002Fhep.24555",{"doi":6915},"10.1002\u002Fhep.24555",{"id":26,"text":6917,"url":26,"identifiers":6918},"Van Zonneveld, 2004, Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B, Hepatology, 39, 804, 10.1002\u002Fhep.20128",{"doi":6919},"10.1002\u002Fhep.20128",{"id":26,"text":6921,"url":26,"identifiers":6922},"Liaw, 2000, Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B, Gastroenterology, 119, 172, 10.1053\u002Fgast.2000.8559",{"doi":6923},"10.1053\u002Fgast.2000.8559",{"id":26,"text":6925,"url":26,"identifiers":6926},"Lok, 2003, Long-term safety of lamivudine treatment in patients with chronic hepatitis B, Gastroenterology, 125, 1714, 10.1053\u002Fj.gastro.2003.09.033",{"doi":6927},"10.1053\u002Fj.gastro.2003.09.033",{"id":26,"text":6929,"url":26,"identifiers":6930},"Leung, 2001, Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy, Hepatology, 33, 1527, 10.1053\u002Fjhep.2001.25084",{"doi":6931},"10.1053\u002Fjhep.2001.25084",{"id":26,"text":6933,"url":26,"identifiers":6934},"Marcellin, 2008, Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B, Hepatology, 48, 750, 10.1002\u002Fhep.22414",{"doi":6935},"10.1002\u002Fhep.22414",{"id":26,"text":6937,"url":26,"identifiers":6938},"Liaw, 2009, 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B, Gastroenterology, 136, 486, 10.1053\u002Fj.gastro.2008.10.026",{"doi":6939},"10.1053\u002Fj.gastro.2008.10.026",{"id":26,"text":6941,"url":26,"identifiers":6942},"Chang, 2010, Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B, Hepatology, 51, 422, 10.1002\u002Fhep.23327",{"doi":6943},"10.1002\u002Fhep.23327",{"id":26,"text":6945,"url":26,"identifiers":6946},"Reijnders, 2010, Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B, Gastroenterology, 139, 491, 10.1053\u002Fj.gastro.2010.03.059",{"doi":6947},"10.1053\u002Fj.gastro.2010.03.059",{"id":26,"text":6949,"url":26,"identifiers":6950},"van Nunen, 2003, Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pre-treatment serum hepatitis B virus DNA and alanine aminotransferase, Gut, 52, 420, 10.1136\u002Fgut.52.3.420",{"doi":6951},"10.1136\u002Fgut.52.3.420",{"id":26,"text":6953,"url":26,"identifiers":6954},"Buster, 2008, Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b, Gastroenterology, 135, 459, 10.1053\u002Fj.gastro.2008.05.031",{"doi":6955},"10.1053\u002Fj.gastro.2008.05.031",{"id":26,"text":6957,"url":26,"identifiers":6958},"Wong, 2010, Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B, Hepatology, 51, 1945, 10.1002\u002Fhep.23568",{"doi":6959},"10.1002\u002Fhep.23568",{"id":26,"text":6961,"url":26,"identifiers":6962},"Yuen, 2011, Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: viral suppression, viral resistance, and clinical safety, Am J Gastroenterol, 106, 1264, 10.1038\u002Fajg.2011.45",{"doi":6963},"10.1038\u002Fajg.2011.45",{"id":26,"text":6965,"url":26,"identifiers":6966},"Marcellin, 2011, Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis, Hepatology, 54, 1011A",{},{"id":26,"text":6968,"url":26,"identifiers":6969},"Heathcote, 2011, Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B, Gastroenterology, 140, 132, 10.1053\u002Fj.gastro.2010.10.011",{"doi":6970},"10.1053\u002Fj.gastro.2010.10.011",{"id":26,"text":6972,"url":26,"identifiers":6973},"Buster, 2009, Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients, Am J Gastroenterol, 104, 2449, 10.1038\u002Fajg.2009.371",{"doi":6974},"10.1038\u002Fajg.2009.371",{"id":26,"text":6976,"url":26,"identifiers":6977},"Moucari, 2009, High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study, J Hepatol, 50, 1084, 10.1016\u002Fj.jhep.2009.01.016",{"doi":6978},"10.1016\u002Fj.jhep.2009.01.016",{"id":26,"text":6980,"url":26,"identifiers":6981},"Piratvisuth, 2008, Sustained response to peginterferon alfa-2a (40kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B, Hepatol Int, 2, 102, 10.1007\u002Fs12072-007-9022-5",{"doi":6982},"10.1007\u002Fs12072-007-9022-5",{"id":26,"text":6984,"url":26,"identifiers":6985},"Gish, 2010, Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B, J Viral Hepat, 17, 16, 10.1111\u002Fj.1365-2893.2009.01146.x",{"doi":6986},"10.1111\u002Fj.1365-2893.2009.01146.x",{"id":26,"text":6988,"url":26,"identifiers":6989},"Tassopoulos, 1999, Efficacy of lamivudine in patients with hepatitis B e antigen-negative\u002Fhepatitis B virus DNA-positive (precore mutant) chronic hepatitis B, Hepatology, 29, 889, 10.1002\u002Fhep.510290321",{"doi":6990},"10.1002\u002Fhep.510290321",{"id":26,"text":6992,"url":26,"identifiers":6993},"Marcellin, 2004, Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B, N Engl J Med, 351, 1206, 10.1056\u002FNEJMoa040431",{"doi":6994},"10.1056\u002FNEJMoa040431",{"id":26,"text":6996,"url":26,"identifiers":6997},"Lai, 2006, Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B, N Engl J Med, 354, 1011, 10.1056\u002FNEJMoa051287",{"doi":6998},"10.1056\u002FNEJMoa051287",{"id":26,"text":7000,"url":26,"identifiers":7001},"Hadziyannis, 2003, Adefovir dipivoxil for the treatment of hepatitis B antigen-negative chronic hepatitis B, N Engl J Med, 348, 800, 10.1056\u002FNEJMoa021812",{"doi":7002},"10.1056\u002FNEJMoa021812",{"id":26,"text":7004,"url":26,"identifiers":7005},"Hadziyannis, 2005, Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B, N Engl J Med, 352, 2673, 10.1056\u002FNEJMoa042957",{"doi":7006},"10.1056\u002FNEJMoa042957",{"id":26,"text":7008,"url":26,"identifiers":7009},"Shouval, 2009, Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy, J Hepatol, 50, 289, 10.1016\u002Fj.jhep.2008.10.017",{"doi":7010},"10.1016\u002Fj.jhep.2008.10.017",{"id":26,"text":7012,"url":26,"identifiers":7013},"Shouval, 2008, Three years of entecavir (ETV) re-treatment of HBeAg(−) ETV patients who previously discontinued ETV treatment: results from study ETV-901, Hepatology, 48, 722A",{},{"id":26,"text":7015,"url":26,"identifiers":7016},"Marcellin, 2009, Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a, Gastroenterology, 136, 2169, 10.1053\u002Fj.gastro.2009.03.006",{"doi":7017},"10.1053\u002Fj.gastro.2009.03.006",{"id":26,"text":7019,"url":26,"identifiers":7020},"Marcellin, 2009, Increasing rates of HBsAg clearance and seroconversion in patients with HBeAg-negative disease treated with peginterferon alfa-2a±lamivudine: results of 5-year post-treatment follow up, J Hepatol, 50, S336",{},{"id":26,"text":7022,"url":26,"identifiers":7023},"Papatheodoridis, 2005, Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine, Hepatology, 42, 121, 10.1002\u002Fhep.20760",{"doi":7024},"10.1002\u002Fhep.20760",{"id":26,"text":7026,"url":26,"identifiers":7027},"Hadziyannis, 2006, Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years, Gastroenterology, 131, 1743, 10.1053\u002Fj.gastro.2006.09.020",{"doi":7028},"10.1053\u002Fj.gastro.2006.09.020",{"id":26,"text":7030,"url":26,"identifiers":7031},"Perrillo, 1990, A randomized, controlled trial of interferon alfa-2B alone and after prednisone withdrawal for the treatment of chronic hepatitis-B, N Engl J Med, 323, 295, 10.1056\u002FNEJM199008023230503",{"doi":7032},"10.1056\u002FNEJM199008023230503",{"id":26,"text":7034,"url":26,"identifiers":7035},"Wong, 1993, Effect of alpha-interferon in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis, Ann Intern Med, 119, 312, 10.7326\u002F0003-4819-119-4-199308150-00011",{"doi":7036},"10.7326\u002F0003-4819-119-4-199308150-00011",{"id":26,"text":7038,"url":26,"identifiers":7039},"Flink, 2006, Treatment with peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype, Am J Gastroenterol, 101, 297, 10.1111\u002Fj.1572-0241.2006.00418.x",{"doi":7040},"10.1111\u002Fj.1572-0241.2006.00418.x",{"id":26,"text":7042,"url":26,"identifiers":7043},"Buster, 2009, Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa, Gastroenterology, 137, 2002, 10.1053\u002Fj.gastro.2009.08.061",{"doi":7044},"10.1053\u002Fj.gastro.2009.08.061",{"id":26,"text":7046,"url":26,"identifiers":7047},"Fried, 2008, HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B, Hepatology, 47, 428, 10.1002\u002Fhep.22065",{"doi":7048},"10.1002\u002Fhep.22065",{"id":26,"text":7050,"url":26,"identifiers":7051},"Flink, 2005, Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during peg-interferon {alpha}-2b therapy, Gut, 54, 1604, 10.1136\u002Fgut.2004.062208",{"doi":7052},"10.1136\u002Fgut.2004.062208",{"id":26,"text":7054,"url":26,"identifiers":7055},"Piratvisuth T, Marcellin P, Popescu M, Kapprell HP, Rothe V, Lu ZM. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int 2011. PMID: 21701902 [Epub ahead of print].",{"doi":7056},"10.1007\u002Fs12072-011-9280-0",{"id":26,"text":7058,"url":26,"identifiers":7059},"Gane, 2011, Neptune study: on-treatment HBsAg level analysis confirms prediction of response observed in phase 3 study of peginterferon alfa-2a in HBeAg-positive patients, J Hepatol, 54, S31, 10.1016\u002FS0168-8278(11)60071-8",{"doi":7060},"10.1016\u002FS0168-8278(11)60071-8",{"id":26,"text":7062,"url":26,"identifiers":7063},"Sonneveld, 2010, Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline, Hepatology, 52, 1251, 10.1002\u002Fhep.23844",{"doi":7064},"10.1002\u002Fhep.23844",{"id":26,"text":7066,"url":26,"identifiers":7067},"Bonino, 2007, Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B, Gut, 56, 699, 10.1136\u002Fgut.2005.089722",{"doi":7068},"10.1136\u002Fgut.2005.089722",{"id":26,"text":7070,"url":26,"identifiers":7071},"Rijckborst, 2010, Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels, Hepatology, 52, 454, 10.1002\u002Fhep.23722",{"doi":7072},"10.1002\u002Fhep.23722",{"id":26,"text":7074,"url":26,"identifiers":7075},"Rijckborst, 2012, Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a, J Hepatol, 56, 1006, 10.1016\u002Fj.jhep.2011.12.007",{"doi":7076},"10.1016\u002Fj.jhep.2011.12.007",{"id":26,"text":7078,"url":26,"identifiers":7079},"Brunetto, 2009, Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B, Hepatology, 49, 1141, 10.1002\u002Fhep.22760",{"doi":7080},"10.1002\u002Fhep.22760",{"id":26,"text":7082,"url":26,"identifiers":7083},"Moucari, 2009, Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients, Hepatology, 49, 1151, 10.1002\u002Fhep.22744",{"doi":7084},"10.1002\u002Fhep.22744",{"id":26,"text":7086,"url":26,"identifiers":7087},"Moucari, 2009, Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a, Antivir Ther, 14, 1183, 10.3851\u002FIMP1458",{"doi":7088},"10.3851\u002FIMP1458",{"id":26,"text":7090,"url":26,"identifiers":7091},"Perrillo, 2002, Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B, Hepatology, 36, 186, 10.1053\u002Fjhep.2002.34294",{"doi":7092},"10.1053\u002Fjhep.2002.34294",{"id":26,"text":7094,"url":26,"identifiers":7095},"Wiegand, 2008, Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence, Antivir Ther, 13, 211, 10.1177\u002F135965350801300217",{"doi":7096},"10.1177\u002F135965350801300217",{"id":26,"text":3641,"url":26,"identifiers":7098},{"doi":3643},{"id":26,"text":7100,"url":26,"identifiers":7101},"Zeuzem, 2009, Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B, J Hepatol, 51, 11, 10.1016\u002Fj.jhep.2008.12.019",{"doi":7102},"10.1016\u002Fj.jhep.2008.12.019",{"id":26,"text":7104,"url":26,"identifiers":7105},"Wursthorn, 2010, Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients, Hepatology, 52, 1611, 10.1002\u002Fhep.23905",{"doi":7106},"10.1002\u002Fhep.23905",{"id":26,"text":7108,"url":26,"identifiers":7109},"Lee, 2011, Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir, Hepatology, 53, 1486, 10.1002\u002Fhep.24221",{"doi":7110},"10.1002\u002Fhep.24221",{"id":26,"text":7112,"url":26,"identifiers":7113},"Marcellin, 2011, HBsAg kinetics in patients with chronic hepatitis B (CHB) treated with tenofovir disoproxil fumarate (TDF) for up to 4 years, J Hepatol, 54, S297, 10.1016\u002FS0168-8278(11)60742-3",{"doi":7114},"10.1016\u002FS0168-8278(11)60742-3",{"id":26,"text":7116,"url":26,"identifiers":7117},"Marcellin, 2011, No detectable resistance to tenofovir disoproxil fumarate (TDF) following up to 240 weeks of treatment in patients with HBeAg+ and HBeAg− chronic hepatitis B virus infection, Hepatology, 54, 480A",{},{"id":26,"text":7119,"url":26,"identifiers":7120},"Lok, 2000, Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy, Hepatology, 32, 1145, 10.1053\u002Fjhep.2000.19622",{"doi":7121},"10.1053\u002Fjhep.2000.19622",{"id":26,"text":7123,"url":26,"identifiers":7124},"Hadziyannis, 2000, Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B, Hepatology, 32, 847, 10.1053\u002Fjhep.2000.17915",{"doi":7125},"10.1053\u002Fjhep.2000.17915",{"id":26,"text":7127,"url":26,"identifiers":7128},"Papatheodoridis, 2002, Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease, Hepatology, 36, 219, 10.1053\u002Fjhep.2002.33894",{"doi":7129},"10.1053\u002Fjhep.2002.33894",{"id":26,"text":7131,"url":26,"identifiers":7132},"Di Marco, 2004, Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine, Hepatology, 40, 883, 10.1002\u002Fhep.1840400418",{"doi":7133},"10.1002\u002Fhep.1840400418",{"id":26,"text":7135,"url":26,"identifiers":7136},"Gane, 2011, Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B, Liver Int, 31, 676, 10.1111\u002Fj.1478-3231.2011.02490.x",{"doi":7137},"10.1111\u002Fj.1478-3231.2011.02490.x",{"id":26,"text":7139,"url":26,"identifiers":7140},"Marcellin, 2010, Telbivudine (LDT) plus peg-interferon (PEGIFN) in HBeAg-positive chronic hepatitis B – very potent antiviral efficacy but risk of peripheral neuropathy (PN), J Hepatol, 52, S6, 10.1016\u002FS0168-8278(10)60015-3",{"doi":7141},"10.1016\u002FS0168-8278(10)60015-3",{"id":26,"text":7143,"url":26,"identifiers":7144},"Lee, 2010, Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B, Hepatology, 51, 415, 10.1002\u002Fhep.23323",{"doi":7145},"10.1002\u002Fhep.23323",{"id":26,"text":7147,"url":26,"identifiers":7148},"Song, 2000, Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea, Hepatology, 32, 803, 10.1053\u002Fjhep.2000.16665",{"doi":7149},"10.1053\u002Fjhep.2000.16665",{"id":26,"text":7151,"url":26,"identifiers":7152},"Dienstag, 2003, Durability of serologic response after lamivudine treatment of chronic hepatitis B, Hepatology, 37, 748, 10.1053\u002Fjhep.2003.50117",{"doi":7153},"10.1053\u002Fjhep.2003.50117",{"id":26,"text":7155,"url":26,"identifiers":7156},"Yoon, 2005, Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion, Intervirology, 48, 341, 10.1159\u002F000086061",{"doi":7157},"10.1159\u002F000086061",{"id":26,"text":7159,"url":26,"identifiers":7160},"Wu, 2008, Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants, Clin Infect Dis, 47, 1305, 10.1086\u002F592570",{"doi":7161},"10.1086\u002F592570",{"id":26,"text":7163,"url":26,"identifiers":7164},"Lok, 2011, Entecavir (ETV) monotherapy for 96 weeks is comparable to combination therapy with ETV plus tenofovir (TDF) in nucleos(t)ide naive patients with chronic hepatitis B: the BELOW study, Hepatology, 54, 471A",{},{"id":26,"text":7166,"url":26,"identifiers":7167},"Lok, 2007, Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management, Hepatology, 46, 254, 10.1002\u002Fhep.21698",{"doi":7168},"10.1002\u002Fhep.21698",{"id":26,"text":7170,"url":26,"identifiers":7171},"Zoutendijk, 2011, Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response, Hepatology, 54, 443, 10.1002\u002Fhep.24406",{"doi":7172},"10.1002\u002Fhep.24406",{"id":26,"text":7174,"url":26,"identifiers":7175},"Lampertico, 2005, Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine, Hepatology, 42, 1414, 10.1002\u002Fhep.20939",{"doi":7176},"10.1002\u002Fhep.20939",{"id":26,"text":7178,"url":26,"identifiers":7179},"Zoulim, 2009, Hepatitis B virus resistance to nucleos(t)ide analogues, Gastroenterology, 137, 1593, 10.1053\u002Fj.gastro.2009.08.063",{"doi":7180},"10.1053\u002Fj.gastro.2009.08.063",{"id":26,"text":7182,"url":26,"identifiers":7183},"Van Bommel, 2010, Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside\u002Fnucleotide analogues, Hepatology, 51, 73, 10.1002\u002Fhep.23246",{"doi":7184},"10.1002\u002Fhep.23246",{"id":26,"text":7186,"url":26,"identifiers":7187},"Reijnders, 2010, Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues, J Hepatol, 52, 493, 10.1016\u002Fj.jhep.2010.01.012",{"doi":7188},"10.1016\u002Fj.jhep.2010.01.012",{"id":26,"text":7190,"url":26,"identifiers":7191},"Berg, 2010, Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection, Gastroenterology, 139, 1207, 10.1053\u002Fj.gastro.2010.06.053",{"doi":7192},"10.1053\u002Fj.gastro.2010.06.053",{"id":26,"text":7194,"url":26,"identifiers":7195},"Manesis, 2001, Interferon-alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B, Gastroenterology, 121, 101, 10.1053\u002Fgast.2001.25524",{"doi":7196},"10.1053\u002Fgast.2001.25524",{"id":26,"text":7198,"url":26,"identifiers":7199},"Gane, 2011, Renal function is improved for chronic hepatitis B (CHB) patients treated with telbivudine, Hepatology, 54, 1044A",{},{"id":26,"text":7201,"url":26,"identifiers":7202},"Ha, 2009, Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil, Hepatology, 50, 727, 10.1002\u002Fhep.23044",{"doi":7203},"10.1002\u002Fhep.23044",{"id":26,"text":7205,"url":26,"identifiers":7206},"Perrillo, 1995, Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus, Gastroenterology, 109, 908, 10.1016\u002F0016-5085(95)90401-8",{"doi":7207},"10.1016\u002F0016-5085(95)90401-8",{"id":26,"text":7209,"url":26,"identifiers":7210},"Buster, 2007, Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis, Hepatology, 46, 388, 10.1002\u002Fhep.21723",{"doi":7211},"10.1002\u002Fhep.21723",{"id":26,"text":7213,"url":26,"identifiers":7214},"Schiff, 2008, Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis, Am J Gastroenterol, 103, 2776, 10.1111\u002Fj.1572-0241.2008.02086.x",{"doi":7215},"10.1111\u002Fj.1572-0241.2008.02086.x",{"id":26,"text":7217,"url":26,"identifiers":7218},"Buti, 2008, Tenofovir disoproxil fumarate is highly active for treatment of chronic hepatitis B in subjects with cirrhosis, J Hepatol, 48, S33, 10.1016\u002FS0168-8278(08)60077-X",{"doi":7219},"10.1016\u002FS0168-8278(08)60077-X",{"id":26,"text":7221,"url":26,"identifiers":7222},"Chang, 2010, Long-term entecavir therapy results in the reversal of fibrosis\u002Fcirrhosis and continued histological improvement in patients with chronic hepatitis B, Hepatology, 52, 886, 10.1002\u002Fhep.23785",{"doi":7223},"10.1002\u002Fhep.23785",{"id":26,"text":7225,"url":26,"identifiers":7226},"Papatheodoridis, 2010, Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review, J Hepatol, 53, 348, 10.1016\u002Fj.jhep.2010.02.035",{"doi":7227},"10.1016\u002Fj.jhep.2010.02.035",{"id":26,"text":7229,"url":26,"identifiers":7230},"Papatheodoridis, 2011, Gut, 60, 1109, 10.1136\u002Fgut.2010.221846",{"doi":7231},"10.1136\u002Fgut.2010.221846",{"id":26,"text":7233,"url":26,"identifiers":7234},"Lange, 2009, Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function, Hepatology, 50, 2001, 10.1002\u002Fhep.23346",{"doi":7235},"10.1002\u002Fhep.23346",{"id":26,"text":7237,"url":26,"identifiers":7238},"Fontana, 2002, Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy, Gastroenterology, 123, 719, 10.1053\u002Fgast.2002.35352",{"doi":7239},"10.1053\u002Fgast.2002.35352",{"id":26,"text":7241,"url":26,"identifiers":7242},"Papatheodoridis, 2009, Current management of hepatitis B virus infection before and after liver transplantation, Liver Int, 29, 1294, 10.1111\u002Fj.1478-3231.2009.02085.x",{"doi":7243},"10.1111\u002Fj.1478-3231.2009.02085.x",{"id":26,"text":7245,"url":26,"identifiers":7246},"Grellier, 1996, Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis, Lancet, 348, 1212, 10.1016\u002FS0140-6736(96)04444-3",{"doi":7247},"10.1016\u002FS0140-6736(96)04444-3",{"id":26,"text":7249,"url":26,"identifiers":7250},"Samuel, 2004, Management of hepatitis B in liver transplantation patients, Semin Liver Dis, 24, 55, 10.1055\u002Fs-2004-828679",{"doi":7251},"10.1055\u002Fs-2004-828679",{"id":26,"text":7253,"url":26,"identifiers":7254},"Schiff, 2007, Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results, Liver Transpl, 13, 349, 10.1002\u002Flt.20981",{"doi":7255},"10.1002\u002Flt.20981",{"id":26,"text":7257,"url":26,"identifiers":7258},"Fung, 2011, Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation, Gastroenterology, 141, 1212, 10.1053\u002Fj.gastro.2011.06.083",{"doi":7259},"10.1053\u002Fj.gastro.2011.06.083",{"id":26,"text":7261,"url":26,"identifiers":7262},"Teperman, 2010, Emtricitabine\u002Ftenofovir DF combination +\u002F− HBIG post-orthotopic liver transplantation to prevent hepatitis B recurrence in patients with normal to moderate renal impairment: interim results, J Hepatol, 52, S12, 10.1016\u002FS0168-8278(10)60030-X",{"doi":7263},"10.1016\u002FS0168-8278(10)60030-X",{"id":26,"text":7265,"url":26,"identifiers":7266},"Di Martino, 2002, Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B, Gastroenterology, 123, 1812, 10.1053\u002Fgast.2002.37061",{"doi":7267},"10.1053\u002Fgast.2002.37061",{"id":26,"text":7269,"url":26,"identifiers":7270},"Hoffmann, 2007, Clinical implications of HIV and hepatitis B co-infection in Asia and Africa, Lancet Infect Dis, 7, 402, 10.1016\u002FS1473-3099(07)70135-4",{"doi":7271},"10.1016\u002FS1473-3099(07)70135-4",{"id":26,"text":7273,"url":26,"identifiers":7274},"Puoti, 2006, Natural history of chronic hepatitis B in co-infected patients, J Hepatol, 44, S65, 10.1016\u002Fj.jhep.2005.11.015",{"doi":7275},"10.1016\u002Fj.jhep.2005.11.015",{"id":26,"text":7277,"url":26,"identifiers":7278},"Rockstroh, 2006, Influence of viral hepatitis on HIV infection, J Hepatol, 44, S25, 10.1016\u002Fj.jhep.2005.11.007",{"doi":7279},"10.1016\u002Fj.jhep.2005.11.007",{"id":26,"text":7281,"url":26,"identifiers":7282},"Soriano, 2005, Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV–HBV International Panel, Aids, 19, 221, 10.1097\u002F01.aids.0000163948.62176.e7",{"doi":7283},"10.1097\u002F01.aids.0000163948.62176.e7",{"id":26,"text":7285,"url":26,"identifiers":7286},"Sulkowski, 2008, Viral hepatitis and HIV coinfection, J Hepatol, 48, 353, 10.1016\u002Fj.jhep.2007.11.009",{"doi":7287},"10.1016\u002Fj.jhep.2007.11.009",{"id":26,"text":7289,"url":26,"identifiers":7290},"Colin, 1999, Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men, Hepatology, 29, 1306, 10.1002\u002Fhep.510290447",{"doi":7291},"10.1002\u002Fhep.510290447",{"id":26,"text":7293,"url":26,"identifiers":7294},"Tuma, 2010, Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy, Antivir Ther, 15, 881, 10.3851\u002FIMP1630",{"doi":7295},"10.3851\u002FIMP1630",{"id":26,"text":7297,"url":26,"identifiers":7298},"Alberti, 2005, Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients, J Hepatol, 42, 615, 10.1016\u002Fj.jhep.2005.03.003",{"doi":7299},"10.1016\u002Fj.jhep.2005.03.003",{"id":26,"text":7301,"url":26,"identifiers":7302},"Rockstroh, 2008, European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults, HIV Med, 9, 82, 10.1111\u002Fj.1468-1293.2007.00535.x",{"doi":7303},"10.1111\u002Fj.1468-1293.2007.00535.x",{"id":26,"text":7305,"url":26,"identifiers":7306},"de Vries-Sluijs, 2010, Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus, Gastroenterology, 139, 1934, 10.1053\u002Fj.gastro.2010.08.045",{"doi":7307},"10.1053\u002Fj.gastro.2010.08.045",{"id":26,"text":7309,"url":26,"identifiers":7310},"Piroth, 2010, Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study, J Hepatol, 53, 1006, 10.1016\u002Fj.jhep.2010.04.041",{"doi":7311},"10.1016\u002Fj.jhep.2010.04.041",{"id":26,"text":7313,"url":26,"identifiers":7314},"Yurdaydin, 2010, Natural history and treatment of chronic delta hepatitis, J Viral Hepat, 17, 749, 10.1111\u002Fj.1365-2893.2010.01353.x",{"doi":7315},"10.1111\u002Fj.1365-2893.2010.01353.x",{"id":26,"text":7317,"url":26,"identifiers":7318},"Hughes, 2011, Hepatitis delta virus, Lancet, 378, 73, 10.1016\u002FS0140-6736(10)61931-9",{"doi":7319},"10.1016\u002FS0140-6736(10)61931-9",{"id":26,"text":7321,"url":26,"identifiers":7322},"Mederacke, 2010, Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics, J Clin Microbiol, 48, 2022, 10.1128\u002FJCM.00084-10",{"doi":7323},"10.1128\u002FJCM.00084-10",{"id":26,"text":7325,"url":26,"identifiers":7326},"Romeo, 2009, A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma, Gastroenterology, 136, 1629, 10.1053\u002Fj.gastro.2009.01.052",{"doi":7327},"10.1053\u002Fj.gastro.2009.01.052",{"id":26,"text":7329,"url":26,"identifiers":7330},"Niro, 2010, Outcome of chronic delta hepatitis in Italy: a long-term cohort study, J Hepatol, 53, 834, 10.1016\u002Fj.jhep.2010.06.008",{"doi":7331},"10.1016\u002Fj.jhep.2010.06.008",{"id":26,"text":7333,"url":26,"identifiers":7334},"Farci, 2006, Treatment of chronic hepatitis D: new advances, old challenges, Hepatology, 44, 536, 10.1002\u002Fhep.21351",{"doi":7335},"10.1002\u002Fhep.21351",{"id":26,"text":7337,"url":26,"identifiers":7338},"Farci, 1994, Treatment of chronic hepatitis D with interferon alfa-2a, N Engl J Med, 330, 88, 10.1056\u002FNEJM199401133300202",{"doi":7339},"10.1056\u002FNEJM199401133300202",{"id":26,"text":7341,"url":26,"identifiers":7342},"Niro, 2006, Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta, Hepatology, 44, 713, 10.1002\u002Fhep.21296",{"doi":7343},"10.1002\u002Fhep.21296",{"id":26,"text":7345,"url":26,"identifiers":7346},"Yurdaydin, 2007, A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis, J Viral Hepat, 14, 812, 10.1111\u002Fj.1365-2893.2007.00875.x",{"doi":7347},"10.1111\u002Fj.1365-2893.2007.00875.x",{"id":26,"text":7349,"url":26,"identifiers":7350},"Wedemeyer, 2011, Peginterferon plus adefovir versus either drug alone for hepatitis delta, N Engl J Med, 364, 322, 10.1056\u002FNEJMoa0912696",{"doi":7351},"10.1056\u002FNEJMoa0912696",{"id":26,"text":7353,"url":26,"identifiers":7354},"Castelnau, 2006, Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up, Hepatology, 44, 728, 10.1002\u002Fhep.21325",{"doi":7355},"10.1002\u002Fhep.21325",{"id":26,"text":7357,"url":26,"identifiers":7358},"Farci, 2004, Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis, Gastroenterology, 126, 1740, 10.1053\u002Fj.gastro.2004.03.017",{"doi":7359},"10.1053\u002Fj.gastro.2004.03.017",{"id":26,"text":7361,"url":26,"identifiers":7362},"Raimondo, 2006, Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus\u002Fhepatitis C virus-coinfected patients, Hepatology, 43, 100, 10.1002\u002Fhep.20944",{"doi":7363},"10.1002\u002Fhep.20944",{"id":26,"text":7365,"url":26,"identifiers":7366},"Schaper, 2010, Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D, J Hepatol, 52, 658, 10.1016\u002Fj.jhep.2009.10.036",{"doi":7367},"10.1016\u002Fj.jhep.2009.10.036",{"id":26,"text":7369,"url":26,"identifiers":7370},"Chu, 2008, Hepatitis B virus\u002Fhepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment, J Gastroenterol Hepatol, 23, 512, 10.1111\u002Fj.1440-1746.2008.05384.x",{"doi":7371},"10.1111\u002Fj.1440-1746.2008.05384.x",{"id":26,"text":7373,"url":26,"identifiers":7374},"Jamma, 2010, Current concepts of HBV\u002FHCV coinfection: coexistence, but not necessarily in harmony, Curr Hepat Rep, 9, 260, 10.1007\u002Fs11901-010-0060-4",{"doi":7375},"10.1007\u002Fs11901-010-0060-4",{"id":26,"text":7377,"url":26,"identifiers":7378},"Donato, 1998, A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma, Int J Cancer, 75, 347, 10.1002\u002F(SICI)1097-0215(19980130)75:3\u003C347::AID-IJC4>3.0.CO;2-2",{"doi":7379},"10.1002\u002F(SICI)1097-0215(19980130)75:3\u003C347::AID-IJC4>3.0.CO;2-2",{"id":26,"text":7381,"url":26,"identifiers":7382},"Bellecave, 2009, Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference, Hepatology, 50, 46, 10.1002\u002Fhep.22951",{"doi":7383},"10.1002\u002Fhep.22951",{"id":26,"text":7385,"url":26,"identifiers":7386},"Potthoff, 2008, The HEP-NET B\u002FC co-infection trial: a prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV\u002FHCV co-infection, J Hepatol, 49, 688, 10.1016\u002Fj.jhep.2008.03.028",{"doi":7387},"10.1016\u002Fj.jhep.2008.03.028",{"id":26,"text":7389,"url":26,"identifiers":7390},"Liu, 2003, Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients, Hepatology, 37, 568, 10.1053\u002Fjhep.2003.50096",{"doi":7391},"10.1053\u002Fjhep.2003.50096",{"id":26,"text":7393,"url":26,"identifiers":7394},"Zhou, 2007, Hepatitis B and C virus coinfection in the TREAT Asia HIV observational database, J Gastroenterol Hepatol, 22, 1510, 10.1111\u002Fj.1440-1746.2007.05062.x",{"doi":7395},"10.1111\u002Fj.1440-1746.2007.05062.x",{"id":26,"text":7397,"url":26,"identifiers":7398},"Saitta, 2006, Virological profiles in hepatitis B virus\u002Fhepatitis C virus coinfected patients under interferon plus ribavirin therapy, Antivir Ther, 11, 931, 10.1177\u002F135965350601100713",{"doi":7399},"10.1177\u002F135965350601100713",{"id":26,"text":7401,"url":26,"identifiers":7402},"Tassopoulos, 1987, Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults, Gastroenterology, 92, 1844, 10.1016\u002F0016-5085(87)90614-7",{"doi":7403},"10.1016\u002F0016-5085(87)90614-7",{"id":26,"text":7405,"url":26,"identifiers":7406},"Tillmann, 2006, Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience, J Viral Hepat, 13, 256, 10.1111\u002Fj.1365-2893.2005.00695.x",{"doi":7407},"10.1111\u002Fj.1365-2893.2005.00695.x",{"id":26,"text":7409,"url":26,"identifiers":7410},"Lee, 2008, Acute liver failure: summary of a workshop, Hepatology, 47, 1401, 10.1002\u002Fhep.22177",{"doi":7411},"10.1002\u002Fhep.22177",{"id":26,"text":7413,"url":26,"identifiers":7414},"Garg, 2011, Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure, Hepatology, 53, 774, 10.1002\u002Fhep.24109",{"doi":7415},"10.1002\u002Fhep.24109",{"id":26,"text":7417,"url":26,"identifiers":7418},"Jonas, 2010, Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options, Hepatology, 52, 2192, 10.1002\u002Fhep.23934",{"doi":7419},"10.1002\u002Fhep.23934",{"id":26,"text":7421,"url":26,"identifiers":7422},"Jonas, 2008, Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to \u003C18 years) with chronic hepatitis B, Hepatology, 47, 1863, 10.1002\u002Fhep.22250",{"doi":7423},"10.1002\u002Fhep.22250",{"id":26,"text":7425,"url":26,"identifiers":7426},"Jonas, 2008, Long-term lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety, J Viral Hepat, 15, 20, 10.1111\u002Fj.1365-2893.2007.00891.x",{"doi":7427},"10.1111\u002Fj.1365-2893.2007.00891.x",{"id":26,"text":7429,"url":26,"identifiers":7430},"Sokal, 2008, The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection, J Clin Pharmacol, 48, 512, 10.1177\u002F0091270007313325",{"doi":7431},"10.1177\u002F0091270007313325",{"id":26,"text":7433,"url":26,"identifiers":7434},"Gunson, 2003, Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients, J Clin Virol, 27, 213, 10.1016\u002FS1386-6532(03)00087-8",{"doi":7435},"10.1016\u002FS1386-6532(03)00087-8",{"id":26,"text":7437,"url":26,"identifiers":7438},"Anonymous. FDA pregnancy class definitions. \u003Chttp:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FPregnancy_category\u002F>; 2010 [accessed 08.10].",{},{"id":26,"text":7440,"url":26,"identifiers":7441},"Anonymous. Antiretroviral Pregnancy Registry. \u003Chttp:\u002F\u002Fwww.apregistry.com\u002F>; 2010 [accessed 08.10].",{},{"id":26,"text":7443,"url":26,"identifiers":7444},"Bzowej, 2010, Therapy in pregnancy, Curr Hepat Rep, 9, 197, 10.1007\u002Fs11901-010-0059-x",{"doi":7445},"10.1007\u002Fs11901-010-0059-x",{"id":26,"text":7447,"url":26,"identifiers":7448},"del, 1997, Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982–1992: protective efficacy and long-term immunogenicity, Vaccine, 15, 1624, 10.1016\u002FS0264-410X(97)00080-7",{"doi":7449},"10.1016\u002FS0264-410X(97)00080-7",{"id":26,"text":7451,"url":26,"identifiers":7452},"Xu, 2009, Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study, J Viral Hepat, 16, 94, 10.1111\u002Fj.1365-2893.2008.01056.x",{"doi":7453},"10.1111\u002Fj.1365-2893.2008.01056.x",{"id":26,"text":7455,"url":26,"identifiers":7456},"Han, 2011, A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection, J Hepatol, 55, 1215, 10.1016\u002Fj.jhep.2011.02.032",{"doi":7457},"10.1016\u002Fj.jhep.2011.02.032",{"id":26,"text":7459,"url":26,"identifiers":7460},"Han, 2011, A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus, World J Gastroenterol, 17, 4321, 10.3748\u002Fwjg.v17.i38.4321",{"doi":7461},"10.3748\u002Fwjg.v17.i38.4321",{"id":26,"text":7463,"url":26,"identifiers":7464},"van Zonneveld, 2003, Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection, J Viral Hepat, 10, 294, 10.1046\u002Fj.1365-2893.2003.00440.x",{"doi":7465},"10.1046\u002Fj.1365-2893.2003.00440.x",{"id":26,"text":7467,"url":26,"identifiers":7468},"Su, 2004, Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy, World J Gastroenterol, 10, 910, 10.3748\u002Fwjg.v10.i6.910",{"doi":7469},"10.3748\u002Fwjg.v10.i6.910",{"id":26,"text":7471,"url":26,"identifiers":7472},"Shi, 2010, Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis, Obstet Gynecol, 116, 147, 10.1097\u002FAOG.0b013e3181e45951",{"doi":7473},"10.1097\u002FAOG.0b013e3181e45951",{"id":26,"text":7475,"url":26,"identifiers":7476},"Rawal, 1991, Symptomatic reactivation of hepatitis B in pregnancy, Lancet, 337, 364, 10.1016\u002F0140-6736(91)90993-Y",{"doi":7477},"10.1016\u002F0140-6736(91)90993-Y",{"id":26,"text":7479,"url":26,"identifiers":7480},"ter Borg, 2008, Exacerbation of chronic hepatitis B infection after delivery, J Viral Hepat, 15, 37, 10.1111\u002Fj.1365-2893.2007.00894.x",{"doi":7481},"10.1111\u002Fj.1365-2893.2007.00894.x",{"id":26,"text":7483,"url":26,"identifiers":7484},"Benaboud, 2011, Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d’Ivoire, in the ANRS 12109 TEmAA Study, Step 2, Antimicrob Agents Chemother, 55, 1315, 10.1128\u002FAAC.00514-10",{"doi":7485},"10.1128\u002FAAC.00514-10",{"id":26,"text":7487,"url":26,"identifiers":7488},"Lok, 1991, Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study, Gastroenterology, 100, 182, 10.1016\u002F0016-5085(91)90599-G",{"doi":7489},"10.1016\u002F0016-5085(91)90599-G",{"id":26,"text":7491,"url":26,"identifiers":7492},"Mindikoglu, 2006, Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention, Clin Gastroenterol Hepatol, 4, 1076, 10.1016\u002Fj.cgh.2006.05.027",{"doi":7493},"10.1016\u002Fj.cgh.2006.05.027",{"id":26,"text":7495,"url":26,"identifiers":7496},"Esteve, 2004, Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis, Gut, 53, 1363, 10.1136\u002Fgut.2004.040675",{"doi":7497},"10.1136\u002Fgut.2004.040675",{"id":26,"text":7499,"url":26,"identifiers":7500},"Evens, 2011, Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports, Ann Oncol, 22, 1170, 10.1093\u002Fannonc\u002Fmdq583",{"doi":7501},"10.1093\u002Fannonc\u002Fmdq583",{"id":26,"text":7503,"url":26,"identifiers":7504},"Hsu, 2008, A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial, Hepatology, 47, 844, 10.1002\u002Fhep.22106",{"doi":7505},"10.1002\u002Fhep.22106",{"id":26,"text":7507,"url":26,"identifiers":7508},"Loomba, 2008, Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy, Ann Intern Med, 148, 519, 10.7326\u002F0003-4819-148-7-200804010-00008",{"doi":7509},"10.7326\u002F0003-4819-148-7-200804010-00008",{"id":26,"text":7511,"url":26,"identifiers":7512},"Lalazar, 2007, Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies, Br J Haematol, 136, 699, 10.1111\u002Fj.1365-2141.2006.06465.x",{"doi":7513},"10.1111\u002Fj.1365-2141.2006.06465.x",{"id":26,"text":7515,"url":26,"identifiers":7516},"Marzano, 2007, Prophylaxis and treatment of hepatitis B in immunocompromised patients, Dig Liver Dis, 39, 397, 10.1016\u002Fj.dld.2006.12.017",{"doi":7517},"10.1016\u002Fj.dld.2006.12.017",{"id":26,"text":7519,"url":26,"identifiers":7520},"Cornberg, 2011, Prophylaxis, diagnosis and therapy of hepatitis B virus infection – the German guideline, Z Gastroenterol, 49, 871, 10.1055\u002Fs-0031-1273462",{"doi":7521},"10.1055\u002Fs-0031-1273462",{"id":26,"text":7523,"url":26,"identifiers":7524},"Vigano, 2011, Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT, Bone Marrow Transplant, 46, 125, 10.1038\u002Fbmt.2010.70",{"doi":7525},"10.1038\u002Fbmt.2010.70",{"id":26,"text":7527,"url":26,"identifiers":7528},"Cholongitas, 2010, Liver grafts from anti-hepatitis B core positive donors: a systematic review, J Hepatol, 52, 272, 10.1016\u002Fj.jhep.2009.11.009",{"doi":7529},"10.1016\u002Fj.jhep.2009.11.009",{"id":7531,"createTime":7532,"updateTime":7532,"relativeEntities":7533,"slug":7534,"properties":7535,"entityType":749,"verifyStatus":25,"verifyTime":7532,"verifyNote":750,"syncStatus":28,"languages":7547,"translateLanguages":26,"viewCount":36,"primaryUrl":7548,"fullTextUrl":26,"authors":7549,"publicationType":895,"publisherRelationship":7571,"citationCount":7600,"citationInfo":7601,"publishDate":7607,"publishYear":7608,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":7609,"isForceReanalyzing":3453},"31c990d3-b14a-4968-a1af-59dc6b10c7b9","2024-09-04T19:14:54.489+00:00",[],"Revising-consensus-in-portal-hypertension-Report-of-the-Baveno-V-consensus-workshop-on-methodology-of-diagnosis-and-therapy-in-portal-hypertension",{"mag":7536,"keywords":7538,"openalex":7539,"abstract":7541,"title":7542,"pm":7544,"doi":7546},{"VOID":7537},"2171716651",{},{"VOID":7540},"W2171716651",{},{"EN":7543},"Revising consensus in portal hypertension: Report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension",{"VOID":7545},"20638742",{"VOID":6551},[102],"https:\u002F\u002Flinkinghub.elsevier.com\u002Fretrieve\u002Fpii\u002FS0168827810005647",[7550],{"id":7551,"sortIndex":36,"researcher":26,"roles":7552,"affiliations":7553,"properties":7564},"c033a698-65d3-4dc4-a005-61dd238da741",[],[7554],{"id":7555,"sortIndex":36,"affiliation":7556,"properties":26},"33a6ed93-f22d-4bdd-a0ed-add85f61ede5",{"id":7557,"createTime":7558,"updateTime":7558,"relativeEntities":7559,"slug":7560,"properties":7561,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"c841d44f-5dfe-4b3f-bb80-9f9b50067fd5","2024-09-04T19:14:54.501+00:00",[],"Department-of-Medical-Sciences-University-of-Milan-Head-Gastroenterology-3-Unit-IRCCS-Ca-Granda-Ospedale-Maggiore-Policlinico-Foundation-Milan-Italy",{"title":7562},{"EN":7563},"Department of Medical Sciences, University of Milan, Head, Gastroenterology 3 Unit, IRCCS Ca’ Granda Ospedale Maggiore Policlinico Foundation, Milan, Italy",{"openalex":7565,"orcid":7567,"title":7569},{"VOID":7566},"A5072866363",{"VOID":7568},"https:\u002F\u002Forcid.org\u002F0000-0002-3486-7097",{"EN":7570},"Roberto de Franchis",{"url":26,"publisher":7572,"properties":7594},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":7573,"slug":663,"properties":7574,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":7577,"manageAffiliations":7578,"indexDatabases":7579,"url":26,"thumbnailPath":26,"statistic":26,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"issn":7575,"title":7576},{"VOID":666},{"EN":668},[],[],[7580,7587],{"id":690,"indexDatabase":7581,"url":705,"indexYears":26,"academicFieldIds":7586,"indexDatabaseRanking":26},{"id":692,"createTime":693,"updateTime":694,"relativeEntities":7582,"label":7583,"description":7584,"key":701,"publicationTags":7585,"standard":26},[],{"EN":697,"VI":697},{"VI":699,"EN":700},[703,704],[707],{"id":709,"indexDatabase":7588,"url":722,"indexYears":723,"academicFieldIds":7593,"indexDatabaseRanking":726},{"id":711,"createTime":712,"updateTime":713,"relativeEntities":7589,"label":7590,"description":7591,"key":719,"publicationTags":7592,"standard":26},[],{"EN":716,"VI":716},{"EN":716,"VI":718},[721],[725],{"volume":7595,"pages":7597,"issue":7599},{"VOID":7596},"53",{"VOID":7598},"762-768",{"VOID":3509},2213,{"total":7600,"publishYear":26,"statisticByYear":7602},{"2012":7603,"2013":615,"2014":626,"2015":7604,"2016":121,"2017":7605,"2018":7606,"2019":361,"2020":7605,"2021":366,"2022":347,"2023":46,"2024":168},158,221,112,110,"2010-10-01",2010,[7610,7613,7615,7617,7620,7622,7624,7626,7630,7633,7637,7640,7643,7646],{"id":26,"text":7611,"url":26,"identifiers":7612},"Burroughs AK, editor. Methodology and review of clinical trials in portal hypertension. Excerpta Medica Congress Service No. 763. New York, Oxford: Amsterdam; 1987.",{},{"id":26,"text":6512,"url":26,"identifiers":7614},{"doi":6514},{"id":26,"text":6516,"url":26,"identifiers":7616},{"doi":6518},{"id":26,"text":7618,"url":26,"identifiers":7619},"de Franchis R, editor. Portal Hypertension II. Proceedings of the second Baveno international consensus workshop on definitions, methodology and therapeutic strategies. Oxford: Blackwell Science; 1996.",{},{"id":26,"text":6523,"url":26,"identifiers":7621},{"doi":6525},{"id":26,"text":6527,"url":26,"identifiers":7623},{"doi":6529},{"id":26,"text":6531,"url":26,"identifiers":7625},{"doi":6533},{"id":26,"text":7627,"url":26,"identifiers":7628},"de Franchis R, editor. Portal hypertension III. Proceedings of the IIIrd Baveno international consensus workshop on definitions, methodology and therapeutic strategies. Oxford, UK: Blackwell Science; 2000.",{"doi":7629},"10.1002\u002F9780470760154",{"id":26,"text":7631,"url":26,"identifiers":7632},"de Franchis, 2005, Evolving consensus in portal hypertension, J Hepatol, 43, 167, 10.1016\u002Fj.jhep.2005.05.009",{"doi":6540},{"id":26,"text":7634,"url":26,"identifiers":7635},"de Franchis R, editor. Portal hypertension IV. Proceedings of the IVth Baveno international consensus workshop on methodology of diagnosis and treatment. Oxford, UK: Blackwell Publishing; 2006.",{"doi":7636},"10.1002\u002F9780470988831",{"id":26,"text":7638,"url":26,"identifiers":7639},"Garcia-Tsao, 2008, Portal hypertension and variceal bleeding, unresolved issues. Summary of an American Association for the study of liver disease and European Association for the study of the liver single-topic conference, Hepatology, 47, 1764, 10.1002\u002Fhep.22273",{"doi":6547},{"id":26,"text":7641,"url":26,"identifiers":7642},"Available from: http:\u002F\u002Fwww.cebm.net\u002Fdownloads\u002FOxford_EBM_Levels_5.rtf.",{},{"id":26,"text":7644,"url":26,"identifiers":7645},"de Franchis, 2010, Revising consensus in portal hypertension: Report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension, J Hepatol, 53, 762, 10.1016\u002Fj.jhep.2010.06.004",{"doi":6551},{"id":26,"text":7647,"url":26,"identifiers":7648},"Thabut D, D’Amico G, Tan P, de Franchis R, Fabricius S, Lebrec D, et al. Diagnostic performance of Baveno II\u002FIII and Baveno IV criteria in cirrhotic patients with gastrointestinal bleeding: analysis of the F7 liver-1288 study population. In: Hepatology. - ISSN 0270-9139. - 48:S1(2008 Oct), pp. 625A-625A. (convegno AASLD meeting tenutosi a S. Francisco, California, USA nel 2008).",{},{"id":7650,"createTime":7651,"updateTime":7651,"relativeEntities":7652,"slug":7653,"properties":7654,"entityType":749,"verifyStatus":25,"verifyTime":7651,"verifyNote":750,"syncStatus":28,"languages":7667,"translateLanguages":26,"viewCount":36,"primaryUrl":7668,"fullTextUrl":26,"authors":7669,"publicationType":895,"publisherRelationship":8021,"citationCount":8050,"citationInfo":8051,"publishDate":8056,"publishYear":8057,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":8058,"isForceReanalyzing":3453},"1a2d7607-59a0-4d1c-8233-09800e714cb7","2024-09-30T12:41:12.574+00:00",[],"BCLC-strategy-for-prognosis-prediction-and-treatment-recommendation-The-2022-update",{"mag":7655,"keywords":7657,"openalex":7658,"abstract":7660,"title":7661,"pm":7663,"doi":7665},{"VOID":7656},"3213277274",{},{"VOID":7659},"W3213277274",{},{"EN":7662},"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update",{"VOID":7664},"34801630",{"VOID":7666},"10.1016\u002Fj.jhep.2021.11.018",[102],"https:\u002F\u002Flinkinghub.elsevier.com\u002Fretrieve\u002Fpii\u002FS0168827821022236",[7670,7692,7712,7734,7755,7787,7811,7832,7850,7872,7890,7913,7936,7964,7987,8004],{"id":7671,"sortIndex":135,"researcher":26,"roles":7672,"affiliations":7673,"properties":7685},"519c6f24-7d9c-4edb-b9e7-179393d9ee9a",[],[7674],{"id":7675,"sortIndex":36,"affiliation":7676,"properties":26},"05e74d75-fe34-4935-afff-20052dae8ce0",{"id":7677,"createTime":7678,"updateTime":7679,"relativeEntities":7680,"slug":7681,"properties":7682,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"6ab029b8-cc1b-4b60-a601-16ceef5a16d1","2024-01-08T09:48:44.467+00:00","2024-09-30T12:41:12.670+00:00",[],"Helen-Diller-Family-Comprehensive-Cancer-Center-University-of-California-San-Francisco-California-USA",{"title":7683},{"VI":7684},"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA",{"openalex":7686,"orcid":7688,"title":7690},{"VOID":7687},"A5019481117",{"VOID":7689},"https:\u002F\u002Forcid.org\u002F0000-0002-1984-2430",{"EN":7691},"Robin Kate Kelley",{"id":7693,"sortIndex":103,"researcher":26,"roles":7694,"affiliations":7695,"properties":7707},"59773dfe-5aad-4c39-8f41-6b500bc43e54",[],[7696],{"id":7697,"sortIndex":36,"affiliation":7698,"properties":26},"20570c14-980d-4d6f-af67-2457d29c7dc0",{"id":7699,"createTime":7700,"updateTime":7701,"relativeEntities":7702,"slug":7703,"properties":7704,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"a780472a-6e12-4ba9-9461-817b363d3e22","2024-01-12T13:31:08.440+00:00","2024-09-30T12:41:12.752+00:00",[],"Hannover-Medical-School-Department-of-Gastroenterology-Hepatology-and-Endocrinology-Hannover-Germany",{"title":7705},{"VI":7706},"Hannover Medical School, Department of Gastroenterology, Hepatology and Endocrinology, Hannover, Germany",{"openalex":7708,"title":7710},{"VOID":7709},"A5059190497",{"EN":7711},"Arndt Vogel",{"id":7713,"sortIndex":53,"researcher":26,"roles":7714,"affiliations":7715,"properties":7727},"37e64800-f78d-4d34-b983-3446fa31c8f0",[],[7716],{"id":7717,"sortIndex":36,"affiliation":7718,"properties":26},"3d68a870-725f-40d4-9872-7bacbe6d0f57",{"id":7719,"createTime":7720,"updateTime":7721,"relativeEntities":7722,"slug":7723,"properties":7724,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"48bf19a3-6ffb-42fd-9728-9c4f15c6ae33","2024-02-08T20:11:38.133+00:00","2024-10-14T22:22:52.587+00:00",[],"Department-of-Internal-Medicine-University-of-Texas-Southwestern-Medical-Center-Dallas-Texas-USA",{"title":7725},{"VI":7726},"Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA",{"openalex":7728,"orcid":7730,"title":7732},{"VOID":7729},"A5014214683",{"VOID":7731},"https:\u002F\u002Forcid.org\u002F0000-0002-1172-3971",{"EN":7733},"Amit G. Singal",{"id":7735,"sortIndex":111,"researcher":26,"roles":7736,"affiliations":7737,"properties":7748},"84a86fe8-4fb6-467f-b025-2a5c11128efb",[],[7738],{"id":7739,"sortIndex":36,"affiliation":7740,"properties":26},"bdfd5a5c-2d00-4c01-be6e-acaa4021172e",{"id":7741,"createTime":7742,"updateTime":7742,"relativeEntities":7743,"slug":7744,"properties":7745,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"3a9e80c3-0146-4c9b-9b60-a066a3852772","2024-09-30T12:41:12.641+00:00",[],"BCLC-Group-Vascular-Department-CDI-Hospital-Clinic-of-Barcelona-Barcelona-University-University-of-Barcelona-Barcelona-Spain",{"title":7746},{"EN":7747},"BCLC Group, Vascular Department, CDI, Hospital Clinic of Barcelona, Barcelona University, University of Barcelona, Barcelona, Spain",{"openalex":7749,"orcid":7751,"title":7753},{"VOID":7750},"A5078639078",{"VOID":7752},"https:\u002F\u002Forcid.org\u002F0000-0002-1545-8239",{"EN":7754},"Marta Burrel",{"id":7756,"sortIndex":298,"researcher":26,"roles":7757,"affiliations":7758,"properties":7780},"cd27868c-edd6-45af-8490-f7ec58e856a8",[],[7759,7769],{"id":7760,"sortIndex":36,"affiliation":7761,"properties":26},"6a4231a8-5cd4-400e-b001-067f7aa6cf6d",{"id":7762,"createTime":7763,"updateTime":7763,"relativeEntities":7764,"slug":7765,"properties":7766,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"90530464-9e80-4802-8726-4a1f196d8259","2024-09-30T12:41:12.630+00:00",[],"BCLC-Group-Radiology-Department-CDI-Hospital-Clinic-of-Barcelona-University-of-Barcelona-Barcelona-Spain",{"title":7767},{"EN":7768},"BCLC Group, Radiology Department, CDI, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain",{"id":7770,"sortIndex":115,"affiliation":7771,"properties":26},"46d66067-84e5-42d6-a5cf-fd79665eb373",{"id":7772,"createTime":7773,"updateTime":7774,"relativeEntities":7775,"slug":7776,"properties":7777,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"970decac-39d0-4c37-a8a1-92bc66f09ec0","2023-12-01T09:31:13.712+00:00","2024-09-30T12:41:12.612+00:00",[],"Centro-de-Investigaci%C3%B3n-Biom%C3%A9dica-en-Red-de-Enfermedades-Hep%C3%A1ticas-y-Digestivas-CIBERehd-Spain",{"title":7778},{"VI":7779},"Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain",{"openalex":7781,"orcid":7783,"title":7785},{"VOID":7782},"A5057743208",{"VOID":7784},"https:\u002F\u002Forcid.org\u002F0000-0002-9606-6957",{"EN":7786},"Carmen Ayuso",{"id":7788,"sortIndex":115,"researcher":26,"roles":7789,"affiliations":7790,"properties":7807},"ab51e1a9-2057-4e09-9104-3642491d20b2",[],[7791,7797],{"id":7792,"sortIndex":115,"affiliation":7793,"properties":26},"1efaf475-5e96-46f9-bdde-48418bb5e815",{"id":7772,"createTime":7773,"updateTime":7774,"relativeEntities":7794,"slug":7776,"properties":7795,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":7796},{"VI":7779},{"id":7798,"sortIndex":36,"affiliation":7799,"properties":26},"743f6733-b373-4542-bfbf-740b34d1e212",{"id":7800,"createTime":7801,"updateTime":7801,"relativeEntities":7802,"slug":7803,"properties":7804,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"118f8a0b-29c7-4221-8d2c-2e2c24d969cd","2024-09-30T12:41:12.607+00:00",[],"BCLC-Group-Liver-Unit-ICMDM-IDIBAPS-Hospital-Clinic-of-Barcelona-University-of-Barcelona-Barcelona-Spain",{"title":7805},{"EN":7806},"BCLC Group, Liver Unit, ICMDM, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain",{"openalex":7808,"orcid":7809,"title":7810},{"VOID":873},{"VOID":875},{"EN":877},{"id":7812,"sortIndex":59,"researcher":26,"roles":7813,"affiliations":7814,"properties":7825},"731b98b2-afae-4650-919e-3bfa8d9e1ca8",[],[7815],{"id":7816,"sortIndex":36,"affiliation":7817,"properties":26},"27b6ccd7-06b2-49a6-a4f9-d6b5ae863ad2",{"id":7818,"createTime":7819,"updateTime":7819,"relativeEntities":7820,"slug":7821,"properties":7822,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"22e67e2b-1eb5-4084-b21c-d66a769ef5c2","2024-09-30T12:41:12.595+00:00",[],"BCLC-Group-Surgery-Department-ICMDM-IDIBAPS-Hospital-Clinic-of-Barcelona-University-of-Barcelona-Barcelona-Spain",{"title":7823},{"EN":7824},"BCLC Group, Surgery Department, ICMDM, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain",{"openalex":7826,"orcid":7828,"title":7830},{"VOID":7827},"A5022049890",{"VOID":7829},"https:\u002F\u002Forcid.org\u002F0000-0002-5723-4209",{"EN":7831},"Joana Ferrer",{"id":7833,"sortIndex":158,"researcher":26,"roles":7834,"affiliations":7835,"properties":7846},"f1b4e353-48c7-4f3c-b3ad-a5b84ae5714b",[],[7836],{"id":7837,"sortIndex":36,"affiliation":7838,"properties":26},"20b9a9a6-3394-498b-a34d-5975b42c5e33",{"id":7839,"createTime":7840,"updateTime":7840,"relativeEntities":7841,"slug":7842,"properties":7843,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"91d99baf-1738-41ca-96f4-ba20ba933dc6","2024-09-30T12:41:12.692+00:00",[],"Department-of-Internal-Medicine-Mainz-University-Medical-Center-Mainz-Germany",{"title":7844},{"EN":7845},"Department of Internal Medicine, Mainz University Medical Center, Mainz, Germany",{"openalex":7847,"orcid":7848,"title":7849},{"VOID":890},{"VOID":892},{"EN":894},{"id":7851,"sortIndex":52,"researcher":26,"roles":7852,"affiliations":7853,"properties":7865},"009e1cce-3f68-408e-b581-307dce72d2fb",[],[7854],{"id":7855,"sortIndex":36,"affiliation":7856,"properties":26},"a7e0ae5e-721e-4f04-ac6f-987d786d6eaa",{"id":7857,"createTime":7858,"updateTime":7859,"relativeEntities":7860,"slug":7861,"properties":7862,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"4852cccc-94f8-4489-ac81-d7a19cc529c2","2023-12-11T08:37:40.759+00:00","2024-09-30T12:41:12.714+00:00",[],"Department-of-Radiology-Section-of-Interventional-Radiology-Northwestern-University-Chicago-IL-USA",{"title":7863},{"VI":7864},"Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL, USA",{"openalex":7866,"orcid":7868,"title":7870},{"VOID":7867},"A5087536545",{"VOID":7869},"https:\u002F\u002Forcid.org\u002F0000-0001-9745-1825",{"EN":7871},"Riad Salem",{"id":7873,"sortIndex":50,"researcher":26,"roles":7874,"affiliations":7875,"properties":7886},"3a864ea7-d9a4-4698-ad6f-440f8f64676d",[],[7876],{"id":7877,"sortIndex":36,"affiliation":7878,"properties":26},"86f23376-f2d6-4dee-9263-e902c51acb42",{"id":7879,"createTime":7880,"updateTime":7880,"relativeEntities":7881,"slug":7882,"properties":7883,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"b2ac70eb-74d2-4156-913a-16ed2b802263","2024-09-30T12:41:12.703+00:00",[],"Department-of-Oncology-University-of-Milan-and-HPB-Surgery-and-Liver-Transplantation-Fondazione-IRCCS-Istituto-Nazionale-Tumori-Milan-Italy",{"title":7884},{"EN":7885},"Department of Oncology, University of Milan and HPB Surgery and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy",{"openalex":7887,"orcid":7888,"title":7889},{"VOID":805},{"VOID":807},{"EN":809},{"id":7891,"sortIndex":356,"researcher":26,"roles":7892,"affiliations":7893,"properties":7906},"207d1050-6d15-438d-b2ec-de59d946cb74",[],[7894,7900],{"id":7895,"sortIndex":115,"affiliation":7896,"properties":26},"9dca9b2a-e189-4361-a62d-7d6e87293c93",{"id":7772,"createTime":7773,"updateTime":7774,"relativeEntities":7897,"slug":7776,"properties":7898,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":7899},{"VI":7779},{"id":7901,"sortIndex":36,"affiliation":7902,"properties":26},"b9a7171e-9ad7-4218-b85f-2408ef732b8e",{"id":7818,"createTime":7819,"updateTime":7819,"relativeEntities":7903,"slug":7821,"properties":7904,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":7905},{"EN":7824},{"openalex":7907,"orcid":7909,"title":7911},{"VOID":7908},"A5079646116",{"VOID":7910},"https:\u002F\u002Forcid.org\u002F0000-0002-1713-4262",{"EN":7912},"Josep Fuster",{"id":7914,"sortIndex":36,"researcher":26,"roles":7915,"affiliations":7916,"properties":7929},"c9b10075-610e-4c41-962d-93f307a6f430",[],[7917,7923],{"id":7918,"sortIndex":115,"affiliation":7919,"properties":26},"093980a4-1c1f-46a0-953b-892bddb9c2fa",{"id":7772,"createTime":7773,"updateTime":7774,"relativeEntities":7920,"slug":7776,"properties":7921,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":7922},{"VI":7779},{"id":7924,"sortIndex":36,"affiliation":7925,"properties":26},"a1db65ba-87a9-4480-85e0-ca3a4815ff96",{"id":7800,"createTime":7801,"updateTime":7801,"relativeEntities":7926,"slug":7803,"properties":7927,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":7928},{"EN":7806},{"openalex":7930,"orcid":7932,"title":7934},{"VOID":7931},"A5080639399",{"VOID":7933},"https:\u002F\u002Forcid.org\u002F0000-0002-5711-9534",{"EN":7935},"María Reig",{"id":7937,"sortIndex":116,"researcher":26,"roles":7938,"affiliations":7939,"properties":7957},"2f180c08-377a-4261-9891-d0c66a641047",[],[7940,7946],{"id":7941,"sortIndex":36,"affiliation":7942,"properties":26},"654afd9a-fcb0-4f05-9954-44cf283c9a5a",{"id":7772,"createTime":7773,"updateTime":7774,"relativeEntities":7943,"slug":7776,"properties":7944,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":7945},{"VI":7779},{"id":7947,"sortIndex":115,"affiliation":7948,"properties":26},"b484e322-b4d0-4dcb-b0da-ffbd67c769e5",{"id":7949,"createTime":7950,"updateTime":7951,"relativeEntities":7952,"slug":7953,"properties":7954,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"dc18b085-a828-4e5c-9dce-c260157db055","2024-01-27T09:36:28.627+00:00","2024-09-30T12:41:12.726+00:00",[],"Liver-Unit-Clinica-Universidad-de-Navarra-Pamplona-Spain",{"title":7955},{"VI":7956},"Liver Unit, Clinica Universidad de Navarra, Pamplona, Spain",{"openalex":7958,"orcid":7960,"title":7962},{"VOID":7959},"A5085766415",{"VOID":7961},"https:\u002F\u002Forcid.org\u002F0000-0002-4177-6417",{"EN":7963},"Bruno Sangro",{"id":7965,"sortIndex":51,"researcher":26,"roles":7966,"affiliations":7967,"properties":7980},"d6fddf1f-dda9-4b24-b140-b7a66096eed2",[],[7968,7974],{"id":7969,"sortIndex":115,"affiliation":7970,"properties":26},"09af5290-715f-4e4e-8946-6dedf1b18cfe",{"id":7772,"createTime":7773,"updateTime":7774,"relativeEntities":7971,"slug":7776,"properties":7972,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":7973},{"VI":7779},{"id":7975,"sortIndex":36,"affiliation":7976,"properties":26},"f97aa766-be04-4c93-a6a1-61421e3d27fc",{"id":7800,"createTime":7801,"updateTime":7801,"relativeEntities":7977,"slug":7803,"properties":7978,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":7979},{"EN":7806},{"openalex":7981,"orcid":7983,"title":7985},{"VOID":7982},"A5080019152",{"VOID":7984},"https:\u002F\u002Forcid.org\u002F0000-0002-9826-0753",{"EN":7986},"Jordi Bruix",{"id":7988,"sortIndex":162,"researcher":26,"roles":7989,"affiliations":7990,"properties":7997},"b16fff24-fee3-44f1-a2f5-53e7dd047578",[],[7991],{"id":7992,"sortIndex":36,"affiliation":7993,"properties":26},"ea106bcd-29fd-4107-bb18-038a7f67ae8f",{"id":7762,"createTime":7763,"updateTime":7763,"relativeEntities":7994,"slug":7765,"properties":7995,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":7996},{"EN":7768},{"openalex":7998,"orcid":8000,"title":8002},{"VOID":7999},"A5010105487",{"VOID":8001},"https:\u002F\u002Forcid.org\u002F0000-0003-3536-4288",{"EN":8003},"Ángeles García‐Criado",{"id":8005,"sortIndex":114,"researcher":26,"roles":8006,"affiliations":8007,"properties":8014},"85cb4cb0-50cb-4cea-84f5-048c5a2a56ed",[],[8008],{"id":8009,"sortIndex":36,"affiliation":8010,"properties":26},"28038586-1d89-4db9-82a2-712cc0441b6b",{"id":7762,"createTime":7763,"updateTime":7763,"relativeEntities":8011,"slug":7765,"properties":8012,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":8013},{"EN":7768},{"openalex":8015,"orcid":8017,"title":8019},{"VOID":8016},"A5048248914",{"VOID":8018},"https:\u002F\u002Forcid.org\u002F0000-0002-1814-4198",{"EN":8020},"Jordi Rimola",{"url":26,"publisher":8022,"properties":8044},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":8023,"slug":663,"properties":8024,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":8027,"manageAffiliations":8028,"indexDatabases":8029,"url":26,"thumbnailPath":26,"statistic":26,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"issn":8025,"title":8026},{"VOID":666},{"EN":668},[],[],[8030,8037],{"id":690,"indexDatabase":8031,"url":705,"indexYears":26,"academicFieldIds":8036,"indexDatabaseRanking":26},{"id":692,"createTime":693,"updateTime":694,"relativeEntities":8032,"label":8033,"description":8034,"key":701,"publicationTags":8035,"standard":26},[],{"EN":697,"VI":697},{"VI":699,"EN":700},[703,704],[707],{"id":709,"indexDatabase":8038,"url":722,"indexYears":723,"academicFieldIds":8043,"indexDatabaseRanking":726},{"id":711,"createTime":712,"updateTime":713,"relativeEntities":8039,"label":8040,"description":8041,"key":719,"publicationTags":8042,"standard":26},[],{"EN":716,"VI":716},{"EN":716,"VI":718},[721],[725],{"volume":8045,"pages":8047,"issue":8049},{"VOID":8046},"76",{"VOID":8048},"681-693",{"VOID":6495},2156,{"total":8050,"publishYear":26,"statisticByYear":8052},{"2022":8053,"2023":8054,"2024":8055},388,925,790,"2022-03-01",2022,[8059,8061,8063,8065,8067,8070,8073,8077,8081,8085,8089,8091,8094,8098,8102,8105,8108,8111,8115,8119,8122,8126,8130,8134,8138,8142,8146,8149,8151,8155,8159,8163,8165,8169,8173,8175,8177,8181,8184,8187,8191,8195,8198,8200,8202,8204,8206,8210,8212,8214,8216,8218,8222,8225,8228,8231,8234,8238,8242,8244,8248,8252,8255,8258,8262,8264,8268,8272,8275,8277,8281,8285,8289,8293,8297,8301,8304,8308,8312,8314,8317,8320,8324,8327,8330,8334,8338,8342,8346,8350,8353,8356,8359,8363,8367,8371,8375,8379,8383,8387,8390,8394,8398,8402,8406,8410,8413,8416,8418,8421,8424,8428,8432,8436,8439,8443,8447,8449,8451,8453,8457,8461,8465,8467,8470,8474,8477],{"id":26,"text":1981,"url":26,"identifiers":8060},{"doi":1983},{"id":26,"text":2021,"url":26,"identifiers":8062},{"doi":2023},{"id":26,"text":2137,"url":26,"identifiers":8064},{"doi":2139},{"id":26,"text":2029,"url":26,"identifiers":8066},{"doi":2031},{"id":26,"text":8068,"url":26,"identifiers":8069},"Forner, 2018, Hepatocellular carcinoma, Lancet, 31, 1301, 10.1016\u002FS0140-6736(18)30010-2",{"doi":1284},{"id":26,"text":8071,"url":26,"identifiers":8072},"Reig, 2014, Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST, Semin Liver Dis, 34, 444",{},{"id":26,"text":8074,"url":26,"identifiers":8075},"Bruix, 2016, Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma, Gastroenterology, 150, 835, 10.1053\u002Fj.gastro.2015.12.041",{"doi":8076},"10.1053\u002Fj.gastro.2015.12.041",{"id":26,"text":8078,"url":26,"identifiers":8079},"Hernán, 2021, Methods of public health research - strengthening causal inference from observational data, N Engl J Med, 385, 10.1056\u002FNEJMp2113319",{"doi":8080},"10.1056\u002FNEJMp2113319",{"id":26,"text":8082,"url":26,"identifiers":8083},"Schag, 1984, Karnofsky performance status revisited: reliability, validity, and guidelines, J Clin Oncol, 2, 187, 10.1200\u002FJCO.1984.2.3.187",{"doi":8084},"10.1200\u002FJCO.1984.2.3.187",{"id":26,"text":8086,"url":26,"identifiers":8087},"Sorensen, 1993, Performance status assessment in cancer patients. An inter-observer variability study, Br J Cancer, 67, 773, 10.1038\u002Fbjc.1993.140",{"doi":8088},"10.1038\u002Fbjc.1993.140",{"id":26,"text":2259,"url":26,"identifiers":8090},{"doi":2261},{"id":26,"text":8092,"url":26,"identifiers":8093},"Kamath, 2001, A model to predict survival in patients with end-stage liver disease, Hepatology, 33, 464, 10.1053\u002Fjhep.2001.22172",{"doi":4229},{"id":26,"text":8095,"url":26,"identifiers":8096},"Kim, 2008, Hyponatremia and mortality among patients on the liver-transplant waiting list, N Engl J Med, 359, 1018, 10.1056\u002FNEJMoa0801209",{"doi":8097},"10.1056\u002FNEJMoa0801209",{"id":26,"text":8099,"url":26,"identifiers":8100},"Kim, 2021, MELD 3.0: the model for end-stage liver disease updated for the modern era, Gastroenterology, 10.1053\u002Fj.gastro.2021.08.050",{"doi":8101},"10.1053\u002Fj.gastro.2021.08.050",{"id":26,"text":8103,"url":26,"identifiers":8104},"Johnson, 2015, Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade, J Clin Oncol, 33, 550, 10.1200\u002FJCO.2014.57.9151",{"doi":2043},{"id":26,"text":8106,"url":26,"identifiers":8107},"Pinato, 2017, The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma, J Hepatol, 66, 338, 10.1016\u002Fj.jhep.2016.09.008",{"doi":2047},{"id":26,"text":8109,"url":26,"identifiers":8110},"Scheiner, 2021, Predicting the outcome of patients with hepatocellular carcinoma treated with immunotherapy-the CRAFITY score, J Hepatol, 75, S236",{},{"id":26,"text":8112,"url":26,"identifiers":8113},"Singal, 2021, International liver cancer association (ILCA) white paper on biomarker development for hepatocellular carcinoma, Gastroenterology, 160, 2572, 10.1053\u002Fj.gastro.2021.01.233",{"doi":8114},"10.1053\u002Fj.gastro.2021.01.233",{"id":26,"text":8116,"url":26,"identifiers":8117},"Cabibbo, 2012, Natural history of untreatable hepatocellular carcinoma: a retrospective cohort study, World J Hepatol, 4, 256, 10.4254\u002Fwjh.v4.i9.256",{"doi":8118},"10.4254\u002Fwjh.v4.i9.256",{"id":26,"text":8120,"url":26,"identifiers":8121},"de Franchis, 2015, Expanding consensus in portal hypertension, J Hepatol, 63, 743, 10.1016\u002Fj.jhep.2015.05.022",{"doi":6441},{"id":26,"text":8123,"url":26,"identifiers":8124},"D’Amico, 2018, Clinical states of cirrhosis and competing risks, J Hepatol, 68, 563, 10.1016\u002Fj.jhep.2017.10.020",{"doi":8125},"10.1016\u002Fj.jhep.2017.10.020",{"id":26,"text":8127,"url":26,"identifiers":8128},"Garcia-Tsao, 2010, Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis, Hepatology, 51, 1445, 10.1002\u002Fhep.23478",{"doi":8129},"10.1002\u002Fhep.23478",{"id":26,"text":8131,"url":26,"identifiers":8132},"Tonon, 2021, Outcomes and mortality of grade 1 ascites and recurrent ascites in patients with cirrhosis, Clin Gastroenterol Hepatol, 19, 358, 10.1016\u002Fj.cgh.2020.03.065",{"doi":8133},"10.1016\u002Fj.cgh.2020.03.065",{"id":26,"text":8135,"url":26,"identifiers":8136},"Llach, 1988, Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites, Gastroenterology, 94, 482, 10.1016\u002F0016-5085(88)90441-6",{"doi":8137},"10.1016\u002F0016-5085(88)90441-6",{"id":26,"text":8139,"url":26,"identifiers":8140},"Pinyol, 2019, Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial, Gut, 68, 1065, 10.1136\u002Fgutjnl-2018-316408",{"doi":8141},"10.1136\u002Fgutjnl-2018-316408",{"id":26,"text":8143,"url":26,"identifiers":8144},"Vogel, 2018, Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†, Ann Oncol, 29, iv238, 10.1093\u002Fannonc\u002Fmdy308",{"doi":8145},"10.1093\u002Fannonc\u002Fmdy308",{"id":26,"text":8147,"url":26,"identifiers":8148},"Galle, 2018, EASL clinical practice guidelines: management of hepatocellular carcinoma, J Hepatol, 69, 182, 10.1016\u002Fj.jhep.2018.03.019",{"doi":748},{"id":26,"text":2524,"url":26,"identifiers":8150},{"doi":2526},{"id":26,"text":8152,"url":26,"identifiers":8153},"Bruix, 2021, Systemic treatment of hepatocellular carcinoma. An EASL position paper, J Hepatol, 75, 960, 10.1016\u002Fj.jhep.2021.07.004",{"doi":8154},"10.1016\u002Fj.jhep.2021.07.004",{"id":26,"text":8156,"url":26,"identifiers":8157},"Gordan, 2020, Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline, J Clin Oncol, 38, 4317, 10.1200\u002FJCO.20.02672",{"doi":8158},"10.1200\u002FJCO.20.02672",{"id":26,"text":8160,"url":26,"identifiers":8161},"Pocock, 2016, The primary outcome is positive — is that good enough?, N Engl J Med, 375, 971, 10.1056\u002FNEJMra1601511",{"doi":8162},"10.1056\u002FNEJMra1601511",{"id":26,"text":2228,"url":26,"identifiers":8164},{"doi":2230},{"id":26,"text":8166,"url":26,"identifiers":8167},"Bruix, 2011, Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques, Hepatology, 54, 2238, 10.1002\u002Fhep.24670",{"doi":8168},"10.1002\u002Fhep.24670",{"id":26,"text":8170,"url":26,"identifiers":8171},"Templeton, 2020, Informative censoring — a neglected cause of bias in oncology trials, Nat Rev Clin Oncol, 17, 327, 10.1038\u002Fs41571-020-0368-0",{"doi":8172},"10.1038\u002Fs41571-020-0368-0",{"id":26,"text":2125,"url":26,"identifiers":8174},{"doi":2127},{"id":26,"text":2129,"url":26,"identifiers":8176},{"doi":2131},{"id":26,"text":8178,"url":26,"identifiers":8179},"Ferrer-Fàbrega, 2016, Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection, Hepatology, 63, 839, 10.1002\u002Fhep.28339",{"doi":8180},"10.1002\u002Fhep.28339",{"id":26,"text":8182,"url":26,"identifiers":8183},"Cho, 2010, Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis, Hepatology, 51, 1284, 10.1002\u002Fhep.23466",{"doi":2123},{"id":26,"text":8185,"url":26,"identifiers":8186},"Cucchetti, 2013, Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma, J Hepatol, 59, 300, 10.1016\u002Fj.jhep.2013.04.009",{"doi":1803},{"id":26,"text":8188,"url":26,"identifiers":8189},"Izumi, 2019, A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF trial), J Clin Oncol, 37, 10.1200\u002FJCO.2019.37.15_suppl.4002",{"doi":8190},"10.1200\u002FJCO.2019.37.15_suppl.4002",{"id":26,"text":8192,"url":26,"identifiers":8193},"Doyle, 2019, Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients, J Hepatol, 70, 866, 10.1016\u002Fj.jhep.2018.12.027",{"doi":8194},"10.1016\u002Fj.jhep.2018.12.027",{"id":26,"text":8196,"url":26,"identifiers":8197},"Mazzaferro, 1996, Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis, N Engl J Med, 334, 693, 10.1056\u002FNEJM199603143341104",{"doi":2514},{"id":26,"text":2528,"url":26,"identifiers":8199},{"doi":2530},{"id":26,"text":2536,"url":26,"identifiers":8201},{"doi":2538},{"id":26,"text":2069,"url":26,"identifiers":8203},{"doi":2071},{"id":26,"text":2085,"url":26,"identifiers":8205},{"doi":2087},{"id":26,"text":8207,"url":26,"identifiers":8208},"Herrero, 2008, Liver transplantation in patients with hepatocellular carcinoma across Milan criteria, Liver Transpl, 14, 272, 10.1002\u002Flt.21368",{"doi":8209},"10.1002\u002Flt.21368",{"id":26,"text":2315,"url":26,"identifiers":8211},{"doi":2317},{"id":26,"text":4021,"url":26,"identifiers":8213},{"doi":2143},{"id":26,"text":2149,"url":26,"identifiers":8215},{"doi":2151},{"id":26,"text":4107,"url":26,"identifiers":8217},{"doi":4109},{"id":26,"text":8219,"url":26,"identifiers":8220},"Ferrusquía-Acosta, 2021, Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis, J Hepatol, 74, 811, 10.1016\u002Fj.jhep.2020.10.003",{"doi":8221},"10.1016\u002Fj.jhep.2020.10.003",{"id":26,"text":8223,"url":26,"identifiers":8224},"Baffy, 2021, Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: is it real and how to measure it?, J Hepatol",{},{"id":26,"text":8226,"url":26,"identifiers":8227},"Chen, 2006, A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma, Ann Surg, 243, 321, 10.1097\u002F01.sla.0000201480.65519.b8",{"doi":2380},{"id":26,"text":8229,"url":26,"identifiers":8230},"Ng, 2017, Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma, Br J Surg, 104, 1775, 10.1002\u002Fbjs.10677",{"doi":2388},{"id":26,"text":8232,"url":26,"identifiers":8233},"Feng, 2012, A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma, J Hepatol, 57, 794, 10.1016\u002Fj.jhep.2012.05.007",{"doi":2384},{"id":26,"text":8235,"url":26,"identifiers":8236},"Nault, 2018, Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations, J Hepatol, 68, 783, 10.1016\u002Fj.jhep.2017.10.004",{"doi":8237},"10.1016\u002Fj.jhep.2017.10.004",{"id":26,"text":8239,"url":26,"identifiers":8240},"Berardi, 2020, Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis, J Hepatol, 75, 10.1016\u002Fj.jhep.2019.08.032",{"doi":8241},"10.1016\u002Fj.jhep.2019.08.032",{"id":26,"text":2346,"url":26,"identifiers":8243},{"doi":2348},{"id":26,"text":8245,"url":26,"identifiers":8246},"Molina, 2018, Benefits of laparoscopic liver resection in patients with hepatocellular carcinoma and portal hypertension: a case-matched study, Surg Endosc, 32, 2345, 10.1007\u002Fs00464-017-5930-1",{"doi":8247},"10.1007\u002Fs00464-017-5930-1",{"id":26,"text":8249,"url":26,"identifiers":8250},"Witowski, 2019, Meta-analysis of short- and long-term outcomes after pure laparoscopic versus open liver surgery in hepatocellular carcinoma patients, Surg Endosc, 33, 1491, 10.1007\u002Fs00464-018-6431-6",{"doi":8251},"10.1007\u002Fs00464-018-6431-6",{"id":26,"text":8253,"url":26,"identifiers":8254},"Morise, 2015, Can we expand the indications for laparoscopic liver resection? A systematic review and meta-analysis of laparoscopic liver resection for patients with hepatocellular carcinoma and chronic liver disease, J Hepatobil Pancreat Sci, 22, 342, 10.1002\u002Fjhbp.215",{"doi":2368},{"id":26,"text":8256,"url":26,"identifiers":8257},"Ciria, 2016, Comparative short-term benefits of laparoscopic liver resection: 9000 cases and climbing, Ann Surg, 263, 761, 10.1097\u002FSLA.0000000000001413",{"doi":2340},{"id":26,"text":8259,"url":26,"identifiers":8260},"Pompili, 2013, Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3 cm. Results of a multicenter Italian survey, J Hepatol, 59, 89, 10.1016\u002Fj.jhep.2013.03.009",{"doi":8261},"10.1016\u002Fj.jhep.2013.03.009",{"id":26,"text":3962,"url":26,"identifiers":8263},{"doi":2095},{"id":26,"text":8265,"url":26,"identifiers":8266},"Shiina, 2012, Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors, Am J Gastroenterol, 107, 569, 10.1038\u002Fajg.2011.425",{"doi":8267},"10.1038\u002Fajg.2011.425",{"id":26,"text":8269,"url":26,"identifiers":8270},"Cucchetti, 2015, When to perform hepatic resection for intermediate-stage hepatocellular carcinoma, Hepatology, 61, 905, 10.1002\u002Fhep.27321",{"doi":8271},"10.1002\u002Fhep.27321",{"id":26,"text":8273,"url":26,"identifiers":8274},"Forner, 2014, Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery, Nat Rev Clin Oncol, 12",{},{"id":26,"text":4035,"url":26,"identifiers":8276},{"doi":4037},{"id":26,"text":8278,"url":26,"identifiers":8279},"Galle, 2017, The treatment of intermediate stage tumours beyond TACE: from surgery to systemic therapy, J Hepatol, 67, 173, 10.1016\u002Fj.jhep.2017.03.007",{"doi":8280},"10.1016\u002Fj.jhep.2017.03.007",{"id":26,"text":8282,"url":26,"identifiers":8283},"Kloeckner, 2021, Local and regional therapies for hepatocellular carcinoma, Hepatology, 73, 137, 10.1002\u002Fhep.31424",{"doi":8284},"10.1002\u002Fhep.31424",{"id":26,"text":8286,"url":26,"identifiers":8287},"Mehta, 2020, Liver transplantation for hepatocellular carcinoma. Working group report from the ILTS transplant oncology consensus conference, Transplantation, 1136, 10.1097\u002FTP.0000000000003174",{"doi":8288},"10.1097\u002FTP.0000000000003174",{"id":26,"text":8290,"url":26,"identifiers":8291},"Kwong, 2021, Expanding the limits of liver transplantation for hepatocellular carcinoma: is there a limit?, Clin Liver Dis, 25, 19, 10.1016\u002Fj.cld.2020.08.002",{"doi":8292},"10.1016\u002Fj.cld.2020.08.002",{"id":26,"text":8294,"url":26,"identifiers":8295},"Ferrer-Fàbrega, 2021, Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival, J Hepatol, 10.1016\u002Fj.jhep.2021.06.015",{"doi":8296},"10.1016\u002Fj.jhep.2021.06.015",{"id":26,"text":8298,"url":26,"identifiers":8299},"Navasa, 2010, Multifaceted perspective of the waiting list for liver transplantation: the value of pharmacokinetic models, Hepatology, 51, 12, 10.1002\u002Fhep.23332",{"doi":8300},"10.1002\u002Fhep.23332",{"id":26,"text":8302,"url":26,"identifiers":8303},"Toso, 2015, Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation, Hepatology, 62, 158, 10.1002\u002Fhep.27787",{"doi":2079},{"id":26,"text":8305,"url":26,"identifiers":8306},"Mehta, 2019, Alpha-fetoprotein decrease from >1000 to \u003C500 ng\u002Fml in patients with hepatocellular carcinoma leads to improved post-transplant outcomes, Hepatology, 69, 1193, 10.1002\u002Fhep.30413",{"doi":8307},"10.1002\u002Fhep.30413",{"id":26,"text":8309,"url":26,"identifiers":8310},"Finn, 2020, Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma, N Engl J Med, 382, 1894, 10.1056\u002FNEJMoa1915745",{"doi":8311},"10.1056\u002FNEJMoa1915745",{"id":26,"text":2208,"url":26,"identifiers":8313},{"doi":2210},{"id":26,"text":8315,"url":26,"identifiers":8316},"Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056\u002FNEJMoa0708857",{"doi":2206},{"id":26,"text":8318,"url":26,"identifiers":8319},"Kudo, 2018, Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial, Lancet, 391, 1163, 10.1016\u002FS0140-6736(18)30207-1",{"doi":2218},{"id":26,"text":8321,"url":26,"identifiers":8322},"Abou-Alfa, 2022, Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA, J Clin Oncol, 40, 379, 10.1200\u002FJCO.2022.40.4_suppl.379",{"doi":8323},"10.1200\u002FJCO.2022.40.4_suppl.379",{"id":26,"text":8325,"url":26,"identifiers":8326},"Kelley, 2021, VP10-2021: cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): results from the randomized phase III COSMIC-312 trial, Ann Oncol",{},{"id":26,"text":8328,"url":26,"identifiers":8329},"Bruix, 2017, Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 389, 56, 10.1016\u002FS0140-6736(16)32453-9",{"doi":2214},{"id":26,"text":8331,"url":26,"identifiers":8332},"Abou-Alfa, 2018, Cabozantinib in patients with advanced and progressing hepatocellular carcinoma, N Engl J Med, 379, 54, 10.1056\u002FNEJMoa1717002",{"doi":8333},"10.1056\u002FNEJMoa1717002",{"id":26,"text":8335,"url":26,"identifiers":8336},"Finn, 2018, Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial, J Hepatol, 69, 353, 10.1016\u002Fj.jhep.2018.04.010",{"doi":8337},"10.1016\u002Fj.jhep.2018.04.010",{"id":26,"text":8339,"url":26,"identifiers":8340},"Zhu, 2019, Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 20, 282, 10.1016\u002FS1470-2045(18)30937-9",{"doi":8341},"10.1016\u002FS1470-2045(18)30937-9",{"id":26,"text":8343,"url":26,"identifiers":8344},"Finn, 2020, Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial, J Clin Oncol, 38, 193, 10.1200\u002FJCO.19.01307",{"doi":8345},"10.1200\u002FJCO.19.01307",{"id":26,"text":8347,"url":26,"identifiers":8348},"Qin S, Chen Z, Fang W, Ren Z, Xu R, l Ryoo BY et al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study. J Clin Oncol 2022 40:4_suppl, 383–383. https:\u002F\u002Fascopubs.org\u002Fdoi\u002F10.1200\u002FJCO.2022.40.4_suppl.383",{"doi":8349},"10.1200\u002FJCO.2022.40.4_suppl.383",{"id":26,"text":8351,"url":26,"identifiers":8352},"Shiina, 2005, A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma, Gastroenterology, 129, 122, 10.1053\u002Fj.gastro.2005.04.009",{"doi":4374},{"id":26,"text":8354,"url":26,"identifiers":8355},"Germani, 2010, Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis, J Hepatol, 52, 380, 10.1016\u002Fj.jhep.2009.12.004",{"doi":2794},{"id":26,"text":8357,"url":26,"identifiers":8358},"Burrel, 2012, Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design, J Hepatol, 56, 1330, 10.1016\u002Fj.jhep.2012.01.008",{"doi":2183},{"id":26,"text":8360,"url":26,"identifiers":8361},"Salem, 2021, Yttrium-90 radioembolization for the treatment of solitary, unresectable hepatocellular carcinoma: the LEGACY study, Hepatology, 74, 2342, 10.1002\u002Fhep.31819",{"doi":8362},"10.1002\u002Fhep.31819",{"id":26,"text":8364,"url":26,"identifiers":8365},"Chen, 2020, Role of external beam radiotherapy in hepatocellular carcinoma, Clin Liver Dis, 24, 701, 10.1016\u002Fj.cld.2020.07.006",{"doi":8366},"10.1016\u002Fj.cld.2020.07.006",{"id":26,"text":8368,"url":26,"identifiers":8369},"Shanker, 2021, Stereotactic ablative radiotherapy for hepatocellular carcinoma: a systematic review and meta-analysis of local control, survival and toxicity outcomes, J Med Imaging Radiat Oncol, 10.1111\u002F1754-9485.13309",{"doi":8370},"10.1111\u002F1754-9485.13309",{"id":26,"text":8372,"url":26,"identifiers":8373},"Yu, 2017, Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial, Gut, 66, 1172, 10.1136\u002Fgutjnl-2016-312629",{"doi":8374},"10.1136\u002Fgutjnl-2016-312629",{"id":26,"text":8376,"url":26,"identifiers":8377},"Vietti Violi, 2018, Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial, Lancet Gastroenterol Hepatol, 3, 317, 10.1016\u002FS2468-1253(18)30029-3",{"doi":8378},"10.1016\u002FS2468-1253(18)30029-3",{"id":26,"text":8380,"url":26,"identifiers":8381},"Han, 2020, Radiofrequency ablation versus microwave ablation for early stage hepatocellular carcinoma: a PRISMA-compliant systematic review and meta-analysis, Medicine (Baltimore), 99, 10.1097\u002FMD.0000000000022703",{"doi":8382},"10.1097\u002FMD.0000000000022703",{"id":26,"text":8384,"url":26,"identifiers":8385},"Chan, 2018, Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection, J Hepatol, 69, 1284, 10.1016\u002Fj.jhep.2018.08.027",{"doi":8386},"10.1016\u002Fj.jhep.2018.08.027",{"id":26,"text":8388,"url":26,"identifiers":8389},"Vitale, 2015, Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study, J Hepatol, 62, 617, 10.1016\u002Fj.jhep.2014.10.037",{"doi":2356},{"id":26,"text":8391,"url":26,"identifiers":8392},"Vouche, 2013, Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection, J Hepatol, 59, 1029, 10.1016\u002Fj.jhep.2013.06.015",{"doi":8393},"10.1016\u002Fj.jhep.2013.06.015",{"id":26,"text":8395,"url":26,"identifiers":8396},"Troisi, 2021, Laparoscopic and open liver resection for hepatocellular carcinoma with Child–Pugh B cirrhosis: multicentre propensity score-matched study, Br J Surg, 108, 196, 10.1093\u002Fbjs\u002Fznaa041",{"doi":8397},"10.1093\u002Fbjs\u002Fznaa041",{"id":26,"text":8399,"url":26,"identifiers":8400},"Reverter, 2019, The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery, J Hepatol, 71, 942, 10.1016\u002Fj.jhep.2019.07.007",{"doi":8401},"10.1016\u002Fj.jhep.2019.07.007",{"id":26,"text":8403,"url":26,"identifiers":8404},"Fukami, 2020, Liver resection for multiple hepatocellular carcinomas: a Japanese nationwide survey, Ann Surg, 272, 145, 10.1097\u002FSLA.0000000000003192",{"doi":8405},"10.1097\u002FSLA.0000000000003192",{"id":26,"text":8407,"url":26,"identifiers":8408},"Raoul, 2019, Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence, Cancer Treat Rev, 72, 28, 10.1016\u002Fj.ctrv.2018.11.002",{"doi":8409},"10.1016\u002Fj.ctrv.2018.11.002",{"id":26,"text":8411,"url":26,"identifiers":8412},"Golfieri, 2014, Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma, Br J Cancer, 111, 255, 10.1038\u002Fbjc.2014.199",{"doi":3004},{"id":26,"text":8414,"url":26,"identifiers":8415},"Varela, 2007, Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics, J Hepatol, 46, 474, 10.1016\u002Fj.jhep.2006.10.020",{"doi":2996},{"id":26,"text":2998,"url":26,"identifiers":8417},{"doi":3000},{"id":26,"text":8419,"url":26,"identifiers":8420},"Meyer, 2013, A randomised phase II\u002FIII trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma, Br J Cancer, 108, 1252, 10.1038\u002Fbjc.2013.85",{"doi":3095},{"id":26,"text":8422,"url":26,"identifiers":8423},"Brown, 2016, Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone, J Clin Oncol, 34, 2046, 10.1200\u002FJCO.2015.64.0821",{"doi":3099},{"id":26,"text":8425,"url":26,"identifiers":8426},"Facciorusso, 2017, Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: a meta-analysis of randomized trials, United Eur Gastroenterol J, 5, 511, 10.1177\u002F2050640616673516",{"doi":8427},"10.1177\u002F2050640616673516",{"id":26,"text":8429,"url":26,"identifiers":8430},"Hameed, 2014, Alpha-fetoprotein level > 1000 ng\u002FmL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria, Liver Transpl, 20, 945, 10.1002\u002Flt.23904",{"doi":8431},"10.1002\u002Flt.23904",{"id":26,"text":8433,"url":26,"identifiers":8434},"Mazzaferro, 2020, Liver transplantation in hepatocellular carcinoma after tumour downstaging: a randomised, controlled, phase 2\u002F3 trial, Lancet Oncol, 21, 947, 10.1016\u002FS1470-2045(20)30224-2",{"doi":8435},"10.1016\u002FS1470-2045(20)30224-2",{"id":26,"text":8437,"url":26,"identifiers":8438},"Yao, 2015, Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria, Hepatology, 61, 1968, 10.1002\u002Fhep.27752",{"doi":2570},{"id":26,"text":8440,"url":26,"identifiers":8441},"Bruix, 2021, End-points in clinical trials for liver cancer and their value in evidence based clinical decision making: an unresolved Gordian knot, J Hepatol, 74, 1483, 10.1016\u002Fj.jhep.2021.01.033",{"doi":8442},"10.1016\u002Fj.jhep.2021.01.033",{"id":26,"text":8444,"url":26,"identifiers":8445},"Ho, 2021, Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity, Nat Cancer, 2, 891, 10.1038\u002Fs43018-021-00234-4",{"doi":8446},"10.1038\u002Fs43018-021-00234-4",{"id":26,"text":3124,"url":26,"identifiers":8448},{"doi":3126},{"id":26,"text":2448,"url":26,"identifiers":8450},{"doi":2450},{"id":26,"text":3128,"url":26,"identifiers":8452},{"doi":3130},{"id":26,"text":8454,"url":26,"identifiers":8455},"Chow, 2018, SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma, J Clin Oncol, 36, 1913, 10.1200\u002FJCO.2017.76.0892",{"doi":8456},"10.1200\u002FJCO.2017.76.0892",{"id":26,"text":8458,"url":26,"identifiers":8459},"Vilgrain, 2017, Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial, Lancet Oncol, 18, 1624, 10.1016\u002FS1470-2045(17)30683-6",{"doi":8460},"10.1016\u002FS1470-2045(17)30683-6",{"id":26,"text":8462,"url":26,"identifiers":8463},"Ricke, 2019, Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma, J Hepatol, 71, 1164, 10.1016\u002Fj.jhep.2019.08.006",{"doi":8464},"10.1016\u002Fj.jhep.2019.08.006",{"id":26,"text":3229,"url":26,"identifiers":8466},{"doi":3231},{"id":26,"text":8468,"url":26,"identifiers":8469},"Iavarone, 2015, Predictors of survival of patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib, Hepatology, 62, 784, 10.1002\u002Fhep.27729",{"doi":3416},{"id":26,"text":8471,"url":26,"identifiers":8472},"Reig, 2021, Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab, Liver Int, 41, 598, 10.1111\u002Fliv.14731",{"doi":8473},"10.1111\u002Fliv.14731",{"id":26,"text":8475,"url":26,"identifiers":8476},"Rimassa, 2018, Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study, Lancet Oncol, 19, 682, 10.1016\u002FS1470-2045(18)30146-3",{"doi":3207},{"id":26,"text":8478,"url":26,"identifiers":8479},"de la Torre-Aláez, 2020, The pattern of progression defines post-progression survival in patients with hepatocellular carcinoma treated with SIRT, Cardiovasc Intervent Radiol, 43, 1165, 10.1007\u002Fs00270-020-02444-2",{"doi":8480},"10.1007\u002Fs00270-020-02444-2",{"id":8482,"createTime":8483,"updateTime":8483,"relativeEntities":8484,"slug":8485,"properties":8486,"entityType":749,"verifyStatus":25,"verifyTime":8483,"verifyNote":750,"syncStatus":28,"languages":8499,"translateLanguages":26,"viewCount":36,"primaryUrl":8500,"fullTextUrl":26,"authors":8501,"publicationType":895,"publisherRelationship":8707,"citationCount":8736,"citationInfo":8737,"publishDate":8744,"publishYear":8745,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":8746,"isForceReanalyzing":3453},"21e18fe3-93ca-437b-94ef-3e2ad00dd758","2024-09-18T22:36:37.310+00:00",[],"The-global-epidemiology-of-NAFLD-and-NASH-in-patients-with-type-2-diabetes-A-systematic-review-and-meta-analysis",{"mag":8487,"keywords":8489,"openalex":8490,"abstract":8492,"title":8493,"pm":8495,"doi":8497},{"VOID":8488},"2955615964",{},{"VOID":8491},"W2955615964",{},{"EN":8494},"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis",{"VOID":8496},"31279902",{"VOID":8498},"10.1016\u002Fj.jhep.2019.06.021",[102],"https:\u002F\u002Flinkinghub.elsevier.com\u002Fretrieve\u002Fpii\u002FS0168827819303939",[8502,8541,8562,8579,8599,8616,8635,8650,8669,8688],{"id":8503,"sortIndex":36,"researcher":26,"roles":8504,"affiliations":8505,"properties":8534},"7d309d06-9399-46e9-96d1-214bbf3610eb",[],[8506,8520],{"id":8507,"sortIndex":115,"affiliation":8508,"properties":8517},"9ce40a50-18e6-4515-b30c-63c3974f1ba7",{"id":8509,"createTime":8510,"updateTime":8511,"relativeEntities":8512,"slug":8513,"properties":8514,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"0b4fe2ae-38e0-46f7-9352-3e69fabfa11e","2024-01-16T04:02:33.543+00:00","2025-06-12T00:11:37.335+00:00",[],"Center-for-Liver-Diseases-Department-of-Medicine-Inova-Fairfax-Hospital-Falls-Church-VA-USA",{"title":8515},{"VI":8516},"Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA",{"title":8518},{"EN":8519},"Center For Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, United States",{"id":8521,"sortIndex":36,"affiliation":8522,"properties":8531},"13dfff87-24a9-4559-9389-8275b721f364",{"id":8523,"createTime":8524,"updateTime":8525,"relativeEntities":8526,"slug":8527,"properties":8528,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"a1d575f4-7d43-4d34-9e3e-e2c6bb06bb9a","2024-01-02T02:27:38.838+00:00","2024-09-29T12:01:46.256+00:00",[],"Betty-and-Guy-Beatty-Center-for-Integrated-Research-Inova-Health-System-Falls-Church-VA-USA",{"title":8529},{"VI":8530},"Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA",{"title":8532},{"EN":8533},"Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, United States",{"openalex":8535,"orcid":8537,"title":8539},{"VOID":8536},"A5080386622",{"VOID":8538},"https:\u002F\u002Forcid.org\u002F0000-0001-9313-577X",{"EN":8540},"Zobair M. Younossi",{"id":8542,"sortIndex":135,"researcher":26,"roles":8543,"affiliations":8544,"properties":8555},"9ef60d67-3489-448c-bf6e-3f7479e4064b",[],[8545],{"id":8546,"sortIndex":36,"affiliation":8547,"properties":26},"1323f242-9ec8-436c-860a-ab016f17c913",{"id":8548,"createTime":8549,"updateTime":8549,"relativeEntities":8550,"slug":8551,"properties":8552,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"f3154cb0-9437-4c09-942f-488a46f28a0a","2024-09-18T22:36:37.434+00:00",[],"Bristol-Myers-Squibb-Princeton-NJ-United-States",{"title":8553},{"EN":8554},"Bristol-Myers Squibb, Princeton, NJ, United States",{"openalex":8556,"orcid":8558,"title":8560},{"VOID":8557},"A5101699195",{"VOID":8559},"https:\u002F\u002Forcid.org\u002F0000-0002-1894-9586",{"EN":8561},"Ying Qiu",{"id":8563,"sortIndex":111,"researcher":26,"roles":8564,"affiliations":8565,"properties":8574},"ce8f8d9c-d28f-45ba-87a2-ae7c8a567e98",[],[8566],{"id":8567,"sortIndex":36,"affiliation":8568,"properties":8572},"3ba7ac0c-1f99-4906-b789-ba81a9f7f2bd",{"id":8523,"createTime":8524,"updateTime":8525,"relativeEntities":8569,"slug":8527,"properties":8570,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":8571},{"VI":8530},{"title":8573},{"EN":8533},{"openalex":8575,"title":8577},{"VOID":8576},"A5038479274",{"EN":8578},"Manirath Srishord",{"id":8580,"sortIndex":50,"researcher":26,"roles":8581,"affiliations":8582,"properties":8594},"ce4aba30-f321-4195-b123-a57c9138442e",[],[8583],{"id":8584,"sortIndex":36,"affiliation":8585,"properties":26},"1d98d127-d7b0-4496-a0ed-7835d623b6d7",{"id":8586,"createTime":8587,"updateTime":8588,"relativeEntities":8589,"slug":8590,"properties":8591,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"01855321-90c2-4e99-9bae-d07d49bc5f2b","2024-09-18T22:36:37.474+00:00","2025-06-11T14:58:24.622+00:00",[],"Center-for-Outcomes-Research-in-Liver-Disease-Washington-DC-United-States",{"title":8592},{"EN":8593},"Center for Outcomes Research in Liver Disease, Washington DC, United States",{"openalex":8595,"title":8597},{"VOID":8596},"A5103453563",{"EN":8598},"Arian Afendy",{"id":8600,"sortIndex":158,"researcher":26,"roles":8601,"affiliations":8602,"properties":8609},"cf496abd-a5dc-4dea-a0af-a346d6677e26",[],[8603],{"id":8604,"sortIndex":36,"affiliation":8605,"properties":26},"12a748ae-bf50-43fa-90fb-ab5b14a5a10a",{"id":8548,"createTime":8549,"updateTime":8549,"relativeEntities":8606,"slug":8551,"properties":8607,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":8608},{"EN":8554},{"openalex":8610,"orcid":8612,"title":8614},{"VOID":8611},"A5031752718",{"VOID":8613},"https:\u002F\u002Forcid.org\u002F0000-0001-8135-3331",{"EN":8615},"Leah Burns",{"id":8617,"sortIndex":59,"researcher":26,"roles":8618,"affiliations":8619,"properties":8628},"63cc0f72-876e-4205-b509-917e50948f5d",[],[8620],{"id":8621,"sortIndex":36,"affiliation":8622,"properties":8626},"dad3349e-6da6-4807-bd06-44493dcf091e",{"id":8523,"createTime":8524,"updateTime":8525,"relativeEntities":8623,"slug":8527,"properties":8624,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":8625},{"VI":8530},{"title":8627},{"EN":8533},{"openalex":8629,"orcid":8631,"title":8633},{"VOID":8630},"A5053950885",{"VOID":8632},"https:\u002F\u002Forcid.org\u002F0000-0003-2294-323X",{"EN":8634},"James M. Paik",{"id":8636,"sortIndex":52,"researcher":26,"roles":8637,"affiliations":8638,"properties":8645},"1af71ca7-da18-4641-af99-c7257be8b155",[],[8639],{"id":8640,"sortIndex":36,"affiliation":8641,"properties":26},"5b6d4a11-f708-4f51-ac52-6f43ae2c33ad",{"id":8586,"createTime":8587,"updateTime":8588,"relativeEntities":8642,"slug":8590,"properties":8643,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":8644},{"EN":8593},{"openalex":8646,"title":8648},{"VOID":8647},"A5037741510",{"EN":8649},"Fatema Nader",{"id":8651,"sortIndex":115,"researcher":26,"roles":8652,"affiliations":8653,"properties":8662},"de610900-fe63-4646-b231-bfcb760524b7",[],[8654],{"id":8655,"sortIndex":36,"affiliation":8656,"properties":8660},"af61c4f6-09a8-4046-87db-ffaf97054547",{"id":8523,"createTime":8524,"updateTime":8525,"relativeEntities":8657,"slug":8527,"properties":8658,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":8659},{"VI":8530},{"title":8661},{"EN":8533},{"openalex":8663,"orcid":8665,"title":8667},{"VOID":8664},"A5084895513",{"VOID":8666},"https:\u002F\u002Forcid.org\u002F0000-0001-9818-0983",{"EN":8668},"Pegah Golabi",{"id":8670,"sortIndex":162,"researcher":26,"roles":8671,"affiliations":8672,"properties":8681},"85a86982-72fe-4f09-9c7f-05dc1844063b",[],[8673],{"id":8674,"sortIndex":36,"affiliation":8675,"properties":8679},"d8a8b639-5420-4bd7-b857-d5a3e52e6813",{"id":8509,"createTime":8510,"updateTime":8511,"relativeEntities":8676,"slug":8513,"properties":8677,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":8678},{"VI":8516},{"title":8680},{"EN":8519},{"openalex":8682,"orcid":8684,"title":8686},{"VOID":8683},"A5048233236",{"VOID":8685},"https:\u002F\u002Forcid.org\u002F0000-0003-2933-0831",{"EN":8687},"Natsu Fukui",{"id":8689,"sortIndex":114,"researcher":26,"roles":8690,"affiliations":8691,"properties":8700},"b698c6c2-4a07-4015-b257-822e9b483805",[],[8692],{"id":8693,"sortIndex":36,"affiliation":8694,"properties":8698},"4f1644f2-7781-4cab-bece-75e1b7d409d4",{"id":8523,"createTime":8524,"updateTime":8525,"relativeEntities":8695,"slug":8527,"properties":8696,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":8697},{"VI":8530},{"title":8699},{"EN":8533},{"openalex":8701,"orcid":8703,"title":8705},{"VOID":8702},"A5011146415",{"VOID":8704},"https:\u002F\u002Forcid.org\u002F0000-0003-3731-8058",{"EN":8706},"Leyla de Avila",{"url":26,"publisher":8708,"properties":8730},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":8709,"slug":663,"properties":8710,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":8713,"manageAffiliations":8714,"indexDatabases":8715,"url":26,"thumbnailPath":26,"statistic":26,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"issn":8711,"title":8712},{"VOID":666},{"EN":668},[],[],[8716,8723],{"id":690,"indexDatabase":8717,"url":705,"indexYears":26,"academicFieldIds":8722,"indexDatabaseRanking":26},{"id":692,"createTime":693,"updateTime":694,"relativeEntities":8718,"label":8719,"description":8720,"key":701,"publicationTags":8721,"standard":26},[],{"EN":697,"VI":697},{"VI":699,"EN":700},[703,704],[707],{"id":709,"indexDatabase":8724,"url":722,"indexYears":723,"academicFieldIds":8729,"indexDatabaseRanking":726},{"id":711,"createTime":712,"updateTime":713,"relativeEntities":8725,"label":8726,"description":8727,"key":719,"publicationTags":8728,"standard":26},[],{"EN":716,"VI":716},{"EN":716,"VI":718},[721],[725],{"volume":8731,"pages":8733,"issue":8735},{"VOID":8732},"71",{"VOID":8734},"793-801",{"VOID":3509},1542,{"total":8736,"publishYear":26,"statisticByYear":8738},{"2019":336,"2020":8739,"2021":8740,"2022":8741,"2023":8742,"2024":8743},186,277,347,411,292,"2019-10-01",2019,[8747,8751,8753,8756,8760,8762,8766,8770,8774,8777,8781,8785,8789,8793,8797,8801,8805,8809,8813,8815,8819,8822,8826,8830,8833,8837,8841,8845,8849,8853,8856,8860,8864,8868,8871,8874,8878,8882,8885,8889,8892,8896,8900,8904,8907,8911,8914,8918,8921,8925,8929,8933,8937,8941,8945],{"id":26,"text":8748,"url":26,"identifiers":8749},"Younossi, 2016, Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, 64, 73, 10.1002\u002Fhep.28431",{"doi":8750},"10.1002\u002Fhep.28431",{"id":26,"text":6259,"url":26,"identifiers":8752},{"doi":6261},{"id":26,"text":8754,"url":26,"identifiers":8755},"Byrne, 2015, NAFLD: a multisystem disease, J Hepatol, 62, S47, 10.1016\u002Fj.jhep.2014.12.012",{"doi":6222},{"id":26,"text":8757,"url":26,"identifiers":8758},"Browning, 2004, Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity, Hepatology, 40, 1387, 10.1002\u002Fhep.20466",{"doi":8759},"10.1002\u002Fhep.20466",{"id":26,"text":6196,"url":26,"identifiers":8761},{"doi":6198},{"id":26,"text":8763,"url":26,"identifiers":8764},"Younossi, 2004, Nonalcoholic fatty liver disease in patients with type 2 diabetes, Clin Gastroenterol Hepatol, 2, 262, 10.1016\u002FS1542-3565(04)00014-X",{"doi":8765},"10.1016\u002FS1542-3565(04)00014-X",{"id":26,"text":8767,"url":26,"identifiers":8768},"Hossain, 2009, Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 7, 10.1016\u002Fj.cgh.2009.06.007",{"doi":8769},"10.1016\u002Fj.cgh.2009.06.007",{"id":26,"text":8771,"url":26,"identifiers":8772},"Stepanova, 2013, Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD), Dig Dis Sci, 58, 3017, 10.1007\u002Fs10620-013-2743-5",{"doi":8773},"10.1007\u002Fs10620-013-2743-5",{"id":26,"text":8775,"url":26,"identifiers":8776},"Fracanzani, 2008, Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes, Hepatology, 48, 792, 10.1002\u002Fhep.22429",{"doi":4803},{"id":26,"text":8778,"url":26,"identifiers":8779},"Mofrad, 2003, Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values, Hepatology, 37, 1286, 10.1053\u002Fjhep.2003.50229",{"doi":8780},"10.1053\u002Fjhep.2003.50229",{"id":26,"text":8782,"url":26,"identifiers":8783},"Portillo-Sanchez, 2015, High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels, J Clin Endocrinol Metab, 100, 2231, 10.1210\u002Fjc.2015-1966",{"doi":8784},"10.1210\u002Fjc.2015-1966",{"id":26,"text":8786,"url":26,"identifiers":8787},"Lonardo, 2016, Fatty liver is associated with an increased risk of diabetes and cardiovascular disease – evidence from three different disease models: NAFLD, HCV and HIV, World J Gastroenterol, 22, 9674, 10.3748\u002Fwjg.v22.i44.9674",{"doi":8788},"10.3748\u002Fwjg.v22.i44.9674",{"id":26,"text":8790,"url":26,"identifiers":8791},"Birkenfeld, 2014, Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes, Hepatology, 59, 713, 10.1002\u002Fhep.26672",{"doi":8792},"10.1002\u002Fhep.26672",{"id":26,"text":8794,"url":26,"identifiers":8795},"Baffy, 2012, Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace, J Hepatol, 56, 1384, 10.1016\u002Fj.jhep.2011.10.027",{"doi":8796},"10.1016\u002Fj.jhep.2011.10.027",{"id":26,"text":8798,"url":26,"identifiers":8799},"Rafiq, 2009, Long-term follow-up of patients with nonalcoholic fatty liver, Clin Gastroenterol Hepatol, 7, 234, 10.1016\u002Fj.cgh.2008.11.005",{"doi":8800},"10.1016\u002Fj.cgh.2008.11.005",{"id":26,"text":8802,"url":26,"identifiers":8803},"Stepanova, 2010, Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study, Gut, 59, 1410, 10.1136\u002Fgut.2010.213553",{"doi":8804},"10.1136\u002Fgut.2010.213553",{"id":26,"text":8806,"url":26,"identifiers":8807},"Estes, 2018, Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease, Hepatology, 67, 123, 10.1002\u002Fhep.29466",{"doi":8808},"10.1002\u002Fhep.29466",{"id":26,"text":8810,"url":26,"identifiers":8811},"Younossi, 2011, Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008, Clin Gastroenterol Hepatol, 9, 10.1016\u002Fj.cgh.2011.03.020",{"doi":8812},"10.1016\u002Fj.cgh.2011.03.020",{"id":26,"text":1123,"url":26,"identifiers":8814},{"doi":1125},{"id":26,"text":8816,"url":26,"identifiers":8817},"Cholankeril, 2017, Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes, Dig Dis Sci, 62, 2915, 10.1007\u002Fs10620-017-4684-x",{"doi":8818},"10.1007\u002Fs10620-017-4684-x",{"id":26,"text":8820,"url":26,"identifiers":8821},"Younossi, 2018, Non-alcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates, Clin Gastroenterol Hepatol",{},{"id":26,"text":8823,"url":26,"identifiers":8824},"Blais, 2015, Nonalcoholic fatty liver disease is underrecognized in the primary care setting, Am J Gastroenterol, 110, 10, 10.1038\u002Fajg.2014.134",{"doi":8825},"10.1038\u002Fajg.2014.134",{"id":26,"text":8827,"url":26,"identifiers":8828},"Sutton, 2000, Modelling publication bias in meta-analysis: a review, Stat Methods Med Res, 9, 421, 10.1177\u002F096228020000900503",{"doi":8829},"10.1177\u002F096228020000900503",{"id":26,"text":8831,"url":26,"identifiers":8832},"Lipsey, 2001, The way in which intervention studies have “personality” and why it is important to meta-analysis, Eval Health Prof, 24, 236",{},{"id":26,"text":8834,"url":26,"identifiers":8835},"Veroniki, 2016, Methods to estimate the between-study variance and its uncertainty in meta-analysis, Res Synth Methods, 7, 55, 10.1002\u002Fjrsm.1164",{"doi":8836},"10.1002\u002Fjrsm.1164",{"id":26,"text":8838,"url":26,"identifiers":8839},"Berkey, 1995, A random-effects regression model for meta-analysis, Stat Med, 14, 395, 10.1002\u002Fsim.4780140406",{"doi":8840},"10.1002\u002Fsim.4780140406",{"id":26,"text":8842,"url":26,"identifiers":8843},"Greenland, 2001, On the bias produced by quality scores in meta-analysis, and a hierarchical view of proposed solutions, Biostatistics, 2, 463, 10.1093\u002Fbiostatistics\u002F2.4.463",{"doi":8844},"10.1093\u002Fbiostatistics\u002F2.4.463",{"id":26,"text":8846,"url":26,"identifiers":8847},"Knapp, 2003, Improved tests for a random effects meta-regression with a single covariate, Stat Med, 22, 2693, 10.1002\u002Fsim.1482",{"doi":8848},"10.1002\u002Fsim.1482",{"id":26,"text":8850,"url":26,"identifiers":8851},"Hommel, 1988, A stagewise rejective multiple test procedure based on a modified Bonferroni test, Biometrika, 75, 383, 10.1093\u002Fbiomet\u002F75.2.383",{"doi":8852},"10.1093\u002Fbiomet\u002F75.2.383",{"id":26,"text":8854,"url":26,"identifiers":8855},"Country Comparison: Population. Central Intelligence Agency (CIA). Central Intelligence Agency (CIA) 2018. https:\u002F\u002Fwww.cia.gov\u002Flibrary\u002Fpublications\u002Fthe-world-factbook\u002Frankorder\u002F2119rank.html (accessed February 4, 2019).",{},{"id":26,"text":8857,"url":26,"identifiers":8858},"Buehler, 1957, Confidence intervals for the product of two binomial parameters, J Am Stat Assoc, 52, 482, 10.1080\u002F01621459.1957.10501404",{"doi":8859},"10.1080\u002F01621459.1957.10501404",{"id":26,"text":8861,"url":26,"identifiers":8862},"Begg, 1994, Operating characteristics of a rank correlation test for publication bias, Biometrics, 50, 1088, 10.2307\u002F2533446",{"doi":8863},"10.2307\u002F2533446",{"id":26,"text":8865,"url":26,"identifiers":8866},"Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136\u002Fbmj.315.7109.629",{"doi":8867},"10.1136\u002Fbmj.315.7109.629",{"id":26,"text":8869,"url":26,"identifiers":8870},"Viechtbauer, 2010, Conducting meta-analyses in R with the metafor package, J Statistical Software, Articles, 36, 1",{},{"id":26,"text":8872,"url":26,"identifiers":8873},"Health Organization W. Global report on diabetes 2016.",{},{"id":26,"text":8875,"url":26,"identifiers":8876},"Dai, 2017, Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis, Medicine, 96, 10.1097\u002FMD.0000000000008179",{"doi":8877},"10.1097\u002FMD.0000000000008179",{"id":26,"text":8879,"url":26,"identifiers":8880},"Mahady, 2018, Burden of non-alcoholic fatty liver disease in Australia, J Gastroenterol Hepatol, 33, 1, 10.1111\u002Fjgh.14270",{"doi":8881},"10.1111\u002Fjgh.14270",{"id":26,"text":8883,"url":26,"identifiers":8884},"Kalra, 2013, Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT), J Assoc Physicians India, 61, 448",{},{"id":26,"text":8886,"url":26,"identifiers":8887},"Targher, 2015, A perspective on metabolic syndrome and nonalcoholic fatty liver disease, Metab Syndr Relat Disord, 13, 235, 10.1089\u002Fmet.2015.1502",{"doi":8888},"10.1089\u002Fmet.2015.1502",{"id":26,"text":8890,"url":26,"identifiers":8891},"Firneisz, 2014, Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?, World J Gastroenterol, 20, 9072",{},{"id":26,"text":8893,"url":26,"identifiers":8894},"Leite, 2009, Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus, Liver Int, 29, 113, 10.1111\u002Fj.1478-3231.2008.01718.x",{"doi":8895},"10.1111\u002Fj.1478-3231.2008.01718.x",{"id":26,"text":8897,"url":26,"identifiers":8898},"Bril, 2017, Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action, Diabetes Care, 40, 419, 10.2337\u002Fdc16-1787",{"doi":8899},"10.2337\u002Fdc16-1787",{"id":26,"text":8901,"url":26,"identifiers":8902},"Hazlehurst, 2016, Non-alcoholic fatty liver disease and diabetes, Metabolism, 65, 1096, 10.1016\u002Fj.metabol.2016.01.001",{"doi":8903},"10.1016\u002Fj.metabol.2016.01.001",{"id":26,"text":8905,"url":26,"identifiers":8906},"CDC. Center for Disease Control and Prevention – Viral hepatitis – Surveillance for viral hepatitis 2014;2018.",{},{"id":26,"text":8908,"url":26,"identifiers":8909},"Burney, 2015, Global and regional trends in COPD mortality, 1990–2010, Eur Respir J, 45, 1239, 10.1183\u002F09031936.00142414",{"doi":8910},"10.1183\u002F09031936.00142414",{"id":26,"text":8912,"url":26,"identifiers":8913},"CDC - Data and Statistics - Chronic Obstructive Pulmonary Disease (COPD) 2018. https:\u002F\u002Fwww.cdc.gov\u002Fcopd\u002Fdata.html (accessed November 26, 2018).",{},{"id":26,"text":8915,"url":26,"identifiers":8916},"Cavaillès, 2013, Comorbidities of COPD, Eur Respir Rev, 22, 454, 10.1183\u002F09059180.00008612",{"doi":8917},"10.1183\u002F09059180.00008612",{"id":26,"text":8919,"url":26,"identifiers":8920},"CDC. Center for Disease Control and Prevention – Chronic obstructive pulmonary disease – Data and statistics 2014;2018.",{},{"id":26,"text":8922,"url":26,"identifiers":8923},"Dulai, 2017, Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis, Hepatology, 65, 1557, 10.1002\u002Fhep.29085",{"doi":8924},"10.1002\u002Fhep.29085",{"id":26,"text":8926,"url":26,"identifiers":8927},"Younossi, 2011, Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality, Hepatology, 53, 1874, 10.1002\u002Fhep.24268",{"doi":8928},"10.1002\u002Fhep.24268",{"id":26,"text":8930,"url":26,"identifiers":8931},"Stepanova, 2017, Patients with diabetes and chronic liver disease are at increased risk for overall mortality: a population study from the United States, Clin Diabetes, 35, 79, 10.2337\u002Fcd16-0018",{"doi":8932},"10.2337\u002Fcd16-0018",{"id":26,"text":8934,"url":26,"identifiers":8935},"Golabi, 2016, Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis, Expert Rev Gastroenterol Hepatol, 10, 63, 10.1586\u002F17474124.2016.1099433",{"doi":8936},"10.1586\u002F17474124.2016.1099433",{"id":26,"text":8938,"url":26,"identifiers":8939},"Anderson, 2015, The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis, PLoS ONE, 10, 10.1371\u002Fjournal.pone.0140908",{"doi":8940},"10.1371\u002Fjournal.pone.0140908",{"id":26,"text":8942,"url":26,"identifiers":8943},"Reade, 2008, Bench-to-bedside review: avoiding pitfalls in critical care meta-analysis–funnel plots, risk estimates, types of heterogeneity, baseline risk and the ecologic fallacy, Crit Care, 12, 220, 10.1186\u002Fcc6941",{"doi":8944},"10.1186\u002Fcc6941",{"id":26,"text":8946,"url":26,"identifiers":8947},"Schwartz, 1994, The fallacy of the ecological fallacy: the potential misuse of a concept and the consequences, Am J Public Health, 84, 819, 10.2105\u002FAJPH.84.5.819",{"doi":8948},"10.2105\u002FAJPH.84.5.819",{"id":8950,"createTime":8951,"updateTime":8951,"relativeEntities":8952,"slug":8953,"properties":8954,"entityType":749,"verifyStatus":25,"verifyTime":8951,"verifyNote":750,"syncStatus":28,"languages":8967,"translateLanguages":26,"viewCount":36,"primaryUrl":8968,"fullTextUrl":26,"authors":8969,"publicationType":895,"publisherRelationship":9144,"citationCount":9173,"citationInfo":9174,"publishDate":9182,"publishYear":9183,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":9184,"isForceReanalyzing":3453},"cb8860c3-6817-46b9-9d01-342c4347d29c","2024-10-06T15:57:03.907+00:00",[],"Guidelines-for-the-diagnosis-and-management-of-intrahepatic-cholangiocarcinoma",{"mag":8955,"keywords":8957,"openalex":8958,"abstract":8960,"title":8961,"pm":8963,"doi":8965},{"VOID":8956},"2011387799",{},{"VOID":8959},"W2011387799",{},{"EN":8962},"Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma",{"VOID":8964},"24681130",{"VOID":8966},"10.1016\u002Fj.jhep.2014.01.021",[102],"https:\u002F\u002Flinkinghub.elsevier.com\u002Fretrieve\u002Fpii\u002FS0168827814000671",[8970,8992,9013,9041,9060,9081,9102,9123],{"id":8971,"sortIndex":111,"researcher":26,"roles":8972,"affiliations":8973,"properties":8985},"b83a39fb-0fcf-435c-b61d-ef8066b5303f",[],[8974],{"id":8975,"sortIndex":36,"affiliation":8976,"properties":26},"e329bc6b-a351-4516-8628-b15e32028e3e",{"id":8977,"createTime":8978,"updateTime":8979,"relativeEntities":8980,"slug":8981,"properties":8982,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"a88a8e4f-8b41-4eef-8979-d22629c2d4be","2024-04-17T00:34:08.749+00:00","2024-10-06T15:57:04.025+00:00",[],"Center-for-Liver-Cancer-National-Cancer-Center-Goyang-Republic-of-Korea",{"title":8983},{"EN":8984},"Center for Liver Cancer, National Cancer Center, Goyang, Republic of Korea",{"openalex":8986,"orcid":8988,"title":8990},{"VOID":8987},"A5011174725",{"VOID":8989},"https:\u002F\u002Forcid.org\u002F0000-0001-9972-0494",{"EN":8991},"Joong‐Won Park",{"id":8993,"sortIndex":36,"researcher":26,"roles":8994,"affiliations":8995,"properties":9006},"6f42dc44-a4c3-449e-befc-78f540269170",[],[8996],{"id":8997,"sortIndex":36,"affiliation":8998,"properties":26},"c001efba-158c-41d3-9235-73337c9791fb",{"id":8999,"createTime":9000,"updateTime":9000,"relativeEntities":9001,"slug":9002,"properties":9003,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"3cf8f3b0-51d5-4847-9532-a18c3e71c494","2024-10-06T15:57:03.926+00:00",[],"University-College-London-Cancer-Institute-72-Huntley-St-London-WC1E-6AA-UK",{"title":9004},{"EN":9005},"University College, London Cancer Institute, 72 Huntley St., London WC1E 6AA, UK",{"openalex":9007,"orcid":9009,"title":9011},{"VOID":9008},"A5083898918",{"VOID":9010},"https:\u002F\u002Forcid.org\u002F0000-0001-9186-1604",{"EN":9012},"John Bridgewater",{"id":9014,"sortIndex":59,"researcher":26,"roles":9015,"affiliations":9016,"properties":9037},"1b225d20-b3aa-4fa6-b8f5-966d0531943a",[],[9017,9027],{"id":9018,"sortIndex":115,"affiliation":9019,"properties":26},"86fccf16-5d15-452e-b8fa-e939080667dd",{"id":9020,"createTime":9021,"updateTime":9021,"relativeEntities":9022,"slug":9023,"properties":9024,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"7cc75a29-46cc-4842-9529-29d57816a703","2024-10-06T15:57:04.007+00:00",[],"Mount-Sinai-Liver-Cancer-Program-Division-of-Liver-Diseases-Icahn-School-of-Medicine-at-Mount-Sinai-New-York-USA",{"title":9025},{"EN":9026},"Mount Sinai Liver Cancer Program, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, USA",{"id":9028,"sortIndex":36,"affiliation":9029,"properties":26},"ec87f74a-e6f1-42c3-9f49-35ab9536da62",{"id":9030,"createTime":9031,"updateTime":9031,"relativeEntities":9032,"slug":9033,"properties":9034,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"b576db30-ae23-4404-832c-909e8815b4bd","2024-10-06T15:57:04.002+00:00",[],"HCC-Translational-Research-Laboratory-Barcelona-Cl%C3%ADnic-Liver-Cancer-Group-Institut-d-Investigacions-Biom%C3%A8diques-August-Pi-i-Sunyer-Hospital-Clinic-Barcelona-Catalonia-Spain",{"title":9035},{"EN":9036},"HCC Translational Research Laboratory, Barcelona-Clínic Liver Cancer Group, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Hospital Clinic Barcelona, Catalonia, Spain",{"openalex":9038,"orcid":9039,"title":9040},{"VOID":839},{"VOID":841},{"EN":843},{"id":9042,"sortIndex":115,"researcher":26,"roles":9043,"affiliations":9044,"properties":9056},"e4bea613-a45f-421b-9f48-0adf6872e829",[],[9045],{"id":9046,"sortIndex":36,"affiliation":9047,"properties":26},"44ada666-9b95-4279-9a9f-ec15f0de95f9",{"id":9048,"createTime":9049,"updateTime":9050,"relativeEntities":9051,"slug":9052,"properties":9053,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"544c36ac-4b5a-4556-beb9-abf286dc5286","2024-01-13T15:23:58.701+00:00","2024-10-06T15:57:03.944+00:00",[],"Department-of-Internal-Medicine-I-University-Medical-Center-Johannes-Gutenberg-University-Mainz-Germany",{"title":9054},{"VI":9055},"Department of Internal Medicine I, University Medical Center, Johannes Gutenberg University Mainz, Germany",{"openalex":9057,"orcid":9058,"title":9059},{"VOID":890},{"VOID":892},{"EN":894},{"id":9061,"sortIndex":158,"researcher":26,"roles":9062,"affiliations":9063,"properties":9074},"07c13f01-2585-4096-8904-382396f92560",[],[9064],{"id":9065,"sortIndex":36,"affiliation":9066,"properties":26},"ace1dbe3-76a5-476d-ab12-84c556a1f2ce",{"id":9067,"createTime":9068,"updateTime":9068,"relativeEntities":9069,"slug":9070,"properties":9071,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"779c749d-8250-4ea1-af80-f38136e1297e","2024-10-06T15:57:04.076+00:00",[],"Division-of-Gastroenterology-and-Hepatology-Mayo-College-of-Medicine-Mayo-Clinic-Rochester-MN-USA",{"title":9072},{"EN":9073},"Division of Gastroenterology and Hepatology, Mayo College of Medicine, Mayo Clinic, Rochester, MN, USA",{"openalex":9075,"orcid":9077,"title":9079},{"VOID":9076},"A5004470985",{"VOID":9078},"https:\u002F\u002Forcid.org\u002F0000-0003-3151-009X",{"EN":9080},"Gregory J. Gores",{"id":9082,"sortIndex":162,"researcher":26,"roles":9083,"affiliations":9084,"properties":9095},"86160471-f7fc-464d-b85c-3a92c6bdf093",[],[9085],{"id":9086,"sortIndex":36,"affiliation":9087,"properties":26},"eb44b28c-b1c5-49ca-8d40-c6aeb8dd97f2",{"id":9088,"createTime":9089,"updateTime":9089,"relativeEntities":9090,"slug":9091,"properties":9092,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"9e215b04-22f2-4a33-b620-2c41788e885f","2024-10-06T15:57:04.040+00:00",[],"Department-of-Transplantation-Mayo-College-of-Medicine-Mayo-Clinic-4500-San-Pablo-Boulevard-Jacksonville-FL-32224-USA",{"title":9093},{"EN":9094},"Department of Transplantation, Mayo College of Medicine, Mayo Clinic, 4500 San Pablo Boulevard, Jacksonville, FL 32224, USA",{"openalex":9096,"orcid":9098,"title":9100},{"VOID":9097},"A5080886228",{"VOID":9099},"https:\u002F\u002Forcid.org\u002F0000-0001-7021-9532",{"EN":9101},"Tushar Patel",{"id":9103,"sortIndex":114,"researcher":26,"roles":9104,"affiliations":9105,"properties":9116},"d6035417-5d2f-4e16-9b38-11df9ad961ce",[],[9106],{"id":9107,"sortIndex":36,"affiliation":9108,"properties":26},"d5133d73-d761-48aa-89af-ec30b5ec25c2",{"id":9109,"createTime":9110,"updateTime":9110,"relativeEntities":9111,"slug":9112,"properties":9113,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"f99a7e8e-99f4-4db5-98f8-be5b45739186","2024-10-06T15:57:03.961+00:00",[],"Hepatology-and-Gastroenterology-Section-Department-of-Medicine-Imperial-College-London-UK",{"title":9114},{"EN":9115},"Hepatology and Gastroenterology Section, Department of Medicine, Imperial College London, UK",{"openalex":9117,"orcid":9119,"title":9121},{"VOID":9118},"A5005117084",{"VOID":9120},"https:\u002F\u002Forcid.org\u002F0000-0003-2538-0911",{"EN":9122},"Shahid A. Khan",{"id":9124,"sortIndex":135,"researcher":26,"roles":9125,"affiliations":9126,"properties":9137},"1cd6d54d-8ba6-4ba7-a8d7-829e19b18232",[],[9127],{"id":9128,"sortIndex":36,"affiliation":9129,"properties":26},"8b5ac80a-c499-4427-a1ab-be91d13e8477",{"id":9130,"createTime":9131,"updateTime":9131,"relativeEntities":9132,"slug":9133,"properties":9134,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"48cff27d-a15e-4494-a507-99b2fbe3e36e","2024-10-06T15:57:04.062+00:00",[],"Department-of-Surgery-Sidney-Kimmel-Cancer-Center-Johns-Hopkins-University-School-of-Medicine-Harvey-611-600-N-Wolfe-Street-Baltimore-MD-21287-USA",{"title":9135},{"EN":9136},"Department of Surgery, Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Harvey 611, 600 N Wolfe Street, Baltimore, MD 21287, USA",{"openalex":9138,"orcid":9140,"title":9142},{"VOID":9139},"A5058146274",{"VOID":9141},"https:\u002F\u002Forcid.org\u002F0000-0002-7994-9870",{"EN":9143},"Timothy M. Pawlik",{"url":26,"publisher":9145,"properties":9167},{"id":659,"createTime":660,"updateTime":661,"relativeEntities":9146,"slug":663,"properties":9147,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":9150,"manageAffiliations":9151,"indexDatabases":9152,"url":26,"thumbnailPath":26,"statistic":26,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"issn":9148,"title":9149},{"VOID":666},{"EN":668},[],[],[9153,9160],{"id":690,"indexDatabase":9154,"url":705,"indexYears":26,"academicFieldIds":9159,"indexDatabaseRanking":26},{"id":692,"createTime":693,"updateTime":694,"relativeEntities":9155,"label":9156,"description":9157,"key":701,"publicationTags":9158,"standard":26},[],{"EN":697,"VI":697},{"VI":699,"EN":700},[703,704],[707],{"id":709,"indexDatabase":9161,"url":722,"indexYears":723,"academicFieldIds":9166,"indexDatabaseRanking":726},{"id":711,"createTime":712,"updateTime":713,"relativeEntities":9162,"label":9163,"description":9164,"key":719,"publicationTags":9165,"standard":26},[],{"EN":716,"VI":716},{"EN":716,"VI":718},[721],[725],{"volume":9168,"pages":9170,"issue":9172},{"VOID":9169},"60",{"VOID":9171},"1268-1289",{"VOID":4768},1270,{"total":9173,"publishYear":26,"statisticByYear":9175},{"2014":116,"2015":569,"2016":9176,"2017":6635,"2018":9177,"2019":9178,"2020":9179,"2021":929,"2022":9180,"2023":629,"2024":9181},55,114,134,175,168,102,"2014-06-01",2014,[9185,9189,9193,9197,9201,9205,9209,9211,9214,9218,9222,9226,9230,9234,9238,9242,9246,9250,9254,9258,9262,9266,9270,9274,9278,9282,9285,9289,9293,9297,9300,9304,9308,9312,9316,9320,9324,9328,9331,9335,9339,9343,9347,9351,9355,9359,9363,9367,9371,9375,9379,9383,9387,9391,9395,9399,9403,9407,9411,9415,9419,9423,9427,9431,9433,9437,9441,9445,9449,9453,9457,9461,9465,9469,9473,9477,9481,9485,9489,9493,9496,9500,9504,9508,9512,9516,9520,9524,9528,9532,9536,9540,9544,9548,9552,9556,9558,9560,9564,9566,9570,9574,9577,9581,9585,9589,9593,9597,9599,9601,9605,9609,9613,9617,9621,9625,9629,9633,9637,9641,9645,9649,9653,9657,9659,9663,9667,9671,9675,9679,9683,9687,9691,9695,9699,9703,9706,9710,9714,9718,9722,9726,9730,9734,9738,9742,9744,9748,9752,9756,9760,9764,9768,9772,9776,9780,9784,9788,9792,9796,9800,9804,9808,9812,9816,9819,9823,9827,9831,9835,9839,9843,9847,9851,9855,9859,9863,9867,9871,9875,9878,9882,9885,9889,9893,9897,9901,9904,9908,9911,9915,9919,9923,9927,9931,9935,9939,9943,9946,9950,9954,9958,9962,9966,9970,9974,9978,9982,9986,9989,9993,9997,10001,10005,10009,10013,10017,10021,10025,10029,10033,10037,10041,10044,10048,10052,10056,10060,10064,10068,10072,10076,10080,10084],{"id":26,"text":9186,"url":26,"identifiers":9187},"Fan, 2012, Cholangiocarcinomas can originate from hepatocytes in mice, J Clin Invest, 122, 2911, 10.1172\u002FJCI63212",{"doi":9188},"10.1172\u002FJCI63212",{"id":26,"text":9190,"url":26,"identifiers":9191},"Sekiya, 2012, Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes, J Clin Invest, 122, 3914, 10.1172\u002FJCI63065",{"doi":9192},"10.1172\u002FJCI63065",{"id":26,"text":9194,"url":26,"identifiers":9195},"Wistuba, 2004, Gallbladder cancer: lessons from a rare tumour, Nat Rev Cancer, 4, 695, 10.1038\u002Fnrc1429",{"doi":9196},"10.1038\u002Fnrc1429",{"id":26,"text":9198,"url":26,"identifiers":9199},"Blechacz, 2011, Clinical diagnosis and staging of cholangiocarcinoma, Nat Rev Gastroenterol Hepatol, 8, 512, 10.1038\u002Fnrgastro.2011.131",{"doi":9200},"10.1038\u002Fnrgastro.2011.131",{"id":26,"text":9202,"url":26,"identifiers":9203},"Yang, 2012, Biliary tract cancers in Olmsted County, Minnesota, 1976–2008, Am J Gastroenterol, 107, 1256, 10.1038\u002Fajg.2012.173",{"doi":9204},"10.1038\u002Fajg.2012.173",{"id":26,"text":9206,"url":26,"identifiers":9207},"Razumilava, 2013, Classification, diagnosis, and management of cholangiocarcinoma, Clin Gastroenterol Hepatol, 11, 13, 10.1016\u002Fj.cgh.2012.09.009",{"doi":9208},"10.1016\u002Fj.cgh.2012.09.009",{"id":26,"text":6760,"url":26,"identifiers":9210},{"doi":6762},{"id":26,"text":9212,"url":26,"identifiers":9213},"Bragazzi, 2012, Cholangiocarcinoma: epidemiology and risk factors, Translational Gastrointestinal Cancer, 1, 21",{},{"id":26,"text":9215,"url":26,"identifiers":9216},"Khan, 2008, Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma, HPB (Oxford), 10, 77, 10.1080\u002F13651820801992641",{"doi":9217},"10.1080\u002F13651820801992641",{"id":26,"text":9219,"url":26,"identifiers":9220},"Shaib, 2004, The epidemiology of cholangiocarcinoma, Semin Liver Dis, 24, 115, 10.1055\u002Fs-2004-828889",{"doi":9221},"10.1055\u002Fs-2004-828889",{"id":26,"text":9223,"url":26,"identifiers":9224},"Shaib, 2004, Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?, J Hepatol, 40, 472, 10.1016\u002Fj.jhep.2003.11.030",{"doi":9225},"10.1016\u002Fj.jhep.2003.11.030",{"id":26,"text":9227,"url":26,"identifiers":9228},"Taylor-Robinson, 2001, Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998, Gut, 48, 816, 10.1136\u002Fgut.48.6.816",{"doi":9229},"10.1136\u002Fgut.48.6.816",{"id":26,"text":9231,"url":26,"identifiers":9232},"Patel, 2001, Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States, Hepatology, 33, 1353, 10.1053\u002Fjhep.2001.25087",{"doi":9233},"10.1053\u002Fjhep.2001.25087",{"id":26,"text":9235,"url":26,"identifiers":9236},"West, 2006, Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971–2001, Br J Cancer, 94, 1751, 10.1038\u002Fsj.bjc.6603127",{"doi":9237},"10.1038\u002Fsj.bjc.6603127",{"id":26,"text":9239,"url":26,"identifiers":9240},"Alvaro, 2010, Descriptive epidemiology of cholangiocarcinoma in Italy, Dig Liver Dis, 42, 490, 10.1016\u002Fj.dld.2009.10.009",{"doi":9241},"10.1016\u002Fj.dld.2009.10.009",{"id":26,"text":9243,"url":26,"identifiers":9244},"von Hahn, 2011, Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany, Scand J Gastroenterol, 46, 1092, 10.3109\u002F00365521.2011.589472",{"doi":9245},"10.3109\u002F00365521.2011.589472",{"id":26,"text":9247,"url":26,"identifiers":9248},"Shin, 2010, Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea, J Korean Med Sci, 25, 1011, 10.3346\u002Fjkms.2010.25.7.1011",{"doi":9249},"10.3346\u002Fjkms.2010.25.7.1011",{"id":26,"text":9251,"url":26,"identifiers":9252},"Khan, 2002, Changing international trends in mortality rates for liver, biliary and pancreatic tumours, J Hepatol, 37, 806, 10.1016\u002FS0168-8278(02)00297-0",{"doi":9253},"10.1016\u002FS0168-8278(02)00297-0",{"id":26,"text":9255,"url":26,"identifiers":9256},"Patel, 2002, Worldwide trends in mortality from biliary tract malignancies, BMC Cancer, 2, 10, 10.1186\u002F1471-2407-2-10",{"doi":9257},"10.1186\u002F1471-2407-2-10",{"id":26,"text":9259,"url":26,"identifiers":9260},"Jepsen, 2007, Incidence rates of intra- and extrahepatic cholangiocarcinomas in Denmark from 1978 through 2002, J Natl Cancer Inst, 99, 895, 10.1093\u002Fjnci\u002Fdjk201",{"doi":9261},"10.1093\u002Fjnci\u002Fdjk201",{"id":26,"text":9263,"url":26,"identifiers":9264},"Tyson, 2011, Risk factors for cholangiocarcinoma, Hepatology, 54, 173, 10.1002\u002Fhep.24351",{"doi":9265},"10.1002\u002Fhep.24351",{"id":26,"text":9267,"url":26,"identifiers":9268},"McLean, 2006, Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States, Liver Int, 26, 1047, 10.1111\u002Fj.1478-3231.2006.01350.x",{"doi":9269},"10.1111\u002Fj.1478-3231.2006.01350.x",{"id":26,"text":9271,"url":26,"identifiers":9272},"McGlynn, 2006, A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States, Cancer Epidemiol Biomarkers Prev, 15, 1198, 10.1158\u002F1055-9965.EPI-05-0811",{"doi":9273},"10.1158\u002F1055-9965.EPI-05-0811",{"id":26,"text":9275,"url":26,"identifiers":9276},"Khan, 2012, Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?, J Hepatol, 56, 848, 10.1016\u002Fj.jhep.2011.11.015",{"doi":9277},"10.1016\u002Fj.jhep.2011.11.015",{"id":26,"text":9279,"url":26,"identifiers":9280},"de Martel, 2010, Cholangiocarcinoma: descriptive epidemiology and risk factors, Gastroenterol Clin Biol, 34, 173, 10.1016\u002Fj.gcb.2010.01.008",{"doi":9281},"10.1016\u002Fj.gcb.2010.01.008",{"id":26,"text":9283,"url":26,"identifiers":9284},"International classification of diseases for oncology (ICD-O). In: Organisation GSWH; 2000.",{},{"id":26,"text":9286,"url":26,"identifiers":9287},"Malhi, 2006, Cholangiocarcinoma: modern advances in understanding a deadly old disease, J Hepatol, 45, 856, 10.1016\u002Fj.jhep.2006.09.001",{"doi":9288},"10.1016\u002Fj.jhep.2006.09.001",{"id":26,"text":9290,"url":26,"identifiers":9291},"Deoliveira, 2011, New staging system and a registry for perihilar cholangiocarcinoma, Hepatology, 53, 1363, 10.1002\u002Fhep.24227",{"doi":9292},"10.1002\u002Fhep.24227",{"id":26,"text":9294,"url":26,"identifiers":9295},"Welzel, 2006, Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States, J Natl Cancer Inst, 98, 873, 10.1093\u002Fjnci\u002Fdjj234",{"doi":9296},"10.1093\u002Fjnci\u002Fdjj234",{"id":26,"text":9298,"url":26,"identifiers":9299},"Shin, 2010, Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma–focus on East and South-Eastern Asia, Asian Pac J Cancer Prev, 11, 1159",{},{"id":26,"text":9301,"url":26,"identifiers":9302},"Nakeeb, 1996, Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors, Ann Surg, 224, 463, 10.1097\u002F00000658-199610000-00005",{"doi":9303},"10.1097\u002F00000658-199610000-00005",{"id":26,"text":9305,"url":26,"identifiers":9306},"DeOliveira, 2007, Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution, Ann Surg, 245, 755, 10.1097\u002F01.sla.0000251366.62632.d3",{"doi":9307},"10.1097\u002F01.sla.0000251366.62632.d3",{"id":26,"text":9309,"url":26,"identifiers":9310},"Khan, 2005, Cholangiocarcinoma, Lancet, 366, 1303, 10.1016\u002FS0140-6736(05)67530-7",{"doi":9311},"10.1016\u002FS0140-6736(05)67530-7",{"id":26,"text":9313,"url":26,"identifiers":9314},"Palmer, 2012, Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma, J Hepatol, 57, 69, 10.1016\u002Fj.jhep.2012.02.022",{"doi":9315},"10.1016\u002Fj.jhep.2012.02.022",{"id":26,"text":9317,"url":26,"identifiers":9318},"Kaewpitoon, 2008, Opisthorchis viverrini: the carcinogenic human liver fluke, World J Gastroenterol, 14, 666, 10.3748\u002Fwjg.14.666",{"doi":9319},"10.3748\u002Fwjg.14.666",{"id":26,"text":9321,"url":26,"identifiers":9322},"Shin, 1996, Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea, Int J Epidemiol, 25, 933, 10.1093\u002Fije\u002F25.5.933",{"doi":9323},"10.1093\u002Fije\u002F25.5.933",{"id":26,"text":9325,"url":26,"identifiers":9326},"Honjo, 2005, Genetic and environmental determinants of risk for cholangiocarcinoma via Opisthorchis viverrini in a densely infested area in Nakhon Phanom, northeast Thailand, Int J Cancer, 117, 854, 10.1002\u002Fijc.21146",{"doi":9327},"10.1002\u002Fijc.21146",{"id":26,"text":9329,"url":26,"identifiers":9330},"Sawanyawisuth, 2009, Genes and cholangiocarcinoma, Southeast Asian J Trop Med Public Health, 40, 701",{},{"id":26,"text":9332,"url":26,"identifiers":9333},"Soreide, 2004, Bile duct cysts in adults, Br J Surg, 91, 1538, 10.1002\u002Fbjs.4815",{"doi":9334},"10.1002\u002Fbjs.4815",{"id":26,"text":9336,"url":26,"identifiers":9337},"Blechacz, 2008, Cholangiocarcinoma, Clin Liver Dis, 12, 131, 10.1016\u002Fj.cld.2007.11.003",{"doi":9338},"10.1016\u002Fj.cld.2007.11.003",{"id":26,"text":9340,"url":26,"identifiers":9341},"Mabrut, 2010, Management of congenital bile duct cysts, Dig Surg, 27, 12, 10.1159\u002F000268109",{"doi":9342},"10.1159\u002F000268109",{"id":26,"text":9344,"url":26,"identifiers":9345},"Edil, 2008, Choledochal cyst disease in children and adults: a 30-year single-institution experience, J Am Coll Surg, 206, 1000, 10.1016\u002Fj.jamcollsurg.2007.12.045",{"doi":9346},"10.1016\u002Fj.jamcollsurg.2007.12.045",{"id":26,"text":9348,"url":26,"identifiers":9349},"Lee, 2008, Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study, Am J Gastroenterol, 103, 1716, 10.1111\u002Fj.1572-0241.2008.01796.x",{"doi":9350},"10.1111\u002Fj.1572-0241.2008.01796.x",{"id":26,"text":9352,"url":26,"identifiers":9353},"Welzel, 2007, Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study, Int J Cancer, 120, 638, 10.1002\u002Fijc.22283",{"doi":9354},"10.1002\u002Fijc.22283",{"id":26,"text":9356,"url":26,"identifiers":9357},"Zhou, 2008, Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China, World J Gastroenterol, 14, 632, 10.3748\u002Fwjg.14.632",{"doi":9358},"10.3748\u002Fwjg.14.632",{"id":26,"text":9360,"url":26,"identifiers":9361},"Donato, 2001, Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy, Cancer Causes Control, 12, 959, 10.1023\u002FA:1013747228572",{"doi":9362},"10.1023\u002FA:1013747228572",{"id":26,"text":9364,"url":26,"identifiers":9365},"Liu, 2011, Risk factors of intrahepatic cholangiocarcinoma in patients with hepatolithiasis: a case-control study, Hepatobiliary Pancreat Dis Int, 10, 626, 10.1016\u002FS1499-3872(11)60106-9",{"doi":9366},"10.1016\u002FS1499-3872(11)60106-9",{"id":26,"text":9368,"url":26,"identifiers":9369},"Shaib, 2005, Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study, Gastroenterology, 128, 620, 10.1053\u002Fj.gastro.2004.12.048",{"doi":9370},"10.1053\u002Fj.gastro.2004.12.048",{"id":26,"text":9372,"url":26,"identifiers":9373},"Sorensen, 1998, Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark, Hepatology, 28, 921, 10.1002\u002Fhep.510280404",{"doi":9374},"10.1002\u002Fhep.510280404",{"id":26,"text":9376,"url":26,"identifiers":9377},"Yamamoto, 2004, Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma, Cancer Sci, 95, 592, 10.1111\u002Fj.1349-7006.2004.tb02492.x",{"doi":9378},"10.1111\u002Fj.1349-7006.2004.tb02492.x",{"id":26,"text":9380,"url":26,"identifiers":9381},"El-Serag, 2009, Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans, Hepatology, 49, 116, 10.1002\u002Fhep.22606",{"doi":9382},"10.1002\u002Fhep.22606",{"id":26,"text":9384,"url":26,"identifiers":9385},"Lee, 2009, Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer, Am J Clin Oncol, 32, 348, 10.1097\u002FCOC.0b013e31818c08ff",{"doi":9386},"10.1097\u002FCOC.0b013e31818c08ff",{"id":26,"text":9388,"url":26,"identifiers":9389},"Shaib, 2007, Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study, Am J Gastroenterol, 102, 1016, 10.1111\u002Fj.1572-0241.2007.01104.x",{"doi":9390},"10.1111\u002Fj.1572-0241.2007.01104.x",{"id":26,"text":9392,"url":26,"identifiers":9393},"Lee, 2009, Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma, Br J Cancer, 100, 1765, 10.1038\u002Fsj.bjc.6605063",{"doi":9394},"10.1038\u002Fsj.bjc.6605063",{"id":26,"text":9396,"url":26,"identifiers":9397},"Peng, 2011, Evaluation of risk factors and clinicopathologic features for intrahepatic cholangiocarcinoma in Southern China: a possible role of hepatitis B virus, Ann Surg Oncol, 18, 1258, 10.1245\u002Fs10434-010-1458-5",{"doi":9398},"10.1245\u002Fs10434-010-1458-5",{"id":26,"text":9400,"url":26,"identifiers":9401},"Grainge, 2009, The antecedents of biliary cancer: a primary care case-control study in the United Kingdom, Br J Cancer, 100, 178, 10.1038\u002Fsj.bjc.6604765",{"doi":9402},"10.1038\u002Fsj.bjc.6604765",{"id":26,"text":9404,"url":26,"identifiers":9405},"Welzel, 2011, Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database, Hepatology, 54, 463, 10.1002\u002Fhep.24397",{"doi":9406},"10.1002\u002Fhep.24397",{"id":26,"text":9408,"url":26,"identifiers":9409},"Sia, 2013, Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes, Gastroenterology, 144, 829, 10.1053\u002Fj.gastro.2013.01.001",{"doi":9410},"10.1053\u002Fj.gastro.2013.01.001",{"id":26,"text":9412,"url":26,"identifiers":9413},"Sia, 2013, Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies, Oncogene, 32, 4861, 10.1038\u002Fonc.2012.617",{"doi":9414},"10.1038\u002Fonc.2012.617",{"id":26,"text":9416,"url":26,"identifiers":9417},"Andersen, 2012, Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors, Gastroenterology, 142, e1015, 10.1053\u002Fj.gastro.2011.12.005",{"doi":9418},"10.1053\u002Fj.gastro.2011.12.005",{"id":26,"text":9420,"url":26,"identifiers":9421},"Andersen, 2012, Genetic profiling of intrahepatic cholangiocarcinoma, Curr Opin Gastroenterol, 28, 266, 10.1097\u002FMOG.0b013e3283523c7e",{"doi":9422},"10.1097\u002FMOG.0b013e3283523c7e",{"id":26,"text":9424,"url":26,"identifiers":9425},"Woo, 2010, Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma, Cancer Res, 70, 3034, 10.1158\u002F0008-5472.CAN-09-2823",{"doi":9426},"10.1158\u002F0008-5472.CAN-09-2823",{"id":26,"text":9428,"url":26,"identifiers":9429},"Oishi, 2012, Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma, Hepatology, 56, 1792, 10.1002\u002Fhep.25890",{"doi":9430},"10.1002\u002Fhep.25890",{"id":26,"text":4068,"url":26,"identifiers":9432},{"doi":4070},{"id":26,"text":9434,"url":26,"identifiers":9435},"Tannapfel, 2000, Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver, Gut, 47, 721, 10.1136\u002Fgut.47.5.721",{"doi":9436},"10.1136\u002Fgut.47.5.721",{"id":26,"text":9438,"url":26,"identifiers":9439},"Voss, 2013, Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions, Hum Pathol, 44, 1216, 10.1016\u002Fj.humpath.2012.11.006",{"doi":9440},"10.1016\u002Fj.humpath.2012.11.006",{"id":26,"text":9442,"url":26,"identifiers":9443},"O’Dell, 2012, Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma, Cancer Res, 72, 1557, 10.1158\u002F0008-5472.CAN-11-3596",{"doi":9444},"10.1158\u002F0008-5472.CAN-11-3596",{"id":26,"text":9446,"url":26,"identifiers":9447},"Hezel, 2010, Genetics of biliary tract cancers and emerging targeted therapies, J Clin Oncol, 28, 3531, 10.1200\u002FJCO.2009.27.4787",{"doi":9448},"10.1200\u002FJCO.2009.27.4787",{"id":26,"text":9450,"url":26,"identifiers":9451},"Farazi, 2006, Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice, Cancer Res, 66, 6622, 10.1158\u002F0008-5472.CAN-05-4609",{"doi":9452},"10.1158\u002F0008-5472.CAN-05-4609",{"id":26,"text":9454,"url":26,"identifiers":9455},"Tannapfel, 2003, Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma, Gut, 52, 706, 10.1136\u002Fgut.52.5.706",{"doi":9456},"10.1136\u002Fgut.52.5.706",{"id":26,"text":9458,"url":26,"identifiers":9459},"Borger, 2012, Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping, Oncologist, 17, 72, 10.1634\u002Ftheoncologist.2011-0386",{"doi":9460},"10.1634\u002Ftheoncologist.2011-0386",{"id":26,"text":9462,"url":26,"identifiers":9463},"Wang, 2013, Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas, Oncogene, 32, 3091, 10.1038\u002Fonc.2012.315",{"doi":9464},"10.1038\u002Fonc.2012.315",{"id":26,"text":9466,"url":26,"identifiers":9467},"Ong, 2012, Exome sequencing of liver fluke-associated cholangiocarcinoma, Nat Genet, 44, 690, 10.1038\u002Fng.2273",{"doi":9468},"10.1038\u002Fng.2273",{"id":26,"text":9470,"url":26,"identifiers":9471},"Koo, 2001, Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma, Cancer Genet Cytogenet, 130, 22, 10.1016\u002FS0165-4608(01)00460-5",{"doi":9472},"10.1016\u002FS0165-4608(01)00460-5",{"id":26,"text":9474,"url":26,"identifiers":9475},"Wong, 2002, Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma, J Hepatol, 37, 633, 10.1016\u002FS0168-8278(02)00269-6",{"doi":9476},"10.1016\u002FS0168-8278(02)00269-6",{"id":26,"text":9478,"url":26,"identifiers":9479},"Uhm, 2005, Chromosomal imbalances in Korean intrahepatic cholangiocarcinoma by comparative genomic hybridization, Cancer Genet Cytogenet, 157, 37, 10.1016\u002Fj.cancergencyto.2004.05.007",{"doi":9480},"10.1016\u002Fj.cancergencyto.2004.05.007",{"id":26,"text":9482,"url":26,"identifiers":9483},"Homayounfar, 2009, Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization, Hum Pathol, 40, 834, 10.1016\u002Fj.humpath.2008.11.005",{"doi":9484},"10.1016\u002Fj.humpath.2008.11.005",{"id":26,"text":9486,"url":26,"identifiers":9487},"Lee, 2004, Genetic alterations in intrahepatic cholangiocarcinoma as revealed by degenerate oligonucleotide primed PCR-comparative genomic hybridization, J Korean Med Sci, 19, 682, 10.3346\u002Fjkms.2004.19.5.682",{"doi":9488},"10.3346\u002Fjkms.2004.19.5.682",{"id":26,"text":9490,"url":26,"identifiers":9491},"Wu, 2013, Identification of targetable FGFR gene fusions in diverse cancers, Cancer Discov, 3, 636, 10.1158\u002F2159-8290.CD-13-0050",{"doi":9492},"10.1158\u002F2159-8290.CD-13-0050",{"id":26,"text":9494,"url":26,"identifiers":9495},"Arai, 2013, FGFR2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma, Hepatology",{},{"id":26,"text":9497,"url":26,"identifiers":9498},"Chen, 2009, The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma, J Hepatol, 50, 358, 10.1016\u002Fj.jhep.2008.09.015",{"doi":9499},"10.1016\u002Fj.jhep.2008.09.015",{"id":26,"text":9501,"url":26,"identifiers":9502},"Tannapfel, 2002, Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma, J Pathol, 197, 624, 10.1002\u002Fpath.1139",{"doi":9503},"10.1002\u002Fpath.1139",{"id":26,"text":9505,"url":26,"identifiers":9506},"Isomoto, 2007, Sustained IL-6\u002FSTAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing, Gastroenterology, 132, 384, 10.1053\u002Fj.gastro.2006.10.037",{"doi":9507},"10.1053\u002Fj.gastro.2006.10.037",{"id":26,"text":9509,"url":26,"identifiers":9510},"Tischoff, 2005, Allele loss and epigenetic inactivation of 3p21.3 in malignant liver tumors, Int J Cancer, 115, 684, 10.1002\u002Fijc.20944",{"doi":9511},"10.1002\u002Fijc.20944",{"id":26,"text":9513,"url":26,"identifiers":9514},"Chan-On, 2013, Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers, Nat Genet, 45, 1474, 10.1038\u002Fng.2806",{"doi":9515},"10.1038\u002Fng.2806",{"id":26,"text":9517,"url":26,"identifiers":9518},"Jiao, 2013, Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas, Nat Genet, 45, 1470, 10.1038\u002Fng.2813",{"doi":9519},"10.1038\u002Fng.2813",{"id":26,"text":9521,"url":26,"identifiers":9522},"Park, 1999, Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line, Hepatology, 30, 1128, 10.1002\u002Fhep.510300522",{"doi":9523},"10.1002\u002Fhep.510300522",{"id":26,"text":9525,"url":26,"identifiers":9526},"Isomoto, 2005, Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells, Hepatology, 42, 1329, 10.1002\u002Fhep.20966",{"doi":9527},"10.1002\u002Fhep.20966",{"id":26,"text":9529,"url":26,"identifiers":9530},"Kobayashi, 2005, Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells, Gastroenterology, 128, 2054, 10.1053\u002Fj.gastro.2005.03.010",{"doi":9531},"10.1053\u002Fj.gastro.2005.03.010",{"id":26,"text":9533,"url":26,"identifiers":9534},"Yoshikawa, 2008, Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma, Br J Cancer, 98, 418, 10.1038\u002Fsj.bjc.6604129",{"doi":9535},"10.1038\u002Fsj.bjc.6604129",{"id":26,"text":9537,"url":26,"identifiers":9538},"Endo, 2002, ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions, Hepatology, 36, 439, 10.1053\u002Fjhep.2002.34435",{"doi":9539},"10.1053\u002Fjhep.2002.34435",{"id":26,"text":9541,"url":26,"identifiers":9542},"Nakazawa, 2005, Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers, J Pathol, 206, 356, 10.1002\u002Fpath.1779",{"doi":9543},"10.1002\u002Fpath.1779",{"id":26,"text":9545,"url":26,"identifiers":9546},"Terada, 1998, Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis, Hum Pathol, 29, 175, 10.1016\u002FS0046-8177(98)90229-5",{"doi":9547},"10.1016\u002FS0046-8177(98)90229-5",{"id":26,"text":9549,"url":26,"identifiers":9550},"Miyamoto, 2011, Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma, Br J Cancer, 105, 131, 10.1038\u002Fbjc.2011.199",{"doi":9551},"10.1038\u002Fbjc.2011.199",{"id":26,"text":9553,"url":26,"identifiers":9554},"Radaeva, 1999, Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: a link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma, Hepatology, 29, 1453, 10.1002\u002Fhep.510290524",{"doi":9555},"10.1002\u002Fhep.510290524",{"id":26,"text":4052,"url":26,"identifiers":9557},{"doi":4054},{"id":26,"text":4056,"url":26,"identifiers":9559},{"doi":4058},{"id":26,"text":9561,"url":26,"identifiers":9562},"Kwak, 2010, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, N Engl J Med, 363, 1693, 10.1056\u002FNEJMoa1006448",{"doi":9563},"10.1056\u002FNEJMoa1006448",{"id":26,"text":4060,"url":26,"identifiers":9565},{"doi":4062},{"id":26,"text":9567,"url":26,"identifiers":9568},"Obama, 2005, Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma, Hepatology, 41, 1339, 10.1002\u002Fhep.20718",{"doi":9569},"10.1002\u002Fhep.20718",{"id":26,"text":9571,"url":26,"identifiers":9572},"Jinawath, 2006, Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma, Hepatology, 44, 1025, 10.1002\u002Fhep.21330",{"doi":9573},"10.1002\u002Fhep.21330",{"id":26,"text":9575,"url":26,"identifiers":9576},"Hamilton, 2000",{},{"id":26,"text":9578,"url":26,"identifiers":9579},"Nakanuma, 2010, Pathological classification of intrahepatic cholangiocarcinoma based on a new concept, World J Hepatol, 2, 419, 10.4254\u002Fwjh.v2.i12.419",{"doi":9580},"10.4254\u002Fwjh.v2.i12.419",{"id":26,"text":9582,"url":26,"identifiers":9583},"Nakajima, 1988, A histopathologic study of 102 cases of intrahepatic cholangiocarcinoma: histologic classification and modes of spreading, Hum Pathol, 19, 1228, 10.1016\u002FS0046-8177(88)80156-4",{"doi":9584},"10.1016\u002FS0046-8177(88)80156-4",{"id":26,"text":9586,"url":26,"identifiers":9587},"Nakanuma, 2003, Anatomic and molecular pathology of intrahepatic cholangiocarcinoma, J Hepatobiliary Pancreat Surg, 10, 265, 10.1007\u002Fs00534-002-0729-3",{"doi":9588},"10.1007\u002Fs00534-002-0729-3",{"id":26,"text":9590,"url":26,"identifiers":9591},"Nakanuma, 2008, Pathology of peripheral intrahepatic cholangiocarcinoma with reference to tumorigenesis, Hepatol Res, 38, 325, 10.1111\u002Fj.1872-034X.2007.00312.x",{"doi":9592},"10.1111\u002Fj.1872-034X.2007.00312.x",{"id":26,"text":9594,"url":26,"identifiers":9595},"Nakanuma, 2011, Pathological spectrum of intrahepatic cholangiocarcinoma arising in non-biliary chronic advanced liver diseases, Pathol Int, 61, 298, 10.1111\u002Fj.1440-1827.2011.02665.x",{"doi":9596},"10.1111\u002Fj.1440-1827.2011.02665.x",{"id":26,"text":1588,"url":26,"identifiers":9598},{"doi":1590},{"id":26,"text":3876,"url":26,"identifiers":9600},{"doi":3878},{"id":26,"text":9602,"url":26,"identifiers":9603},"Goodman, 2007, Neoplasms of the liver, Mod Pathol, 20, S49, 10.1038\u002Fmodpathol.3800682",{"doi":9604},"10.1038\u002Fmodpathol.3800682",{"id":26,"text":9606,"url":26,"identifiers":9607},"Cabibi, 2003, Expression of cytokeratin 7 and 20 in pathological conditions of the bile tract, Pathol Res Pract, 199, 65, 10.1078\u002F0344-0338-00356",{"doi":9608},"10.1078\u002F0344-0338-00356",{"id":26,"text":9610,"url":26,"identifiers":9611},"Rullier, 2000, Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis, Am J Surg Pathol, 24, 870, 10.1097\u002F00000478-200006000-00014",{"doi":9612},"10.1097\u002F00000478-200006000-00014",{"id":26,"text":9614,"url":26,"identifiers":9615},"Valls, 2000, Intrahepatic peripheral cholangiocarcinoma: CT evaluation, Abdom Imaging, 25, 490, 10.1007\u002Fs002610000079",{"doi":9616},"10.1007\u002Fs002610000079",{"id":26,"text":9618,"url":26,"identifiers":9619},"Kim, 2011, Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma, AJR Am J Roentgenol, 196, W205, 10.2214\u002FAJR.10.4937",{"doi":9620},"10.2214\u002FAJR.10.4937",{"id":26,"text":9622,"url":26,"identifiers":9623},"Kim, 2011, Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection, Eur J Radiol, 80, e221, 10.1016\u002Fj.ejrad.2010.09.019",{"doi":9624},"10.1016\u002Fj.ejrad.2010.09.019",{"id":26,"text":9626,"url":26,"identifiers":9627},"Hamrick-Turner, 1992, Intrahepatic cholangiocarcinoma: MR appearance, AJR Am J Roentgenol, 158, 77, 10.2214\u002Fajr.158.1.1309221",{"doi":9628},"10.2214\u002Fajr.158.1.1309221",{"id":26,"text":9630,"url":26,"identifiers":9631},"Fan, 1993, Intrahepatic cholangiocarcinoma: spin-echo and contrast-enhanced dynamic MR imaging, AJR Am J Roentgenol, 161, 313, 10.2214\u002Fajr.161.2.8392787",{"doi":9632},"10.2214\u002Fajr.161.2.8392787",{"id":26,"text":9634,"url":26,"identifiers":9635},"Murakami, 1995, Contrast-enhanced MR imaging of intrahepatic cholangiocarcinoma: pathologic correlation study, J Magn Reson Imaging, 5, 165, 10.1002\u002Fjmri.1880050210",{"doi":9636},"10.1002\u002Fjmri.1880050210",{"id":26,"text":9638,"url":26,"identifiers":9639},"Anderson, 2004, Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma, J Gastrointest Surg, 8, 90, 10.1016\u002Fj.gassur.2003.10.003",{"doi":9640},"10.1016\u002Fj.gassur.2003.10.003",{"id":26,"text":9642,"url":26,"identifiers":9643},"Delbeke, 1998, Evaluation of benign vs. malignant hepatic lesions with positron emission tomography, Arch Surg, 133, 510, 10.1001\u002Farchsurg.133.5.510",{"doi":9644},"10.1001\u002Farchsurg.133.5.510",{"id":26,"text":9646,"url":26,"identifiers":9647},"Kim, 2003, Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma, Eur J Nucl Med Mol Imaging, 30, 1467, 10.1007\u002Fs00259-003-1297-8",{"doi":9648},"10.1007\u002Fs00259-003-1297-8",{"id":26,"text":9650,"url":26,"identifiers":9651},"Lan, 2012, Positron emission tomography in hepatobiliary and pancreatic malignancies: a review, Am J Surg, 204, 232, 10.1016\u002Fj.amjsurg.2011.07.025",{"doi":9652},"10.1016\u002Fj.amjsurg.2011.07.025",{"id":26,"text":9654,"url":26,"identifiers":9655},"Xu, 2012, Contrast-enhanced ultrasound of intrahepatic cholangiocarcinoma: correlation with pathological examination, Br J Radiol, 85, 1029, 10.1259\u002Fbjr\u002F21653786",{"doi":9656},"10.1259\u002Fbjr\u002F21653786",{"id":26,"text":1728,"url":26,"identifiers":9658},{"doi":1730},{"id":26,"text":9660,"url":26,"identifiers":9661},"Chong, 2012, Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI, Clin Radiol, 67, 766, 10.1016\u002Fj.crad.2012.01.004",{"doi":9662},"10.1016\u002Fj.crad.2012.01.004",{"id":26,"text":9664,"url":26,"identifiers":9665},"Patel, 2000, The utility of CA 19–9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis, Am J Gastroenterol, 95, 204, 10.1111\u002Fj.1572-0241.2000.01685.x",{"doi":9666},"10.1111\u002Fj.1572-0241.2000.01685.x",{"id":26,"text":9668,"url":26,"identifiers":9669},"Tamandl, 2008, Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma, Ann Surg Oncol, 15, 2787, 10.1245\u002Fs10434-008-0081-1",{"doi":9670},"10.1245\u002Fs10434-008-0081-1",{"id":26,"text":9672,"url":26,"identifiers":9673},"Uenishi, 2008, Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma, Ann Surg Oncol, 15, 583, 10.1245\u002Fs10434-007-9650-y",{"doi":9674},"10.1245\u002Fs10434-007-9650-y",{"id":26,"text":9676,"url":26,"identifiers":9677},"Karakatsanis, 2013, Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance, Mol Carcinog, 52, 297, 10.1002\u002Fmc.21864",{"doi":9678},"10.1002\u002Fmc.21864",{"id":26,"text":9680,"url":26,"identifiers":9681},"Nishino, 2008, Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma, J Hepatol, 49, 207, 10.1016\u002Fj.jhep.2008.03.025",{"doi":9682},"10.1016\u002Fj.jhep.2008.03.025",{"id":26,"text":9684,"url":26,"identifiers":9685},"Schmitz, 2007, GNAS1 T393C polymorphism is associated with clinical course in patients with intrahepatic cholangiocarcinoma, Neoplasia, 9, 159, 10.1593\u002Fneo.06796",{"doi":9686},"10.1593\u002Fneo.06796",{"id":26,"text":9688,"url":26,"identifiers":9689},"Hann, 1998, Tumor involvement in hepatic veins: comparison of MR imaging and US for preoperative assessment, Radiology, 206, 651, 10.1148\u002Fradiology.206.3.9494482",{"doi":9690},"10.1148\u002Fradiology.206.3.9494482",{"id":26,"text":9692,"url":26,"identifiers":9693},"Bach, 1996, Portal vein evaluation with US: comparison to angiography combined with CT arterial portography, Radiology, 201, 149, 10.1148\u002Fradiology.201.1.8816536",{"doi":9694},"10.1148\u002Fradiology.201.1.8816536",{"id":26,"text":9696,"url":26,"identifiers":9697},"Corvera, 2008, 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer, J Am Coll Surg, 206, 57, 10.1016\u002Fj.jamcollsurg.2007.07.002",{"doi":9698},"10.1016\u002Fj.jamcollsurg.2007.07.002",{"id":26,"text":9700,"url":26,"identifiers":9701},"Kim, 2008, Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging, Am J Gastroenterol, 103, 1145, 10.1111\u002Fj.1572-0241.2007.01710.x",{"doi":9702},"10.1111\u002Fj.1572-0241.2007.01710.x",{"id":26,"text":9704,"url":26,"identifiers":9705},"Greene, 2002, The American Joint Committee on Cancer: updating the strategies in cancer staging, Bull Am Coll Surg, 87, 13",{},{"id":26,"text":9707,"url":26,"identifiers":9708},"Edge, 2010, The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM, Ann Surg Oncol, 17, 1471, 10.1245\u002Fs10434-010-0985-4",{"doi":9709},"10.1245\u002Fs10434-010-0985-4",{"id":26,"text":9711,"url":26,"identifiers":9712},"Tsai, 2010, Primary liver cancer: intrahepatic cholangiocarcinoma emerges from the shadows, Updates Surg, 62, 5, 10.1007\u002Fs13304-010-0011-1",{"doi":9713},"10.1007\u002Fs13304-010-0011-1",{"id":26,"text":9715,"url":26,"identifiers":9716},"Nathan, 2010, Staging of intrahepatic cholangiocarcinoma, Curr Opin Gastroenterol, 26, 269, 10.1097\u002FMOG.0b013e328337c899",{"doi":9717},"10.1097\u002FMOG.0b013e328337c899",{"id":26,"text":9719,"url":26,"identifiers":9720},"Yamasaki, 2003, Intrahepatic cholangiocarcinoma: macroscopic type and stage classification, J Hepatobiliary Pancreat Surg, 10, 288, 10.1007\u002Fs00534-002-0732-8",{"doi":9721},"10.1007\u002Fs00534-002-0732-8",{"id":26,"text":9723,"url":26,"identifiers":9724},"Okabayashi, 2001, A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables, Cancer, 92, 2374, 10.1002\u002F1097-0142(20011101)92:9\u003C2374::AID-CNCR1585>3.0.CO;2-L",{"doi":9725},"10.1002\u002F1097-0142(20011101)92:9\u003C2374::AID-CNCR1585>3.0.CO;2-L",{"id":26,"text":9727,"url":26,"identifiers":9728},"Nathan, 2009, A proposed staging system for intrahepatic cholangiocarcinoma, Ann Surg Oncol, 16, 14, 10.1245\u002Fs10434-008-0180-z",{"doi":9729},"10.1245\u002Fs10434-008-0180-z",{"id":26,"text":9731,"url":26,"identifiers":9732},"Farges, 2011, AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: by the AFC-IHCC-2009 study group, Cancer, 117, 2170, 10.1002\u002Fcncr.25712",{"doi":9733},"10.1002\u002Fcncr.25712",{"id":26,"text":9735,"url":26,"identifiers":9736},"Chung, 2009, Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation, Radiographics, 29, 683, 10.1148\u002Frg.293085729",{"doi":9737},"10.1148\u002Frg.293085729",{"id":26,"text":9739,"url":26,"identifiers":9740},"Manfredi, 2004, Magnetic resonance imaging of cholangiocarcinoma, Semin Liver Dis, 24, 155, 10.1055\u002Fs-2004-828892",{"doi":9741},"10.1055\u002Fs-2004-828892",{"id":26,"text":1556,"url":26,"identifiers":9743},{"doi":1558},{"id":26,"text":9745,"url":26,"identifiers":9746},"Weber, 2001, Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes, J Am Coll Surg, 193, 384, 10.1016\u002FS1072-7515(01)01016-X",{"doi":9747},"10.1016\u002FS1072-7515(01)01016-X",{"id":26,"text":9749,"url":26,"identifiers":9750},"Tan, 2008, Surgical management of intrahepatic cholangiocarcinoma – a population-based study, Ann Surg Oncol, 15, 600, 10.1245\u002Fs10434-007-9627-x",{"doi":9751},"10.1245\u002Fs10434-007-9627-x",{"id":26,"text":9753,"url":26,"identifiers":9754},"de Jong, 2011, Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment, J Clin Oncol, 29, 3140, 10.1200\u002FJCO.2011.35.6519",{"doi":9755},"10.1200\u002FJCO.2011.35.6519",{"id":26,"text":9757,"url":26,"identifiers":9758},"Sotiropoulos, 2009, R0 liver resections for primary malignant liver tumors in the noncirrhotic liver: a diagnosis-related analysis, Dig Dis Sci, 54, 887, 10.1007\u002Fs10620-008-0408-6",{"doi":9759},"10.1007\u002Fs10620-008-0408-6",{"id":26,"text":9761,"url":26,"identifiers":9762},"Endo, 2008, Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection, Ann Surg, 248, 84, 10.1097\u002FSLA.0b013e318176c4d3",{"doi":9763},"10.1097\u002FSLA.0b013e318176c4d3",{"id":26,"text":9765,"url":26,"identifiers":9766},"Konstadoulakis, 2008, Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome, Surgery, 143, 366, 10.1016\u002Fj.surg.2007.10.010",{"doi":9767},"10.1016\u002Fj.surg.2007.10.010",{"id":26,"text":9769,"url":26,"identifiers":9770},"Lang, 2009, Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients, J Am Coll Surg, 208, 218, 10.1016\u002Fj.jamcollsurg.2008.10.017",{"doi":9771},"10.1016\u002Fj.jamcollsurg.2008.10.017",{"id":26,"text":9773,"url":26,"identifiers":9774},"Nakagohri, 2008, Surgical outcome and prognostic factors in intrahepatic cholangiocarcinoma, World J Surg, 32, 2675, 10.1007\u002Fs00268-008-9778-3",{"doi":9775},"10.1007\u002Fs00268-008-9778-3",{"id":26,"text":9777,"url":26,"identifiers":9778},"Shimada, 2009, Therapeutic value of lymph node dissection during hepatectomy in patients with intrahepatic cholangiocellular carcinoma with negative lymph node involvement, Surgery, 145, 411, 10.1016\u002Fj.surg.2008.11.010",{"doi":9779},"10.1016\u002Fj.surg.2008.11.010",{"id":26,"text":9781,"url":26,"identifiers":9782},"Nakagawa, 2005, Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma, World J Surg, 29, 728, 10.1007\u002Fs00268-005-7761-9",{"doi":9783},"10.1007\u002Fs00268-005-7761-9",{"id":26,"text":9785,"url":26,"identifiers":9786},"Choi, 2009, The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival, Ann Surg Oncol, 16, 3048, 10.1245\u002Fs10434-009-0631-1",{"doi":9787},"10.1245\u002Fs10434-009-0631-1",{"id":26,"text":9789,"url":26,"identifiers":9790},"Yamamoto, 2001, Recurrence after surgical resection of intrahepatic cholangiocarcinoma, J Hepatobiliary Pancreat Surg, 8, 154, 10.1007\u002Fs005340170039",{"doi":9791},"10.1007\u002Fs005340170039",{"id":26,"text":9793,"url":26,"identifiers":9794},"Uenishi, 2008, Indications for surgical treatment of intrahepatic cholangiocarcinoma with lymph node metastases, J Hepatobiliary Pancreat Surg, 15, 417, 10.1007\u002Fs00534-007-1315-5",{"doi":9795},"10.1007\u002Fs00534-007-1315-5",{"id":26,"text":9797,"url":26,"identifiers":9798},"Paik, 2008, What prognostic factors are important for resected intrahepatic cholangiocarcinoma?, J Gastroenterol Hepatol, 23, 766, 10.1111\u002Fj.1440-1746.2007.05040.x",{"doi":9799},"10.1111\u002Fj.1440-1746.2007.05040.x",{"id":26,"text":9801,"url":26,"identifiers":9802},"Ohtsuka, 2002, Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival, Br J Surg, 89, 1525, 10.1046\u002Fj.1365-2168.2002.02268.x",{"doi":9803},"10.1046\u002Fj.1365-2168.2002.02268.x",{"id":26,"text":9805,"url":26,"identifiers":9806},"Nuzzo, 2012, Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients, Arch Surg, 147, 26, 10.1001\u002Farchsurg.2011.771",{"doi":9807},"10.1001\u002Farchsurg.2011.771",{"id":26,"text":9809,"url":26,"identifiers":9810},"Jaeck, 2003, The significance of hepatic pedicle lymph nodes metastases in surgical management of colorectal liver metastases and of other liver malignancies, Ann Surg Oncol, 10, 1007, 10.1245\u002FASO.2003.09.903",{"doi":9811},"10.1245\u002FASO.2003.09.903",{"id":26,"text":9813,"url":26,"identifiers":9814},"Hyder, 2013, Recurrence after operative management of intrahepatic cholangiocarcinoma, Surgery, 153, 811, 10.1016\u002Fj.surg.2012.12.005",{"doi":9815},"10.1016\u002Fj.surg.2012.12.005",{"id":26,"text":9817,"url":26,"identifiers":9818},"Takada, 1998, Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial, Hepatogastroenterology, 45, 2020",{},{"id":26,"text":9820,"url":26,"identifiers":9821},"Neoptolemos, 2004, A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer, N Engl J Med, 350, 1200, 10.1056\u002FNEJMoa032295",{"doi":9822},"10.1056\u002FNEJMoa032295",{"id":26,"text":9824,"url":26,"identifiers":9825},"Neoptolemos, 2012, Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs. observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial, JAMA, 308, 147, 10.1001\u002Fjama.2012.7352",{"doi":9826},"10.1001\u002Fjama.2012.7352",{"id":26,"text":9828,"url":26,"identifiers":9829},"Darwish Murad, 2012, Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers, Gastroenterology, 143, 88, 10.1053\u002Fj.gastro.2012.04.008",{"doi":9830},"10.1053\u002Fj.gastro.2012.04.008",{"id":26,"text":9832,"url":26,"identifiers":9833},"Shimoda, 2001, Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature, Liver Transpl, 7, 1023, 10.1053\u002Fjlts.2001.29419",{"doi":9834},"10.1053\u002Fjlts.2001.29419",{"id":26,"text":9836,"url":26,"identifiers":9837},"Fu, 2011, The role of liver transplantation for intrahepatic cholangiocarcinoma: a single-center experience, Eur Surg Res, 47, 218, 10.1159\u002F000332827",{"doi":9838},"10.1159\u002F000332827",{"id":26,"text":9840,"url":26,"identifiers":9841},"Robles, 2004, Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma, Ann Surg, 239, 265, 10.1097\u002F01.sla.0000108702.45715.81",{"doi":9842},"10.1097\u002F01.sla.0000108702.45715.81",{"id":26,"text":9844,"url":26,"identifiers":9845},"Sotiropoulos, 2008, Liver transplantation as a primary indication for intrahepatic cholangiocarcinoma: a single-center experience, Transplant Proc, 40, 3194, 10.1016\u002Fj.transproceed.2008.08.053",{"doi":9846},"10.1016\u002Fj.transproceed.2008.08.053",{"id":26,"text":9848,"url":26,"identifiers":9849},"Hong, 2011, Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center, Arch Surg, 146, 683, 10.1001\u002Farchsurg.2011.116",{"doi":9850},"10.1001\u002Farchsurg.2011.116",{"id":26,"text":9852,"url":26,"identifiers":9853},"Hong, 2011, Predictive index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinoma, J Am Coll Surg, 212, 514, 10.1016\u002Fj.jamcollsurg.2010.12.005",{"doi":9854},"10.1016\u002Fj.jamcollsurg.2010.12.005",{"id":26,"text":9856,"url":26,"identifiers":9857},"Rana, 2012, Orthotopic liver transplantation in combination with neoadjuvant therapy: a new paradigm in the treatment of unresectable intrahepatic cholangiocarcinoma, Curr Opin Gastroenterol, 28, 258, 10.1097\u002FMOG.0b013e32835168db",{"doi":9858},"10.1097\u002FMOG.0b013e32835168db",{"id":26,"text":9860,"url":26,"identifiers":9861},"Wolfe, 2010, Trends in organ donation and transplantation in the United States, 1999–2008, Am J Transplant, 10, 961, 10.1111\u002Fj.1600-6143.2010.03021.x",{"doi":9862},"10.1111\u002Fj.1600-6143.2010.03021.x",{"id":26,"text":9864,"url":26,"identifiers":9865},"Maganty, 2010, Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma: outcome after liver transplantation, Dig Dis Sci, 55, 3597, 10.1007\u002Fs10620-010-1402-3",{"doi":9866},"10.1007\u002Fs10620-010-1402-3",{"id":26,"text":9868,"url":26,"identifiers":9869},"Sapisochin, 2011, Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma, Liver Transpl, 17, 934, 10.1002\u002Flt.22307",{"doi":9870},"10.1002\u002Flt.22307",{"id":26,"text":9872,"url":26,"identifiers":9873},"Morise, 2010, Surgery and chemotherapy for intrahepatic cholangiocarcinoma, World J Hepatol, 2, 58, 10.4254\u002Fwjh.v2.i2.58",{"doi":9874},"10.4254\u002Fwjh.v2.i2.58",{"id":26,"text":9876,"url":26,"identifiers":9877},"Lazaridis, 2011, Cholangiocarcinoma, 1032",{},{"id":26,"text":9879,"url":26,"identifiers":9880},"Chen, 2010, Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients, BMC Cancer, 10, 492, 10.1186\u002F1471-2407-10-492",{"doi":9881},"10.1186\u002F1471-2407-10-492",{"id":26,"text":9883,"url":26,"identifiers":9884},"Zeng, 2006, Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 75 patients, Cancer J, 12, 113",{},{"id":26,"text":9886,"url":26,"identifiers":9887},"Barney, 2012, Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma, Radiat Oncol, 7, 67, 10.1186\u002F1748-717X-7-67",{"doi":9888},"10.1186\u002F1748-717X-7-67",{"id":26,"text":9890,"url":26,"identifiers":9891},"Ibarra, 2012, Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors, Acta Oncol, 51, 575, 10.3109\u002F0284186X.2011.652736",{"doi":9892},"10.3109\u002F0284186X.2011.652736",{"id":26,"text":9894,"url":26,"identifiers":9895},"Shinohara, 2008, Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma, Int J Radiat Oncol Biol Phys, 72, 1495, 10.1016\u002Fj.ijrobp.2008.03.018",{"doi":9896},"10.1016\u002Fj.ijrobp.2008.03.018",{"id":26,"text":9898,"url":26,"identifiers":9899},"Jiang, 2010, Benefit of radiotherapy for 90 patients with resected intrahepatic cholangiocarcinoma and concurrent lymph node metastases, J Cancer Res Clin Oncol, 136, 1323, 10.1007\u002Fs00432-010-0783-1",{"doi":9900},"10.1007\u002Fs00432-010-0783-1",{"id":26,"text":9902,"url":26,"identifiers":9903},"Kim YI, Park JW, Kim BH, Woo SM, Kim TH, Koh YH, et al. The effect of chemoradiotherapy for unresectable advanced intrahepatic cholangiocarcinoma. International Liver Cancer Association Meeting; 2012.",{},{"id":26,"text":9905,"url":26,"identifiers":9906},"O’Connor, 2011, Stereotactic body radiation therapy in the treatment of unresectable intrahepatic cholangiocarcinoma, J Clin Oncol, 29, abstr 335, 10.1200\u002Fjco.2011.29.4_suppl.335",{"doi":9907},"10.1200\u002Fjco.2011.29.4_suppl.335",{"id":26,"text":9909,"url":26,"identifiers":9910},"EASL-EORTC clinical practice guidelines, 2012, Management of hepatocellular carcinoma, J Hepatol, 56, 908, 10.1016\u002Fj.jhep.2011.12.001",{"doi":947},{"id":26,"text":9912,"url":26,"identifiers":9913},"Hong, 2010, Locoregional intra-arterial therapies for unresectable intrahepatic cholangiocarcinoma, Semin Oncol, 37, 110, 10.1053\u002Fj.seminoncol.2010.03.002",{"doi":9914},"10.1053\u002Fj.seminoncol.2010.03.002",{"id":26,"text":9916,"url":26,"identifiers":9917},"Park, 2011, Transarterial chemoembolization vs. supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma, Clin Radiol, 66, 322, 10.1016\u002Fj.crad.2010.11.002",{"doi":9918},"10.1016\u002Fj.crad.2010.11.002",{"id":26,"text":9920,"url":26,"identifiers":9921},"Edwards, 2012, Transarterial therapies for unresectable cholangiocarcinoma: a meta-analysis, J Vasc Interv Radiol, 23, S101, 10.1016\u002Fj.jvir.2011.12.298",{"doi":9922},"10.1016\u002Fj.jvir.2011.12.298",{"id":26,"text":9924,"url":26,"identifiers":9925},"Kiefer, 2011, Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study, Cancer, 117, 1498, 10.1002\u002Fcncr.25625",{"doi":9926},"10.1002\u002Fcncr.25625",{"id":26,"text":9928,"url":26,"identifiers":9929},"Stuebs, 2012, Developments of treatment of advanced intrahepatic cholangiocarcinoma: an analysis of systemic and local therapy modes in 57 patients, J Clin Oncol, 30, abstr 356, 10.1200\u002Fjco.2012.30.4_suppl.346",{"doi":9930},"10.1200\u002Fjco.2012.30.4_suppl.346",{"id":26,"text":9932,"url":26,"identifiers":9933},"Shen, 2011, Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study, World J Surg, 35, 2083, 10.1007\u002Fs00268-011-1171-y",{"doi":9934},"10.1007\u002Fs00268-011-1171-y",{"id":26,"text":9936,"url":26,"identifiers":9937},"Aliberti, 2008, Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results, Cardiovasc Intervent Radiol, 31, 883, 10.1007\u002Fs00270-008-9336-2",{"doi":9938},"10.1007\u002Fs00270-008-9336-2",{"id":26,"text":9940,"url":26,"identifiers":9941},"Poggi, 2009, OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma, Cardiovasc Intervent Radiol, 32, 1187, 10.1007\u002Fs00270-009-9694-4",{"doi":9942},"10.1007\u002Fs00270-009-9694-4",{"id":26,"text":9944,"url":26,"identifiers":9945},"Kuhlmann, 2012, Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy, Eur J Gastroenterol Hepatol, 24, 437",{},{"id":26,"text":9947,"url":26,"identifiers":9948},"Tanaka, 2002, Arterial chemoinfusion therapy through an implanted port system for patients with unresectable intrahepatic cholangiocarcinoma–initial experience, Eur J Radiol, 41, 42, 10.1016\u002FS0720-048X(01)00414-4",{"doi":9949},"10.1016\u002FS0720-048X(01)00414-4",{"id":26,"text":9951,"url":26,"identifiers":9952},"Vogl, 2006, Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy, J Cancer Res Clin Oncol, 132, 745, 10.1007\u002Fs00432-006-0138-0",{"doi":9953},"10.1007\u002Fs00432-006-0138-0",{"id":26,"text":9955,"url":26,"identifiers":9956},"Shitara, 2008, Hepatic arterial infusion of mitomycin C with degradable starch microspheres for unresectable intrahepatic cholangiocarcinoma, Clin Oncol (R Coll Radiol), 20, 241, 10.1016\u002Fj.clon.2007.12.007",{"doi":9957},"10.1016\u002Fj.clon.2007.12.007",{"id":26,"text":9959,"url":26,"identifiers":9960},"Ibrahim, 2008, Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study, Cancer, 113, 2119, 10.1002\u002Fcncr.23818",{"doi":9961},"10.1002\u002Fcncr.23818",{"id":26,"text":9963,"url":26,"identifiers":9964},"Saxena, 2010, Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option, Ann Surg Oncol, 17, 484, 10.1245\u002Fs10434-009-0777-x",{"doi":9965},"10.1245\u002Fs10434-009-0777-x",{"id":26,"text":9967,"url":26,"identifiers":9968},"Hoffmann, 2012, Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival, Cardiovasc Intervent Radiol, 35, 105, 10.1007\u002Fs00270-011-0142-x",{"doi":9969},"10.1007\u002Fs00270-011-0142-x",{"id":26,"text":9971,"url":26,"identifiers":9972},"Chiou, 2005, Percutaneous ultrasound-guided radiofrequency ablation of intrahepatic cholangiocarcinoma, Kaohsiung J Med Sci, 21, 304, 10.1016\u002FS1607-551X(09)70125-1",{"doi":9973},"10.1016\u002FS1607-551X(09)70125-1",{"id":26,"text":9975,"url":26,"identifiers":9976},"Carrafiello, 2010, Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience, Cardiovasc Intervent Radiol, 33, 835, 10.1007\u002Fs00270-010-9849-3",{"doi":9977},"10.1007\u002Fs00270-010-9849-3",{"id":26,"text":9979,"url":26,"identifiers":9980},"Kim, 2011, Intrahepatic mass-forming cholangiocarcinomas: enhancement patterns at multiphasic CT, with special emphasis on arterial enhancement pattern–correlation with clinicopathologic findings, Radiology, 260, 148, 10.1148\u002Fradiol.11101777",{"doi":9981},"10.1148\u002Fradiol.11101777",{"id":26,"text":9983,"url":26,"identifiers":9984},"Haidu, 2012, Stereotactic radiofrequency ablation of unresectable intrahepatic cholangiocarcinomas: a retrospective study, Cardiovasc Intervent Radiol, 35, 1074, 10.1007\u002Fs00270-011-0288-6",{"doi":9985},"10.1007\u002Fs00270-011-0288-6",{"id":26,"text":9987,"url":26,"identifiers":9988},"Giorgio, 2011, Radiofrequency ablation for intrahepatic cholangiocarcinoma: retrospective analysis of a single centre experience, Anticancer Res, 31, 4575",{},{"id":26,"text":9990,"url":26,"identifiers":9991},"Fu, 2012, Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma, J Vasc Interv Radiol, 23, 642, 10.1016\u002Fj.jvir.2012.01.081",{"doi":9992},"10.1016\u002Fj.jvir.2012.01.081",{"id":26,"text":9994,"url":26,"identifiers":9995},"Kamphues, 2010, Recurrent intrahepatic cholangiocarcinoma: single-center experience using repeated hepatectomy and radiofrequency ablation, J Hepatobiliary Pancreat Sci, 17, 509, 10.1007\u002Fs00534-009-0256-6",{"doi":9996},"10.1007\u002Fs00534-009-0256-6",{"id":26,"text":9998,"url":26,"identifiers":9999},"Livraghi, 2012, Complications of microwave ablation for liver tumors: results of a multicenter study, Cardiovasc Intervent Radiol, 35, 868, 10.1007\u002Fs00270-011-0241-8",{"doi":10000},"10.1007\u002Fs00270-011-0241-8",{"id":26,"text":10002,"url":26,"identifiers":10003},"Glimelius, 1996, Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer, Ann Oncol, 7, 593, 10.1093\u002Foxfordjournals.annonc.a010676",{"doi":10004},"10.1093\u002Foxfordjournals.annonc.a010676",{"id":26,"text":10006,"url":26,"identifiers":10007},"Sharma, 2010, Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study, J Clin Oncol, 28, 4581, 10.1200\u002FJCO.2010.29.3605",{"doi":10008},"10.1200\u002FJCO.2010.29.3605",{"id":26,"text":10010,"url":26,"identifiers":10011},"Eckel, 2007, Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials, Br J Cancer, 96, 896, 10.1038\u002Fsj.bjc.6603648",{"doi":10012},"10.1038\u002Fsj.bjc.6603648",{"id":26,"text":10014,"url":26,"identifiers":10015},"Valle, 2009, Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study, Br J Cancer, 101, 621, 10.1038\u002Fsj.bjc.6605211",{"doi":10016},"10.1038\u002Fsj.bjc.6605211",{"id":26,"text":10018,"url":26,"identifiers":10019},"Valle, 2010, Cisplatin plus gemcitabine vs. gemcitabine for biliary tract cancer, N Engl J Med, 362, 1273, 10.1056\u002FNEJMoa0908721",{"doi":10020},"10.1056\u002FNEJMoa0908721",{"id":26,"text":10022,"url":26,"identifiers":10023},"Okusaka, 2010, Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan, Br J Cancer, 103, 469, 10.1038\u002Fsj.bjc.6605779",{"doi":10024},"10.1038\u002Fsj.bjc.6605779",{"id":26,"text":10026,"url":26,"identifiers":10027},"Oh, 2011, Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness, Invest New Drugs, 29, 1066, 10.1007\u002Fs10637-010-9417-3",{"doi":10028},"10.1007\u002Fs10637-010-9417-3",{"id":26,"text":10030,"url":26,"identifiers":10031},"Bekaii-Saab, 2011, Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers, J Clin Oncol, 29, 2357, 10.1200\u002FJCO.2010.33.9473",{"doi":10032},"10.1200\u002FJCO.2010.33.9473",{"id":26,"text":10034,"url":26,"identifiers":10035},"Malka, 2009, A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: interim analysis of the BINGO trial, J Clin Oncol, 27, 4520, 10.1200\u002Fjco.2009.27.15_suppl.4520",{"doi":10036},"10.1200\u002Fjco.2009.27.15_suppl.4520",{"id":26,"text":10038,"url":26,"identifiers":10039},"Moehler, 2011, A randomized, double-blind, multicenter phase II AIO trial with gemcitabine plus sorafenib vs. gemcitabine plus placebo in patients with chemotherapy-naive advanced or metastatic biliary tract cancer: first safety and efficacy data, J Clin Oncol, 29, abstr 4077, 10.1200\u002Fjco.2011.29.15_suppl.4077",{"doi":10040},"10.1200\u002Fjco.2011.29.15_suppl.4077",{"id":26,"text":10042,"url":26,"identifiers":10043},"Ko, 2006, Polymorphisms of 5,10-methylenetetrahydrofolate reductase (MTHFR C677T) and thymidylate synthase enhancer region (TSER) as a risk factor of cholangiocarcinoma in a Korean population, Anticancer Res, 26, 4229",{},{"id":26,"text":10045,"url":26,"identifiers":10046},"Marahatta, 2006, Polymorphism of glutathione S-transferase omega gene and risk of cancer, Cancer Lett, 236, 276, 10.1016\u002Fj.canlet.2005.05.020",{"doi":10047},"10.1016\u002Fj.canlet.2005.05.020",{"id":26,"text":10049,"url":26,"identifiers":10050},"Hoblinger, 2009, Association of the c.3972C>T variant of the multidrug resistance-associated protein 2 Gene (MRP2\u002FABCC2) with susceptibility to bile duct cancer, Digestion, 80, 36, 10.1159\u002F000212990",{"doi":10051},"10.1159\u002F000212990",{"id":26,"text":10053,"url":26,"identifiers":10054},"Wadsworth, 2011, Genetic factors in the pathogenesis of cholangiocarcinoma, Dig Dis, 29, 93, 10.1159\u002F000324688",{"doi":10055},"10.1159\u002F000324688",{"id":26,"text":10057,"url":26,"identifiers":10058},"Melum, 2008, Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms, Hepatology, 47, 90, 10.1002\u002Fhep.21964",{"doi":10059},"10.1002\u002Fhep.21964",{"id":26,"text":10061,"url":26,"identifiers":10062},"Huang, 2008, Selected base excision repair gene polymorphisms and susceptibility to biliary tract cancer and biliary stones: a population-based case-control study in China, Carcinogenesis, 29, 100, 10.1093\u002Fcarcin\u002Fbgm247",{"doi":10063},"10.1093\u002Fcarcin\u002Fbgm247",{"id":26,"text":10065,"url":26,"identifiers":10066},"Sakoda, 2006, Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China, Carcinogenesis, 27, 1251, 10.1093\u002Fcarcin\u002Fbgi314",{"doi":10067},"10.1093\u002Fcarcin\u002Fbgi314",{"id":26,"text":10069,"url":26,"identifiers":10070},"Mihalache, 2011, Heterozygosity for the alpha1-antitrypsin Z allele may confer genetic risk of cholangiocarcinoma, Aliment Pharmacol Ther, 33, 389, 10.1111\u002Fj.1365-2036.2010.04534.x",{"doi":10071},"10.1111\u002Fj.1365-2036.2010.04534.x",{"id":26,"text":10073,"url":26,"identifiers":10074},"Glimelius, 1998, Bolus injection (2–4min) vs. short-term (10–20min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group, Eur J Cancer, 34, 674, 10.1016\u002FS0959-8049(97)10055-7",{"doi":10075},"10.1016\u002FS0959-8049(97)10055-7",{"id":26,"text":10077,"url":26,"identifiers":10078},"Kornek, 2004, Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial, Ann Oncol, 15, 478, 10.1093\u002Fannonc\u002Fmdh096",{"doi":10079},"10.1093\u002Fannonc\u002Fmdh096",{"id":26,"text":10081,"url":26,"identifiers":10082},"Ducreux, 2005, A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial, Eur J Cancer, 41, 398, 10.1016\u002Fj.ejca.2004.10.026",{"doi":10083},"10.1016\u002Fj.ejca.2004.10.026",{"id":26,"text":10085,"url":26,"identifiers":10086},"Rao, 2005, Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer, Br J Cancer, 92, 1650, 10.1038\u002Fsj.bjc.6602576",{"doi":10087},"10.1038\u002Fsj.bjc.6602576"]